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Zusammenfassung 
 
Hintergrund. Unter den weltweit häufigsten Gesundheitsproblemen befinden sich 
obstruktive respiratorische Erkrankungen wie Asthma oder chronisch obstruktive 
Lungenerkrankung (COPD). Beide zeigen sehr heterogene Erscheinungsformen und werden 
meistens durch Lungenfunktionsmessungen diagnostiziert. Neben etablierten Umweltrisiken 
gibt es auch genetische Faktoren, welche die Lungenfunktion wesentlich mitbestimmen. 
Insbesondere SERPINA1 Genvarianten, welche die Konzentration von Alpha1-Antitrypsin 
(AAT) im Blut stark reduzieren und folglich zu einem gestörten Gleichgewicht von 
Proteasen und Antiproteasen in der Lunge führen, sind seit vielen Jahren als Risikofaktor 
bekannt. Hingegen sind Genvarianten, welche zu einem schwachen oder intermediär 
ausgeprägten Mangel an AAT im Blut führen, vermutlich nur für einen Teil der 
Bevölkerung ein Risikofaktor, aber weder wissen wir genau, wie der Konzentrationsbereich 
eines solchen Mangels am besten zu definieren ist, noch welche Zusatzfaktoren 
gesundheitsrelevant für betroffene Personen sind.  
Methoden. In dieser Arbeit wurde mithilfe der schweizerischen Kohortenstudie über 
Luftverschmutzung und Lungenerkrankungen bei Erwachsenen (SAPALDIA) ermittelt, 
welche genetischen Polymorphismen die AAT-Serumkonzentration hauptsächlich 
bestimmen. Im Weiteren wurden die Konzentrationsbereiche einer AAT-Defizienz für die 
Allgemeinbevölkerung neu festgelegt und die Assoziation zwischen SERPINA1 
Defizienzgenotypen und altersbedingter Lungenfunktionsabnahme umfassend untersucht. 
Die Beurteilung von Gen-Umwelt-Interaktionen in Bezug auf respiratorische Gesundheit 
war dabei ein zentraler Teil der Arbeit und umfasste neben SERPINA1 auch weitere Gene. 
Der umweltbezogene Fokus wurde auf Rauchen, Luftverschmutzung, berufliche Exposition 
gegenüber Dämpfen, Gas, Staub und Rauch sowie Fettleibigkeit gelegt; alles Faktoren, die 
in Verdacht stehen, Entzündungen zu begünstigen. Da in SAPALDIA Blutwerte von 
Entzündungsmarkern inklusive AAT, genomweite Daten inklusive zusätzlicher Genotyp- 
und Sequenzdaten des SERPINA1 Gens sowie umfassende und detaillierte Umwelt- und 
respiratorische Gesundheitsdaten erhoben wurden, war die Studie wie keine andere 
prädestiniert, die beschriebenen Zusammenhänge und Interaktionen zu untersuchen.  
Resultate. Wir beobachteten eine homogenere Verteilung von AAT-Serumkonzentrationen 
in Personen mit intermediär ausgeprägter AAT-Defizienz als aus der Literatur bekannt und 
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verdeutlichten die Abhängigkeit der AAT-Blutwerte von anderen Entzündungsmarkern. 
Weiter konnten wir bestätigen, dass seltene Varianten des SERPINA1 Gens die 
hauptsächlichen genetischen Determinanten der AAT-Blutwerte sind und wiesen auf einige 
der inhärenten Schwächen von genomweiten Assoziationsstudien hin. Eine hohe Belastung 
mit entzündungsfördernden Einflüssen modifizierte die Assoziation zwischen intermediär 
ausgeprägter AAT-Defizienz und Lungenfunktionsabnahme. Genetische Interaktionen mit 
Fettleibigkeit hinsichtlich Asthma und mit Luftverschmutzung hinsichtlich 
Lungenfunktionsabnahme wurden ebenfalls gefunden, was auf der einen Seite das immer 
noch reichhaltige Forschungsgebiet der Gen-Umweltinteraktionen aufzeigt, welches noch 
nicht systematisch untersucht worden ist, aber auf der anderen Seite die Komplexität 
offenbart, allgemeingültige Schlussfolgerungen aus solchen Analysen ziehen zu können.  
Diskussion und Schlussfolgerung. Zusammenfassend lässt sich sagen, dass diese Arbeit 
möglicherweise den Ablauf des diagnostischen Verfahrens vereinfacht, mit dem sich 
Patienten mit einer vermuteten AAT-Defizienz konfrontiert sehen. Obwohl Personen mit 
einer intermediär ausgeprägten AAT-Defizienz im Allgemeinen nicht als eine Risikogruppe 
für respiratorische Gesundheitsbeeinträchtigungen angeschaut werden, scheinen sie 
anfälliger als die Allgemeinbevölkerung auf entzündliche Stressoren zu sein. So würden sie 
möglicherweise stärker von Massnahmen wie Beratungen gegen die Aufnahme des 
Rauchens, für gesunde Ernährung oder für verbesserte betriebliche Sicherheit.  
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Summary 
 
Background. One of the globally most frequent health problems are obstructive lung 
diseases such as asthma and chronic obstructive pulmonary disease. Both of them show 
heterogeneous phenotypes and are most commonly diagnosed by lung function 
measurements. Apart from several well-established environmental risk factors, there are 
also genetic factors which play an important role in determining lung function. Notably, 
SERPINA1 gene variants which severely reduce the alpha1-antitrypsin (AAT) concentration 
in the blood and consequently lead to a protease-antiprotease disequilibrium in the lung 
have been known as risk factors for several years. Intermediate deficiency of AAT serum 
level is however assumed to be a risk factor in only part of the population, but neither is it 
entirely clear how to define this range of protein concentration for the general population, 
nor do we know which co-factors are health-relevant in intermediately deficient individuals. 
Methods. In this work, SAPALDIA, the Swiss cohort study on air pollution and lung 
disease in adults, was used to find the essential genetic polymorphisms which determine 
AAT serum level. Deficiency ranges for AAT were defined in the general population, and 
the association between SERPINA1 deficiency genotypes and age-related lung function 
decline was investigated in a comprehensive way. The assessment of gene-environment 
interactions in terms of pulmonary health was a central part of this work and embraced also 
genes beyond SERPINA1. The environment-related focus was set on factors associated with 
inflammatory stress, namely smoking, air pollution, high occupational exposure to vapours, 
gas, dusts and fumes as well as obesity. The availability of serum inflammatory markers 
including AAT, genome-wide data including additional genotype and sequence information 
of the SERPINA1 gene as well as very comprehensive and detailed environmental and 
respiratory health data made SAPALDIA, unlike any other study, ideally suited to 
investigate the aforementioned associations and interactions. 
Results. This work found a smaller range of AAT serum level in subjects with intermediate 
AAT deficiency than reported in the literature and clarified the role of elevated 
inflammatory conditions on AAT serum level. It confirmed uncommon variants in the 
SERPINA1 locus as the major genetic determinants of AAT blood level and pointed to some 
of the inherent weaknesses of genome-wide association studies. A high burden of 
inflammatory stress was suggested to modify the association between intermediate AAT 
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deficiency and lung function decline. Further genetic interaction with obesity in terms of 
asthma and with air pollution in terms of lung function decline was suggested, pointing on 
the one hand to a still proliferative research area of gene-environment interactions which has 
not yet been systematically assessed, but revealing on the other hand the complexity of 
drawing firm conclusions from such analyses.
Discussion and Conclusion. In summary, this work may potentially facilitate the diagnostic 
procedure for subjects with an assumed AAT deficiency. Although generally not regarded 
as a risk group for adverse pulmonary health, individuals with an intermediate AAT 
deficiency seem more susceptible to elevated inflammatory conditions compared to the 
general population. They would potentially more strongly benefit from measures like 
counselling against the uptake of smoking, for healthy diet programmes or improvements of 
occupational safety. 
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1 Background 
 
1.1 Setting the Stage: Non-Communicable Disease Research in the 
Framework of Genetic Epidemiology 
Non-communicable diseases (NCDs) are medical conditions which are not directly 
transmissible from person to person and usually of slow progression, long duration and 
therefore age-related. The term chronic disease is often used interchangeably, but this is 
not entirely correct as some chronic diseases may also be caused by infections. Major types 
of NCDs include cardiovascular diseases (CVDs), cancers, respiratory diseases, auto-
immune diseases as well as endocrinal and neurological disorders.  
Genetic epidemiology is a research field which concentrates on studying the role of genetic 
variation and its interaction with the environment in determining health and disease at the 
population level. Comparably novel instruments have recently revolutionised this discipline 
and will therefore be presented in sufficient depth in the first part of the introductory 
chapter. The second part is then dedicated more specifically to the traits and diseases which 
were actually investigated during this PhD work. 
 
1.1.1 Global Impact and Aetiology of Non-Communicable Diseases 
The global burden of disease estimates show that the burden of NCDs has steadily increased 
over the past 20 years. In 2010, NCDs accounted for more than 50% of all disability-
adjusted life years (DALYs) [1], a measure that adds the years of life lost to those lived with 
disability. Most prominently ranked are the diseases of blood circulation, cancers and 
chronic respiratory diseases. The proportion of NCDs on global DALYs is expected to 
further rise in future, in particular owing to the increasing life expectancy of the worlds 
population, the increasing rates of risk factors like smoking and overweight and the better 
management of communicable diseases. 
The aetiology of NCDs is usually complex and often described as depending on a heritable 
genetic component as well as on the non-heritable environment. However, this distinction is 
not very clear-cut. Genetics also consists of a non-heritable part (e.g. the postzygotic 
mutations crucial in the aetiology of many cancers), and the environment may lead under 
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certain circumstances to heritable modifications in germ cells (e.g. by inducing epigenetic 
changes during development). Nevertheless, when making the gene vs. environment 
distinction, we restrict the genetic component to its heritable part and regard the 
environment as a proxy for all non-heritable influences including also stochastic events.  
 
1.1.2 Environment 
Important factors include behavioural and social determinants beside factors of the in- and 
outdoor ambience. Globally, it was estimated that the highest-ranking risk factors based on 
DALYs for 2010 were high blood pressure, tobacco smoking and household air pollution 
[2]. A large part of the environmental component is modifiable and therefore of high public 
health relevance. In practice, however, it has turned out to be difficult to modify the 
distribution of some of the most relevant environmental risk factors (e.g. tobacco smoking). 
It is important to note that the inference of causality in any given association between an 
environmental factor and a disease is all but a trivial endeavour. Observational studies 
typically investigating the impact of such factors (exposures) on certain traits or diseases 
(outcomes) are renowned for the high risk of detecting spurious associations. Different types 
of biases, confounding and reverse causality issues have to be taken into account. This can 
be best countered by using a randomised controlled trial (RCT) study design, but this is 
often not practically or ethically feasible. Cohort studies can at least overcome some of 
these pitfalls due to the temporal sequence of cause and effect. Other important challenges 
are the generally long latency period between cause and effect and the often inaccurate or 
unreliable measurement (or allocation) of environmental factors, additionally complicated 
by time-dependency. Susceptibility to a certain exposure may depend on unknown time 
windows or on the duration of exposure [3]. One approach sometimes used to infer causality 
is Mendelian randomisation. If a genetic factor can serve as a proxy for an environmental 
exposure, and if the genetic factor is additionally associated with the respective outcome, we 
could infer causality to the association between the exposure and the outcome. This is 
because genetic factors are not believed to be associated with possible factors that confound 
the association. Nevertheless, the method is only useful if the environmental factor is a 
biomarker or a behaviour (for which we normally find genetic surrogates) and if pleiotropy 
(i.e. if the genetic factor is linked via different pathways to the exposure and to the outcome) 
is unlikely [4].  
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1.1.3 Heritability 
The proportion of a traits phenotypic variation which is due to heritable genetic factors is 
defined as the traits (broad-sense) heritability. This term is normally defined for a specific 
population at a specific age and in a particular environment [5]. Non-additive components 
of the heritable factors are interaction effects either between alleles at the same locus 
(dominance) or at different loci (gene-gene interactions, epistasis). They are difficult to 
assess, but are believed to be minor compared to the additive components, i.e. the additive 
effects of the alleles [6,7]. Therefore, one usually refers to the narrow-sense heritability, 
which is the ratio between the additive components of the heritable factors and the total 
phenotypic variation. Several methods are in use to estimate this proportion including 
quantification of trait or disease correlation in pairs of relatives of a specific type or 
assessment of differences among monozygotic and dizygotic twins [8]. Such family- or 
pedigree-based methods have the advantage that they do not have to consider population 
heterogeneity, but they are usually not very powerful and struggle with shared environment 
issues. Another method to get a measure of the additive genetic variance uses the effects of 
all genetic variants in total, as typically provided by a genome-wide association study 
(GWAS, see 1.1.5) [9]. Such a measure is likely an underestimation of the true value and 
can serve as a lower limit of the heritability since independent effects of rare variants are not 
taken into account.  
Heritability estimates from pedigree studies typically lie in the range of 0.3 to 0.9 (30  
90%) for many common metabolic and anthropomorphic traits as well as for a range of 
metabolic, auto-immune and neurological diseases [10,11]. This apparently contrasts with 
the high importance of environmental risk factors in the aetiology of many NCDs, which is 
for instance evident by the steep increase of such diseases in certain migrant populations 
[12]. Heritability estimates depend however on the distribution of environmental factors and 
should therefore ideally be reported according to sex, age, area and population. Additional 
caution in the interpretation of heritability estimates is required due to the different 
estimation methods.  
 
1.1.4 Identification of Genes: The Candidate Gene Approach 
Genetic linkage studies, in which the chromosomal segregation is compared with the disease 
segregation in families, proved unsuitable to detect genetic variants associated with complex 
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diseases. Hence, the approach which was normally used until the year 2006 was the 
investigation of associations between variants of candidate genes and a specific outcome. 
Compared to environmental risk factors (see 1.1.2), genetic risk factors are in many ways 
easier to deal with in association studies. They inherently antedate any disease outcome, 
they do not change during lifetime, and they can be measured with high accuracy and 
reliability. Since genetic polymorphisms assort randomly during meiosis, environmental 
factors (with the exception of population heterogeneity) are not expected to confound 
genetic associations with traits or diseases. Adjusting for environmental factors is therefore 
hardly crucial, but makes sense in the case of behavioural factors since they may lie on the 
causal pathway between the genetic risk factor and the disease.  
Nevertheless, replication studies and meta-analyses showed that reported associations of 
genetic variants, usually single nucleotide polymorphisms (SNPs), could rarely be 
confirmed [13]. This had likely to do with the fact that the investigated SNPs were not 
necessarily the causal ones, but correlated with them (i.e. lying in linkage disequilibrium, 
LD), and the correlation structure differs across populations. There were also other reasons 
for non-replication. Most importantly, confounding by population heterogeneity (because 
allele as well as disease frequencies deviate considerably across populations) might often 
have led to spurious association within studies. In addition, publication bias was assumed to 
be common, and since the number of potentially functional genetic variants per gene is 
large, selective reporting might have occurred. Studies were often small with little power to 
detect SNPs with small effects, and correction for multiple testing was fairly uncommon. 
Therefore, the number of reported false-negative and false-positive results was likely to be 
high. Problems also arose from the use of heterogeneous phenotypes. An important intrinsic 
drawback of candidate gene association studies is the requirement of a hypothesis. Since 
knowledge about the pathophysiology of many diseases was incomplete, this type of study 
could at most identify a small amount of the relevant genetic variants. A final point of 
criticism concerns the fact that single genetic marker analysis is not a very genuine 
representation of how gene products act in vivo. The combination of several SNPs in a gene 
or even in a pathway and its on-aggregate testing for disease association might represent a 
more promising approach.  
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1.1.5 Identification of Genes: The Genome-Wide Approach 
In the year 2005, GWAS appeared as a novel method to conduct genetic association 
analyses. In a GWAS, a set of hundreds of thousands of genetic polymorphisms 
representing the entire genome is put on a genotyping array. Originally, only common SNPs 
(those with a minor allele frequency, MAF > 5%) were considered, assuming that they 
would play the most important role in the underlying trait or disease architecture (common 
disease-common variant hypothesis). All the genotyped SNPs are then tested one after the 
other for disease association in a hypothesis-free manner. The GWAS approach makes use 
of the LD structure in the genome. If two SNPs are in LD, i.e. if they are inherited together 
more often than expected by chance, they may serve as proxies for each other. A set of less 
than one million SNPs could thus tag over 90% of the common genetic variation at the 
population level [14]. The international HapMap [15] and 1000 genomes [16] projects 
revealed the correlation structure by determining the haplotypes of all the sequenced 
individuals. The LD structure in the HapMap and 1000 genomes reference panels is also 
used to predict the genotypes of ungenotyped SNPs. Such an imputation procedure 
facilitates the comparison of data deriving from different genotyping platforms.  
GWAS are typically carried out in a two-stage design to combine high power with reduced 
genotyping costs. A discovery sample is investigated for statistically significant 
associations, which are then tested in an often larger replication sample. SNPs are usually 
selected for replication by their P-value in the association (typically P < 5*10-8, considering 
Bonferroni correction for one million independent tests) or by the control of the false 
discovery rate. Due to the winners curse bias in the discovery sample, the expected effect in 
the replication set is smaller. Joint analyses of discovery and replication sample are also 
often reported in the literature since they are slightly superior in terms of statistical power 
[17]. The statistical power, i.e. the probability of detecting a truly associated variant, 
depends generally on the effect size and the frequency of this variant, the underlying disease 
model, the sample size and the SNP coverage of the array. An additive genetic model (in 
which risks increase additively per allele on the log-scale) is usually most plausible; and as 
it meanwhile turned out that most SNPs contributed individually only marginally to disease 
outcomes (typically conferring relative risks in the range of 1.1 to 1.3), optimal sample sizes 
reach several thousands. 
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GWAS have produced more robust results than candidate gene association studies for a 
number of reasons. Stringent correction for multiple testing is applied, which minimizes the 
risk for false positives. Confounding by ethnicity is normally taken into account by 
adjusting the regression models for principal components standing for differences in 
population substructure [18]. Quality control measures further reduce the chance of 
inaccurate SNP assessment. In the past years, GWAS have evolved to the most important 
tool to discover genetic variants influencing traits with complex aetiology. Over 1600 
papers have been published reporting more than 2000 robust associations with more than 
300 human traits and diseases [19]. The original concern that many top findings were 
outside of coding regions has been constantly weakened and replaced by the view that 
common SNPs lying in regulatory regions are more important with respect to disease 
associations than those lying in coding regions. Many novel mechanisms of disease 
aetiology have been reported, but limitations derive from the fact that only relatively 
frequent SNPs and those which tag the genome have been considered. In order to infer 
causality, more sophisticated GWAS and follow-up methods are indispensable (Table 1 and 
see 1.1.6, 1.1.7). This may also relieve the hitherto most strongly debated concern about the 
relevance of GWAS results, namely the fact that they only explain little of the estimated 
heritability of the respective traits or diseases (see 1.1.8, 1.1.9).  
Table 1. Current methodological trends to complement and refine results from traditional 
genome-wide association analyses. 
Progress within the GWAS approach Progress beyond the GWAS approach 
Large sample sizes and meta-analyses Targeted fine-mapping and conditional analyses 
Advanced genotyping arrays and reference panels Transcriptomics and proteomics 
Homogenous populations and trans-ethnical comparisons Functional annotation (in vivo, in vitro, in silico) 
Refined and intermediate phenotypes Pathway association analyses 
 Whole exome and whole genome sequencing 
 
1.1.6 Identification of Genes: Where Does the Genome-Wide Approach Move to? 
There are currently several observable trends to make the GWAS output more informative.  
First, the number of included samples gets higher in order to gain statistical power. Since 
pooling of different data sets (joint analysis) is often difficult to achieve, large consortia 
emerged which combined GWAS results in meta-analyses by exchanging summary 
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statistics. This increases the power in a similar way as joint analyses would do, but without 
the need to share individual-level data. Moreover, study-specific sets of covariates are 
allowed, and heterogeneity between the studies (e.g. due to different genotyping arrays, 
imputation methods, ethnic groups or covariate assessment) can be assessed. GWAS meta-
analyses became meanwhile the standard for investigating many traits and diseases. They 
were able to reduce the number of false-positive findings, detected robustly associated 
variants with steadily decreasing effect sizes and reduced some of the missing heritability 
[20]. Another advantage of such large-scale endeavours is the prevention of publication bias 
issues. 
Second, the design of the genotyping arrays gets more advanced. Modern chips like the 
Illumina Omni5-Quad contain already five million SNPs and claim to capture variation in 
the full low-frequency range (MAF 1  5%) in European, African and Asian populations. 
Moreover, this chip covers more than 73% of all SNPs found in the sequenced individuals 
of the 1000 genomes project with high LD (r2 > 0.8) [21]. By imputing the GWAS data with 
1000 genomes reference panels, up to 30 million variants may get tested. Developments 
abandoning the hypothesis-free array design are currently also promoted. Chips are 
produced which collect SNPs lying in loci known to be important for certain traits (e.g. the 
MetaboChip [22]).  
Third, comparisons of trans-ethnic GWAS results get more common. Under the assumption 
of same disease mechanisms among different ethnic groups, such comparisons help to 
strengthen the findings and could often refine the results due to the different underlying LD 
structure. High levels of diversity in the African genomes let research communities formerly 
focus on GWAS in Europeans and Asian populations. But newer reference panels take 
African populations more into consideration, allowing for better SNP coverage on the arrays 
and better imputation quality. Besides ethical reasons, the origin of human history, the 
higher prevalence of communicable diseases, but also the often larger differences in 
exposures and co-morbidities are good reasons not to let Africa aside in genetic 
epidemiology [23].  
Forth, phenotypic heterogeneity is regarded as a problem in the comparability of GWAS on 
a particular outcome. There is a trend to use more refined phenotypes or disease subtypes in 
GWAS. The major drawback is the loss of statistical power, but there are methods with 
minimal power loss that divide the outcome into different subtypes allowing for different 
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genetic effects [24]. Another approach is the usage of intermediate phenotypes. This is 
promising since genetic variants do not directly act on higher-order diseases. Stronger 
results are therefore expected by testing the genomic variability against a proxy for the 
manifested disease either on the cell (e.g. a cellular transcript or protein pattern) or on the 
tissue level (e.g. the concentration of blood or urine metabolites [25]). A kind of a large-
scale Mendelian randomisation approach recently showed that SNPs associated with 
metabolic traits could also be associated with medically relevant phenotypes, suggesting 
hence causal links between the metabolic traits and the phenotypes [26]. This could help to 
identify the crucial pathways in the aetiology of diseases. There is generally some evidence 
that a limited number of pathways, especially those for systemic inflammation, could be 
important for a large number of NCDs [27]. Some recent GWAS approaches did therefore 
not concentrate on one or a few separate metabolites, but created metabolic network 
outcomes by the correlation structure of many metabolites [28]. Such approaches may 
reveal promising loci playing a role in the aetiology of many NCDs. 
 
1.1.7 Follow-up on GWAS: How to Detect the Causal Variants? 
The most promising approach to refine a GWAS signal at a certain locus is targeted fine 
mapping, in which the respective locus is sequenced in a number of samples often followed 
by genotyping the detected variants in a larger sample. Conditional analyses in order to find 
independent effects within a locus can directly be applied if individual-level data are 
available. Even if only summary statistics for individual SNPs are available, conditional and 
joint effects can be estimated with the help of LD estimates, which can also be taken from 
public domain data [29]. Targeted fine mapping will most likely lose importance due to the 
meanwhile very high coverage of modern genotyping arrays in the common and low-
frequency spectra. Targeted sequencing would however still reveal rare variants, which can 
be used on aggregate to assess excess in cases or extreme phenotypes.  
Large-scale expression studies have recently become a popular follow-up method on 
GWAS. Expression quantitative trait loci (eQTL) are publicly available for a number of 
tissues, and look-ups in these data sets are often conducted to confer functionality to a SNP. 
An eQTL study is done by linking an expression trait with the most associated SNP. The 
SNP may lie within one megabase of the transcription start or stop of the corresponding 
gene (cis eQTL) or outside this range including on other chromosomes (trans eQTL) [30]. 
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Non-association does not deduce that the SNP is irrelevant with respect to the gene product. 
Namely, the SNP could act on the protein structure without modifying the expression levels 
(e.g. the SERPINA1 PiZ variant is not associated with the SERPINA1 transcripts [28], but 
with the protein levels, see 1.4.2), or its impact on the expression could be restricted to a 
specific tissue cell type, time-window or to the presence of an environmental factor. 
Another way to assess a role for a SNP in influencing expression levels is by determining 
allele-specific expression. It is measured in individuals heterozygous for the candidate SNP 
by assessing via RNA-sequencing if allelic transcripts deviate from a one-to-one ratio [31]. 
A further step would be the association of SNPs with the protein products of a cell (protein-
QTL). The accurate and reliable assessment of the whole proteome at a certain time point is 
still challenging though, but recent methodological progress towards this aim has been 
reported [32].  
The actual strength of the GWAS design is also a weakness: prior knowledge is not taken 
into account. Bioinformatic tools are valuable instruments to estimate the likelihood of a 
GWAS signal to be causal. While prediction of the impact of exonic SNPs on protein 
structure is well-established, functional prediction of non-exonic SNPs is more challenging. 
However, recent rapid progress resulted in the fact that over 80% of the human genome is 
currently allocated to some biochemical function in at least one cell type according to 
ENCODE [33]. Predicted elements with functional relevance include promoters and 
enhancers (via DNA methylation or histone modification patterns), chromatin accessibility 
(via DNAse I footprints), copy number variations (CNVs), transcription factor binding sites 
(via chromatin-immunoprecipitation, ChIP) and microRNA binding sites. Synonymous 
variation in coding regions could also play a greater role in functionality than previously 
expected owing to translational efficiency changes [34]. The main challenge in predicting 
functionality comes from the tissue-, time- or environment-dependency of these elements. 
Functional annotation by in silico methods cannot reliably predict in vivo relevance. Animal 
models therefore remain important, and so do in vitro cell cultures. Some of the challenges 
these experimental methods face are the low penetrance of the causal variants associated 
with complex diseases, differences in the genetic structure between animals and humans, the 
general lack of transferability between animals and humans and last but not least the lack of 
resources to carry out such studies for all GWAS signals.  
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Pathway association methods are another approach to include knowledge and functionally 
bridge genetic variation with a trait or disease. One could either compare pathways for 
enrichments of GWAS top signals or test if SNPs lying in the genes of a certain pathway are 
associated with the outcome. The burden of multiple testing can be substantially reduced by 
such methods, but several challenges apply. There are for instance various ways how to 
define a pathway (usually via publically available databases), how to allocate SNPs to a 
gene (e.g. by physical location or by eQTL data) and how to deal with different gene lengths 
or SNP densities in the association tests [35,36].  
Finally, since sequencing costs rapidly decreased in recent years, whole exome sequencing 
(WES) and eventually whole genome sequencing (WGS) are expected to rapidly gain 
ground. In a first step, they may lead to better SNP arrays and reference panels for 
imputation, but eventually, they may generally replace genotyping procedures. However, 
compared to association tests with common or low-frequent variants, the methodology for 
association tests with rare variants (MAF < 1%) is far less standardized. Testing all rare 
variants separately would lead to a huge burden of multiple testing, and, unlike for common 
variants, relying on a much smaller set of proxies is not meaningful due to the much lower 
level of correlations. Since rare variants are often population-specific, accounting for 
ancestry will be most crucial to draw valid conclusions from association results. In addition, 
association studies with rare variants have low power even when the sample is large. The 
most common strategy applied is the collapsing of rare variants in the genetic region of 
interest. Such methods have been published, and their performance in simulated data sets 
depends strongly on the number of assumed non-causal variants as well as on the presence 
of effects of different magnitudes and directions in the region of interest. They differ also by 
the possibility of accommodating covariate information or including interactions [37]. The 
allele-specific allocation of rare variants in a certain region of interest would also be a 
desirable property before combining them, but it is not straightforward to derive haplotype 
information from sequence or genotype data. It is important to note that, independent of the 
unsolved methodological challenges, aggregate rare variant analyses always lead to an 
underestimation of the contribution of rare variants to complex traits [38].  
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1.1.8 Where is the Missing Heritability? Non-Additive Components and Gene-
Environment Interactions 
There is considerable debate why GWAS results for most traits and diseases only explain a 
small part of the estimated heritability. One hypothesis propagates the erroneous estimation 
of heritabilities by pedigree-based methods owing to an underestimation of shared 
environment effects [39]. Current narrow-sense heritability estimates may further be inflated 
by the fact that they are based on the assumption that non-additive components (see 1.1.3) 
represent a negligible fraction of the broad-sense heritability. While dominance effects are 
indeed not believed to be of high importance to the missing heritability problem, it was 
recently reported that epistasis could explain a substantial part of current heritability 
estimates [40].  
The presence of a gene-gene interaction is usually assessed by evaluating if the combined 
risk of the two genetic risk factors departs from multiplying the relative risks of the separate 
risk factors. Gene-gene interactions seem biologically highly plausible, but established 
examples in humans have not been reported. Relevant contributions of epistasis to many 
outcomes were observed in yeast [41]. Since yeast is a haploid organism which can be held 
under uniform environment, epistasis as the only non-additive component contributing to 
heritability could be easily estimated. In humans, the computational burden of testing 
epistasis on a genome-wide scale would be enormous due to the sheer number of possible 
interactions. A reduction in the number of tests could be achieved by only focusing on the 
SNPs with the strongest main effects or on those potentially related to known protein-
protein interactions. Two-stage design methods with reduced computational burden and 
only minimal power loss have also been proposed [42]. 
Gene-environment interactions are assessed in an analogous way. They are often not 
considered in heritability studies since they are difficult to estimate. Moreover, erroneously 
ignoring them would rather inflate the environmental component than the heritability 
estimates [5]. There is however some disagreement in the literature if their presence could 
actually reduce the missing heritability problem. In any case, the assessment of such 
interactions is crucial in order to identify those individuals who are most susceptible to 
certain environmental influences. Support for the existence of gene-environment 
interactions comes from animal studies, in which the environment can be modelled and such 
interactions therefore more easily detected [43]. 
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In humans, the presence of such interactions also seems likely. Environmental factors may 
only exert their effects in the presence of certain enzyme variants (e.g. the effects of certain 
toxins may depend on the genetic variation in the detoxifying enzymes). Analogous to the 
history of genetic association studies, the primary approach to assess gene-environment 
interactions were candidate gene-environment interaction studies. Although this term 
describes different concepts, there is always an underlying biological plausible hypothesis 
[44]. The investigation of a genetic variant modifying a known environmental cause of a 
disease represents a first concept. The candidate gene would be selected by lying in the 
pathway in which the environmental effect is believed to work. A reverse perspective is 
taken when we test the role of an environmental factor which potentially acts on the known 
genetic effect causing the outcome. Even if the genetic effect was only assumed to be causal 
(e.g. if the genetic variant was associated with the outcome in a GWAS in the absence of 
any functional knowledge), testing for such an interaction would be a valid candidate gene-
environment interaction approach. A positive result would in that case confer function to the 
functionally unknown genetic variant. A much younger approach based on the GWAS 
concept are genome-wide interaction studies (GWIS), which do not imply a hypothesis [45]. 
Studies with genome-wide as well as environmental data can test each single SNP for 
interaction with an environmental factor in the same way as performed in a GWAS.  
In spite of considerable efforts, very few successfully replicated examples of gene-
environment interactions have been reported in humans [46]. This is mostly attributed to 
methodological challenges. They are present in the exposure assessment (e.g. methods, 
exposure distributions and measurement errors may vary between different studies), in the 
candidate design (e.g. publication bias) and especially in the lack of statistical power. It is 
estimated that a four times larger sample is needed to detect an interaction compared to a 
main effect of similar magnitude [47]. Like in any genome-wide approach, the high burden 
of multiple testing is also a major issue in GWIS. Several multi-step designs for GWIS have 
been proposed to combine cost efficiency and statistical power [45].  
There is a last aspect on a more philosophical side why it is so difficult to observe robust 
gene-environment (or gene-gene) interactions. It is argued that statistical interaction as 
described above is not very adequate to describe biological interaction [48]. Namely, the 
same statistical model is applied to evaluate whether effects of one factor over different 
levels of the other factor go in opposite directions or in the same direction, but at different 
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strength. The model is furthermore supposed to correctly evaluate if a factor depends on the 
presence or absence of another factor like assumed in cellular pathways. It is therefore 
questionable if simply more accurate data and larger sample sizes would lead to compelling 
evidence of gene-environment interactions. More sophisticated modelling techniques for 
interactions could prove useful, but epidemiologic observations might be inherently limited 
to infer mechanisms of biologic interactions [49]. Some authors see non-parametric methods 
like data mining and machine learning, which include prior knowledge, as much more 
promising to detect biological interactions [50].  
 
1.1.9 Where is the Missing Heritability? Additive Components 
Most researchers still see the bulk of the missing heritability in additive components. More 
heritability might be hidden in common variants because GWAS are still underpowered to 
detect such variants if they have very small effect sizes. Hence, many more common 
variants significantly associated with the respective outcome would be expected by simply 
enlarging the sample size [51]. Others see rarer variants not covered by current chip designs 
as the culprit for the missing heritability problem. Larger application of WGS in association 
analyses will soon provide answers on that issue. CNVs are also neglected on genotyping 
arrays, and there is some evidence that they not only play an important role in causing rare 
Mendelian diseases, but also impact common complex diseases [52].  
More challenging is the estimation of the impact of epigenetics. Although epigenetic 
modifications like histone alterations and DNA methylations generally question the concept 
that genetic variation is stable over time and in each cell from the start of conception, they 
may be of minor importance to heritability estimates since they are mostly reset during 
gametogenesis and evolve newly during development. However, some modifications are 
most likely transmissible from one generation to the next. Inheritance models of the 
environment-sensitive epigenetic variation showed that a relevant contribution to the 
missing heritability issue was possible [53]. Several rare genetic disorders are in fact 
influenced by genomic imprinting [54], an epigenetic mechanism leading to the expression 
of only one allele. 
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1.2 Asthma and Chronic Obstructive Pulmonary Disease 
Asthma is a very heterogeneous disease, typically defined by reversible airflow obstruction 
in combination with wheeze, cough and shortness of breath. The inflammation of the airway 
wall is mainly driven by different subsets of T helper cells and by eosinophils. The 
associated airway remodelling process results in hypertrophy and -plasie of bronchial 
smooth muscle tissue, thickening of the airway mucosa as well as stronger mucus 
production and blood supply in the airways [55]. Asthma is often, but not always, 
accompanied by a general tendency to be allergic and can therefore be divided in atopic 
(measured by a positive skin prick test or generally high immunoglobulin E levels) and non-
atopic. Another distinction is early-onset (before puberty) vs. late-onset asthma. Obesity-
related asthma has recently also been described as a specific phenotype [56].  
In chronic obstructive pulmonary disease (COPD), a term which combines chronic 
bronchitis and emphysema, the airflow obstruction is not fully reversible. The underlying 
inflammatory process is predominantly based on neutrophils and cytotoxic T cells and 
results, together with oxidative stress and elevated proteolytic digestion in the lung 
parenchyma, in fibrotic changes and narrowing of the small airways as well as in loss of 
tissue walls between the alveoli [57]. Symptoms include chronic cough, wheezing, phlegm 
and shortness of breath. There is obviously a high overlap between the two diseases, but as 
opposed to asthma, the inflammation in COPD includes the lung parenchyma, is less 
prominent with eosinophils, is more resistant to corticosteroid treatment and usually gets 
worse over time [58]. A clear distinction between the two diseases is not always possible 
though, in particular since the asthma-COPD overlap syndrome, i.e. the coexistence of both 
diseases, is phenotypically heterogeneous and relatively common, especially in the elderly 
[59,60]. 
Both asthma and COPD are typical NCDs with chronic characteristics and complex disease 
aetiologies. Environmental exposures are strong determinants for disease manifestation, but 
susceptibility is assumed to depend on many genes. The genetic contribution is believed to 
be high due to the fact that equal exposures lead to high individual differences in terms of 
disease susceptibility [61]. In fact, heritability estimates for both asthma and COPD lie at 
around 60% [62,63]. 
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1.2.1 Public Health Burden and Diagnosis 
It is estimated that up to 300 million people worldwide suffer from asthma and the annual 
death toll is 0.25 million [64]. Corresponding World Health Organisation estimates for 
COPD are 64 and 3 million. While COPD is ranked in the top ten in terms of DALYs over 
all age-groups, asthma is very prominently ranked during childhood [1]. The relevance of 
both disorders is expected to rise with Western lifestyle and globally still increasing 
smoking rates [65].  
Asthma is usually diagnosed by the enquiry of symptoms and by the assessment of variable 
airway obstruction. This is done by comparisons of pre- and post-bronchodilation 
spirometry and by assessment of responses to bronchial provocation (i.e. by testing airway 
hyperresponsiveness). As this is a very laborious and stressful procedure, common practice 
in epidemiological studies is to use questions about an asthma diagnosis by a physician or 
about prescribed asthma medication. There is evidence that such information represents a 
valid proxy for real asthma [66].  
COPD is a very heterogeneous syndrome and clinical presentation, physiology, imaging by 
computed tomography scanning, decline in lung function or response to therapy differ 
substantially. Although this insufficiently captures the heterogeneity of the disease [67], 
COPD is mostly assessed by measuring the degree of airflow obstruction by spirometry 
after bronchodilation. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 
recommends as diagnostic criteria, in addition to measuring the severity of airflow 
obstruction, the assessment of symptoms, the history of exacerbations and the presence of 
comorbidities [68]. The spirometric definition of COPD is FEV1/FVC < 0.7 (FEV1 stands 
for the air volume exhaled during the first second of forced expiration and FVC for the 
maximally exhaled volume, see 1.3.1). Four grades of severity (from mild to very severe) 
are defined according to the correspondent FEV1 value, which is set in relation to a 
predicted value (%-predicted) depending on the individuals sex, age, height and a regional 
context. It is widely acknowledged that the mentioned cut-off value for the FEV1/FVC ratio 
is a suboptimal solution. Since this ratio naturally declines with age, elderly people are 
overrepresented in COPD cases. This misclassification issue has brought up the proposal of 
using the lower limit of normal of the FEV1/FVC ratio to define the threshold of 
obstruction. It is calculated as the fifth percentile of the normal distribution in healthy never-
smokers for a given population according to sex, age and height. 
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1.2.2 Risk Factors for Asthma 
Asthma prevalence shows dependency on sex with lower rates in girls than boys, but 
consistently higher rates in adult women than men [69]. Sex hormones seem to play a role in 
this sexual dimorphism as postmenopausal women taking hormone replacement therapy 
show higher rates than those not taking them [70]. Black Americans and Hispanics seem to 
have higher rates than White Americans [71]. Western lifestyle in general seems a key 
driver for the observed rise of asthma [72], and obesity is associated with asthma in 
numerous studies [73]. Further risk factors associated with asthma include maternal 
smoking during pregnancy [74], early exposure to tobacco smoke, infections in early life, 
exposure to house-dust mites or pets as well as indoor and outdoor air pollution [72].  
Before the first efforts to carry out GWAS started, some 120 candidate genes had been 
described in the literature to be associated with asthma or related phenotypes, including a 
handful genes determined by genetic linkage studies and subsequent positional cloning [75]. 
The genes represented categories like innate immunity, T helper cell differentiation, lung 
function or airway remodelling. Due to the typical limitations of candidate gene association 
studies (see 1.1.4), reviews were only conducted in a non-systematic style, and firm 
conclusions could not be drawn from these results.   
The first GWAS on (childhood-onset) asthma pointed to ORMDL3 [76], a signal later 
refined to GSDMB, for which interaction with environmental tobacco smoke (ETS) was also 
observed [77]. Candidate genes previously associated with asthma were looked up in the 
results of a GWAS on early-onset asthma, and only four genes (TGFB1, IL1RL1, IL18R1 
and DPP10) remained plausible candidates [78]. Such investigations further discredited the 
design of candidate gene association studies, but did not directly argue against their validity, 
as GWAS ignored environmental factors. Larger GWAS as well as GWAS meta-analyses 
confirmed the GSDMB locus and extended the number of statistically significant findings 
especially by different interleukin receptor-related polymorphisms [79-81]. This may 
highlight the importance of immunoregulation in the pathogenesis of asthma. While the first 
GWAS of asthma in Africans failed to confirm any hitherto known loci [82], results in 
ethnic strata in later GWAS pointed to considerable agreement in genetic effects across the 
ethnicities [81,83]. GWAS on discriminable asthma phenotypes is likely to be a promising 
strategy to refine current signals [84]. Currently, more than 30 GWAS on asthma are listed 
and more than 50 SNPs have been linked to asthma [19].  
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Further efforts to find more loci or to refine the detected signals have been carried out. Fine 
mapping procedures in asthma candidate genes led to the discovery of asthma-associated 
rare variants [85]. Expression analyses of GWAS top hits were sometimes conducted [76], 
and studies prioritizing GWAS findings with eQTL results revealed a few further signals 
and important networks in asthma pathogenesis [86,87]. Evidence for some of the 
interleukin-related genes came also from functional studies [88,89]. Asthma-associated non-
coding SNPs have recently been shown to be enriched in genomic regions, acting as 
promoters or enhancers in immune cells contributing to asthma [90]. Pathway analyses 
resulted in the identification of 21 potentially causal pathways [91]. In terms of interactions, 
mostly genes involved in immune pathways have been tested in combination with smoking, 
air pollution, microbial or workplace exposures [92,93]. Owing to the same reasons as in 
candidate gene association studies, and additionally due to the often very crude exposure 
assessment, it has been difficult to draw firm conclusions from these reviews. A first GWIS 
on asthma and atopy found no statistically significant interaction between a genetic 
polymorphism and farming environment [94]. There was also no strong evidence for genetic 
interactions with smoking or hay fever status in a genome-wide scan [95].  
Taking together, several environmental and genetic factors have been observed to be 
robustly associated with asthma. However, the major part of the heritability remains 
unexplained by current knowledge, and very little is known how the environment and the 
genetics work together.  
 
1.2.3 Risk Factors for COPD 
COPD occurs much more in men than in women, but this is most likely due to the different 
smoking habits. Although COPD can generally be described as a smoking disease [96], up 
to 45% of concerned patients have never smoked [97]. Underestimated for a long time, 
smoke from biomass fuel for heating and cooking (indoor air pollution) is possibly at least 
as important since the number of exposed people is believed to be higher than for smoking. 
Other inhalation exposures such as outdoor air pollution from industry and traffic, 
occupational hazards as well as respiratory infections including tuberculosis are also of 
relevance [97-99]. Systemic inflammation is associated with COPD outcomes, but a large 
Mendelian randomisation study pointed against causality [100].  
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On the molecular level, the state of two equilibrium conditions seems crucial for the COPD 
pathogenesis. The protease-antiprotease hypothesis is mainly driven by the early 
observation that genetic polymorphisms leading to a severe lack of alpha1-antitrypsin 
(AAT) were associated with early-onset emphysema (see 1.4.3). The oxidant-antioxidant 
hypothesis is based on the observation that cigarette smoke contains high concentrations of 
oxidants. The two hypotheses are physiologically linked via inflammatory pathways. Not 
surprisingly, predominantly variants in genes allocated to these pathways have so far been 
selected as candidate genes in COPD association studies. Examples include the genes for 
matrix metalloproteases, heme-oxygenases, glutathion S-transferases, transforming growth 
factor beta and tumour necrosis factor alpha. Replication studies produced often inconsistent 
results, and meta-analyses pointed to very few robust associations [101,102]. Genome-wide 
linkage analysis of lung function measures and airway obstruction in severe COPD was a 
more unbiased way to suggest candidate genes and found evidence for regions on 
chromosomes 2q and 12p [103,104]. These regions could later be narrowed down to the 
genes SERPINE2 and SOX5 in independent candidate gene association studies on COPD 
[105,106].  
A first GWAS on COPD detected CHRNA 3/5, a locus previously associated with smoking 
behaviour [107]. Since this locus was not associated with the amount of smoking in the 
GWAS, its effect might at least be partially independent of smoking behaviour. HHIP, a 
locus simultaneously described by its association with lung function [108], was also 
associated with COPD. A subsequent GWAS confirmed these results and found FAM13A 
(also associated with lung function [109]) as a new signal [110]. It was later shown that 
these three loci affect different subphenotypes of COPD [111]. The importance of a detailed 
phenotypic characterization in COPD studies was further taken into account when a GWAS 
on computed tomography-assessed emphysema was carried out and identified BICD1, a 
gene associated with telomere length (cell aging), as the only genome-wide associated locus 
[112]. More recently, larger GWAS on COPD as well as on lower limit of normal-based 
airflow obstruction found evidence for a locus on chromosome 19q13, previously associated 
with smoking behaviour, and for HTR4, a gene previously related to FEV1/FVC [113,114]. 
In general, many regions associated with lung function, typically identified in much larger 
GWAS (see 1.3.2), show nominally significant association with COPD [114,115].  
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Further steps to determine the causal variants have been reported. Expression of the CHRNA 
3/5 locus in lung tissue [114] and a regulating mechanism for HHIP expression were 
published [116]. SOX5 was shown to be necessary for normal lung development in mice 
[106]. Epigenetic patterns in numerous genes which lie in biologically plausible pathways 
were found associated with COPD, making this a promising biomarker [117]. However, 
reverse causality could also explain these associations, and some may question in general 
the usefulness of the methylome in peripheral blood cells with respect to lung diseases. 
Although COPD represents the classic paradigm of gene-environment interactions (see 
1.4.4), very few interaction studies have been conducted. In one of the largest candidate 
gene association studies, the MMP12 association with COPD was restricted to smokers 
[118]. Some evidence for the presence of interactions of ambient air pollution with genes in 
the oxidative stress system was reported [119]. No study on COPD is currently available in 
the literature that assessed gene-environment interactions on a genome-wide scale.  
Taking together, knowledge on environmental risk factors is better for COPD than for 
asthma, but the genetics are even less understood. There are fewer and smaller GWAS on 
COPD or airway obstruction available, probably owing to the fact that asthma-diagnosis 
often relies on simple self-reports. Nevertheless, the high overlap with the genetics of 
general lung function is a promising feature for a better understanding of the COPD genetics 
in the future. 
 
1.3 Lung Function 
Lung function is the most widely used marker to assess airflow obstruction (see 1.2.1). It is 
furthermore inversely associated with higher cardiovascular risk and general mortality 
[120,121]. Deficits can arise from diminished growth during childhood and adolescence or 
from accelerated decline during adulthood. 
 
1.3.1 Measures 
The spirometric testing procedures must fulfil quality standards [122]. These include for 
instance guidelines for device maintenance and patient instructions. The motivation of 
patients to invest the largest possible effort in the manoeuvres is thereby crucial. Most 
frequently assessed measures are FEV1 and FVC. Its ratio is a measure of airway 
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obstruction as narrowing of the larger bronchi primarily affects FEV1 and to a lesser extent 
FVC. The forced expiratory flow during the middle half of FVC (FEF25-75%) is an alternative 
measure, which correlates generally well with FEV1, but which shows a higher variability. 
The middle half of the FVC volume is thereby divided by the time of duration for its 
expiration. Changes in FEF25-75% in airflow-obstructed patients are often more pronounced 
than those in FEV1, and it was suggested that FEF25-75% can provide additional evidence to 
FEV1/FVC for small airway disease [123].  
 
1.3.2 Risk Factors 
Environmental risk factors for lung function are generally those already listed for COPD. 
Heritability estimates for lung function measures were shown to be somewhat lower than for 
the disease outcomes and varied between 0.25 and 0.45 for the general population as well as 
for individuals with impaired lung function [124,125]. The heritability for longitudinal lung 
function is probably lower [126]. 
Candidate gene association studies looking at cross-sectional or longitudinal lung function 
in the general population have not been as frequently carried out as those in patient cohorts 
or as those using a disease-related outcome definition. A genetic linkage study identified a 
region on chromosome 6q27 as a candidate locus [127], a signal later assigned to SMOC2 
[128]. The first large GWAS on lung function used %-predicted FEV1/FVC as outcome and 
identified HHIP, a locus contributing to lung morphogenesis, as an associated locus [108]. 
Large GWAS meta-analyses by the SpiroMeta [129] and Charge [109] consortia confirmed 
that locus and found several others associated with FEV1 and FEV1/FVC, many of them 
biologically plausible candidate genes in lung remodelling or morphogenesis processes. 
Interestingly, a thorough analysis focusing on previously defined candidate genes for COPD 
and lung function could not identify any region associated with lung function in the results 
of the GWAS meta-analysis by SpiroMeta [130]. By further increasing the sample size to 
almost 50 000 individuals in the discovery set and a similar number in the replication set, 16 
further regions were observed as risk loci, and expression in lung tissue for most of the 
transcripts was reported [131]. Those top-ranking SNPs did not interact with smoking. A 
recent meta-analysis on lung function in a similar study sample jointly considered gene 
main effects and gene-smoking interactions on a genome-wide scale [132]. This resulted in 
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three novel loci of potential importance for lung function, although interaction analyses per 
se did not yield any significant results on the genome-wide level.  
Studies on longitudinal lung function have so far been carried out in much smaller samples 
and no significant results on the genome-wide level have been reported. In one GWAS 
meta-analysis, suggestive loci showed a strong heterogeneity according to asthma status 
[133]. In another study, associations of TMEM26 and FOXA1 with lung function decline 
were identified in individuals with mild COPD, but these findings were not successfully 
replicated in general population cohorts [134].  
We summarize that, despite the higher sample sizes in the GWAS and a much more 
homogeneous phenotype as opposed to asthma or COPD, the heritability for cross-sectional 
lung function explained by the associated SNPs is still very low and has so far not exceeded 
10% [131].  
 
1.4 Alpha1-Antitrypsin 
AAT is a 52-kDa glycoprotein and the most prevalent protease inhibitor in the human blood 
with serum concentrations of about 120 mg/dl. It is mainly synthesized in the liver, and its 
main function is the protection of lung parenchyma from digestion by neutrophil elastase 
(Figure 1). Deficient blood levels were first detected by unusual serum protein 
electrophoresis patterns some 50 years ago [135].  
 
Figure 1. Structure of a complex between AAT (red) and elastase-1 (green). Source: Protein 
Data Bank in Europe (PDBe). 
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1.4.1 Environmental Determinants 
Being an acute-phase protein with anti-inflammatory properties, the concentration of AAT 
can rise up to four-fold of normal and stays elevated for a week in case of an acute 
inflammation. Sex, age, blood pressure, smoking and body mass index (BMI) were all 
associated with AAT, independent of the presence of an inflammatory condition [136]. 
Elevated AAT levels were also measured in individuals with lung function impairment, but 
adjustment for the inflammatory marker C-reactive protein (CRP) cancelled out this 
association [136].  
 
1.4.2 Genetic Determinants 
The heritability of AAT has to our knowledge never been estimated, but may lie in the range 
of other serum proteins (e.g. 0.3  0.4 for CRP and albumin in middle-aged White 
Americans [137] or 0.5  0.6 for a wide range of serum lipid proteins in a population of 
young Finnish adults [25]). The protease inhibitor S and Z variants (PiS and PiZ) are the 
most common AAT deficiency alleles. The alphabetic designation is based on the mobility 
of the protein form in an electric field as used in isoelectric focussing (phenotyping). The M 
variant (PiM) is the variant with normal mobility properties. Phenotyping has long been the 
standard to determine deficiency alleles, and only recently, genotyping by real-time 
fluorescent polymerase chain reaction (PCR) has started to gain ground. The PiS and PiZ 
variants are non-synonymous SNPs in SERPINA1, the gene encoding for AAT. They do not 
influence AAT expression levels, but lead to a reduced secretion of plasma protein in the 
liver due to intracellular erroneous processes at the protein level. While the PiS form results 
in an increased degradation [138], the misfolded PiZ form accumulates and polymerizes in 
the hepatocytes [139], leading to chronic apoptosis and a higher risk for neonatal hepatitis 
[140] and cirrhosis or liver cancer later in life [141]. While individuals homozygous for PiS 
still produce approximately 70% of normal AAT levels, PiZZ carriers only exhibit about 
15% of normal serum levels [142]. Highest prevalence occur on the Iberian Peninsula for 
PiS (up to one homozygote in 500 persons) and in Scandinavia for PiZ (up to one 
homozygote in 1500 persons) [143]. Dozens of rarer deficiency alleles have been described 
in case reports, and a few null alleles (PiQ0), in whom no secretable protein is built, are also 
known [144].  
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1.4.3 AAT Deficiency, COPD and Lung Function 
PiZZ carriers are at higher risk for COPD, in particular shown for early-onset panacinar 
emphysema. This has led to the formulation of the protease-antiprotease imbalance 
hypothesis in the causation of COPD, meaning that reduced levels of AAT cannot 
sufficiently inhibit neutrophil elastase activity in the lung tissue. Support for this hypothesis 
comes from individuals with PiQ0 alleles, who also show elevated risks for COPD. The 
protective threshold, below which the association with COPD has been well-established, 
corresponds to about 40% of normal AAT concentrations (11 µM or 50 mg/dl). Such a 
strongly reduced AAT level, also known as severe AAT deficiency, is rare (mainly caused 
by the PiZZ genotype) and accounts for about 1  2% of all COPD cases. However, studies 
investigating the impact of PiZZ are hampered by ascertainment bias because they usually 
include disproportionally many people with lung disease (and their families). In fact, non-
smoking PiZZ carriers identified by screening do likely not have a much increased mortality 
compared with the general population [145]. This lack of pathological symptoms is one of 
the main reasons why PiZZ is a strongly underrecognised genetic disorder. Determinants of 
airflow obstruction or elevated lung function decline in PiZZ individuals are, in addition to 
cigarette smoking, which is the by far most crucial factor, the patients sex, age and asthma 
status as well as occupational exposure [146,147] and air pollution [148,149]. The 
heritability of lung function in persons with severe AAT deficiency is estimated at about 
15% [150].  
The PiS allele is only believed to be a risk factor for COPD in combination with the PiZ 
allele [151]. Individuals with such a compound heterozygosity (PiSZ) exhibit AAT serum 
levels around or slightly above the protective threshold. The impact of one PiZ allele 
(PiMZ), a condition which preserves about 70% of the normal serum level and is often 
referred to as intermediate deficiency, is controversially discussed. Case-control, cross-
sectional and family-based studies slightly favour an enhanced risk for airflow obstruction 
[152,153]. The question if PiMZ individuals have a higher age-related lung function decline 
has also been addressed. While the answer may be more on the negative side for the general 
population [154,155], studies showed that in rapid decliners and incident COPD cases, the 
PiMZ genotype is disproportionally frequent, suggesting other predisposing factors [156-
158]. Some of the rare deficiency alleles have also been associated with a higher COPD risk 
[144], but they do not play an important role at the population level. 
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Weekly intravenous doses of purified human AAT is the only remedy for individuals with 
severe AAT deficiency to hold levels constantly above the protective threshold. Its 
prescription is controversial though due to the non-proven efficacy and the high costs of 
treatment (well above US$ 10 000 per year). While it is widely used in PiZZ carriers in the 
USA, many European countries do not even offer this therapy. Meta-analysed results from 
available studies tend to give arguments in favour of the augmentation therapy [159], but the 
two proper RCTs were not supportive of a beneficial effect [160,161]. RCTs are, however, a 
suboptimal study design for a very slowly progressing disease like emphysema. There are a 
few ideas why substitution therapy may not be as efficacious as expected [144]. First, 
although the administered dose usually results in blood concentrations above the protective 
threshold, acute or chronic inflammatory conditions may require further up-regulated 
circulating levels. Second, AAT is also produced in alveolar macrophages as well as in 
bronchial and alveolar epithelial cells. Locally produced PiZZ polymers have been found at 
these sites [162], and their chemotactic, pro-inflammatory properties may maintain the 
enhanced level of tissue destruction [163]. It is therefore hypothesized that individuals with 
severe deficiency variants that do not polymerise would benefit most, whereas carriers of 
deficiency variants that build polymers (carriers of PiZZ and a few very rare genotypes) 
may not only have the enhanced risk of liver disease, but may also benefit less from 
augmentation therapy in terms of their pulmonary health.  
 
1.4.4 A Textbook Example for Gene-Environment Interaction? 
PiZZ carriers who smoke develop earlier and more severe COPD than non-smoking subjects 
with PiZZ genotype [164], and their FEV1 decline is higher [165]. The interaction between 
deficiency variants in the SERPINA1 gene and smoking has been considered the classic 
example of gene-environment interaction for several decades. The use of the term gene-
environment interaction in that case was based on the idea that genes and environment work 
together to cause a certain disease. Gene-environment interaction in a statistical sense is a 
different concept (see 1.1.8) and was reported for the PiZ deficiency allele and smoking 
only once (with respect to cross-sectional FEV1) [166]. Support for such a statistical 
interaction comes especially from the biochemical side. While the increased oxidative stress 
level in the lung constitutes the main effect of cigarette smoke, it may also directly affect the 
protease-antiprotease disequilibrium. Cigarette smoke oxidises and thereby inactivates 
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functional AAT [167]. Moreover, oxidation has also been related to AAT polymerization in 
mice [168], which may attract in return more neutrophils and proteolytic enzymes. Figure 2 
summarizes the current understanding of how PiZZ genotype and cigarette smoke jointly 
exert their adverse impact on pulmonary health. 
 
Figure 2. The role of the PiZ-form of AAT in combination with cigarette smoke in the 
development of emphysema. ROS, reactive oxygen species. Source: Alam S, et al. (2011), 
[168]. 
In summary, there is severe lack of functional AAT in the lung because of a reduced 
secretion from the liver, a reduced inhibitory activity of the (non-polymerized) PiZ form and 
the local building of inactive PiZ polymers. This condition is exacerbated by the smoking-
induced oxidation and additional polymerization of the remaining functional AAT, which 
deteriorates the influx of neutrophils, resulting in inflammation, proteolysis and finally 
tissue destruction.  
Some studies looked at risk modification of AAT deficiency by occupational and 
environmental inhalants other than smoking. Unfortunately, a formal test for interaction has 
not been assessed in any study with adults, mostly due to the lack of investigating a control 
group [169].  
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2 Aims 
 
2.1 Genetic Modifiers of the Obesity-Asthma Association 
Obesity is a well-established risk factor for asthma in children and adults (see 1.2.2), but the 
underlying aetiology remains obscure. Obesity is associated with low-grade systemic 
inflammation, which may provide a link to the airway remodelling processes (including the 
altered survival of different airway cell types) observed in asthmatics. We investigated 
therefore if genetic polymorphisms believed to be important for cell division modified the 
obesity-asthma association. This is an example of a candidate gene-environment interaction 
study with the hypothesis that a known environmental cause is modified by a genetic variant 
lying in a pathway in which the environmental effect is believed to work (see 1.1.8). The 
selected SNPs had previously been associated with increased risk for several types of cancer 
[170,171] and had been suggested to modify the effect of air pollution change on 
longitudinal lung function [172].  
Results are presented in chapter 4.1.  
 
2.2 SERPINA1 Deficiency Alleles and Reference Values in the General 
Population 
Severely reduced AAT serum levels are responsible for an estimated 1  2% of COPD cases 
(see 1.4.3). Moreover, some SERPINA1 genotypes leading to a severe deficiency are also 
associated with liver disease. Intermediate AAT deficiency (mainly caused by PiMZ 
genotype) is a risk factor in subgroups, but since this genotype is much more frequent than 
PiZZ, it may account for as many COPD cases as severe AAT deficiency [158]. The 
identification of AAT deficiencies is therefore crucial, and a first step towards this aim is 
the determination of AAT serum concentrations in dedicated laboratories. This diagnostic 
procedure is recommended for all patients with COPD, unexplained liver disease, asthma 
that is incompletely reversible after treatment with bronchodilators as well as for siblings of 
severely AAT deficient individuals [173]. It is thereby important to specify appropriate 
reference values for deficiency genotypes and to determine cut-offs below which further 
testing (in the form of phenotyping, genotyping or sequencing) is meaningful from an 
economical and public health perspective. Previously determined reference values were 
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assessed in patient study samples and hampered by either the application of outdates 
methods (e.g. radial immunodiffusion) or rarely used protein purification procedures and 
concentration units [142]. We aimed at establishing a strong phenotype-genotype correlation 
between AAT blood levels and PiM, PiS and PiZ alleles that also included the consideration 
of inflammatory conditions in a large population-based sample. 
Results are presented in chapter 5.1.  
 
2.3 Genetic Determinants of AAT Serum Level 
The strong influence of PiS and PiZ alleles on AAT serum level dominates our knowledge 
about genetic variants influencing AAT (see 1.4.2). While several other rare deficiency or 
even null-variants in the SERPINA1 gene are also present in the literature [144], common 
variants modulating AAT expression or protein secretion have not been reported so far, 
neither within the SERPINA1 gene nor outside. We therefore performed a GWAS on AAT 
serum level in a population-based sample. Depending on the number and location of the top-
ranking SNPs and their magnitude of association with AAT, replication in independent 
study samples, targeted fine-mapping or functional characterisation was conducted. AAT-
associated SNPs were furthermore tested for association with lung function.  
Results are presented in chapter 5.2. 
 
2.4 SERPINA1 PiMZ Genotype and Elevated Lung Function Decline: 
Which are the Predisposing Factors? 
Heterozygous carriers of the PiZ allele are disproportionally frequent in COPD cohorts or 
among individuals with rapid lung function decline (see 1.4.3). Furthermore, within 
subgroups with clinically established COPD diagnosis, persons with PiMZ genotypes 
showed lower lung function than those with PiMM genotypes [174]. That points to a subset 
of PiMZ carriers which is at elevated risk for losing lung function or getting COPD when 
other predisposing factors are present. Another interesting observation suggesting further 
predisposing factors is the worse lung function in PiMZ parents of PiZZ individuals with 
COPD as opposed to the respective parents of PiZZ carriers without COPD, a difference 
which could not be explained by the amount of smoking in the past [175].  
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2.4.1 Inflammatory Triggers as Predisposing Factors 
PiMZ individuals were reported to have worse pulmonary function when smoking than 
persons without the PiZ allele, whereas no difference was found in non-smokers [176]. 
Moreover, cigarette smoke is believed to act on AAT directly and therefore possibly interact 
with reduced AAT levels (see 1.4.4). Hence, we investigated if the lung function decline 
effect of one PiZ allele is dependent on the exposure to cigarette smoke or to other pro-
inflammatory triggers like obesity. Incidence rates of respiratory health symptoms were also 
considered.  
Results are presented in chapter 5.3. 
 
2.4.2 Air Pollution and Occupational Exposure as Predisposing Factors 
A few underpowered studies suspected interaction between occupational exposure or air 
pollution and AAT deficiency on longitudinal pulmonary health [169,177,178]. We aimed 
at elucidating more rigorously the role of the PiMZ genotype in the associations of lung 
function decline with occupational exposure to vapours, gas, dusts and fumes and with the 
change in ambient air pollution, respectively. This is of high public health interest because 
of the reduced capacity of individuals to avoid these types of exposure. We pursued in this 
project a reverse perspective of a candidate gene-environment interaction than in project 
described under 2.4.1 (see 1.1.8). While a possible environmental modification of the 
unevenly distributed genetic effect of the PiMZ genotype on longitudinal pulmonary health 
was examined in the previous case, we tested here a possible role of the PiMZ genotype on 
established associations between environmental factors and lung function decline. This 
latter approach is more useful with respect to targeting modifiable factors for prevention. 
Results are presented in chapter 5.4. 
 
2.5 Further Candidate SNPs Influencing the Beneficial Effects of Air 
Pollution Decline 
Ambient air pollution is thought to be a risk factor for COPD (see 1.2.3). In particular, 
improved air quality with respect to particulate matter < 10 µm (PM10) was shown to result 
in attenuated lung function decline [179]. Profit from air pollution decline in the general 
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population is likely dependent on genetic factors. The candidate genes tested for interaction 
with air pollution on pulmonary health have so far been selected by biological knowledge, 
i.e. by lying in promising pathways [119,172]. In this study, we selected SNPs robustly 
associated with lung function, but for which the determining mechanisms had not been 
elucidated [131] (see 1.3.2). By testing if these SNPs modify the association between 
improved air quality and reduced loss in lung function, we not only aimed to gain 
knowledge about genetic factors determining the differing profits from air pollution decline 
in the general population, but also to get insight into the functionally unexplained 
associations of these variants with lung function.  
Results are presented in chapter 6.1. 
 
41 
 
 
 
3 Methods 
 
All the different projects were carried out using the Swiss Study on Air Pollution and Lung 
Disease in Adults (SAPALDIA). A very brief overview about the study design and the data 
is given here; more detailed and project-specific methods can be found within the papers 
(chapters 4-6).  
 
3.1 Description of SAPALDIA 
3.1.1 Study Design 
SAPALDIA is a cohort study which was initiated in 1991 in order to study the health effects 
of long-term air pollution in the general population [180]. A random sample of Swiss adults 
was selected from eight communities with different grades of urbanization. The first follow-
up examination (SAPALDIA 2) took place from 2001 to 2003 [181] and the third survey 
was completed in 2011. SAPALDIA boasts of a very motivated study sample as more than 
60% of the originally 9651 participants were still part of the third survey 20 years later 
(4934 participated at the respective study centre, and an additional 1205 participated at 
home over the telephone or by filling in questionnaires).The main health-related focus over 
the past 20 years was set on understanding the development and progression of respiratory 
diseases and CVDs.  
 
3.1.2 Data 
The different types of data contributing to the SAPALDIA research potential are depicted in 
Figure 3. Due to the still on-going collection and cleaning process of SAPALDIA 3 data at 
the time of carrying out this PhD work, all the projects of the current thesis did not involve 
any data from the third survey. 
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Figure 3. The SAPALDIA research potential. The most relevant data for this PhD work are 
depicted in the red rectangle. 
Computer-assisted interviews were performed at the first two examinations comprising 
questions about the presence of asthma and respiratory symptoms, detailed personal 
smoking history, exposure to ETS at home or at the workplace, occupational exposure to 
vapours, gas, dusts and fumes, anthropometric factors and other data less relevant for this 
PhD work. Asthma-related questions included a self-report of having ever suffered from 
asthma and statements about a diagnosis by a physician and the recent use of medication. 
Lung function testing was performed with identical spirometers at both examinations [182]. 
Resource constraints only allowed spirometry without the application of bronchodilation. 
Expiratory flows were taken from the flow-volume curve with the highest sum of FVC and 
FEV1. Blood markers (e.g. AAT and CRP) and genetic data were only measured in follow-
up surveys. Longitudinal blood-derived data could hence not be used in the projects of this 
thesis. The genotyping of SNPs in candidate genes was performed by fluorescent 5 
nuclease real-time PCR in dedicated laboratories in Zürich, Pavia and Innsbruck. Roughly 
6000 persons agreed to genetic testing. In the framework of the GABRIEL study, about a 
quarter of them (i.e. all self-reported asthmatics as well as a random sample of non-
asthmatics) were genome-wide assessed on the Illumina Human610-Quad platform [79]. 
43 
 
 
 
More than half a million genotyped SNPs passed the quality control measures, and another 2 
million autosomal SNPs could be inferred by HapMap-based imputation. 1000 genomes-
based imputation was only partly available at the time of carrying out the analyses. PM10 
exposure, a health-relevant air pollution measure consisting of particles which deposit in the 
airways and the lung, was predicted based on a Gaussian dispersion model for the years 
1990 and 2000 with a 200 m grid resolution throughout Switzerland [183]. Individual 
exposures were derived by mapping the geo-referenced residential address of each study 
participant to the corresponding model grid cell. Annual exposure values for other years 
were derived by inter- and extrapolating the estimates from 1990 and 2000 based on trends 
from fixed monitoring stations.  
Taking together, SAPALDIA is a well-representative sample of the adult Swiss population 
and comprises little population heterogeneity due to language and duration of residence 
requirements in the sampling process. Some general methodological restrictions important 
for all the projects shall be mentioned here. Asthma status was not physiologically defined 
and was therefore subject to misclassification. COPD prevalence and incidence in a sample 
of middle-aged adults from the general population is moderate, which results in little 
statistical power when considering these outcomes. Moreover, the non-availability of post-
bronchodilator spirometry did not allow us to properly define COPD. In fact, more than 
20% of (GOLD-defined) obstructed SAPALDIA baseline participants lost obstruction 
during follow-up, which points to measurement error or misclassification [184]. The use of 
longitudinal lung function was therefore superior in terms of statistical power and validity. 
The possibly distorting influence of asthmatics was generally taken into account in 
sensitivity analyses. Follow-up participants were on average healthier at baseline than those 
lost to follow-up. Inverse probability weighting was therefore regularly applied in 
sensitivity analyses to take a possible participation bias into consideration. A large number 
of potential confounders were included in the regression analyses of all the projects, but on 
two factors with conceivable relevance to pulmonary health (namely physical activity and 
dietary habits), we had not collected longitudinal data.  
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4 Results: Cell Cycle Genes in the Obesity-Asthma Association 
 
4.1 Paper 1: The Association of a Variant in the Cell Cycle Control Gene 
CCND1 and Obesity on the Development of Asthma in the Swiss 
SAPALDIA Study. 
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GENETICS
The Association of a Variant in the Cell Cycle Control Gene CCND1 and
Obesity on the Development of Asthma in the Swiss SAPALDIA Study
GIAN ANDRI THUN, M.S.,1,2 MEDEA IMBODEN, PH.D.,1,2 WOLFGANG BERGER, PH.D.,3
THIERRY ROCHAT, M.D.,4 AND NICOLE M. PROBST-HENSCH, PH.D.,1,2,*
1Swiss Tropical and Public Health Institute, Basel, Switzerland.
2University of Basel, Basel, Switzerland.
3Institute of Medical Molecular Genetics, University of Zurich, Zurich, Switzerland.
4
Division of Pulmonary Medicine, University Hospital of Geneva, Geneva, Switzerland.
Objective. The molecular mechanisms underlying the association between obesity (BMI  30 kg/m2) and asthma are poorly understood. Since
shifts in the fate of bronchial cells due to low-grade systemic inflammation may provide a possible explanation, we investigated whether two of the
best documented functional variants in cell cycle control genes modify the obesity–asthma association.Methods.We genotyped 5930 SAPALDIA
cohort participants for the single-nucleotide polymorphisms (SNPs) rs9344 in the cyclin D1 gene (CCND1) and rs1042522 in the gene encoding
tumor protein 53 (TP53). We assessed the independent association of these SNPs and obesity with asthma prevalence and incidence. Results. The
CCND1 SNP modified the association between obesity and asthma prevalence (pinteraction ¼ 0.03). The odds ratios (ORs) and 95% confidence
intervals (CIs) for reporting a physician diagnosis of asthma at baseline, comparing obese with non-obese participants, were 1.09 (0.51–2.33), 1.64
(0.94–2.88), and 3.51 (1.63–7.53) for GG, GA, and AA genotypes, respectively. We found comparable genotype differences for incident asthma
within the 11 years of follow-up. As for the TP53 SNP, the interactions with obesity status with respect to asthma were not statistically significant.
Conclusions. Our results suggest that obesity may contribute to asthma and associated tissue remodeling by modifying the processes related to the
CCND1 gene activity.
Keywords candidate gene association study, cell proliferation genes, gene–lifestyle interaction, overweight, population-based cohort, single-
nucleotide polymorphism
INTRODUCTION
In many parts of the world, obesity prevalence is still
on the rise and represents a major public health concern.
Obesity increases the risk for later asthma (1), but the
underlying etiologic mechanisms for this epidemiologic
association remain poorly understood. Explanations
based solely on mechanistic effects of excessive
body weight seem insufficient, as other aspects of the
metabolic syndrome are also associated with impaired
lung function (2). Obesity-related inflammatory markers
or adipose derived hormones may influence bronchial
hyperresponsiveness (BHR) as well as airway inflamma-
tion and associated tissue remodeling, as demonstrated in
mouse models (3,4). But in human asthma studies, the data
in favor of an effect of these circulating molecules on
asthma risk remain inconclusive (5,6).
Investigating if gene variants of relevance to inflammatory
pathways modify the obesity–asthma association may
improve understanding of underlying etiologic mechanisms
involved. Currently, there are very few studies available in
adults which examine gene–obesity interactions with respect
to asthma (7). Candidate genes not yet looked at include those
essential to cell cycle control, as airway inflammation and
remodeling in asthmatics are associated with altered apopto-
sis and proliferation of different bronchial cells types such as
airway smoothmuscle (ASM) and epithelial cells, fibroblasts,
as well as cells of the immune system (8–11).
We therefore selected a functionally well-described
polymorphism in each of two genes crucial for cell divi-
sion in order to assess gene–obesity interactions in asthma
in a highly focused manner. The cyclin D1 gene (CCND1)
promotes cell proliferation through cell cycle G1–S phase
transition, while the tumor protein 53 gene (TP53) is a
tumor suppressor gene with a pivotal role in apoptosis. The
expression of both genes is commonly altered in numerous
cancer types. The single-nucleotide polymorphisms
(SNPs) rs9344 [P242P] in CCND1 and rs1042522
[R72P] in TP53 are functionally very well characterized
and have been associated with various cancer types,
including in large meta-analyses (12–14). We previously
demonstrated furthermore that these two polymorphisms
modified the effect of particulate matter (PM10) air pollu-
tion on lung function decline in the SAPALDIA cohort
(15). In this same cohort representing the general popula-
tion from eight Swiss communities, we now investigated
whether these two SNPs also affect asthma risk and its
relation to obesity. We argue that modification of the
asthma–obesity association by variants in cell cycle con-
trol genes adds to the evidence for a causal obesity effect,
mediated in part by inflammatory pathways.
*Corresponding author: Nicole Probst-Hensch, Ph.D., Head Unit Chronic
Disease Epidemiology, Swiss Tropical and Public Health Institute,
Socinstrasse 57, PO Box 4002 Basel, Switzerland; Tel: þ41 61 284 83 78
(direct);þ41 61 284 83 88 (admin); Fax:þ41 61 284 81 05; E-mail: Nicole.
Probst@unibas.ch
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METHODS
Study Population
Themethods of the SAPALDIA study have been described
in detail elsewhere (16,17). In short, the study population
consists of a random population sample of white adults
aged 18–60 years from eight areas of Switzerland. Totally,
9651 persons participated in the first assessment in 1991,
and at the follow-up examination in 2002, 8047 were
reassessed with a least a short screening questionnaire.
Blood donation and consent to genetic analyses at follow-
up was given by 6058 participants of whom 6040 led to
successful genotype determination. We could furthermore
not include 110 subjects who either had missing informa-
tion on asthma, smoking status or body mass index (BMI),
or reported an asthma diagnosis which had not been con-
firmed by a physician. Taken together, 3721 individuals of
the original study sample could not be considered for the
present analysis (hereinafter called non-participants). The
analyzed study sample consists hence of a total of 5930
participants. Written consent was obtained from all study
participants separately for each assessment procedure.
Approval of the study was given by the Swiss Academy
of Medical Sciences and the regional ethics committees.
Definition of Smoking Status, Asthma Status, and Obesity
At both surveys, participants underwent a detailed,
computer-assisted interview comprising questions
about smoking behavior, exposure to environmental
tobacco smoke, workplace exposure to dust and fumes,
co-morbidities including asthma, medication use, and
socio-economic factors. Never smokers were defined
as persons who at the time of the interview had smoked
less than 20 packs of cigarettes or 360 g of tobacco
during their lifetime. Former smokers reported quitting
at least one month before the interview. Asthmatics were
defined in two ways. First, physician-diagnosed asthma
was defined by affirmative answers to “Have you ever
had asthma?” and “Was this confirmed by a doctor?”
Second, current asthmatics, presenting a subset of those
who were diagnosed by a physician, were classified by
an affirmative answer to at least one of the following two
questions: “Have you had an attack of asthma in the last
12 months?” and “Are you currently taking any medi-
cines including inhalers, aerosols or tablets for asthma?”
Incident asthma was defined as a new report of
asthma among subjects without asthma at baseline.
BMI was divided into four categories: low BMI (BMI
< 20 kg/m2), normal weight (20 kg/m2  BMI <
25 kg/m2), overweight (25 kg/m2  BMI < 30 kg/m2),
and obese (BMI  30 kg/m2).
Genotyping
DNA extraction from EDTA-buffered whole blood has
been previously described (17). Originally, in each of
three candidate genes pivotal for cell cycle control
(CCND1, TP53, and CDKN1A, the gene encoding cyclin-
dependent kinase inhibitor 1A, also called p21), one pro-
mising candidate SNP was selected according to its
frequency and its reported functionality in cell division
and apoptosis (rs9344 in CCND1, rs1042522 in TP53,
and rs1801270 in CDKN1A). Genotyping was carried out
using fluorescent 5-nuclease real-time PCR methodology
(TaqMan, Applera Europe, Rotkreuz, Switzerland) and
ABI Prism 7900 sequence detection system (ABI,
Rotkreuz, Switzerland). The SNP-specific primers and
LNA® dual-labeled fluorogenic probes were designed by
Sigma Proligo (Evry, France). A 10% random sample of
all DNA samples was re-genotyped, and all genotypes
were confirmed. The genotype call rate was >99% for all
the three SNPs. Hardy–Weinberg equilibrium was pre-
served apart from rs1801270 (p ¼ 0.04). Since this latter
SNP also showed a low minor allele frequency
(MAF ¼ 7%), statistical power to investigate effects on
asthma and obesity was insufficient, and we excluded this
SNP from the analyses of this study.
Statistical Analysis
Main effects of alleles and BMI on physician-diagnosed
and current asthma at baseline were assessed using multi-
variate unconditional logistic regression. CCND1 and
TP53 genotypes were generally included in a co-dominant
fashion using the homozygous genotype of the more fre-
quent allele as the reference category. Due to the limited
number of TP53 CC carriers, this category was combined
with the group of heterozygous GC carriers for the ana-
lyses of incident asthma, assuming a dominant genetic
model. All regression models included study area, sex,
age at baseline, and smoking status (never vs. former vs.
current) at baseline as covariates. These factors were cho-
sen a priori as they may confound the obesity–asthma
association. Models investigating the longitudinal effects
of genotypes and change in BMI on incident asthma were
additionally adjusted for smoking status at follow-up.
Interaction between obesity and genotypes was tested by
integrating multiplicative terms in the regression models.
Significance levels for two-sided tests of main effects were
chosen at α ¼ 0.05, and at α ¼ 0.10 for tests of
effect modification. All statistical analyses were performed
using STATA version 10.1 (StataCorp, College Station,
TX, USA).
RESULTS
A detailed characterization of the study population can be
found in Table 1. Study participants were about half a year
older on average and had a slightly lower BMI than non-
participants. Totally, 6.2% declared to have ever received
an asthma diagnosis by a physician, whereas 2.6% suffered
from current asthma. These percentages were higher in
non-participants. Never smokers were more likely to be
included in this study, confirming that a sample with
higher health awareness was attracted to the follow-up
examination.
The cross-sectional associations of the genetic poly-
morphisms in CCND1 and TP53 with the prevalence of
asthma at baseline are presented in Table 2. The prevalence
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of physician-diagnosed asthma was lower among CCND1
rs9344 AA genotypes compared to homozygous GG indi-
viduals (p¼ 0.05), but this difference could not be detected
for current asthma. The polymorphism in TP53 was not
associated with either asthma phenotype.
By dividing the individuals into four BMI categories,
we confirmed the well-established association between
asthma and obesity (Table 3). Compared to those with
BMI between 20 and 25, obese individuals had a 1.81
times higher odds of having an asthma diagnosis by a
physician (p ¼ 0.003) and a 2.69 times higher odds of
suffering from current asthma (p < .001). Interestingly, the
cross-sectional association between asthma and obesity
depended on the genotype of the CCND1 SNP. The asso-
ciation of obesity with the risk of asthma was restricted to
the AA genotype as graphically displayed in Figure 1 for
physician-diagnosed asthma. Since low BMI and over-
weight did not essentially alter the odds of being an asth-
matic of normal weight people, we classified all non-obese
subjects (BMI < 30 kg/m2) into one category and com-
pared them with obese subjects. Overall, obese subjects
were 1.78 times (95% confidence interval (CI) 1.22–2.61)
more likely to report an asthma diagnosis confirmed by a
physician. For AA carriers of rs9344 in CCND1, this odds
ratio (OR) increased to 3.51 (95% CI 1.63–7.53). The
equivalent ORs for current asthma were even more pro-
nounced (overall OR 2.65, 95% CI 1.60–4.40; and for AA
carriers OR 7.17, 95% CI 2.89–17.83). Interaction terms
between CCND1 genotype and obesity were significant
for both asthma definitions (p ¼ 0.03 for physician-
diagnosed asthma and p ¼ 0.1 for current asthma). As
for rs1042522 in TP53, obesity tended to be more strongly
associated with the risk of asthma in homozygotes for the
G allele than in heterozygotes, but these differences were
based on very small sample sizes. When including BMI as
a continuous variable, we observed similar patterns of
associations.
Table 4 presents the longitudinal association of asthma
incidence with the change in obesity status during follow-
up. Obesity development was categorized into three dis-
tinct groups: participants who were never obese, partici-
pants who reached obesity at follow-up, and participants
who were obese at both times of data collection. The latter
group had the highest risk for developing asthma between
baseline and follow-up (OR 2.05 for physician-diagnosed
asthma and OR 2.58 for current asthma, compared to those
who were never obese). Stratification by CCND1 geno-
types modified this risk. We observed the highest risk
amongAA carriers (p< 0.001 for both asthma definitions).
Despite the wide confidence intervals, the p-values for
interaction between CCND1 genotype and obesity devel-
opment in relation to asthma incidence were marginally
statistically significant (p ¼ 0.09 for physician-diagnosed
asthma and p ¼ 0.03 for current asthma). The TP53 SNP
did not modify the association between obesity develop-
ment and asthma incidence.
Additional adjustment for atopy (positive skin prick
test), smoking intensity, early childhood infection,
family history of asthma, and exposure to gas, dust,
or fumes did not substantially alter the results (data
not shown).
TABLE 2.—Associations of genetic polymorphisms with asthma prevalence
at baseline.
Genotype N Prevalence (%) OR (95% CI) p-Value
Physician-diagnosed asthma
CCND1, rs9344
GG 1648 7.1 1
GA 2942 6.1 0.85 (0.66–1.08) 0.17
AA 1340 5.3 0.73 (0.54–0.99) 0.05
TP53, rs1042522
GG 3257 6.0 1
GC 2291 6.5 1.10 (0.88–1.36) 0.42
CC 382 5.5 0.89 (0.56–1.42) 0.62
Current asthma
CCND1, rs9344
GG 1648 2.5 1
GA 2942 2.6 1.05 (0.71–1.53) 0.82
AA 1340 2.8 1.09 (0.69–1.70) 0.72
TP53, rs1042522
GG 3257 2.5 1
GC 2291 3.0 1.21 (0.87–1.68) 0.26
CC 382 2.1 0.82 (0.39–1.70) 0.59
Notes: ORs were based on regression models adjusted for age, sex, study area, and
smoking status. OR, odds ratio; CI, confidence interval.
TABLE 1.—Baseline characteristics of participants and non-participants in this study.
Participants, N ¼ 5930 Non-participants
Mean SD % Mean SD % N (with info) p-Value
Female 50.2 51.8 3721 0.16
Age (years) 41.2 11.4 40.7 12.0 3721 0.06
BMI (kg/m2) 23.8 3.6 24.2 4.2 3622 <0.01
BMI  30 kg/m2 5.8 9.0 3622 <0.01
Physician-diagnosed asthma 6.2 7.8 3624 <0.01
Current asthma 2.6 3.4 3616 0.02
Smoking-status: never 47.3 38.5 3706
Smoking-status: former 23.1 21.7 3706 <0.01
Smoking-status: current 29.6 39.8 3706
Notes: Participants include all SAPALDIA follow-up subjects with valid information on sex, age, recruiting area, BMI, smoking status, and who could be successfully genotyped.
Answers to questions about self- and physician-diagnosed asthma, as well as recent asthma attacks and asthmamedication had to be complete and unambiguous. All SAPALDIA subjects
from the original study sample (N¼ 9651) who could not be considered in the present analysis were combined and referred to as non-participants. Equal proportions were tested by chi-
square test, equal distributions in age and BMI by Mann–Whitney test. SD, standard deviation; BMI, body mass index.
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DISCUSSION
We show for the first time that the cross-sectional and
longitudinal association of obesity and asthma is modified
by a SNP in a gene which exhibits a central role in cell
cycle control. The associations appear to be stronger
among subjects homozygous for the CCND1 A allele in
rs9344, the same genotype which in numerous studies
including a large meta-analysis predisposed to various
cancer subtypes across different ethnic populations (13).
According to our study, these participants’ lung tissue may
be more prone to remodeling in response to obesity-related
processes.
Asthma in Obese People
Our results confirm the well-established association of
obesity with asthma risk. Current knowledge include that
the obesity–asthma association decreases with progressive
age (18) and may in part be mediated by low-grade sys-
temic inflammation (19). Twin studies suggest that shared
genetic pathways for asthma and obesity may partly
explain the observed associations (20). Candidate gene
studies and, more recently, genome-wide association stu-
dies have identified a large number of genes associated
with either of the two conditions, but these genes do not
seem to have a substantial impact on both phenotypes
simultaneously (21). Candidate genes which seemed to
be important for the asthma risk in obese people or for
the higher BMI in asthmatics encompass LEP, TNFA, and
PRKCA, regions encoding the adipose tissue derived
TABLE 3.—Cross-sectional association of BMI with asthma risk at baseline, overall and stratified by CCND1 and TP53 genotypes.
Physician-diagnosed asthma Current asthma
BMI Yes/no OR 95% CI p-Value Yes/no OR 95% CI p-Value
All <20 40/712 0.85 0.59–1.22 0.38 16/736 0.80 0.45 to 1.39 0.42
20–25 195/3053 1 ref 81/3167 1 ref
25–30 98/1490 1.09 0.84–1.41 0.53 40/1548 1.11 0.75 to 1.66 0.60
30 33/309 1.81 1.22–2.68 0.003 19/323 2.69 1.59 to 4.56 <0.001
<30 333/5255 1 ref 137/5451 1 ref
30 33/309 1.78 1.22–2.61 0.003 19/323 2.65 1.60 to 4.40 <0.001
Continuous 366/5564 1.05 1.02–1.08 0.003 156/5774 1.08 1.04 to 1.12 <0.001
CCND1, rs9344 GG <30 109/1433 1 ref 39/1503 1 ref
30 8/98 1.09 0.51–2.33 0.83 3/103 1.20 0.35 to 4.09 0.77
Continuous 117/1531 0.98 0.93–1.04 0.55 42/1606 0.99 0.90 to 1.09 0.83
GA <30 163/2607 1 ref 69/2701 1 ref
30 15/157 1.64 0.94–2.88 0.08 8/164 2.07 0.97 to 4.44 0.06
Continuous 178/2764 1.06 1.02–1.10 0.005 77/2865 1.08 1.02 to 1.14 0.006
AA <30 61/1215 1 ref 29/1247 1 ref
30 10/54 3.51 1.63–7.53 0.001 8/56 7.17 2.89 to 17.83 <0.001
Continuous 71/1269 1.11 1.04–1.19 0.003 37/1303 1.17 1.07 to 1.28 <0.001
TP53, rs1042522 GG <30 172/2887 1 ref 68/2991 1 ref
30 23/175 2.41 1.50–3.87 <0.001 12/186 3.27 1.69 to 6.30 <0.001
Continuous 195/3062 1.06 1.02–1.11 0.002 80/3177 1.08 1.02 to 1.14 0.01
GC <30 142/2027 1 ref 63/2106 1 ref
30 8/114 1.04 0.49–2.19 0.92 5/117 1.59 0.62 to 4.11 0.34
Continuous 150/2141 1.01 0.96–1.06 0.68 68/2223 1.06 0.99 to 1.13 0.08
CC <30 19/341 1 ref 6/354 1 ref
30 2/20 2.45 0.46–13.03 0.29 2/20 8.29 1.05 to 65.36 0.05
Continuous 21/361 1.16 1.01–1.32 0.03 8/374 1.34 1.06 to 1.69 0.02
Notes: Regression models were adjusted for age, sex, study area and smoking status. p-Values for interaction between CCND1 genotype and obesity were 0.03 (physician-diagnosed
asthma) and 0.01 (current asthma). p-Values for interaction betweenCCND1 genotype and continuous BMI were 0.02 (physician-diagnosed asthma) and 0.03 (current asthma). p-Values
for interaction between TP53 genotype and obesity were 0.14 (physician-diagnosed asthma) and 0.64 (current asthma). p-Values for interaction between TP53 genotype and continuous
BMI were 0.86 (physician-diagnosed asthma) and 0.50 (current asthma). BMI, body mass index; OR, odds ratio; CI, confidence interval.
FIGURE 1.—Odds ratios (bars) and 95% confidence intervals (lines) for the
cross-sectional association of body mass index (BMI) category and
physician-diagnosed asthma stratified by CCND1 genotype. BMI categories
represent from darker to lighter color: <20 kg/m2, 20–25 kg/m2, 25–30
kg/m2, and 30 kg/m2. The reference group corresponded to individuals
with normal weight (BMI 20–25 kg/m2).
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molecules leptin and tumor necrosis factor alpha (TNFα)
as well as the ubiquitously expressed protein kinase C
alpha, a factor associated with adipocyte differentiation
and insulin signaling (7,22,23). Cell cycle control genes
have so far not been investigated in this respect, but their
importance in inflammatory processes confer them etiolo-
gic plausibility to potentially modify the obesity–asthma
relationship. Interestingly, an in vitro study with asthma
serum-sensitized human ASM cells recently found protein
kinase C alpha to upregulate cyclin D1 expression (24).
Asthma: High Inflammatory Stress and Altered Cell Cycle
Control
In the present study, the CCND1 polymorphism rs9344
was associated with physician-diagnosed asthma at bor-
derline significance level, but not with current asthma.
This effect seems hence to originate from a history of
asthma or a form of asthma which does not manifest itself
in attacks on a regular basis. The inflammatory processes
in the bronchial tissue of untreated asthma lead to struc-
tural changes in the airways. Gene array techniques com-
paring gene expression profiles of various cell types in
bronchial tissue as well as in peripheral blood between
asthmatics and healthy controls exhibit significant differ-
ences in numerous genes (25). For instance, atopic asthma
has been associated with both reduced apoptosis of airway
inflammatory cells as well as reduced net TP53 activity
and thus reduced apoptosis of peripheral blood mononuc-
lear cells (8,26). ASM mass and cell proliferation is
increased in asthma (9), and this feature seems to involve
CCND1 the expression of which was elevated in asthma
serum-sensitized human ASM cells (24). A significant
suppression of bronchial epithelial cell proliferation asso-
ciated with increased CDKN1A expression was observed
in the asthmatic bronchial epithelium in humans (27).
Inherited differences in the cell cycle response to inflam-
matory and other oxidative stressors could hence in part
underlie asthma etiology. In agreement, asthma risk factors
with oxidative properties like tobacco smoke or air pollu-
tants were shown to alter cell proliferation in the airways
(28) and to alter lung function in a manner dependent on
cell cycle gene variants (15).
Obesity and Molecular Pathways of Potential Relevance
to Asthma
Obesity shares with some of the inhaled asthma triggers
the capacity to induce a status of low-grade systemic
inflammation. Diseases associated with over-nutrition are
characterized by alterations in circulating levels of inflam-
matory cytokines and adipose derived hormones (29). This
so-called metabolic inflammation interferes with the reg-
ulation of intracellular molecular pathways that include
cell cycle control mechanisms and could therefore also
play a role in asthma etiology.
The PI3K/Akt signal pathway is activated by many of
the factors which are altered in obesity and lead to
increased cell survival (30). This pathway is also crucial
in asthma pathophysiology. Namely, it has recently been
TABLE 4.—Longitudinal association of change in obesity status during follow-up with asthma incidence, overall and stratified by CCND1 and TP53 genotypes.
Incidence of physician-diagnosed asthma
(N ¼ 174 cases) Incidence of current asthma (N ¼ 115 cases)
BMI (baseline/follow up) Yes/no OR 95% CI p-Value Yes/no OR 95% CI p-Value
All <30/<30 145/4481 1 ref 89/4735 1 ref
<30/30 15/551 0.91 0.53–1.57 0.73 15/588 1.47 0.84–2.57 0.18
30/30 14/266 2.05 1.15–3.66 0.02 11/282 2.58 1.34–4.96 0.005
CCND1, rs9344
GG <30/<30 42/1231 1 ref 29/1309 1 ref
<30/30 2/140 0.46 0.11–1.94 0.29 1/158 0.30 0.04–2.28 0.24
30/30 4/85 1.90 0.63–5.74 0.25 3/90 1.73 0.50–6.05 0.41
GA <30/<30 80/2212 1 ref 45/2344 1 ref
<30/30 11/272 1.25 0.65–2.40 0.51 10/287 2.01 0.99–4.09 0.05
30/30 5/138 1.18 0.46–3.00 0.73 4/146 1.72 0.60–4.94 0.32
AA <30/<30 23/1038 1 ref 15/1082 1 ref
<30/30 2/139 0.68 0.16–3.01 0.61 4/143 2.24 0.71–7.11 0.17
30/30 5/43 8.86 2.82–27.81 <0.001 4/46 11.85 3.32–42.24 <0.001
TP53, rs1042522
GG <30/<30 85/2443 1 ref 53/2576 1 ref
<30/30 10/318 0.94 0.48–1.85 0.73 9/341 1.27 0.62–2.63 0.62
30/30 9/153 2.10 1.01–4.37 0.02 8/164 2.85 1.29–6.26 0.004
GC/CC <30/<30 60/2038 1 ref 36/2159 1 ref
<30/30 5/233 0.81 0.32–2.07 0.66 6/247 1.68 0.69–4.12 0.25
30/30 5/113 1.90 0.73–4.92 0.19 3/118 1.96 0.58–6.64 0.28
Notes: Included are participants without asthma at baseline (N¼ 5472 for physician-diagnosed asthma and N¼ 5720 for current asthma). Regression models were adjusted for age, sex,
study area, and smoking status at baseline and follow-up. GC and CC genotypes of rs1042522 were taken together since the number of these genotypes was very low. p-Values for
interaction between CCND1 genotype and obesity development were 0.09 (incidence of physician-diagnosed asthma) and 0.03 (incidence of current asthma). p-Values for interaction
between TP53 genotype and obesity development were 0.79 (incidence of physician-diagnosed asthma) and 0.68 (incidence of current asthma). BMI, body mass index; OR, odds ratio;
CI, confidence interval.
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shown that osteopontin, an extracellular matrix protein
upregulated in the lungs of asthmatics, activates the
PI3K/Akt pathway, and is associated with airway remodel-
ing and disease severity in human asthma (31,32).
The transcription factor nuclear factor kappa B
(NF-κB), one of the downstream targets of PI3K/Akt,
interacts with several adipose-derived molecules. For
instance, leptin stimulates and adiponectin reduces NF-
κB signaling in endothelial cells (33,34), while the cyto-
kine TNFα has been shown to interact with NF-κB signal-
ing in ASM cells (35). We previously reported a complex
joint effect of obesity with a TNFA polymorphism on
asthma in two large cohort studies including SAPALDIA
(7). NF-κB also exhibits a central role in the proliferating
airway epithelium of asthmatics (36). Its interplay with
different cell cycle control genes including TP53 and
CCND1 is diverse (37,38). Compatible with this picture,
leptin and adiponectin have also been found to be able to
modulate expression levels of cyclin D1 or p53 in different
types of cancer cells (39,40).
Both adiponectin and leptin are stimuli of the AMP-
activated protein kinase (AMPK) (41). AMPK serves as an
energy sensor and suppresses cell proliferation in non-
malignant and tumor cells by interacting with the cell
cycle machinery (42). As cell growth and proliferation
are energy-intensive processes, AMPK may act as an
energy checkpoint, permitting progression through the
cell cycle only in the presence of sufficient energy
reserves. Interestingly, metformin, an AMPK activator
used in the treatment of obesity-related diabetes, was
found to inhibit ASM cell proliferation (43).
Since obesity is also an established risk factor for colon
cancer and many of the described pathways and mechan-
isms are also discussed in the etiology of that disease (30),
results from colon cancer epidemiology are relevant to the
interpretation of our findings, as they support the notion
that cell cycle genes interact with inflammatory and other
oxidative stressors including obesity.We reported an inter-
acting effect on the risk of colorectal cancer for theCCND1
SNP studied in this work with dietary antioxidants and
proteins exhibiting antioxidative properties (44). Taken
together, these findings corroborate the view that (a)
obesity-mediated inflammation may directly affect cell
cycle control, proliferation, and apoptosis in a variety of
different tissues and that (b) the efficiency of these effects
can depend on polymorphisms in cell cycle control master
regulatory genes.
Strengths and Limitations of This Study
This study has several advantages. The study sample was
selected to be representative of the adult population in the
eight study areas. The study population is well character-
ized and comparatively large. Population stratification is at
best of minor influence since participants had to be local
residents for at least 3 years prior to the first survey, had to
show a good command of one of the national languages,
and there was no difference in genotype frequencies
between Swiss and non-Swiss citizens (p ¼ 0.88 for
rs9344 in CCND1 and p ¼ 0.26 for rs1042522 in TP53).
Moreover, stratification of the associations by study center
or language region did not materially alter the main find-
ings. The assessment of asthma relied on internationally
validated questions identical to those used in the European
Respiratory Health Survey (45).
Nevertheless, some limitations apply. Like in many
studies on asthma the definitions of asthma relied solely
on the self-report of asthma diagnosis, attacks, and medi-
cations. Asthma status may therefore be subject to mis-
classification. Furthermore, there is indication that obesity-
related asthma is a clearly distinct phenotype from general
asthma and should be addressed differently. In fact, tradi-
tional inflammatory mechanisms in the airways have not
been found to be relevant (6) and common asthma medica-
tion is far less helpful in obese subjects (46). Moreover, the
usually observed asthma remission after weight loss (47)
does not seem to support extensive airway remodeling.
However, it has been recently demonstrated that airway
remodeling may persist in asthmatics with complete
asthma remission (48).
We cannot exclude participation bias. Smokers and
patients with asthma and related phenotypes were less
likely to participate at follow-up. Respiratory health of
study participants is therefore slightly better than in non-
participants. However, unless participation of asthmatics
and non-asthmatics at baseline and follow-up was influ-
enced by one of the genotypes investigated, substantial
bias of the results due to non-participation is unlikely. A
further limitation is the absence of adequate data on phy-
sical activity. This does not allow us to properly differenti-
ate between modification of obesity and physical activity
by the genetic polymorphisms investigated.
The study focused on selected SNPs in the genes of
interest by giving priority to SNPs intensively studied in
cancer. The CCND1 rs9344 A allele leads to modulated
splicing and consequently elevated production of the
cyclin D1b isoform, a transcript with a higher cellular
transformation potential (49,50). Even though this isoform
is not solely dependent on rs9344, this polymorphism has
been associated with different types of cancer (12). Apart
from the high-penetrance mutations in TP53 that lead to
Li–Fraumeni syndrome, the non-synonymous SNP
rs1042522 is arguably the most likely with functional
relevance (14). The G allele is more powerful in inducing
apoptosis (51), and an analysis summarizing several stu-
dies looking at different types of cancer could find a
statistically marginally higher risk for carriers of the C
allele (52). Further functional studies on the protein level
are needed to clarify how the CCND1 and TP53 poly-
morphisms influence the cell division activity.
Finally, despite the large sample size of our study, the
statistical power became limited in some of the stratified
analyses, especially for the TP53 genotypes and asthma
incidence. Replication of the results in an independent
cohort study is therefore essential, and with the help of
pathway analysis involving many more SNPs and genes,
the importance of cell cycle control activity in the asthma–
obesity association could be more rigorously assessed.
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CONCLUSION
Since obesity is a worldwide rapidly growing phenom-
enon, it is of high public health relevance to clarify caus-
ality and mechanisms of its association with asthma. Our
results, if confirmed, suggest that obesity may contribute to
asthma and associated tissue remodeling by modifying
processes related to the CCND1 gene activity.
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5 Results: Genetic Determinants of AAT Serum Level and their 
Interplay with the Environment on Determining Lung 
Function 
 
5.1 Paper 2: Serum Levels and Genotype Distribution of Alpha1-
Antitrypsin in the General Population. 
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Serum levels and genotype distribution of a1-antitrypsin
in the general population
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ABSTRACT
Rationale a1-Antitrypsin (AAT) deficiency is one of the
commonest rare respiratory disorders worldwide.
Diagnosis, assessment of risk for developing chronic
obstructive pulmonary disease (COPD), and management
of replacement therapy require the availability of precise
and updated ranges for protein serum levels.
Objective This paper aims to provide ranges of serum
AAT according to the main genotype classes in the
general population.
Methods The authors correlated mean AAT serum
levels with the main SERPINA1 variants (M1Ala/M1Val
(rs6647), M3 (rs1303), M2/M4 (rs709932), S (rs17580)
and Z (rs28929474)) in 6057 individuals enrolled in the
Swiss Cohort Study on Air Pollution and Lung Diseases in
Adults (SAPALDIA) cohort.
Results The following ranges (5the95th percentile) of
AAT were found in the serum (g/litre): 1.050e1.640 for
PI*MM, 0.880e1.369 for PI*MS, 0.730e1.060 for
PI*SS, 0.660e0.997 for PI*MZ and 0.490e0.660
for PI*SZ. There was very little overlap in AAT serum
levels between genotype classes generally not believed
to confer an enhanced health risk (MM and MS) and
those associated with an intermediate AAT deficiency
and a potentially mildly enhanced health risk (SS, MZ).
Conclusion This work resulted in three important findings:
technically updated and narrower serum ranges for AAT
according to PI genotype; a suggestion for a population-
based ‘protective threshold’ of AAT serum level, used in
decision-making for replacement therapy; and more precise
ranges framing the intermediate AAT deficiency area,
a potential target for future primary prevention.
INTRODUCTION
One of the few unambiguously ascertained individual
risk factors for chronic obstructive pulmonary disease
(COPD) is the serum level of a1-antitrypsin (AAT),
which in turn is strongly determined by the AAT
genotype variant system, classically named PI type. A
large body of evidence suggests that the degree of risk
for COPD is inversely related to the serum AAT level
according to the hierarchy PI NullNull > PI ZZ > PI
SZ > PI MZ.1e4 Therefore, accuracy in AAT serum
level determination is a relevant factor in COPD risk
assessment. Above the area termed ‘severe’ AAT defi-
ciency (AATD), bounded by the AAT protective
threshold level of 11 mM5 and at high risk for devel-
oping COPD, lies the area of ‘intermediate’ AATD,
whose threshold has not been determined but is
currently used as a proxy for the PI*MZ genotype.
Notably, the currently used standard reference values
for AAT in serum6 show a broad and overlapping
range of values for the PI MM, PI MZ, PI MS and PI
SS classes and do not represent data from the general
population. In the absence of such data, only AAT
serum values below 11 mM are of use for the assess-
ment of severe AATD and for COPD risk prediction,
whereas meaningful reference values to classify inter-
mediate AATD associated with different AATD
genotypes are lacking. Careful evaluation of serum
AAT concentration is the initial diagnostic test in
patients with suspected AATD.7 This measurement
can be routinely performed in any clinical chemistry
laboratory, and it is the determining factor that
justifies further analysis such as genotyping and
sequencing, which are performed in dedicated labo-
ratories.8 Thus, the need for updated reference
intervals for AAT according to the different PI types
is of clinical relevance. This is especially true for
reference values related to PI MZ, which may also
require clinical attention in the form of smoking
counselling in light of evidence for an increased risk
of developing airflow obstruction.4 9
Key messages
What is the key question?
< What are the ranges of serum a1-antitrypsin
(AAT) level in the general population?
What is the bottom line?
< State-of-the-art methodologies allowed identifi-
cation of AAT ranges according to the major
genotypes, narrower than those previously
available. Moreover, the authors defined the
intermediate AAT deficiency area (0.92e0.49 g/
litre) of particular interest being a possible target
for future interventional options and clarified the
longstanding controversy in the conversion from
mM to g/litre of the ‘protective threshold’ of AAT
serum level, used in decision-making for
replacement therapy.
Why read on?
< It is important to clearly identify the protective
threshold for AAT deficiency and, in turn, the
serum level of AAT characterising patients with
severe AAT deficiency. It is also important to
correctly diagnose patients with intermediate AAT
deficiency (mostly with the PI*MZ genotype).
< Additional materials are
published online only. To view
these files please visit the
journal online (http://thorax.bmj.
com/content/67/8.toc).
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The aim of this paper was to correlate serum AAT levels with
the main PI variants, using current standards of measurement
and diagnosis, including the molecular characterisation of the
SERPINA1 gene encoding AAT.8 To the best of our knowledge,
this information has not been published for a large general
population sample.
We took advantage of the first follow-up examination of the
(Swiss Cohort Study on Air Pollution and Lung Diseases in
Adults) SAPALDIA cohort, which included 8047 people
randomly selected from eight population registries representing
the three major Swiss language regions, including both urban
and rural areas.10 The SAPALDIA biobank, which includes blood
and DNA samples for more than 6000 people, was used to
perform a previous study on the SERPINA1 molecular charac-
terisation of 1399 samples displaying reduced serum AAT
levels.11 In this study all 6057 samples from subjects who gave
consent for genetic analyses, including the 1399 mentioned
above, were investigated for normal M and deficient Z and S
SERPINA1 variants. The data presented were used to define the
prevalence of those variants and the levels of serum AAT
according to the main genotypes in the general population.
MATERIALS AND METHODS
Subjects
The SAPALDIA cohort has been previously described.10 At the
baseline in 1991 the subjects, who were 18e60 years old and
predominantly Caucasian of Swiss nationality, were randomly
selected from eight population registries. The current cross-
sectional investigation of serum AAT is restricted to follow-up data
collected in 2002e2003 when the biobank was established and
includes 6057 subjects who donated blood and consented to genetic
analysis. The study was approved by the Central Ethics
Committee of the Swiss Academy of Medical Science and Cantonal
Ethics Committees for each of the eight examination areas.
Serum analysis
AAT (g/litre) and C-reactive protein (CRP, mg/litre) concentra-
tions were determined by latex-enhanced immunoturbidimetric
assay (COBAS Integra analyzer, Roche Diagnostics, Indian-
apolis, Indiana, USA), a robust assay with principles that are
perfectly comparable to those of nephelometry.12 The interassay
coefficient of variation (CV) was 3.6e4.6%; lower detection
thresholds for the AAT and CRP assays were 0.21 g/litre and
1 mg/litre, respectively, and reference values were 0.9e2.0 g/litre
and <8 mg/litre, respectively. Each new batch of antiserum was
compared with previous batches for value recovery and
proportionality in actual assays. A clarified, delipidated,
commercially available serum calibrant (Calibrator f.a.s.
Proteins, Roche Diagnostics) was used during the study; the
same calibration batch, buffers and other reagents were used
throughout the entire study.
Single nucleotide polymorphism analysis
All subjects were typed for give SNPs: S (rs17580), Z (rs28929474),
M1Ala/M1Val (rs6647), M3 (rs1303), M2/M4 (rs709932).
Typing was performed by PCR with fluorescently labelled Taq-
Man probes (Vic or Fam labels) on a LigthCycler480 (Roche
Diagnostics). All single nucleotide polymorphisms (SNPs) were
in HardyeWeinberg equilibrium. Further details on SNP analysis
are available in the online data supplement.
Detection of rare deficient variants
The presence of rare deficient mutations was determined by
sequencing the coding region of the SERPINA1 gene, as
previously described, on selected samples as reported by
Zorzetto and coworkers.11
Statistical analysis
AAT concentrations were normally distributed and analysis of
variance (ANOVA) was applied to compare means in different
subgroups. Reference values covered the range from the 5th to
the 95th percentile of AAT serum values. Linear and quantile
regression was used to calculate adjusted means and percentiles.
Covariates in the regression models were selected according to
a former publication13 and they were all significantly associated
with AAT concentrations. The receiver operating characteristic
(ROC) curve was used to estimate the predictive accuracy of
serum AAT, and maximation of the Youden index (ie, the sum of
sensitivity and specificity minus 1) defined the optimal
threshold for discrimination of genotype classes. Bootstrapping
procedures were used to estimate the 95% CIs of the optimal
thresholds. Statistical analysis was performed with MedCalc
9.4.2.0 (MedCalc Software, Mariakerke, Belgium), Stata V.10.1
IC and SAS V.9.2.
RESULTS
As a first step we identified the number of subjects belonging to
different SERPINA1 genotype classes and determined their
frequency in the general population (table 1). The PI*MM
genotype accounted for 5398 individuals (89.12% of the overall
population), whereas PI*MS was the second genotype in order
of frequency (7.48%), followed by PI*MZ (2.36%). Only one
subject carrying the PI*ZZ genotype (0.02%) was identified. The
two classes defined in table 1 as rare variants and novel variants,
accounting for 42 subjects (0.69%), were very heterogeneous
groups of variants and were therefore excluded from further
analyses on the relationship between AAT serum levels and
SERPINA1 genotypes. Nevertheless, means and ranges of AAT
serum levels did not notably change if rare and novel variants
were not excluded (data not shown). The frequencies of S and Z
alleles in the three main Swiss language groups (German, French,
Italian) are shown in online table E1 and are further described in
the online data supplement.
Table 1 Frequency of the SERPINA1 genotype classes detected in 6057 subjects from the Swiss Cohort
Study on Air Pollution and Lung Diseases in Adults (SAPALDIA) cohort
Genotype PI*MMy PI*MS PI*SS PI*MZ PI*SZ PI*ZZ Rare variantsz Novel variantsx
Number of subjects 5398 453 10 143 10 1 34 8
Frequency (%) 89.12 7.48 0.16 2.36 0.17 0.02 0.56 0.13
yThe PI*MM genotype class encompasses different combinations of normal M variants (M1Ala/Val, M3, M2/M4). Details are reported
in the online data supplement.
zThis class includes subjects heterozygous for rare deficient variants, such as I, Plowell, Mmalton, MWurzburg etc. These data were
previously analysed in more detail.11
xThis class includes novel putative deficient variants detected during SERPINA1 gene sequencing. These data were previously
analysed in more detail.11
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Unadjusted and adjusted means and reference intervals for
AAT serum concentration in the six main SERPINA1 genotype
classes are presented in table 2. Adjusting for age, sex, study area,
alcohol intake (yes vs no), systolic blood pressure, body mass
index (BMI), smoking status (never, former, current) and CRP
levels did not essentially alter the results. The 5the95th
percentiles were subsequently compared with previously
reported American Thoracic Society (ATS)/European Respira-
tory Society (ERS) reference values6 (table 3). The AAT serum
level ranges determined in our investigation are markedly more
narrow than those previously reported. Data are also graphically
reported in figure E1, in which AAT serum concentrations are
mathematically converted to mM.
Since AAT is a acute phase protein, we recalculated the
reference intervals of AAT serum concentrations in subgroups of
subjects according to systemic inflammatory status. A CRP
value of 8 mg/litre, which is the upper normal limit for this
protein as suggested by the equipment used in the present study,
was used as the cutoff to stratify subjects as being without
(<8 mg/litre) or with ($8 mg/litre) systemic inflammation
(table E2). Comparison of AAT means between the two CRP
strata revealed higher values in the systemic inflammation
stratum for all genotype classes. This difference was statistically
significant in the PI*MM subgroup (p<0.001).
As a next step we assessed the accuracy of predicting geno-
type classes which are not believed to represent a risk for
developing emphysema (PI*MM and PI*MS) and those associ-
ated with intermediate AATD and arguably a slightly increased
risk for developing emphysema (PI*SS and PI*MZ) from AAT
concentrations using ROC statistics.4 14 For this analysis we
included the rare variant carriers of the respective groups to get
a representative sample for the general population. The findings
were highly accurate for the area under the curve (AUC ¼
0.9907) (figure E2). The optimal threshold according to the
Youden index provided a cutoff at 1.00 g/litre AAT level (95% CI
0.97 to 1.06), which presents a sensitivity of 95.8% and a speci-
ficity of 94.8%. For discrimination between PI*MM and any
other genotype carrying at least one S or Z allele an optimal
cutoff at 1.10 g/litre was determined (73.4% sensibility, 88.5%
specificity). The impact of sex, smoking status and CRP levels
on these genotype discriminations are described in the online
data supplement (table E3).
Finally we analysed the influence of the different PI*M
subtypes on AAT serum level. This result is reported in the
online data supplement (table E4 and figure E3).
DISCUSSION
This study ideally represents the most valid setting to date to
derive reference values for serum AAT by genotype group in the
general population. We applied state-of-the-art technology for
the assessment of serum AAT and SERPINA1 genotypes in the
Swiss population, which is a combination of three language
groups that adequately represent the genetic structure of the
European population.15 To the best of our knowledge, only a few
studies have been performed in the general population that
measure circulating AAT protein7 or SERPINA1 gene variants9 or
both.16 17 The most comparable study is the Copenhagen City
Heart study, a longitudinal survey of 7963 subjects from
Copenhagen who were genotyped for PI*Z and PI*S but in
whom only a small sample of AATconcentrations in blood were
measured (n¼592).9 In the study by Sveger,16 blood from
200 000 infants was drawn for simultaneous AAT determination
by semi-quantitative electroimmunoassay and Pi typing with
isoelectric focusing. However, the analytical methods used in
this study were out of date and therefore these data can no
longer be used as a reference. The study by Silverman et al17
applied an automated immunoassay to measure AAT in plasma
samples from 20 000 blood donors from the St Louis area. Plasma
samples that met criteria of <50% of plasma pool reactivity
were examined by isoelectric focusing to determine PI type. The
reported St Louis Z allele frequency was 0.0116, but no data on
the reference values for the concentration of AAT in plasma were
extrapolated. In summary, current AAT serum levelegenotype
relationships seem obsolete as updated diagnostic standards for
AATD have never been applied to a general population sample.
Our work generated a number of outputs. First, a more precise
allele and genotype frequency was identified for SERPINA1
variants in Switzerland’s general population. We calculated an
updated Pi*S gene frequency of 0.0401 whereas that of PI*Z was
0.0130. Compared with previous estimates for this population,18
Table 2 Unadjusted and adjusted means and intervals (5th and 95th percentiles) for a1-antitrypsin (AAT) serum concentration in the six main
SERPINA1 genotype classes
SERPINA1
genotype
Unadjusted AAT serum concentrations, N[5981* Adjusted AAT serum concentrations,y N[5768z
N Mean, SD (g/litre) 5th percentile 95th percentile N Mean (g/litre) 5th percentile 95th percentile
MM 5366 1.298, 0.18 1.05 1.64 5175 1.298 1.079 1.572
MS 451 1.085, 0.16 0.88 1.37 438 1.082 0.902 1.312
SS 10 0.849, 0.10 0.73 1.06 10 0.823 0.735 1.009
MZ 143 0.805, 0.11 0.66 1.00 136 0.811 0.672 1.011
SZ 10 0.555, 0.06 0.49 0.66 9 0.554 0.480 0.638
ZZ 1 0.320, 0.00
*Subjects with rare variants (42) and samples with missing AAT levels (34) were excluded.
yAdjusted for age, sex, area, alcohol consumption (yes/no), systolic blood pressure, body mass index, smoking habit (never, former, current) and C-reactive protein levels.
zAdditionally excluded were subjects with missing covariate data (212) and ZZ genotype due to insufficient frequency (1).
Table 3 Comparison between two published ranges (5the95th
percentiles) of a1-antitrypsin serum levels according to different
phenotypes (PI),1 one in mM and one in g/litre,6 and the range, according
to different genotypes (PI*), as deduced by our analysis2
Phenotypeegenotype Units Reference ranges1 Present paper2
PI MMePI*MM mM 20e48 20.2e31.5
g/l 1.50e3.50 1.05e1.64
PI SSePI*SS mM 15e33 14.0e20.4
g/l 1.00e2.00 0.73e1.06
PI MZePI*MZ mM 17e33 12.7e19.2
g/l 0.90e2.10 0.66e1.00
PI SZePI*SZ mM 8e16 9.4e12.7
g/l 0.75e1.20 0.49e0.66
The g/litre values in our analysis were mathematically converted to mM, based on
a molecular weight of 52 kDa. Note that the PI*MS data are not present because this
genotype was not included in the original American Thoracic Society/European Respiratory
Society guidelines.
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PI*S frequency was similar whereas PI*Z frequency was slightly
higher. Further discussion of this topic is provided in the online
data supplement.
A second major outcome of the study was the analysis of AAT
serum concentration and genotypes of the SERPINA1 gene in
a large cohort representative of the general population. This
enabled the extrapolation of updated protein ranges according to
the main normal and deficient genotype classes and evaluation
of whether reference values need to be specific for sex, smoking
status and CRP level.
To date, no epidemiological data on AAT serum concentration
according to the SERPINA1 genotype have been reported for the
general population. Some studies identified mean values or
reference intervals of AAT serum concentration but they were
limited to target groups, mostly COPD cases or populations in
which the frequency of AATD is low, such as Japanese19 and
Korean populations,20 or in patients with a peculiar clinical
phenotype, such as Peyronie’s disease,21 or characteristic cohorts,
such as paediatric subjects7 and pregnant women.22 The use of
advanced technologies makes this study innovative. These
technologies include SNP detection for genotyping and the
exclusion of potentially confounding genetic factors, that is,
deficient variants other than S and Z alleles, from the final
analysis. The presence of other variables that could affect the
AATconcentration in serum were considered and adjusted for in
an additional analysis. This resulted in much narrower serum
AAT ranges than those presented in the ATS/ERS consensus
document,6 with a drastic reduction in the overlap among
genotypes (table 3). Moreover, the mean values of AAT
concentration according to SERPINA1 genotypical classes (table
2), were lower than those reported so far,9 likely due to a smaller
upper dispersion of measurements. Although 70e80% of the
variation in total AATserum concentration is explained by the Pi
type (after age and sex adjustment),23 other factors can influence
variation.13 Since AAT is an acute-phase reactant, inflammatory
status may increase the serum level of AAT.11 13 24 As shown in
table E2, when SAPALDIA subjects were stratified according to
the presence or absence of an inflammatory condition, most
SERPINA1 genotypes showed even narrower ranges, particularly
those with CRP <8 mg/litre. However, ranges for individuals
with elevated CRP were generally higher. In the real world of
routine AAT serum measurement, our data do not justify
systematic measurement of the inflammatory status and the
stratified ranges can be used only in reference laboratories.8
Other factors that impact AAT concentration variability
include active smoking25 and age.21 An in-depth analysis of the
same SAPALDIA population has shown that an inter-relation-
ship among circulating AAT, smoke exposure, gender and
systemic inflammatory status exists.13 However, in this study
with narrower diagnostic purposes, we demonstrated that
inclusion of sex and current smoking status to predict inter-
mediate deficiency genotypes was not necessary. We also
addressed a further putative factor for AATserum concentration
variability, that is, the intrinsic effect of the different PI*M
subtypes (figure E3). The effect of this variable seems to be
negligible because only two PI*MZ haplotypes displayed
significant changes in AAT serum concentration.
In this study, we also analysed the limits of the so-called
‘protective threshold’ and we tried to address the controversy
and confusion about the expression of serum AATconcentration.
The term ‘protective threshold’ derives from evidence that
subjects with AATD and an AATserum level above the threshold
are at reduced risk of developing emphysema. This is not merely
a theoretical cutoff because it is considered the decisional cutoff
below which subjects with AATD are eligible for AAT replace-
ment therapy.6 Therefore, it is a very important concept in
AATD patient management. An excellent discussion on this
topic by Tonelli and Brantly has recently been published.26 The
concept was originally developed by Hutchinson et al27 and
Stockley,28 based on evidence that subjects displaying the PI SZ
phenotype had a reduced risk of developing emphysema
compared with those displaying the PI ZZ phenotype3 and are
therefore seldom suitable for replacement therapy. The
threshold was fixed at the serum AAT level corresponding to
0.8 g/litre, measured by radial immunodiffusion. A few years
later, to resolve the lack of standardisation among laboratories
that caused so much confusion in the definition of the AAT
measurements, a highly purified AATstandard, expressed as mM,
was introduced.29 In the same report, the protective threshold
using the highly purified AAT standard determined by nephe-
lometry was fixed at 11 mM; that is, the 10th percentile of the
AAT serum range for subjects with PI SZ, which is considered
adequate to protect the lungs from proteolytic attack. Since
then, in countries where the AATconcentration was expressed as
g/litre, the 0.8 threshold was often considered equivalent to
11 mM. However, radial immunodiffusion cannot be considered
equivalent to nephelometry because the former, obsolete
method overestimates the real AAT concentration by about
Figure 1 Suggested areas
corresponding to severe a1-antitrypsin
(AAT) deficiency (below the protective
threshold) and intermediate AAT
deficiency (above the protective
threshold and below the 10th percentile
of the AAT range for subjects carrying
the PI*MS genotype). Bars represent
5th/95th percentiles of AAT serum
levels.
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50%.30 The value corresponding to the 10th percentile of AAT
serum concentration for the PI*SZ group in SAPALDIA, which is
suitable to derive threshold values in the general population, is
0.49 g/litre.
Intermediate deficiency is a term usually referred to as
synonymous with the PI*MZ genotype, which may represent
a slightly increased risk of developing COPD.4 We believe that
correct diagnosis of subjects carrying the PI*MZ genotype is
a critical issue for a number of reasons. First, having been
identified as a group at risk of developing COPD, they are
subjects particularly suitable for an effective prevention and
smoking cessation campaign, as suggested by an increased rate
of attempting to quit smoking following genetic testing.31
Second, correct diagnosis is mandatory for genetic counselling.
Third, subjects with COPD carrying the PI*MZ genotype could
be suitable for future, specific therapeutic interventions.
Expressed as a range of serum levels, we propose that corre-
sponding values stretch from the protective threshold (0.49 g/
litre) to the 10th percentile of the AAT concentration range for
subjects carrying the PI*MS genotype, who are believed not to
be at risk of developing emphysema,14 which would correspond
to 0.92 g/litre in SAPALDIA. This area includes 87% of subjects
carrying the PI*MZ genotype in our cohort. The reported
thresholds and related areas are depicted in figure 1.
One of the aims of this paper was to provide a clear cutoff,
below which suspicion of AATD is reasonable, and to resolve the
controversy around this issue. The choice of the AAT cutoff,
below which samples should be selected for PI pheno/geno-
typing, has important financial and clinical implications. The
cutoffs determined by individual laboratories currently range
between 1.00 and 1.30 g/litre and they strongly depend on
specific requirements. For example, the clinical importance of
PI*MS detection is considered to be far less than PI*MZ detec-
tion due to the different risks for emphysema for the two
genotypes.4 14 Therefore, we reported two different cutoffs, one
focused on avoiding the omission of deficient S or Z alleles
(1.10 g/litre) and the second set to identify genotypes at a likely
increased risk of emphysema (1.00 g/litre). We also considered
the previously reported cutoff of 1.13 g/litre,32 which is still
useful since no Z alleles (and PI*SS) have been found in indi-
viduals with AAT blood levels above this level (100% sensitivity
and 78.6% specificity for detecting AATD genotypes), while 31%
of all assigned subjects with the PI*MS genotype show AAT
blood levels higher than 1.13 g/litre (78.6% sensitivity and 82.6%
specificity for detecting any deficient S or Z allele).
In conclusion, we provided values for serum AAT level
according to the major genotype classes in the general popula-
tion. In addition, these data have helped us to address contro-
versies related to the different opinions in the definition of limits
for the ‘protective threshold’ and to define a useful range for
intermediate AATD. We believe that these findings will be
helpful in the future for the investigation of AATD-related risk
for COPD and for a more precise definition of when to imple-
ment AAT replacement therapy. Finally, the reported data show
that the geneeenvironmental analysis is critical in the ongoing
SAPALDIA longitudinal assessment of the impact of SERPINA1
on pulmonary health.
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Methods 
SNP analysis 
The PCR conditions were identical for all applications: 0.125 µl of 20X working stock of 
SNPGenotypingAssay, 2.5 µl LightCycler 480 Probes Master (Roche Diagnostics), and 20 ng DNA 
sample, in a total volume of 5 µl. PCR cycling conditions were also identical for all assays: initial 
denaturation step of 95°C for 10 minutes, followed by 40 cycles of denaturation at 95°C for 15 
seconds, and annealing at 60°C for 1 minute. After the amplification, melting curves were 
generated by slowly (ramp rate 2.2°C/second) cooling the sample to 40°C. The sequences of 
primers and probes are available on request. 
 
Results  
Frequency of Z and S alleles in the Swiss language groups 
As an aside, we analyzed the frequency of S and Z alleles in the three language groups: German 
(n=3,288), French (n=1,938) and Italian (n=831) (Table E1). Interestingly, while the PI*Z allele was 
homogeneously distributed among the three language groups, the frequency of the PI*S allele was 
significantly higher in the French subgroup (0.053) than in the German (0.036) and in the Italian 
(0.025) (p<0.001 for both comparisons).  
 
ROC analysis for best cut-off calculation and accuracy of predicting genotype classes 
We assessed the accuracy of predicting genotype classes which are not believed to represent a risk 
for developing emphysema (PI*MM and PI*MS) and those associated with intermediate AATD and 
arguably a slightly increased risk for developing emphysema, i.e. PI*SS and PI*MZ, from AAT 
concentrations using ROC statistics
E1,E2
. For this analysis we included the rare variant carriers of 
the respective groups in order to get a representative sample for the general population. The 
3 
 
findings were highly accurate for the area under the curve (AUC=0.9907) (Figure E2). The optimal 
threshold according to the Youden index provides the cut-off at 1.00g/L AAT level (95% CI 0.97 to 
1.06), which represents a sensitivity of 95.8% and a specificity of 94.8%. As we had previously 
reported differences in circulating AAT concentrations by gender, smoking status and CRP levels
E3
, 
we tried to assess whether prediction of PI*SS or MZ genotypes could be improved by considering 
the influence of these factors on AAT blood levels. We found a marginal enhancement of 
prediction quality when adjusting for sex and current smoking status, but not for CRP 
(AUC=0.9927, p=0.05). We subsequently recalculated values for normal (PI*MM and PI*MS) vs. 
intermediate deficiency genotype classes (PI*MZ and PI*SS) by gender and current smoking (Table 
E2). Despite slight differences in the stratified specific means, the impact of the genotype played a 
much bigger role than that of gender and current smoking.  
For discrimination between PI*MM and any other genotype carrying at least one S or Z allele, an 
optimal cut-off at 1.10g/L was determined (73.4% sensibility, 88.5% specificity). 
 
Analysis of normal M variant subtypes 
The analysis of the three SNPs for normal variants (M1Ala/M1Val - rs6647; M3 - rs1303; M2/M4 - 
rs709932) by haplotype reconstruction revealed 14 normal genotypic classes in the PI*MM group, 
5 classes in the PI*MS group and 5 classes in the PI*MZ group (Table E3). Among these, the most 
common were PI*M1(Val)M1(Val), PI*M1(Ala)M1(Val), and M1(Val)M2 (frequencies of 0.28, 0.21, 
and 0.15, respectively). The reference intervals (5
th
-95
th
 percentiles) for AAT serum concentration 
have been calculated in each group (Figure E3). Comparison of means within each group revealed 
only a significant difference between PI*M1(Val)Z and PI*M1(Ala)Z (0.819 vs. 0.754 g/L, p=0.003). 
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Discussion 
Frequency of SERPINA1 gene variants in Switzerland. 
The estimated mean gene frequencies for PiS and PiZ in Switzerland are 0.0384 and 0.0073, 
respectively
E4
. These data are based on the analysis of three Swiss cohorts
E5,E6
 previously 
phenotyped for PI. The estimate is similar to ours for the S allele, but we obtained a slightly higher 
frequency for the Z allele. When we divided the population into the three language groups, we 
found evidence of a significantly higher frequency for the S allele in the French subgroup (p<0.001 
for both comparisons, Table E1). This is in agreement with the hypothesis that the S mutation, 
which arose in the Portuguese population
E7
, moved eastbound to the rest of Europe as a 
consequence of the late-glacial resettlement of Europe
E8
, resulting in decreasing frequencies from 
southwest to the north and east. 
 
AAT cut-off value for diagnostic purposes 
One of the aims of this paper was to provide a clear cut-off, below which suspicion of AATD is 
reasonable, and to resolve the controversy around this issue. The choice of the AAT cut-off, below 
which samples should be selected for Pi pheno/genotyping, has important financial and clinical 
implications. The cut-offs determined by individual laboratories currently comprise a wide range 
between 1.00 and 1.30 g/L
E9-E11
, and they strongly depend on specific requirements. For example, 
the clinical importance of PI*MS detection is considered far less important than PI*MZ detection, 
due to the different risks for emphysema for the two genotypes
E1,E2
. Therefore we reported two 
different cut-offs, one focused on avoiding the omission of deficient alleles S or Z (1.10 g/L) and 
the second identified genotypes at a likely risk for emphysema (1.00 g/L). We considered as well 
the previously referred cut-off of 1.13 g/L
E12
, which is still useful since no Z alleles (and PI*SS) have 
been found in individuals with AAT blood levels above this level (100% sensitivity and 78.6% 
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specificity for detecting AATD genotypes), while 31% of all assigned PI*MS subjects show AAT 
blood levels higher than 1.13 g/L (78.6% sensitivity and 82.6% specificity for detecting any 
deficiency allele S or Z). 
 
Effect of SERPINA1 M variants on AAT serum concentration. 
The normal variants of AAT, usually called M, are characterized by point mutations that do not 
change either the phenotype or the serum concentration of the AAT protein. The most common 
are M1(Ala)/M1(Val) (213Ala, 213Val)
E13
, M2 (213Val, 376Asp, and 101His)
E14
, M3 (213Val and 
376Asp)
E15
, M4 (213Val, 101His)
E16
. It is well known that individuals bearing these mutations have 
normal AAT serum levels and that the protein functions normally as an inhibitor of neutrophil 
elastase. Evaluation of the crystallographic structure of AAT
E17
 revealed that the substitution at 
position 101 occurs in helix D and the 376 substitution occurs in sheet 4B of the molecule, which 
are areas where changes are likely to cause minor conformational changes in the molecule. 
Nevertheless, epidemiological studies of these normal variants are limited to their geographic 
distribution or prevalence data, and comparison among different genotypes, in terms of serum 
concentration of AAT, has never been performed. A side aim of this paper was to confirm the 
absence of quantitative differences among PI*MM subtypes; therefore, an analysis of all possible 
combinations of M1, M2, M3, and M4 alleles in the cluster PI*MM, was performed. The effect of 
the M1(Ala) allele, in combination with the Z allele, in reducing the mean concentration of AAT in 
serum (Figure E3), should be considered with caution. 
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Legends to Supplemental Figures  
 
Figure E1. Intervals (5
th
-95
th
 percentiles ) for unadjusted serum AAT levels in the main SERPINA1 
genotypic classes; 1
st
-99
th
 percentiles are represented with lines, where possible. In this figure, the 
g/L values of our analysis were mathematically converted to µM, based on a molecular weight of 
52kDa.  
 
Figure E2. ROC curve for predicting MM/MS vs. SS/MZ genotype classes from unadjusted AAT 
blood level (rare variants included). 
 
Figure E3. Intervals (5
th
-95
th
 percentiles) for AAT serum concentration in individuals stratified 
according to the haplotype reconstruction resulting in 24 genotypic classes. 
 
 
Table E1. Frequencies of Z and S alleles in the cohort and the three language groups.  
 Z allele (%) S allele (%) 
General population (n=6,057) 1.30 4.01 
German subgroup (n=3,288) 1.22 3.65 
French subgroup (n=1,938) 1.44 5.26 
Italian subgroup (n=831) 1.26 2.53 
p-value (chi-square-test) 0.61 <0.001 
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Table E2. Influence of gender and current smoking status on unadjusted AAT reference values. 
 n median 5
th
/95
th
 perc. 
MM/MS all 5,848 1.26 1.01/1.63 
MM/MS, male-smoker 791 1.29 1.01/1.59 
MM/MS, female-smoker 663 1.36 1.07/1.74 
MM/MS, male-nonsmoker 2,127 1.19 0.98/1.48 
MM/MS, female-nonsmoker 2,267 1.28 1.03/1.69 
SS/MZ, all 155 0.79 0.66/1.01 
SS/MZ, male-smoker 16 0.79 0.69/1.02 
SS/MZ, female-smoker 14 0.88 0.76/1.07 
SS/MZ, male-nonsmoker 55 0.75 0.62/0.91 
SS/MZ, female-nonsmoker 70 0.81 0.66/1.04 
 
Table E3. Frequencies of the genotypic classes. 
PI Group PI Genotype  Frequencies 
PI*MM   
 M1(Val) M1(Val) 0.2512 
 M1(Ala) M1(Val) 0.1850 
 M1(Val) M2 or M3 M4 0.1620 
 M1(Val) M3 0.0908 
 M1(Ala) M2 0.0559 
 M1(Ala) M1(Ala) 0.0351 
 M1(Ala) M3 0.0328 
10 
 
 M2 M3 0.0266 
 M2 M2 0.0253 
 M1(Val) M4 0.0113 
 M3 M3 0.0105 
 M1(Ala) M4 0.0060 
 M3 M4 0.0042 
 M4 M4 0.0007 
PI*MS   
 M1(Val) S 0.0379 
 M1(Ala) S 0.0173 
 M2 S 0.0110 
 M3 S 0.0078 
 M4 S 0.0013 
PI*MZ   
 M1(Val) Z 0.0133 
 M1(Ala) Z 0.0047 
 M3 Z 0.0028 
 M2 Z 0.0027 
 M4 Z 0.0003 
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Abstract
Several infrequent genetic polymorphisms in the SERPINA1 gene are known to substantially reduce concentration of alpha1-
antitrypsin (AAT) in the blood. Since low AAT serum levels fail to protect pulmonary tissue from enzymatic degradation,
these polymorphisms also increase the risk for early onset chronic obstructive pulmonary disease (COPD). The role of more
common SERPINA1 single nucleotide polymorphisms (SNPs) in respiratory health remains poorly understood. We present
here an agnostic investigation of genetic determinants of circulating AAT levels in a general population sample by
performing a genome-wide association study (GWAS) in 1392 individuals of the SAPALDIA cohort. Five common SNPs,
defined by showing minor allele frequencies (MAFs) .5%, reached genome-wide significance, all located in the SERPINA
gene cluster at 14q32.13. The top-ranking genotyped SNP rs4905179 was associated with an estimated effect of
b=20.068 g/L per minor allele (P = 1.20*10212). But denser SERPINA1 locus genotyping in 5569 participants with
subsequent stepwise conditional analysis, as well as exon-sequencing in a subsample (N = 410), suggested that AAT serum
level is causally determined at this locus by rare (MAF,1%) and low-frequent (MAF 1–5%) variants only, in particular by the
well-documented protein inhibitor S and Z (PI S, PI Z) variants. Replication of the association of rs4905179 with AAT serum
levels in the Copenhagen City Heart Study (N = 8273) was successful (P,0.0001), as was the replication of its synthetic
nature (the effect disappeared after adjusting for PI S and Z, P = 0.57). Extending the analysis to lung function revealed a
more complex situation. Only in individuals with severely compromised pulmonary health (N= 397), associations of
common SNPs at this locus with lung function were driven by rarer PI S or Z variants. Overall, our meta-analysis of lung
function in ever-smokers does not support a functional role of common SNPs in the SERPINA gene cluster in the general
population.
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Introduction
Alpha1-antitrypsin (AAT) is a serum marker for inflammation
produced in the liver. Its main function is to inhibit neutrophil
elastase and consequently protect pulmonary tissue. The SER-
PINA1 gene encoding the AAT protein is known to be
polymorphic in the general population. The best studied single
nucleotide polymorphisms (SNPs) causing a reduction in AAT
serum levels are the protease inhibitor S (PI S, rs17580) and the
protease inhibitor Z (PI Z, rs28929474) variants [1]. The loss of
function mechanism is especially well investigated for the PI Z
variant. The resulting amino acid change in AAT leads to the
protein’s intracellular polymerization in hepatocytes and therefore
to a reduced level of secreted serum AAT [2]. Homozygosity for
PI Z (PI ZZ genotype) with a frequency of about 0.01% in
Caucasian populations [3] causes blood AAT levels below 30% of
normal. This genotype is clearly associated with elevated chronic
obstructive pulmonary disease (COPD) risk accounting for 1–2%
of all cases [4,5]. There is also strong evidence that accelerated
lung function decline and increased obstructive disease risk can be
caused by compound heterozygosity of PI Z and PI S (PI SZ
genotype). The case is less clear for PI MZ, PI MS or PI SS
genotypes (PI M standing for the normal allele), which cause a less
pronounced reduction in AAT concentration, as previous studies
produced inconsistent evidence [6–9].
Further of note, large-scale genome-wide association studies
(GWAS) on COPD or on cross-sectional or longitudinal lung
function have not identified the SERPINA1 gene to be a major
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genetic determinant [10–12]. But a recent GWAS on emphysema
[13] and a comprehensive evaluation of candidate regions for lung
function [14] reported rs4905179 and rs3748312, two common
SNPs (minor allele frequencies (MAFs) .5%) located in the
SERPINA gene cluster on 14q32.13, among their most strongly
associated results. This locus encompasses SERPINA1 and ten
other genes (SERPINA2 to SERPINA6 and SERPINA9 to
SERPINA13) encoding extracellular ‘clade A’ serpins with very
heterogeneous functions [15]. It is currently not known whether
such association signals observed for this locus reflect a causal role
of common variants or whether they are merely synthetic,
reflecting effects of rarer causal variants [16]. Towards that aim,
but also to detect further chromosomal loci of potential relevance
to circulating levels of AAT, we first performed a GWAS on AAT
serum level using a subset of the population-based Swiss Cohort
Study of Air Pollution and Lung Disease in Adults (SAPALDIA) as
discovery sample, and a second subset of SAPALDIA as well as an
independent cohort, the Copenhagen City Heart Study (hence-
forth referred to as Copenhagen), as replication sample. We also
conducted fine mapping analyses of the SERPINA1 gene in the
SAPALDIA cohort. Finally, we meta-analyzed the lung function
effect of common and low-frequent SERPINA1 SNPs previously
observed to be associated with pulmonary health in ever-smokers,
based on data provided by several population- and patient-based
studies.
Results
The discovery population and the design used to determine
AAT-associated genetic variants are depicted in Figure S1 and
further described in the Materials and Methods section. A
comparison between the characteristics of the genome-wide
analyzed sample (SAPALDIA discovery arm, N=1392) and the
remainder of the SAPALDIA cohort (SAPALDIA replication arm,
N=4245) did not reveal substantial differences in AAT serum
levels or covariate distribution (Table S1), although asthmatics
were overrepresented (39.4%) in the SAPALDIA discovery arm
and absent in the replication arm, which is due to previous study
design [17]. The participants of the independent replication cohort
Copenhagen (N= 8273) were on average five years older and had
twice as many current smokers (Table S1). This was in line with
substantially lower lung function levels (more than 800 mL lower
forced expiratory volume in 1 second, FEV1, compared to both
SAPALDIA subsets) and slightly elevated AAT blood levels
(1.339 g/L vs. 1.257 and 1.255 g/L, respectively). The charac-
teristics of the study populations contributing to the genetic
association analyses with lung function are given in Table S2.
GWAS on AAT Serum Level
The association of more than 2.1 million genome-wide SNPs
with AAT serum levels is shown in Figure 1. The ten most
strongly associated SNPs were all located in the SERPINA gene
cluster, half of them reached genome-wide significance
(P,5*1028, Table 1). The top 100 ranking SNPs are provided
in Table S3. A regional association plot for the SERPINA gene
cluster is shown in Figure 2. Both the top-ranking imputed SNP,
rs2736887, and the top-ranking genotyped SNP, rs4905179, were
located in close proximity to the SERPINA6 gene and approx-
imately 33 kb and 50 kb downstream of SERPINA1 (effect
estimates b=20.071 and 20.068 g/L per minor allele;
P = 2.48*10213 and 1.20*10212, respectively). Linkage disequi-
librium (LD) between these two variants based on HapMap2
CEU (Utah residents with Northern and Western European
ancestry) derived haplotype data [18] was strong (r2=0.88,
D9= 1), but Figure 2 suggests that the LD, expressed in r2 values,
between the top-ranking SNP and the other SNPs in the region is
generally modest. The genomic inflation factor lambda was low
(l= 1.02), suggesting minimal population stratification. The
quantile-quantile plot (Q-Q plot) showed good adherence to null
expectation and substantial positive deviation between observed
and expected p-values for the top-ranking SNPs (Figure S2). In a
sensitivity analysis adjusting for additional covariates, including
high sensitivity C-reactive protein (hs-CRP), body mass index
(BMI), passive smoking and alcohol intake, the genome-wide
association results did not show an increase in the strength of the
top-ranking loci, nor did they point to additional loci (data not
shown). Even though this GWAS was enriched with asthma
patients, GWAS stratification according to asthma status did not
show heterogeneity for the top-ranking signals between partici-
pants with and without asthma (data not shown).
Association of 1000 Genomes Imputed Data for the
SERPINA Gene Cluster with AAT Serum Level
In order to further refine association signals in this region, we
imputed additional SNPs on chromosome 14 using haplotype
data from the 1000 Genomes Project (1000G) [19]. The 1000G
imputation yielded a three times higher number of imputed
variants with reasonable quality scores (imputation-r2.0.5)
compared to HapMap-derived imputed variants. A region
defined by 1 Mb up- and downstream of the SERPINA1 gene
revealed 24 additional variants that were associated below a
local significance level of P,3*1025, adjusting for approximately
1800 SNPs covering a region of 2 Mb (Table S4). Among them,
four low-frequent variants and one rare variant showed p-values
reaching genome-wide significance level, and interestingly, none
of them was in high LD (r2.0.8) with any other regional variant
tested. The most strongly associated signal came from the PI Z
variant, which is well known to be associated with reduced
AAT serum levels (b=20.620 g/L per minor allele,
P = 4.61*10243, MAF=0.84%). The other well established
Author Summary
Low levels of alpha1-antitrypsin (AAT) in the blood are a
well-established risk factor for accelerated loss in lung
function and chronic obstructive pulmonary disease. While
a few infrequent genetic polymorphisms are known to
influence the serum levels of this enzyme, the role of
common genetic variants has not been examined so far.
The present genome-wide scan for associated variants in
approximately 1400 Swiss inhabitants revealed a chromo-
somal locus containing the functionally established vari-
ants of AAT deficiency and variants previously associated
with lung function and emphysema. We used dense
genotyping of this genetic region in more than 5500
individuals and subsequent conditional analyses to unravel
which of these associated variants contribute indepen-
dently to the phenotype’s variability. All associations of
common variants could be attributed to the rarer
functionally established variants, a result which was then
replicated in an independent population-based Danish
cohort. Hence, this locus represents a textbook example of
how a large part of a trait’s heritability can be hidden in
infrequent genetic polymorphisms. The attempt to transfer
these results to lung function furthermore suggests that
effects of common variants in this genetic region in ever-
smokers may also be explained by rarer variants, but only
in individuals with hampered pulmonary health.
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causal polymorphism, the PI S variant, was less prominently
ranked (b=20.110 g/L per minor allele, P = 1.95*1026,
MAF= 5.70%) and exhibited an insufficient imputation quality
(imputation-r2=0.45).
GWAS on AAT Serum Level, Conditional on PI S and PI Z
Variants
Accuracy of the imputed PI S and PI Z results was confirmed by
direct genotyping of the samples [20]. The discovery arm revealed
33 PI Z carriers, 111 PI S carriers and two compound
heterozygous carriers of PI S and PI Z (MAF=1.26% for PI Z
and 4.06% for PI S, respectively). No homozygous PI S or PI Z
genotypes were detected.
To test the influence of these variants on the initially reported
GWAS results (Figure 1), we performed a conditional GWAS by
additionally adjusting the regression models for the presence of PI
S and PI Z alleles. We observed a drastic change in the
association of the SERPINA gene cluster SNPs with AAT serum
Figure 1. Manhattan plot of genome-wide -log(10) p-values for association with AAT serum level. SNPs reaching genome-wide
significance are shown in green. They all belong to the SERPINA gene cluster.
doi:10.1371/journal.pgen.1003585.g001
Table 1. The ten most strongly associated SNPs in the unconditional GWAS on AAT serum level in SAPALDIA (N = 1392).
SNP Chromosome Position Gene Location Determination MAF Imp-r2
Allele
Effect P
rs2736887 14 93882733 intergenic imputed 0.185 0.950 0.071 2.48E-13
rs926144 14 93883155 intergenic imputed 0.186 0.950 0.071 2.72E-13
rs7151526 14 93933389 SERPINA1 59UTR imputed 0.065 0.769 0.116 6.78E-13
rs4905179 14 93865245 SERPINA6 59UTR genotyped 0.180 1.000 0.068 1.20E-12
rs11621961 14 93839229 SERPINA6 39UTR genotyped 0.355 0.945 0.052 1.37E-11
rs17751837 14 93937997 SERPINA1 59UTR genotyped 0.097 0.995 0.063 8.56E-08
rs1028580 14 93919635 SERPINA1 intron imputed 0.154 0.979 0.051 4.87E-07
rs8010121 14 93920367 SERPINA1 intron genotyped 0.155 0.999 0.049 6.64E-07
rs3748312 14 93924017 SERPINA1 intron imputed 0.148 0.846 0.053 9.84E-07
rs17752593 14 94007781 SERPINA9 intron genotyped 0.129 0.997 0.053 1.59E-06
Abbreviations: AAT, alpha1-antitrypsin; GWAS, genome-wide association study; MAF, minor allele frequency; SNP, single nucleotide polymorphism.
Imp-r2 is an indicator for imputation quality. SNPs with MAF,0.05 or imp-r2,0.5 were excluded.
Chromosomal position is based on reference panel, NCBI build 36.3. Allele effects are shown in absolute numbers.
doi:10.1371/journal.pgen.1003585.t001
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level (Figure 3 and Table 2). The strong signal on chromosome
14 observed in the original GWAS disappeared completely and
the top-ranking imputed and genotyped SNPs (rs2736887 and
rs4905179) were no longer significant (P = 0.44 and 0.31,
respectively). In fact, no SNP was found near the SERPINA gene
cluster among the 100 most strongly associated common variants
(Table S5). In addition, the 1000G imputed data, comprising
sequences 1 Mb up- and downstream of the SERPINA1 gene, did
not show evidence of other independent AAT-associated SNPs.
An alternative approach that excluded all PI S and PI Z carriers
from the GWAS sample (N= 146), instead of adjusting for them,
confirmed the results. Both analyses revealed an intergenic region
on chromosome 3 with borderline genome-wide significance (top-
ranking SNP rs2566347, b=20.043 g/L per minor allele,
P = 7.88*1028, in the adjusted GWAS). The top SNPs in this
region were located in proximity to MFSD1 and RARRES1, which
are two genes with sparsely annotated function. The 1000G
imputation of this region did not reveal further variants. In
addition, we were unable to replicate this association signal in the
SAPALDIA replication arm (N= 4245, b=20.004 g/L per
minor allele, P = 0.46).
Replication in the Copenhagen City Heart Study
The effect of rs4905179, the top genotyped SNP in our GWAS,
on AAT serum levels was tested for replication in Copenhagen
(Table 3). The minor allele was associated with b=20.097 g/L
(P,0.0001, N=8332). As observed in the GWAS, adjustment for
PI S and Z polymorphisms resulted in a complete loss of this signal
(b=0.003 g/L, P= 0.57, N= 8273).
Impact of Common and Low-Frequent SERPINA1 Genetic
Variants on AAT Serum Level
In a first fine mapping step, 16 SERPINA1 SNPs (see Materials
and Methods section for a description of the SNP selection) were
successfully genotyped in 5569 SAPALDIA subjects (discovery and
replication arm combined). The genotype results in the discovery
arm allowed us to compare allele frequencies with imputed results
derived from the 1000G data. Table S6 shows that the agreement
was very high. Stepwise conditional regression analyses were then
applied to evaluate the independent effects of each of these SNPs
on AAT serum levels (Table 4). The PI Z variant was most
strongly associated with circulating levels of AAT. The PI S
variant remained strongly associated after conditioning on PI Z.
Two variants located in the 59 non-coding gene region (rs2896268
and rs1956707) were marginally associated with the phenotype in
two further steps after conditioning on PI S and PI Z. The total
variance of AAT explained by statistical models increased from
8.8% (model with only non-genetic factors) to 32.6% (adding PI S
and PI Z alleles), and to 32.8% adding rs2896268 and rs1956707.
Based on genotype data from the SAPALDIA cohort, the
SERPINA1 gene contains three haplotype blocks using D9-based
block definition (Figure 4). The AAT deficiency variants PI S and
PI Z are located in block 1, while rs2896268 and rs1956707 are
located in block 3, roughly 8 kb upstream of exon 1.
Impact of Rare SERPINA1 Genetic Variants on AAT Serum
Level
In a second fine mapping step, exon sequencing was performed
in 410 subjects with low AAT levels that were independent of the
Figure 2. Regional plot for the SERPINA gene cluster (93.8–94.2 Mb on chromosome 14q32.13, reference panel: NCBI build 36.3).
Presented are -log(10) p-values and LD (r2) with top-ranking SNP rs2736887 (purple diamond) for all SNPs in this region. The blue line shows
recombination rate.
doi:10.1371/journal.pgen.1003585.g002
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presence of PI S or PI Z alleles [21]. 16 additional SERPINA1
variants (two deletions and 14 SNPs) were detected, of which all
but one had already been described [21–29] (Table S7). Three
of the SNPs were synonymous, and five had no accession
numbers in public databases (as of April 1st, 2013). Most of the
non-synonymous SNPs have already been described as poten-
tially lowering AAT serum level, and computational tools only
classified one of them as no damaging to the protein’s tertiary
structure. In order to estimate the phenotypic influence of these
rare variants, we compared mean AAT blood levels, adjusted for
sex, age, study center, current smoking, as well as for the
presence of PI S and Z alleles, between samples without rare
variants (N= 346) and those with a single rare variant (N= 63)
or more than one (N= 1). The subjects with rare variants had a
lower adjusted mean AAT level (0.904 g/L, 95% CI 0.884 to
0.924 g/L) compared to those without rare variants (0.992 g/L,
95% CI 0.984 to 1.000 g/L, P,0.001). Although this difference
is small, the range covers the recently proposed upper limit of
intermediate AAT deficiency (0.92 g/L), a value with some
clinical relevance [20]. AAT levels of carriers of synonymous
mutations or non-synonymous mutations without predicted
damaging consequences to protein structure (N= 20) were not
different from those carrying no rare variants (0.985 vs. 0.990 g/
L, P= 0.77). Assuming that unsequenced samples were negative
for mutations with predicted deleterious functional effects, the
total variance of explained AAT further increased from 32.8%
to 35.4% (based on a statistical model adding all rare
mutations with predicted damaging consequences to the protein
structure).
Common and Low-Frequent SERPINA1 SNPs Previously
Associated with Lung Function
Results from a previous GWAS on emphysema [13] and a
large-scale evaluation of candidate loci on lung function [14]
pointed to a role of common variants in the SERPINA gene cluster.
The SNPs rs4905179 (associated with emphysema in smokers [13])
and rs3748312 (associated with cross-sectional lung function
among ever smokers [14]) were strongly associated with AAT in
our study (Tables 1 and 4), but both signals disappeared upon
adjustment for the low-frequent variants PI S and Z. In order to
clarify whether the association of the two common SNPs with
pulmonary health could also be explained by effects of the rarer
SNPs, we conducted a meta-analysis for cross-sectional lung
function in ever-smokers across 17 studies with a total sample size
of N= 24,446 (Table S2). We included nine studies which had
contributed to the original finding on lung function [14] and had
available genotypes or 1000G imputed genotype data on PI S and
Z. The meta-analysis in cohorts of general population study design
showed that rs4905179 was not associated with lung function in
ever-smokers (P = 0.90 in the fixed-effect meta-analysis,
N= 20,153, Figure 5). Yet smaller studies recruited within
population isolates showed a trend for the rare allele to be
associated with low lung function (random-effect P= 0.02,
N= 1623, Figure 5), and in contrast to the association with AAT
serum levels, adjusting for PI S and Z alleles did not modify the
association of rs4905179 with lung function (Figure 6). For the
second common SNP, rs3748312, we could nominally replicate
the statistically significant allele effect on FEV1 in the general
population of ever-smokers (P = 0.02, N=15,450), and the
Figure 3. Manhattan plot of genome-wide -log(10) p-values for association with AAT serum level, conditional on PI S and PI Z
alleles.
doi:10.1371/journal.pgen.1003585.g003
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stronger effect that was published [14] seems to be driven by
population isolates (Figure 7). Again, as for rs4905179, the
associations were not dependent on S and Z alleles (Figure 8).
Meta-analyses of the associations of PI S and Z alleles with lung
function revealed no consistent associations between these
functional AAT level determining variants and reduced FEV1
(Figures S3 and S4). Remarkably, the significant associations of
rs4905179 and rs3748312 with lung function assessed in two
additional studies with patients featuring compromised pulmonary
health and undergoing lung resection, showed evidence for
synthetic associations of the common SNPs with lung function
that are consistent with our results for circulating AAT (Table 5).
The minor alleles were associated with lower lung function and the
association completely disappeared when conditioned on the
presence of PI S and Z alleles.
Discussion
We present here the first GWAS on circulating AAT blood
levels. Our results confirm that genetic variation in the SERPINA1
gene is a strong determinant of serum AAT levels. Fine mapping
of SERPINA1 and subsequent stepwise regression analyses further
revealed that the associations with common variants in the
SERPINA locus could be attributed to rarer variants previously
identified to be causally linked with AAT deficiency.
There is an ongoing debate about whether rare variants are
responsible for the missing heritability observed in GWAS on
many complex outcomes [30]. We show here an example in which
the polymorphisms PI S and PI Z seem to account for basically all
observable effects of common variants in the SERPINA gene
cluster on AAT serum level. The top-ranking genotyped SNP in
our GWAS, rs4905179, was in low r2-based LD with PI S
(r2=0.18) and PI Z (r2=0.06), reflecting in part the unequal allele
frequencies of these SNPs. However, PI S and PI Z showed very
high LD in terms of D9 with the GWAS top signals (e.g. D9=0.95
and 0.96, respectively, with rs4905179) and generally with many
common variants in this locus (Figure 4), suggesting little genetic
recombination. This proof-of-principle approach, revealing that
signals of common variants in fact merely reflect rarer variants, has
recently also been shown for some of the loci regulating low-
density lipoprotein (LDL) cholesterol [31,32]. Yet for other loci
linked to LDL cholesterol, as well as for loci influencing other
traits, both common and low-frequent variants contributed
independently of the original GWAS signal to the phenotypic
trait [31,33,34].
Using regional 1000G imputation within the top-ranking loci
can allow the identification of additional association signals of
stronger size to support the initial GWAS top result, as observed
here for the SERPINA cluster, but not for the locus near MFSD1,
an association which was not confirmed in the SAPALDIA
replication arm. The resequencing strategy of the GWAS-
identified locus in a sample with low AAT concentrations yielded
in the identification of rare variants being strongly associated with
reduced AAT blood levels. Such an accumulation of rare variants
in the extreme range of the respective phenotype has also been
reported by others [35,36]. As for the relative contribution of
Table 2. The ten most strongly associated SNPs in the GWAS on AAT serum level, conditional on PI S and PI Z alleles in SAPALDIA
(N= 1392).
SNP Chromosome Position Gene Location Determination MAF Imp-r2
Allele
Effect P
rs2566347 3 159974071 intergenic imputed 0.192 0.998 0.043 7.88E-08
rs1560417 3 159972476 intergenic imputed 0.200 0.998 0.042 1.11E-07
rs1560418 3 159972335 intergenic genotyped 0.200 1.000 0.042 1.11E-07
rs1430414 3 159987697 MFSD1 59UTR imputed 0.137 0.984 0.045 9.26E-07
rs6761989 3 159983253 intergenic imputed 0.137 0.993 0.044 1.14E-06
rs17643917 3 159968433 intergenic imputed 0.137 1.000 0.044 1.23E-06
rs17643860 3 159967954 intergenic imputed 0.137 1.000 0.044 1.24E-06
rs17700475 3 159967627 intergenic genotyped 0.137 1.000 0.044 1.25E-06
rs3863076 3 159969394 intergenic genotyped 0.145 1.000 0.042 1.69E-06
rs2206593 1 184909052 PTGS2 39UTR genotyped 0.065 0.956 0.060 4.60E-06
Abbreviations: AAT, alpha1-antitrypsin; GWAS, genome-wide association study; MAF, minor allele frequency; SNP, single nucleotide polymorphism.
Imp-r2 is an indicator for imputation quality. SNPs with MAF,0.05 or imp-r2,0.5 were excluded.
Chromosomal position is based on reference panel, NCBI build 36.3. Allele effects are shown in absolute numbers.
doi:10.1371/journal.pgen.1003585.t002
Table 3. Minor allele effects of PI S, PI Z and rs4905179 on AAT serum levels in the Copenhagen City Heart Study.
SNP N MAF (genotyped) Allele Effect (g/L) 95% Confidence Intervals P
rs17580 (PI S) 8338 0.029 20.188 20.211 to 20.165 ,0.0001
rs28929474 (PI Z) 8338 0.027 20.492 20.514 to 20.470 ,0.0001
rs4905179 8332 0.186 20.097 20.107 to 20.087 ,0.0001
rs4905179, adjusted for PI S and Z 8273 0.186 0.003 20.007 to 0.013 0.57
Abbreviations: MAF, minor allele frequency; SNP, single nucleotide polymorphism.
doi:10.1371/journal.pgen.1003585.t003
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genetic variants on the phenotype, we confirmed that effect sizes of
PI S and Z on AAT serum levels were comparably strong,
explaining alone a high proportion of the total variability (24.2%).
We estimated that rare variants explained at least another 2% in
our population-based sample, but since we did not sequence the
entire SAPALDIA sample for rare variants, we cannot reliably
quantify this contribution. In terms of blood markers, similar
examples exist in which one genetic variant could explain well
above 5% of the phenotype’s variability (e.g. lipoprotein(a) [37],
bilirubin [38] or adiponectin [39]), but for many other markers
like serum lipid levels, only variants with small effects have been
detected so far [40].
Association patterns between SERPINA1 variants and circulat-
ing AAT did not translate to according associations with lung
function level in a straightforward manner. Lung function is a
complex phenotype associated with numerous genetic variants
[11,12]. Studies on the associations of SERPINA1 polymorphisms
with lung function and COPD have produced mixed results. It is
well accepted that severe AAT deficiency caused by PI null
mutations or by the presence of two PI Z alleles puts a subgroup of
carriers at higher risk of emphysema and COPD, especially when
smoking [5]. Studies on COPD found suggestive evidence for an
association with heterozygous status for the PI Z allele [6,8], but
we observed no associations in our meta-analysis between PI Z
and lung function level in ever-smokers. In the SAPALDIA
general population sample, we had previously reported that an
effect of the PI Z allele on lung function decline is restricted to
persistent smokers and primarily observed for forced expiratory
flow 25–75% [9]. Other variation in or close to the SERPINA1
gene has been proposed to play a role for pulmonary health. First,
a haplotype pattern of five common SNPs was reported to be more
frequent in COPD cases than in controls in a study with limited
statistical power [41]. The only SNP which was also separately
associated with COPD in that analysis was not associated with
reduced serum levels in our study (rs8004738, Table 4). Second,
the minor allele of rs4905179, which was the top signal in the
current AAT GWAS, was positively associated with emphysema
assessed by chest tomography in three independent cohorts
consisting of smoking COPD patients without severe AAT
deficiency (PI ZZ) [13]. Finally, the minor allele of the intronic
SNP rs3748312 was positively associated with lung function in
ever-smokers from different population-based studies of the
SpiroMeta Consortium [14]. The association of these two SNPs
with lung function in ever-smokers was heterogeneous across
studies in our meta-analysis. Dependency on PI S and Z was
limited to studies in patients with lung resection (Groningen,
UBC), consistent with the notion that SERPINA1 may only confer
risk in selected population subgroups.
There are several possible explanations for the poor translation
of genetic association patterns with serum AAT to lung function
and for the heterogeneity of associations between SERPINA1
variants and lung function. First, lung function is influenced by
mechanisms in addition to protease-antiprotease disequilibrium.
Second, the contribution of the SERPINA1 gene variants as a
Table 4. Common and low-frequent SERPINA1 SNPs and their association with AAT serum level, univariate and conditional on
significantly associated SNPs (N = 5569a), in SAPALDIA.
SNP Location Position Selectionb MAF Univariate
c Conditionald
Allele Effect P
Allele
Effect P
rs2896268 59UTR 93935461 C 0.495 0.006 0.10 0.013 4.1E-05
rs1956707 59UTR 93933946 C 0.038 0.016 0.10 0.029 5.0E-04
rs8004738 exon 1 93926667 D 0.490 0.005 0.15 0.001 0.81
rs1570142 intron 1 93926015 A,B,C 0.488 0.005 0.19 0.001 0.88
rs3748312 intron 1 93924017 A,B 0.153 0.035 2.4E-12 0.002 0.70
rs3748316 intron 1 93923617 A,C 0.181 0.011 0.02 0.002 0.63
rs3748317 intron 1 93923432 A 0.158 0.020 5.5E-05 0.004 0.36
rs1980617 intron 1 93922287 A 0.389 0.030 5.0E-16 0.003 0.31
rs1980618 intron 1 93922176 A,C 0.383 0.030 1.3E-16 0.005 0.15
rs2753935 intron 1 93920690 A 0.435 0.012 9.7E-04 0.004 0.24
rs2144831 intron 1 93919723 A,C 0.240 0.021 9.8E-07 0.002 0.71
rs709932 exon 2 93918954 A,C 0.169 0.021 1.2E-05 0.003 0.50
rs6647 exon 3 93917168 A,C 0.200 0.026 7.2E-09 0.003 0.51
rs17580 (PI S) exon 3 93917015 D 0.041 0.210 1.9E-127 0.218 1.9E-163
rs28929474 (PI Z) exon 5 93914700 D 0.013 0.483 1.3E-240 0.482 5.2E-269
rs1303 exon 5 93914596 A,C 0.247 0.015 4.7E-04 0.001 0.89
Abbreviations: AAT, alpha1-antitrypsin; MAF, minor allele frequency; SNP, single nucleotide polymorphism.
Chromosomal position is based on reference panel, NCBI build 36.3.
aIncludes subjects for whom all the 16 SNPs have been successfully genotyped.
bSNP selection was based on extreme trait sequence data (A), tagging SNPs according to HapMap (B), TAMAL software (C) and publication about functionality (D); see
Materials and Methods for a more detailed description.
cUnivariate analyses were adjusted for non-genetic factors only (sex, age, recruiting area and current smoking status). Allele effects are shown in absolute numbers and
P,0.005 was considered statistically significant.
dIn a forward selection approach of stepwise regression, the four SNPs in bold contributed statistically significantly to the variability in AAT serum levels and were
included in the final statistical model. Allele effects and p-values refer to this final model.
doi:10.1371/journal.pgen.1003585.t004
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determinant of lung function likely depends on both the
evolutionary pressure in isolated populations and the prevalence
of effect modifiers in the respective study populations. These
include smoking and smoking intensity, and likely other markers of
inflammation. AAT itself plays a dual role in its relationship with
lung function. While chronic AAT deficiency is etiologically
associated with adverse pulmonary health, individuals with lung
function impairment in fact exhibit higher AAT levels for a given
genetic background due to AAT’s role as an acute-phase
inflammation marker [42,43]. Third, tissue-specific regulation of
the SERPINA1 locus may play an important role. Serum AAT
levels are driven by SERPINA1 expression, protein formation and
secretion in hepatocytes, so that regulatory SNPs associated with
serum AAT likely reflect processes in the liver. One way to infer
causality of potentially regulatory SNPs is by testing if they are
simultaneously associated with health outcome and gene expres-
sion in the relevant tissue [44]. We therefore conducted a look-up
in an expression quantitative loci (eQTL) database of lung tissue
[45], but could not find any common variant which was
significantly associated in cis with the transcripts deriving from
the SERPINA1 locus. In a recent study on networks of blood
metabolites, the SNPs rs11628917 and rs1884549 were the most
strongly associated blood and liver eQTLs with respect to
SERPINA1 expression [46]. They both lie in the 39 untranslated
region of SERPINA1, but were not associated with blood AAT in
our GWAS (P= 0.80 and P=0.21, respectively). Moreover, we
could not detect epistasis between those variants and the
deleterious coding variants PI S and Z in terms of AAT serum
levels. The absence of such an interaction does not point to
regulatory function of the common SNPs [47] and argues in favor
of tissue-specific heterogeneity. Forth, the role of SERPINA1 in
selected subgroups of persons exhibiting accelerated lung function
decline or COPD needs to be considered from a perspective
beyond genetic variation, as a recent study investigating epigenetic
mechanisms of disease revealed methylation status of the
SERPINA1 gene to be most strongly associated with cross-sectional
lung function and COPD [48].
The strength of this study is that it combines the report of a
GWAS on AAT serum levels with meta-analyses of the
associations of some of the GWAS top variants with lung
function. The effects of the underlying functional variants are
thoroughly investigated resulting in the hitherto largest meta-
Figure 4. LD plot among common and low-frequent SNPs in the SERPINA1 gene within the SAPALDIA study. Shading represent r2
values, whereas numbers represent D9 values (no number equals D9=1). Red framed SNPs are independently associated with AAT serum levels after
forward selection stepwise regression modeling. Rs17580 is the PI S variant and rs28929474 is the PI Z variant.
doi:10.1371/journal.pgen.1003585.g004
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analysis of PI S and Z on FEV1 in ever-smokers. Ascertainment
and study design of the many participating studies were
sufficiently diverse to informatively address heterogeneity in
association of common and rarer variants in the SERPINA gene
cluster with lung function. The strength of the discovery sample
is the population-based study design and the detailed charac-
terization of the participants. Sex, age and smoking are
important modifiers of AAT blood levels in the general
population [43] and were included in all regression models.
More refined smoking variables covering smoking intensity were
not included as this information is less complete than smoking
status in SAPALDIA and would lower the sample size. By
excluding samples with elevated hs-CRP values we avoided the
masking of AAT deficiencies due to a chronic or acute
inflammation. On the methodological side, conditional analysis
is a well-established tool for identifying independent signals
within a certain locus [38,49,50]. Furthermore, 1000G imputa-
tion was able to point to the causal variant demonstrating its
reliability to correctly assign alleles close to the 1% MAF
threshold.
The limitations of this investigation include firstly the small
sample size of the GWAS discovery arm, resulting in a high
susceptibility to false negative findings. We calculated 63% power
to detect SNPs with an allele effect of 0.1 g/L AAT serum level
( = 2.4% of the phenotypic variance) to a genome-wide significance
level of 5*1028. However, if we define the clinically important
threshold of AAT as the upper limit of intermediate AAT
deficiency, which has been recently suggested as 0.92 g/L [20], we
have more than 99.9% power to detect such a large-impact
variant. Nevertheless, genes that contribute to AAT serum levels
with smaller effects than SERPINA1 were likely to be missed. This
could be a reason why neither SNPs in interleukin 6 (IL-6) nor in
hepatocyte nuclear factor 1a (HNF-1a)/HNF-4, both important
regulators of AAT expression [51], were associated with circulat-
ing AAT concentrations. Furthermore, by sequencing only the
coding region of SERPINA1, rare variants in introns and outside
the gene could not be determined. Another potential limitation of
our GWAS on AAT serum level is the overrepresentation of
asthmatics in the discovery sample. Asthma patients usually show
higher levels of inflammatory markers in their lungs. However, we
did not find heterogeneity in the effects of the most strongly
associated SNPs when comparing asthmatics with non-asthmatics.
Moreover, AAT mean values between the discovery and the
replication arm were not significantly different, as participants
with elevated hs-CRP had been excluded.
In conclusion, our study confirms the SERPINA1 locus as the
major genetic determinant of AAT blood levels. Methodolog-
ically, it represents a powerful example how low-frequent
variants, separated by several kilobases from the top-ranking
GWAS signals, can create purely synthetic associations which
do not add to the variance of the respective outcome. In terms
of lung function, our data do not support a functional role of
Figure 5. Forest plot of meta-analyzed results for the effect per minor allele of rs4905179 on FEV1 in ever-smokers, adjusted for
sex, age, height and population stratification factors. Studies based on population isolates with a high degree of cryptic relatedness are
presented separately. Effect estimates of meta-analyses are shown with green diamonds. I2 is a measure of the heterogeneity between studies.
Random effect meta-analyses are included if I2.0.5. Study weights (blue squares) correspond to fixed effect meta-analyses.
doi:10.1371/journal.pgen.1003585.g005
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any common SNP in the SERPINA cluster in the general
population.
Materials and Methods
Ethics Statement
SAPALDIA was approved by the Swiss Academy of Medical
Sciences, the national ethics committee for clinical research
(UREK, Project Approval Number 123/00) and the Cantonal
Ethics Committees for each of the eight examination areas
(Ethics commissions of the cantons Aargau, Basel, Geneva,
Grisons, Ticino, Valais, Vaud and Zurich). Participants were
required to give written consent before any part of the health
examination was conducted either globally (for all health
examinations) or separately for each investigation. For ethics
statements of the additional studies contributing to this work, see
Table S8.
Study Population
SAPALDIA. In 1991, a random sample of 9651 adults,
aged 18–60 years, from eight areas in Switzerland responded
to a questionnaire about respiratory health, occupational and
lifestyle exposures. 99.0% of them also underwent spirometry
testing [52]. Eleven years later, 8047 persons were reassessed
and 6058 subjects provided blood samples and consented to
DNA analysis [53]. In the present study, we used a subgroup of
the second survey (N = 1640) that underwent genotyping in the
context of the GWAS on asthma by the GABRIEL consortium
[17]. This sample included all asthmatics (positive answer to
the question ‘‘Have you ever had asthma?’’ at either survey) as
well as a random sample of non-asthmatic controls. 248
participants were removed due to several reasons, including
elevated levels of the inflammatory marker hs-CRP (.10 mg/
L, N = 54), leading to a discovery arm of 1392 individuals
(Figure S1). The discovery arm contained 548 (39.4%) self-
declared asthmatics, whereas there were no self-declared
asthmatics in the replication arm. Both the discovery and the
replication sample were submitted to a first step of fine
mapping of SERPINA1 resulting in 5569 individuals from
whom all the selected SNPs could be successfully determined.
In a second step, a subsample with abnormally low AAT
measurements additionally underwent SERPINA1 exon se-
quencing.
Additional Studies. The populations are briefly described in
Table S8.
Phenotype Measurements
AAT serum levels in SAPALDIA were determined by latex-
enhanced immunoturbidimetric assays (Roche Diagnostics, on a
Roche Cobas Integra analyzer) with interassay coefficients of
Figure 6. Forest plot of meta-analyzed results for the effect per minor allele of rs4905179 on FEV1 in ever-smokers, adjusted for
sex, age, height, population stratification factors and the presence of PI S and Z alleles. Studies based on population isolates with a high
degree of cryptic relatedness are presented separately. Effect estimates of meta-analyses are shown with green diamonds. I2 is a measure of the
heterogeneity between studies. Random effect meta-analyses are included if I2.0.5. Study weights (blue squares) correspond to fixed effect meta-
analyses.
doi:10.1371/journal.pgen.1003585.g006
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variation below 5% and lower detection rate of 0.21 g/L. Serum
concentrations in Copenhagen were measured by immunoturbidi-
metric assays (Thermo Scientific, on a Thermo Scientific Konelab
analyzer) with coefficients of variation below 5% and lower
detection rate of 0.10 g/L.
Lung function was measured in all participating studies by
spirometry without bronchodilation ([52] and Table S8). In the
patient-based studies, in which a lung resection was carried out
(Groningen, UBC), lung function measurements were carried out
prior to the intervention.
Genotyping
SAPALDIA. Genomic DNA was extracted from blood sam-
ples using the Puregene DNA Isolation Kit (Gentra Systems).
Genotyping of the GWA-bound subset was performed on the
Illumina Human 610quad array. Asthmatic and non-asthmatic
samples were tested in random blinded order to avoid systematic
array-related artifacts. 567,589 autosomal SNPs were satisfactorily
genotyped (mean call rate: 99.7%). 69,892 were excluded from
analysis due to violation of Hardy Weinberg Equilibrium (HWE,
P,1024), low call rate (,97%) or MAF,5%.
Genotyping of GWAS finding rs2566347 on chromosome 3 in
the SAPALDIA replication arm was carried out using the
MassARRAY iPLEX Gold (Sequenom).
The SNPs selected in the first fine mapping step were genotyped
by polymerase chain reaction (PCR) with fluorescently labeled
Taq-Man probes (Vic or Fam labels) on a Light Cycler 480 (Roche
Diagnostics). All SNPs were in HWE (P.0.01) [20].
Additional Studies. PI S and Z genotypes were determined
by PCR in Copenhagen and LHS as previously described [54,55].
The SNP rs4905179 was genotyped in the course of GWAS
projects in B58C, BHS, Copenhagen, Korcula, KORA S3,
KORA F4, LBC36, LHS, NSPHS, ORCADES, Split, UBC,
and Vis.
Imputation
SAPALDIA. We have carried out genome-wide imputation
from 60 CEU HapMap2 (release 22, NCBI build 36) reference
panels [18] using MACH 1.0.16 [56] resulting in 2,588,592
autosomal HapMap-based SNPs. 2,168,668 SNPs fulfilled the
quality criteria, which are as mentioned above for genotyped SNPs
and additionally consisted of an imputation-r2.0.5.
Further imputation was carried out in the most promising loci
using 566 EUR reference haplotypes from the August 2010 release
of 1000G on the MACH (pre-phasing) and Minimac-omp
programs. SNPs with an imputation-r2.0.5 and MAF.0.1%
passed the quality check.
Additional Studies. Rs4905197 was imputed based on
1000G reference panels in Groningen, NFBC66, and SHIP
(imputation-r2$0.99). Rs3748312, rs17580 (PI S) and rs28929474
(PI Z) were 1000G imputed in B58C, BHS, Groningen, Korcula,
KORA S3, KORA F4, LBC36, NFBC66, NSPHS, ORCADES,
Figure 7. Forest plot of meta-analyzed results for the effect per minor allele of rs3748312 on FEV1 in ever-smokers, adjusted for
sex, age, height and population stratification factors. Studies based on population isolates with a high degree of cryptic relatedness are
presented separately. Effect estimates of meta-analyses are shown with green diamonds. I2 is a measure of the heterogeneity between studies.
Random effect meta-analyses are included if I2.0.5. Study weights (blue squares) correspond to fixed effect meta-analyses.
doi:10.1371/journal.pgen.1003585.g007
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Split, SHIP, UBC, and Vis (imputation-r2 0.86–0.98, 0.69–0.83,
and 0.82–0.98, respectively).
SERPINA1 SNP Selection for Fine Mapping in SAPALDIA
In an attempt to find AAT modifying SERPINA1 gene variants
acting independently of each other, a multiple strategy to
optimally cover the gene was applied. Sequencing of the whole
SERPINA1 gene in 25 unrelated samples from the Italian registry
of AAT deficiency which demonstrated extreme phenotypes was
used to identify common SNPs not present in HapMap. Extreme
phenotypes consisted of 11 samples with AAT.1.60 g/L and hs-
CRP ,8 mg/L, 3 samples with PI ZZ or PI SZ genotype and
AAT,0.20 g/L, 2 samples with PI MZ genotype and
AAT,0.60 g/L, as well as 9 non-carriers of PI S or PI Z alleles
Figure 8. Forest plot of meta-analyzed results for the effect per minor allele of rs3748312 on FEV1 in ever-smokers, adjusted for
sex, age, height, population stratification factors and the presence of PI S and Z alleles. Studies based on population isolates with a high
degree of cryptic relatedness are presented separately. Effect estimates of meta-analyses are shown with green diamonds. I2 is a measure of the
heterogeneity between studies. Random effect meta-analyses are included if I2.0.5. Study weights (blue squares) correspond to fixed effect meta-
analyses.
doi:10.1371/journal.pgen.1003585.g008
Table 5. Minor allele effects on FEV1 of low-frequent and common SNPs in the SERPINA gene cluster in ever-smokers undergoing
lung resection.
SNP MAF Imp-r
2
Allele
Effect (L) P MAF Imp-r2
Allele
Effect (L) P
Groningen (N=133) University of British Columbia, UBC (N=264)
rs17580 (PI S) 0.055 0.72 0.42 0.10 0.079 0.76 20.15 0.29
rs28929474 (PI Z) 0.123 0.98 20.68 ,0.001 0.032 0.98 20.81 ,0.0001
rs4905179 0.299 1.00 20.22 0.04 0.249 naa 20.23 0.002
rs4905179, adjusted for PI S and Z 20.07 0.65 20.08 0.36
rs3748312 0.233 0.95 20.34 0.008 0.148 0.94 20.16 0.07
rs3748312, adjusted for PI S and Z 0.16 0.37 0.09 0.35
Abbreviations: FEV1, forced expiratory volume in one second; MAF, minor allele frequency; SNP, single nucleotide polymorphism.
Imp-r2 is an indicator for imputation quality. The analyses were adjusted for age, sex and height.
aRs4905179 was genotyped in UBC.
doi:10.1371/journal.pgen.1003585.t005
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with blood levels .0.65 and ,1.10 g/L. In these 25 samples, a
total of 129 mutations were identified in the SERPINA1 gene. After
removing SNPs which were monomorphic in our data, SNPs
deviating from HWE or lying in high LD with an adjacent marker
(D9.0.8 and r2.0.4 according to JLIN [57]), we finally obtained a
list of 22 common SNPs (Table 4, selection A). In a second
strategy, HapMap CEU data was used to select tagging SNPs
(Haploview 3.32) [58], resulting in 8 polymorphisms (selection B).
Third, TAMAL [59] was used to identify promising SNPs in the
region of the SERPINA1 gene (selection C). Pairwise LD and the
feasibility of designing a corresponding TaqMan assay reduced the
number of SNPs to 13. Two established (PI S and Z) and one
suggestive (rs8004738 [60]) functional SNPs were added (selection
D), resulting in 16 SNPs used in the conditional analysis. Three of
them were already part of the SNP array genotyped for the
GWAS. The 5 SNPs in coding regions (exons 2–5) were all non-
synonymous.
Exon Sequencing in SAPALDIA
We sequenced 410 individuals with abnormally low AAT levels
with the Sanger chain-termination method. Different thresholds
according to the deficiency genotypes and hs-CRP values were
applied to define an abnormally low AAT concentration (PI MM:
1.13 g/L if hs-CRP .8 mg/L and 1.00 g/L if hs-CRP #8 mg/L;
PI MS: 0.85 g/L; PI MZ: 0.65 g/L) [21]. The cut-off of 1.13 g/L
was earlier reported to be the best to differentiate AAT-deficient
patients from healthy individuals [61]. Since exon 1 is non-coding,
the sequencing procedure was only applied to exons 2 to 5.
Statistical Analysis
AAT serum levels were only marginally skewed to the right,
and a log-transformation of these data was omitted since it led to
a stronger deviation from normality. Student’s t-test was used to
compare adjusted mean AAT levels between different subgroups
of the sequenced samples. The genome-wide association of 2.17
million quality-controlled SNPs with serum AAT levels was
assessed using fixed effects linear regression with ProbABEL [62].
An additive genetic model was applied and the association was
adjusted for sex, age, study center, dichotomous current smoking
status, as well as population stratification factors. To account for
population stratification, we relied on previously inferred
ancestry-informative principal components using EIGENSTRAT
2.0 software [63] and HapMap data, as well as additional
reference European samples [64]. Cryptic relatedness was
detected based on identity-by-state (IBS) analysis. Influence of
additional suggestive determinants of AAT, such as hs-CRP,
BMI, alcohol intake and passive smoking was assessed in a
sensitivity analysis. We also performed genome-wide analysis
conditioned on the functionally established PI S and PI Z
variants. Bonferroni correction for multiple testing was applied,
resulting in P,5*1028 to designate genome-wide significance,
taking account of one million independent tests for common
variants across the genome. For the SNPs imputed by using
1000G reference samples, we considered a three times lower p-
value as adequate as roughly three times more SNPs on
chromosome 14 passed an imputation-r2 threshold of 0.5
(219,471 1000G-derived variants vs. 82,296 HapMap2-derived
variants). Applying this to a 2 Mb chromosomal stretch (with
approximately 600 HapMap2-derived SNPs) resulted in a
significance threshold of roughly 3*1025.
For the replicated SNP in the SAPALDIA replication arm, as
well as for the lung function analysis, a two-sided p-value of 0.05
was considered significant. We investigated heterogeneity between
asthmatics and non-asthmatics in the discovery arm by testing for
a difference between the two effects, using a chi-square test with
one degree of freedom.
Replication analysis for AAT in Copenhagen, as well as
association analyses of the 16 genotyped SERPINA1 SNPs in both
the SAPALDIA discovery and replication arm, was carried out
applying the same statistical model as in the GWAS apart from the
adjustment for population stratification factors. Stepwise condi-
tional analyses were conducted by testing each SNP for AAT
association after including at each step the most significantly
associated SNP in the model. As some of these SNPs turned out to
be in unexpectedly high LD, we applied a threshold level for
statistical significance of P= 0.005, accounting for approximately
ten independent tests [65].
To be as close as possible to the calculations carried out in the
original publication [14], multivariate linear regression models for
lung function analyses were used adjusted for sex, age, height and
population stratification factors (if available).
All the SAPALDIA regression analyses were performed with
STATA 12.1 IC.
Further Software
Manhattan, Q-Q and forest plots were created with the help of
R 2.15.1 (www.r-project.org). Regional association plots were
drawn using LocusZoom [66]. Pairwise LD was calculated for
HapMap2 and 1000G CEU data using SNAP [67]. The LD plot
was produced with HaploView 4.2 [58]. The effect of non-
synonymous SNPs on protein structure was predicted by SIFT
[68]. Finally, Quanto 1.2.4 (hydra.usc.edu/gxe/) was used for
power calculations for the GWAS.
Supporting Information
Figure S1 SAPALDIA study design for the determination of
AAT associated genetic variants.a consisting of subjects with
abnormally low AAT levels independent of PI S or Z alleles (see
Materials and Methods).
(TIF)
Figure S2 Q-Q plot of genome-wide -log(10) p-values for
association with AAT serum level.
(TIF)
Figure S3 Forest plot of meta-analyzed results for the effect per
minor allele of rs17580 (PI S) on FEV1 in ever-smokers, adjusted
for sex, age, height and population stratification factors. Studies
based on population isolates with a high degree of cryptic
relatedness are presented separately. Effect estimates of meta-
analyses are shown with green diamonds. I2 is a measure of the
heterogeneity between studies. Random effect meta-analyses are
included if I2.0.5. Study weights (blue squares) correspond to the
fixed effect meta-analyses.
(TIF)
Figure S4 Forest plot of meta-analyzed results for the effect per
minor allele of rs28929474 (PI Z) on FEV1 in ever-smokers,
adjusted for sex, age, height and population stratification factors.
Studies based on population isolates with a high degree of cryptic
relatedness are presented separately. Effect estimates of meta-
analyses are shown with green diamonds. I2 is a measure of the
heterogeneity between studies. Random effect meta-analyses are
included if I2.0.5. Study weights (blue squares) correspond to the
fixed effect meta-analyses.
(TIF)
Table S1 Characteristics of SAPALDIA follow-up participants
belonging to the discovery (N= 1392) and replication arm
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(N= 4245), and of participants of the Copenhagen City Heart
Study (N= 8273).
(DOC)
Table S2 Characteristics of study populations contributing to
the SNP association analyses with FEV1.
(XLS)
Table S3 The top 100 ranking SNPs associated with AAT
serum level in SAPALDIA (N=1392).
(DOC)
Table S4 SERPINA regional variants based on 1000 Genomes
imputation reaching statistical significance for the association with
AAT serum level in SAPALDIA (N=1392).
(DOC)
Table S5 The top 100 ranking SNPs associated with AAT
serum level, conditional on PI S and Z alleles in SAPALDIA
(N=1392).
(DOC)
Table S6 Accuracy of 1000 Genomes based imputation in the
SERPINA1 region in SAPALDIA (N=1392).
(DOC)
Table S7 Further variants in the SERPINA1 coding region,
present in a SAPALDIA subsample with abnormally low AAT
serum levels (N=410).
(DOC)
Table S8 Descriptions and acknowledgments of individual
studies contributing to the SNP association analyses with FEV1.
(XLS)
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 Table S1. Characteristics of SAPALDIA follow-up participants belonging to the discovery 
(N=1392) and replication arm (N=4245), and of participants of the Copenhagen City Heart 
Study (N=8273). 
 
 
SAPALDIA 
discovery  
SAPALDIA 
replication  
Copenhagen City 
Heart Study 
Age (mean; SD), years 52.17; 11.18 52.17; 11.40 57.91; 15.12 
% women 51.29 50.27 55.12 
% current smokers 23.20 25.06 (N=4237) 48.29 
% asthmaticsa 39.37 0 (N=4239) 6.01 
FEV1 (mean; SD), mL 3530; 859 (N=1329) 3607; 828 (N=4032) 2728; 1021 
% airflow obstructiveb 25.14 (N=1281) 20.48 (N=3916) 17.42 
AAT blood levels (mean; SD), g/L 1.257; 0.200 1.255; 0.199 1.339; 0.276 
 
Abbreviations: AAT, alpha1-antitrypsin; FEV1, forced expiratory volume in one second; 
FVC, forced vital capacity; SD, standard deviation. 
a
 Defined as self-reported at baseline or follow-up. 
b Defined as pre-bronchodilation FEV1/FVC ratio <0.7. 
 Table S2. Characteristics of study populations contributing to the SNP association analyses with FEV1. 
  
Study 
Sample Size 
(Ever Smokers) Women [%] 
Age [years], 
mean; SD 
FEV1 [ml], 
mean; SD 
Current smokers 
[%] 
Height 
[cm], mean; 
SD 
BMI 
[kg/m2], 
mean; SD 
British 1958 Birth Cohort (B58C) 4225 49.2 45.1; 0.4 3268; 473 33.2 169.6; 6.3 27.3; 4.8 
Busselton Health Study (BHS) 1977 46.1 53.5; 15.9 2980; 951 28.0 169.6; 9.2 26.5; 4.2 
Copenhagen City Heart Study 
(Copenhagen) 6437 51.8 58.6; 14.4 2671; 993 62.6 168.6; 9.4 25.6; 4.3 
Kooperative 
Gesundheitsforschung in der 
Region Augsburg (KORA S3) 536 45.9 44.2; 8.6 3617; 821 45.2 171.3; 9.2 25.5; 3.8 
Kooperative 
Gesundheitsforschung in der 
Region Augsburg (KORA F4) 802 48.0 51.5; 5.7 3368; 807 36.2 170.8; 9.1 27.6; 5.1 
Lothian Birth Cohort 1936 (LBC36) 554 42.2 69.6; 0.8 2332; 705 22.2 167.0; 8.7 28.0; 4.5 
Lung Health Study (LHS) 539 37.5 48.6; 6.7 2591; 574 100.0 171.3; 8.6 na 
Northern Finland Birth Cohort 
1966 (NFBC66) 3324 52.0 31.0; 0.2 3973; 788 61.5 171.5; 9.1 24.8; 4.3 
SAPALDIA 3037 44.4 42.0; 10.5 3617; 815 56.0 170.2; 8.6 24.0; 3.6 
Study of Health in Pomerania 
(SHIP) 995 39.0 46.5; 13.8 3380; 871 57.9 171.5; 8.6 28.1; 4.8 
CROTIA-Korcula (Korcula) 423 55.1 52.7; 13.1 2892; 748 46.3 170.1; 8.9 27.5; 4.2 
Northern Swedish Population 
Health Study (NSPHS) 121 52.1 51.5; 16.8 2788; 1005 100.0 164.3; 9.8 25.9; 4.3 
Orkney Complex Disease Study 
(ORCADES) 288 43.8 55.7; 15.0 2903; 828 20.8 168.6; 8.5 27.9; 4.8 
CROTIA-Split (Split) 254 53.1 49.1; 13.4 3207; 876 48.0 173.7; 9.1 26.9; 4.2 
CROTIA-Vis (Vis) 537 43.6 53.1; 14.8 3677; 116 45.5 170.1; 9.5 27.2; 4.4 
eQTL-Groningen (Groningen) 133 47.7 57.2; 10.2 2200; 900 23.0 172.1; 10.2 23.9; 3.9 
eQTL-University of British 
Columbia (UBC) 264 44.3 60.7; 13.2 2200; 830 37.9 167.9; 10.4  25.5; 5.3 
Table S3. The top 100 ranking SNPs associated with AAT serum level in SAPALDIA (N=1392). 
 
SNP Chromosome Position Gene Location Determination MAF Imp-r2 Allele Effect P 
rs2736887 14 93882733 intergenic imputed 0.185 0.950 0.071 2.48E-13 
rs926144 14 93883155 intergenic imputed 0.186 0.950 0.071 2.72E-13 
rs7151526 14 93933389 SERPINA1 5‘UTR imputed 0.065 0.769 0.116 6.78E-13 
rs4905179 14 93865245 SERPINA6 5‘UTR genotyped 0.180 1.000 0.068 1.20E-12 
rs11621961 14 93839229 SERPINA6 3‘UTR genotyped 0.355 0.945 0.052 1.37E-11 
rs17751837 14 93937997 SERPINA1 5‘UTR genotyped 0.097 0.995 0.063 8.56E-08 
rs1028580 14 93919635 SERPINA1 intron imputed 0.154 0.979 0.051 4.87E-07 
rs8010121 14 93920367 SERPINA1 intron genotyped 0.155 0.999 0.049 6.64E-07 
rs3748312 14 93924017 SERPINA1 intron imputed 0.148 0.846 0.053 9.84E-07 
rs17752593 14 94007781 SERPINA9 intron genotyped 0.129 0.997 0.053 1.59E-06 
rs2566347 3 159974071 intergenic imputed 0.192 0.998 0.044 1.87E-06 
rs4703798 5 79448084 SERINC5 intron genotyped 0.386 0.999 0.035 2.73E-06 
rs11160184 14 94007744 SERPINA9 intron imputed 0.144 0.933 0.049 4.42E-06 
rs1430414 3 159987697 MFSD1 5‘UTR imputed 0.137 0.984 0.048 4.44E-06 
rs1560417 3 159972476 intergenic imputed 0.200 0.998 0.041 5.06E-06 
rs1560418 3 159972335 intergenic genotyped 0.200 1.000 0.041 5.07E-06 
rs6761989 3 159983253 intergenic imputed 0.137 0.993 0.047 5.44E-06 
rs17643917 3 159968433 intergenic imputed 0.137 1.000 0.047 5.99E-06 
rs17643860 3 159967954 intergenic imputed 0.137 1.000 0.047 6.02E-06 
rs17700475 3 159967627 intergenic genotyped 0.137 1.000 0.047 6.04E-06 
rs6580353 5 139390871 NRG2 intron genotyped 0.248 0.948 0.039 6.63E-06 
rs6893779 5 129825798 intergenic imputed 0.188 0.980 0.041 7.63E-06 
rs6595951 5 129874072 intergenic genotyped 0.182 0.999 0.042 8.17E-06 
rs12089980 1 150698555 intergenic genotyped 0.091 1.000 0.054 9.47E-06 
rs7731657 5 129971218 intergenic imputed 0.170 0.942 0.044 1.01E-05 
rs4836515 5 129965471 intergenic imputed 0.170 0.951 0.044 1.03E-05 
rs10069896 5 129938264 intergenic imputed 0.171 0.971 0.043 1.04E-05 
rs10035791 5 129919660 intergenic genotyped 0.172 1.000 0.042 1.05E-05 
rs10039487 5 129980823 intergenic imputed 0.169 0.941 0.044 1.13E-05 
rs10276467 7 2701239 AMZ1 intron genotyped 0.089 0.987 0.056 1.18E-05 
rs6874868 5 129825862 intergenic imputed 0.185 0.989 0.041 1.18E-05 
rs12516876 5 129818959 intergenic imputed 0.185 0.989 0.041 1.28E-05 
rs7714333 5 6370260 FLJ33360 intron genotyped 0.459 0.972 0.032 1.32E-05 
rs16882595 8 112874500 intergenic imputed 0.243 0.987 0.038 1.33E-05 
rs12479315 2 56960739 intergenic imputed 0.491 0.963 0.032 1.38E-05 
rs2216407 2 56963650 intergenic imputed 0.491 0.969 0.032 1.39E-05 
rs12081541 1 150707990 intergenic imputed 0.091 0.904 0.056 1.43E-05 
rs16861952 3 150735514 WWTR1 intron imputed 0.074 0.981 0.060 1.45E-05 
rs7141205 14 93838612 SERPINA6 3‘UTR genotyped 0.179 0.954 0.043 1.49E-05 
rs13181256 5 129806017 intergenic imputed 0.184 0.980 0.041 1.53E-05 
rs4150667 11 18339487 GTF2H1 intron genotyped 0.310 0.999 0.034 1.62E-05 
rs4263026 18 71438977 intergenic imputed 0.198 0.983 0.039 1.72E-05 
rs3863076 3 159969394 intergenic genotyped 0.145 1.000 0.044 1.73E-05 
rs12497958 3 160010142 MFSD1 intron imputed 0.109 1.000 0.050 1.82E-05 
rs6441226 3 160008917 MFSD1 intron genotyped 0.109 1.000 0.050 1.82E-05 
rs256435 5 79441982 SERINC5 3‘UTR imputed 0.438 0.789 0.035 1.84E-05 
rs7624420 3 159993368 MFSD1 5‘UTR imputed 0.102 0.990 0.052 1.85E-05 
rs13184933 5 129873782 intergenic imputed 0.203 0.935 0.039 1.86E-05 
rs2041342 7 2696291 AMZ1 intron imputed 0.093 0.924 0.055 1.94E-05 
rs9348171 6 167009010 RPS6KA2 intron imputed 0.207 0.916 0.038 2.18E-05 
rs12462442 19 18094195 MAST3 intron imputed 0.142 1.000 0.043 2.30E-05 
rs11086090 19 18093754 MAST3 intron genotyped 0.142 1.000 0.043 2.30E-05 
rs756322 10 72414636 intergenic imputed 0.089 0.680 0.065 2.51E-05 
rs6420430 16 80703651 HSD17B2 3‘UTR imputed 0.094 0.961 0.053 2.59E-05 
rs1251581 1 76198013 ASB17 5‘UTR imputed 0.377 0.956 0.032 2.78E-05 
rs10771459 12 29026497 intergenic imputed 0.436 0.994 0.030 2.80E-05 
rs10936162 3 160018817 MFSD1 intron imputed 0.109 0.973 0.050 2.83E-05 
rs2399702 15 95849200 intergenic imputed 0.078 0.638 0.070 2.86E-05 
rs12611216 19 18095005 MAST3 intron imputed 0.145 0.984 0.042 2.89E-05 
rs8104096 19 2561822 GNG7 intron genotyped 0.253 0.979 0.035 2.89E-05 
rs1689271 1 76165450 ASB17 intron imputed 0.365 0.948 0.032 3.05E-05 
rs12372252 12 29025493 intergenic imputed 0.436 0.995 0.030 3.15E-05 
rs12605699 18 71433743 intergenic imputed 0.190 0.857 0.041 3.23E-05 
rs17290460 13 73463470 KLF12 intron imputed 0.096 0.927 0.052 3.35E-05 
rs2281143 6 167015841 RPS6KA2 intron imputed 0.222 0.986 0.035 3.45E-05 
rs4835994 5 129749756 intergenic imputed 0.173 0.972 0.040 3.46E-05 
rs1658737 1 76240227 intergenic imputed 0.371 0.991 0.031 3.47E-05 
rs1251531 1 76241922 intergenic genotyped 0.371 1.000 0.031 3.48E-05 
rs10484524 6 167016267 RPS6KA2 intron genotyped 0.224 0.999 0.035 3.55E-05 
rs2623960 6 152935134 SYNE1 intron genotyped 0.232 0.999 0.036 3.57E-05 
rs1251551 1 76236265 intergenic imputed 0.370 0.985 0.031 3.58E-05 
rs1251550 1 76234909 intergenic imputed 0.370 0.989 0.031 3.69E-05 
rs17218496 13 73468873 KLF12 intron imputed 0.099 0.950 0.051 3.72E-05 
rs10145569 14 70722923 c14orf56 3‘UTR imputed 0.400 0.972 0.031 3.76E-05 
rs740692 19 18095567 MAST3 intron imputed 0.147 0.980 0.041 3.81E-05 
rs6458184 6 40873668 intergenic imputed 0.271 0.992 0.034 3.86E-05 
rs17290439 13 73462261 KLF12 intron imputed 0.098 0.911 0.052 3.92E-05 
rs1796812 1 76174419 ASB17 5‘UTR imputed 0.356 0.989 0.031 3.94E-05 
rs4695888 4 174998288 intergenic genotyped 0.500 0.998 0.029 3.97E-05 
rs10843288 12 29023614 intergenic imputed 0.437 0.996 0.030 4.03E-05 
rs6930345 6 40873538 intergenic genotyped 0.271 0.999 0.034 4.20E-05 
rs7299873 12 29029495 intergenic imputed 0.440 0.989 0.030 4.28E-05 
rs1741547 4 3491737 LRPAP1 intron imputed 0.300 0.949 0.033 4.32E-05 
rs6574008 14 70722644 c14orf56 3‘UTR imputed 0.402 0.964 0.031 4.39E-05 
rs10771458 12 29023602 intergenic imputed 0.437 0.997 0.030 4.40E-05 
rs1794444 4 3487530 LRPAP1 intron imputed 0.300 0.949 0.033 4.48E-05 
rs6564966 16 80700610 HSD17B2 3‘UTR imputed 0.082 0.906 0.056 4.65E-05 
rs2184658 1 219119080 HLX 5‘UTR imputed 0.179 0.936 0.039 4.66E-05 
rs11049978 12 29030367 intergenic imputed 0.440 0.992 0.030 4.70E-05 
rs1850629 6 118200284 intergenic imputed 0.092 0.744 0.059 4.73E-05 
rs11049971 12 29021467 intergenic genotyped 0.438 0.999 0.030 4.80E-05 
rs740693 19 18095639 MAST3 intron imputed 0.148 0.974 0.040 4.88E-05 
rs6789 4 3484493 LRPAP1 3‘UTR imputed 0.301 0.952 0.033 4.98E-05 
rs1359422 13 73480470 KLF12 intron genotyped 0.098 0.999 0.049 5.03E-05 
rs1607369 6 118187203 NUS1 3‘UTR imputed 0.091 0.735 0.059 5.20E-05 
rs973229 5 129775011 intergenic imputed 0.171 0.983 0.039 5.26E-05 
rs3738182 1 219124285 HLX exon imputed 0.178 0.933 0.039 5.40E-05 
rs7303799 12 29033635 intergenic imputed 0.425 0.957 0.030 5.45E-05 
rs2189378 5 129763506 intergenic imputed 0.169 0.980 0.039 5.46E-05 
rs1489078 12 29032680 intergenic genotyped 0.441 1.000 0.029 5.77E-05 
 
Abbreviations: AAT, alpha1-antitrypsin; MAF, minor allele frequency; SNP, single nucleotide polymorphism.  
Imp-r2 is an indicator of imputation quality. SNPs with MAF <0.05 or imp-r2 <0.5 were excluded.  
Chromosomal position is based on reference panel, NCBI build 36.3. Allele Effects are shown in absolute numbers. 
Table S4. SERPINA regional variants based on 1000 Genomes imputation reaching statistical significance for the association with AAT serum 
level in SAPALDIA (N=1392). 
 
SNP Position Gene Location MAF Imp-r2 Allele Effect P GWAS inclusion 
rs28929474 94844947 SERPINA1 exon 0.008 0.684 0.620 4.61E-43 no 
rs112458284 94672731 PPP4R4 intron 0.028 0.578 0.363 5.35E-32 no 
rs149837463 94632757 intergenic 0.022 0.529 0.388 1.09E-26 no 
rs111974986 94533735 DDX24 intron 0.017 0.641 0.332 8.33E-20 no 
rs7151526 94863636 SERPINA1 5‘UTR 0.057 0.702 0.144 5.88E-15 yes 
rs61980636 94784618 SERPINA6 intron 0.181 0.977 0.070 2.70E-13 no, but in high LD 
rs2736887 94812980 intergenic 0.195 0.980 0.068 4.91E-13 yes 
rs926144 94813402 intergenic 0.195 0.980 0.068 5.05E-13 yes 
rs965344 94818078 intergenic 0.195 0.980 0.068 6.62E-13 no, but in high LD 
rs4905179 94795492 SERPINA6 5‘UTR 0.184 1.000 0.068 6.90E-13 yes 
rs61280460 94796184 SERPINA6 5‘UTR 0.184 1.000 0.068 6.98E-13 no, but in high LD 
rs7149605 94854041 SERPINA1 intron 0.095 0.853 0.084 5.14E-11 no, but in high LD 
rs11621961 94769476 SERPINA6 3‘UTR 0.353 0.986 0.048 9.52E-11 yes 
rs75416602 94554409 IFI27L1 intron 0.041 0.897 0.122 3.12E-09 no 
rs79811936 94510275 OTUB2 intron 0.040 0.824 0.122 1.04E-08 no, but in high LD 
rs74712407 94506729 OTUB2 intron 0.040 0.823 0.122 1.16E-08 no, but in high LD 
rs55862705 94866482 SERPINA1 5‘UTR 0.093 0.949 0.070 1.49E-08 no, but in high LD 
rs17751837 94868244 SERPINA1 5‘UTR 0.099 0.998 0.063 6.54E-08 yes 
rs145730801 94768196 SERPINA6 3‘UTR 0.052 0.608 0.112 7.01E-08 no 
rs35306951 94873695 intergenic 0.098 0.971 0.064 9.35E-08 no, but in high LD 
rs8015929 94763787 intergenic 0.370 0.635 0.048 1.78E-07 no 
rs3748312 94854264 SERPINA1 intron 0.161 0.864 0.055 2.09E-07 yes 
rs7146221 94769081 SERPINA6 3‘UTR 0.443 0.902 0.039 3.57E-07 no 
rs72692809 94904542 SERPINA11 3‘UTR 0.104 0.583 0.076 3.64E-07 no 
rs55683719 94936222 SERPINA9 intron 0.136 0.791 0.058 4.42E-07 no, but in high LD 
rs1028580 94849882 SERPINA1 intron 0.163 0.998 0.050 5.35E-07 yes 
rs8010121 94850614 SERPINA1 intron 0.163 1.000 0.049 5.90E-07 yes 
rs72704312 94733695 PPP4R4 intron 0.072 0.541 0.092 9.09E-07 no 
rs61976073 95050970 SERPINA5 intron 0.075 0.861 0.067 9.95E-07 no 
rs17752593 94938028 SERPINA9 intron 0.123 0.981 0.053 1.59E-06 yes 
rs11160167 94763621 intergenic 0.495 0.748 0.039 2.29E-06 no 
rs56149519 94554061 IFI27L1 intron 0.067 0.803 0.077 2.34E-06 no, but in high LD 
rs11160184 94937991 SERPINA9 intron 0.150 0.903 0.048 5.29E-06 yes 
rs11622665 94774995 SERPINA6 intron 0.160 0.988 0.045 5.98E-06 yes 
rs12892767 94767211 SERPINA6 3‘UTR 0.444 0.831 0.035 9.58E-06 no 
rs61976081 95066611 intergenic 0.084 0.693 0.064 1.55E-05 no 
 
Abbreviations: AAT, alpha1-antitrypsin; LD, linkage disequilibrium; MAF, minor allele frequency; SNP, single nucleotide polymorphism.  
Imp-r2 is an indicator of imputation quality. SNPs with MAF <0.001 or imp-r2 <0.5 were excluded. Presented are results with P<3*10(-5) within a 2 
Mb region from 93,857 kb to 95,857 kb on chromosome 14. 
Chromosomal position is based on panel GRCh37.p5, NCBI build 37.3. Allele Effects are shown in absolute numbers. High LD is defined as a LD-
r2 >0.8 using SNAP software. 
Table S5. The top 100 ranking SNPs associated with AAT serum level, conditional on PI S and Z alleles in SAPALDIA (N=1392). 
 
SNP Chromosome Position Gene Location Determination MAF Imp-r2 Allele Effect P 
rs2566347 3 159974071 intergenic imputed 0.192 0.998 0.043 7.88E-08 
rs1560417 3 159972476 intergenic imputed 0.200 0.998 0.042 1.11E-07 
rs1560418 3 159972335 intergenic genotyped 0.200 1.000 0.042 1.11E-07 
rs1430414 3 159987697 MFSD1 5‘UTR imputed 0.137 0.984 0.045 9.26E-07 
rs6761989 3 159983253 intergenic imputed 0.137 0.993 0.044 1.14E-06 
rs17643917 3 159968433 intergenic imputed 0.137 1.000 0.044 1.23E-06 
rs17643860 3 159967954 intergenic imputed 0.137 1.000 0.044 1.24E-06 
rs17700475 3 159967627 intergenic genotyped 0.137 1.000 0.044 1.25E-06 
rs3863076 3 159969394 intergenic genotyped 0.145 1.000 0.042 1.69E-06 
rs2206593 1 184909052 PTGS2 3‘UTR genotyped 0.065 0.956 0.060 4.60E-06 
rs12462442 19 18094195 MAST3 intron imputed 0.142 1.000 0.040 5.74E-06 
rs11086090 19 18093754 MAST3 intron genotyped 0.142 1.000 0.040 5.74E-06 
rs9541793 13 68628588 intergenic imputed 0.258 0.990 0.032 7.37E-06 
rs1446378 13 68626607 intergenic imputed 0.258 0.994 0.032 7.45E-06 
rs4703798 5 79448084 SERINC5 intron genotyped 0.386 0.999 0.029 7.50E-06 
rs1446379 13 68626323 intergenic imputed 0.258 0.995 0.032 7.61E-06 
rs13400830 2 12972015 intergenic genotyped 0.083 0.989 0.051 7.83E-06 
rs1023818 13 68625043 intergenic genotyped 0.258 1.000 0.031 8.04E-06 
rs16861952 3 150735514 WWTR1 intron imputed 0.074 0.981 0.054 8.28E-06 
rs16859504 2 12972809 intergenic imputed 0.081 0.926 0.053 8.38E-06 
rs12611216 19 18095005 MAST3 intron imputed 0.145 0.984 0.039 1.01E-05 
rs6682093 1 179309512 MR1 3‘UTR imputed 0.362 0.983 0.029 1.03E-05 
rs1119065 1 184924695 PTGS2 5‘UTR imputed 0.066 0.810 0.062 1.03E-05 
rs1013665 1 184814763 intergenic imputed 0.177 0.809 0.040 1.05E-05 
rs7514491 1 184865641 intergenic genotyped 0.173 0.998 0.036 1.19E-05 
rs9599423 13 68623359 intergenic imputed 0.261 0.989 0.031 1.31E-05 
rs6662507 1 179322783 IER5 5‘UTR imputed 0.346 0.955 0.029 1.42E-05 
rs9511045 13 23564937 SPATA13 5‘UTR imputed 0.112 0.931 0.044 1.44E-05 
rs7300338 12 4010161 LOC100507511 3‘UTR imputed 0.384 0.865 0.030 1.61E-05 
rs9541789 13 68620213 intergenic imputed 0.262 0.985 0.030 1.63E-05 
rs3856068 1 179312991 MR1 3‘UTR imputed 0.365 0.982 0.028 1.67E-05 
rs9529519 13 68620322 intergenic imputed 0.262 0.986 0.030 1.68E-05 
rs740692 19 18095567 MAST3 intron imputed 0.147 0.980 0.037 1.74E-05 
rs2275470 1 179332430 IER5 3‘UTR imputed 0.344 0.924 0.030 1.79E-05 
rs12479315 2 56960739 intergenic imputed 0.491 0.963 0.027 1.86E-05 
rs2216407 2 56963650 intergenic imputed 0.491 0.969 0.027 1.92E-05 
rs2304408 3 159803574 MLF1 intron imputed 0.229 0.972 0.032 1.99E-05 
rs7624771 3 159818103 MLF1 3‘UTR imputed 0.228 0.982 0.032 2.28E-05 
rs11923661 3 71284796 FOXP1 intron genotyped 0.446 0.999 0.027 2.34E-05 
rs453176 21 45407444 ADARB1 intron imputed 0.053 0.932 0.063 2.37E-05 
rs407550 21 45408504 ADARB1 intron imputed 0.053 0.932 0.063 2.37E-05 
rs17699324 3 159907255 RARRES1 intron genotyped 0.225 0.998 0.032 2.40E-05 
rs17699103 3 159902483 RARRES1 intron imputed 0.225 0.976 0.032 2.41E-05 
rs7610009 3 159903063 RARRES1 intron imputed 0.225 0.978 0.032 2.41E-05 
rs2745557 1 184915844 PTGS2 intron imputed 0.179 0.882 0.037 2.43E-05 
rs3867391 3 159898534 RARRES1 intron imputed 0.226 0.970 0.032 2.44E-05 
rs17698754 3 159894398 GFM1 3‘UTR imputed 0.226 0.968 0.032 2.46E-05 
rs9541803 13 68639250 intergenic imputed 0.280 0.988 0.029 2.46E-05 
rs17004749 21 45418411 ADARB1 intron imputed 0.052 0.941 0.063 2.54E-05 
rs6776901 3 159843286 GFM1 5‘UTR imputed 0.228 0.991 0.032 2.55E-05 
rs6777231 3 159843638 GFM1 5‘UTR imputed 0.228 0.989 0.032 2.56E-05 
rs17698494 3 159888567 GFM1 intron imputed 0.227 0.969 0.032 2.57E-05 
rs740693 19 18095639 MAST3 intron imputed 0.148 0.974 0.037 2.59E-05 
rs17697458 3 159859048 GFM1 intron imputed 0.227 0.970 0.032 2.62E-05 
rs1522178 3 71286953 FOXP1 intron imputed 0.449 0.972 0.027 2.63E-05 
rs7279483 21 45421702 ADARB1 intron imputed 0.052 0.945 0.063 2.65E-05 
rs17630607 3 159872554 GFM1 intron imputed 0.227 0.974 0.032 2.67E-05 
rs4338667 13 67094362 intergenic genotyped 0.184 0.998 0.034 2.71E-05 
rs6971526 7 66998462 intergenic genotyped 0.479 0.999 0.026 2.74E-05 
rs480075 1 184722959 PDC 5‘UTR imputed 0.179 0.693 0.041 2.76E-05 
rs9390650 6 149363751 UST intron genotyped 0.409 1.000 0.027 2.78E-05 
rs9541790 13 68621026 intergenic genotyped 0.283 0.999 0.028 2.90E-05 
rs497285 1 184721052 PDC 5‘UTR imputed 0.180 0.693 0.041 2.94E-05 
rs2745559 1 184918625 PTGS2 5‘UTR imputed 0.179 0.862 0.037 3.03E-05 
rs1983870 13 23568163 SPATA13 5‘UTR genotyped 0.105 0.992 0.043 3.04E-05 
rs7770997 6 149373032 UST intron imputed 0.411 0.987 0.027 3.16E-05 
rs10172921 2 12960321 intergenic imputed 0.093 0.956 0.045 3.30E-05 
rs9484838 6 144385865 PLAGL1 intron imputed 0.132 0.942 0.039 3.34E-05 
rs10182783 2 12939134 intergenic imputed 0.124 0.837 0.043 3.37E-05 
rs4835994 5 129749756 intergenic imputed 0.173 0.972 0.035 3.38E-05 
rs7653672 3 71284144 FOXP1 intron imputed 0.448 0.963 0.027 3.45E-05 
rs4263026 18 71438977 intergenic imputed 0.198 0.983 0.033 3.47E-05 
rs11099924 4 155070285 intergenic imputed 0.405 0.920 0.028 3.50E-05 
rs13388631 2 12960274 intergenic imputed 0.093 0.961 0.045 3.56E-05 
rs11593082 10 8080437 TAF3 intron genotyped 0.077 0.997 0.048 3.69E-05 
rs447590 13 112495212 ATP11A intron imputed 0.427 0.902 0.028 3.75E-05 
rs13395897 2 77520241 LRRTM4 intron imputed 0.078 0.689 0.057 3.76E-05 
rs13430556 2 12960160 intergenic imputed 0.093 0.968 0.045 3.82E-05 
rs4411966 4 155074041 intergenic imputed 0.404 0.917 0.028 3.90E-05 
rs2688352 8 3816166 CSMD1 intron genotyped 0.188 0.993 0.033 3.93E-05 
rs12489730 3 159940608 RARRES1 5‘UTR imputed 0.218 0.983 0.031 3.94E-05 
rs2460535 10 43141386 RASGEF1A 5‘UTR imputed 0.101 0.899 0.047 3.95E-05 
rs2399702 15 95849200 intergenic imputed 0.078 0.638 0.060 3.95E-05 
rs4798376 18 5594240 EPB41L3 5‘UTR genotyped 0.254 0.992 0.030 4.03E-05 
rs10145569 14 70722923 c14orf56 3‘UTR imputed 0.400 0.972 0.027 4.03E-05 
rs13279316 8 112676764 intergenic genotyped 0.260 0.998 0.029 4.09E-05 
rs12609740 19 18101298 MAST3 intron imputed 0.149 0.968 0.036 4.16E-05 
rs13390247 2 12963014 intergenic imputed 0.090 0.961 0.045 4.20E-05 
rs12698626 7 66991554 intergenic imputed 0.476 0.915 0.026 4.20E-05 
rs2129818 12 16834202 intergenic genotyped 0.399 1.000 0.026 4.28E-05 
rs7624420 3 159993368 MFSD1 5‘UTR imputed 0.102 0.990 0.043 4.43E-05 
rs6574008 14 70722644 c14orf56 3‘UTR imputed 0.402 0.964 0.027 4.51E-05 
rs1468488 22 15970744 IL17RA 3‘UTR imputed 0.291 0.922 0.029 4.52E-05 
rs6728142 2 12958541 intergenic imputed 0.092 0.982 0.044 4.54E-05 
rs6930963 6 149396494 UST intron imputed 0.410 0.954 0.027 4.55E-05 
rs6893779 5 129825798 intergenic imputed 0.188 0.980 0.033 4.63E-05 
rs8002029 13 23564535 SPATA13 5‘UTR genotyped 0.081 0.998 0.046 4.65E-05 
rs4622983 4 155074124 intergenic imputed 0.405 0.910 0.027 4.71E-05 
rs1386819 12 16847868 intergenic imputed 0.398 0.967 0.026 4.72E-05 
rs7984719 13 23564571 SPATA13 5‘UTR imputed 0.081 0.989 0.046 4.73E-05 
 
Abbreviations: AAT, alpha1-antitrypsin; MAF, minor allele frequency; SNP, single nucleotide polymorphism.  
Imp-r2 is an indicator of imputation quality. SNPs with MAF <0.05 or imp-r2 <0.5 were excluded.  
Chromosomal position is based on reference panel, NCBI build 36.3. Allele Effects are shown in absolute numbers. 
Table S6. Accuracy of 1000 Genomes based imputation in the SERPINA1 region in 
SAPALDIA (N=1392). 
 
SNP Location MAF (genotyped) MAF (imputed) 
rs2896268 5’UTR 0.491 0.488 
rs1956707 5’UTR 0.036 0.037 
rs8004738 exon 1 0.489 0.478 
rs1570142 intron 1 0.488 0.478 
rs3748312 intron 1 0.158 0.161 
rs3748316 intron 1 0.178 genotyped, Illumina 610quad 
rs3748317 intron 1 0.162 0.159 
rs1980617 intron 1 0.393 0.385 
rs1980618 intron 1 0.388 0.385 
rs2753935 intron 1 0.428 0.440 
rs2144831 intron 1 0.238 0.238 
rs709932 exon 2 0.174 genotyped, Illumina 610quad 
rs6647 exon 3 0.208 0.220 
rs17580 (S) exon 3 0.040 0.057 
rs28929474 (Z) exon 5 0.013 0.008 
rs1303 exon 5 0.258 genotyped, Illumina 610quad 
 
Abbreviations: GWAS, genome-wide association study; MAF, minor allele frequency; SNP, 
single nucleotide polymorphism.  
 
 
Table S7. Further variants in the SERPINA1 coding region, present in a SAPALDIA subsample with abnormally low AAT serum levels (N=410). 
 
Variant, name Na Location Position Function Description Computational prediction [68] 
rs28931570, I 9 exon 2 93919141 SNP, non-synonymous deficiency variant [24] damaging 
∆F52, Mmalton 3 exon 2 93919100-02 codon deletion deficiency variant [24] n/a 
rs111850950, M6passau 5 exon 2 93919078 SNP, non-synonymous neutral variant [27] damaging 
Q105P 1 exon 2 93918942 SNP, non-synonymous putative deficiency variant [21] damaging 
rs20546, M3riedenburg 17 exon 2 93918904 SNP, synonymous neutral variant [27] n/a 
rs112030253, V 1 exon 2 93918814 SNP, non-synonymous neutral variant [27] tolerated 
A153A 1 exon 2 93918797 SNP, synonymous novel n/a 
∆Y160, Q0granitefalls 1 exon 2 93918776 nucleotide deletion null variant [23] n/a 
rs28929470, F 3 exon 3 93917139 SNP, non-synonymous neutral variant [26] damaging 
rs28929472, Plowell 9 exon 3 93917039 SNP, non-synonymous deficiency variant [25] damaging 
rs1049800, Psaint albans 1 exon 3 93917038 SNP, synonymous neutral variant [25] n/a 
K259I 6 exon 3 93917030 SNP, non-synonymous deficiency variant [29] damaging 
T268I 1 exon 3 93917003 SNP, non-synonymous putative deficiency variant [21] damaging 
D270Nb 1 exon 3 93916998 SNP, non-synonymous putative deficiency variant [21] damaging 
rs200945035, Etokyo 1 exon 5 93914721 SNP, non-synonymous neutral variant [22] damaging 
rs61761869, Mwurzburg 5 exon 5 93914619 SNP, non-synonymous deficiency variant [28] damaging 
 
Abbreviations: AAT, alpha1-antitrypsin; MAF, minor allele frequency; SNP, single nucleotide polymorphism; n/a, not applicable. 
Chromosomal position is based on reference panel, NCBI build 36.3. 
a
 Number of participants carrying the variant heterozygously.  
b This individual also had the F-variant (rs28929470). 
 Table S8. Descriptions and acknowledgments of individual studies contributing to the SNP association analyses with FEV1 . 
 Study General Description Acknowledgments 
British 1958 Birth 
Cohort (B58C) 
The British 1958 Birth Cohort is an ongoing follow-up of all persons born in England, 
Scotland and Wales during one week in 1958. At the age of 44-45 years, the cohort were 
followed up with a biomedical examination, including spirometry as described in more 
detail elsewhere [Strachan DP, et al. (2007). Int J Epidemiol 36: 522-531] and blood 
sampling, from which a DNA collection was established as a nationally representative 
reference panel (http://www.b58cgene.sgul.ac.uk/). Non-overlapping subsets of the DNA 
collection were genotyped by the Wellcome Trust Case-Control Consortium (WTCCC), 
the Type 1 Diabetes Genetics Consortium (T1DGC) and the GABRIEL consortium. 
Genotyping by the WTCCC used both the Affymetrix 500K array and the Illumina 550K 
(version 1) array. Since the T1DGC used the Illumina 550K (version 3) array and 
GABRIEL used the Illumina 610K array, a combined dataset was created of SNPs in 
common across these three panels. SNPs were excluded from subsequent imputation if 
they had MAF<1%, call-rate<95%, HWE p-value<0.0001, or differences in allele 
frequency across the three deposits (p<0.0001 on pairwise comparisons). Pre-
imputation phasing was performed using MACH. Imputations against the March 2012 
release of 1000-genomes all-ethnicities reference haplotypes were performed using 
Minimac. Associations of imputed allele dosages with lung function, as measured at the 
44-45-year follow-up, were analyzed using ProbABEL. 
We acknowledge use of phenotype and 
genotype data from the British 1958 
Birth Cohort DNA collection, funded by 
the Medical Research Council and 
Wellcome Trust.  
Busselton Health 
Study (BHS) 
The Busselton Health Study (BHS) is a longitudinal survey of the town of Busselton in 
the south-western region of Western Australia that began in 1966. In 1994/1995 a cross-
sectional community follow-up study was undertaken where blood was taken for DNA 
extraction. A sample of 1,168 European-ancestry individuals were genotyped using the 
Illumina 610-Quad BeadChip (BHS1), and subsequent genotyping was carried out on an 
independent group of 3,038 European-ancestry individuals (BHS2). 
The Busselton Health Study (BHS) 
acknowledges the generous support for 
the 1994/1995 follow-up study from 
Healthway, Western Australia, and the 
numerous Busselton community 
volunteers who assisted with data 
collection and the study participants 
from the Shire of Busselton. The 
Busselton Health Study is supported by 
The Great Wine Estates of the Margaret 
River region of Western Australia. 
Copenhagen City 
Heart Study 
(Copenhagen) 
This prospective general population sample was initiated in 1976 and up until now the 
participants have been invited to four examinations. At each examination, a 
questionnaire was completed concerning life style factors and physical measurements 
were taken. At the third examination in 1991-1994, blood samples were drawn for DNA 
extraction; 8,338 samples were genotyped for S, Z, or rs4905179. The study was 
approved by Herlev Hospital and Danish ethical committees, and was conducted 
according to the Declaration of Helsinki. Written informed consent was obtained from all 
participants [Thomsen M, et al. (2012). Eur Respir J 39: 558-566].   
Hanne Damm, Anne-Merete Bengtsen, 
and Charlotte Worm are thanked for 
expert technical assistance and the 
participants of the Copenhagen City 
Heart Study for their willingness to 
participate. 
CROTIA-Korcula, 
CROTIA-Split, 
CROTIA-Vis (Korcula, 
Split, Vis) 
The CROATIA-Korcula study includes 969 Croatians between the ages of 18 and 98. 
The field work was performed in 2007 and 2008 in the eastern part of the island, 
targeting healthy volunteers from the town of Korčula and the villages of Lumbarda, 
Žrnovo and Račišće. The CROATIA-Split study is a population-based, cross-sectional 
study in the Dalmatian City of Split  which was undertaken between 2009 and 2011 and 
included 1012 examinees aged 18-95. The CROATIA-Vis study includes 1008 
Croatians, aged 18–93 years, who were recruited from the villages of Vis and Komiza on 
the Dalmatian island of Vis during 2003 and 2004 within a larger genetic epidemiology 
program. SNP genotyping of the CROATIA-Vis samples was carried out by the Genetics 
Core Laboratory at the Wellcome Trust Clinical Research Facility, WGH, Edinburgh, 
Scotland. SNP genotyping for CROATIA-Korcula was performed by Helmholtz Zentrum 
München, GmbH, Neuherberg, Germany. The SNP genotyping for the CROATIA-Split 
cohort was performed by AROS Applied Biotechnology, Aarhus, Denmark. All studies 
conformed to the ethical guidelines of the 1975 Declaration of Helsinki and were 
approved by appropriate ethics boards with all participants signing informed consent 
prior to participation.  
The CROATIA studies would like to 
acknowledge the invaluable 
contributions of the recruitment teams 
(including those from the Institute of 
Anthropological Research in Zagreb) in 
Vis, Korcula and Split, the administrative 
teams in Croatia and Edinburgh, and 
the people of Vis, Korcula and Split.  
The eQTL-Study 
(University of British 
Columbina (UBC) and 
University of 
Groningen 
(Groningen)) 
University of British Columbia: Lung specimens were provided by the James Hogg 
Research Center Biobank at St Paul's Hospital and subjects provided written informed 
consent. The study was approved by the ethics committees at the UBC-Providence 
Health Care Research Institute Ethics Board, UBC Ethics approval number H09-00801. 
University of Groningen: Lung specimens were provided by the local tissue bank of the 
Department of Pathology and the study protocol was consistent with the Research Code 
of the University Medical Center Groningen and Dutch national ethical and professional 
guidelines (“Code of conduct; Dutch federation of biomedical scientific societies”; 
http://www.federa.org).  
The UBC biobank that was used for the 
lung gene expression analyses was 
developed by Drs J C Hogg, Don Sin 
and P D Pare with the technical 
assistance of Dr Mark Elliott. 
Kooperative 
Gesundheitsforschung 
in der Region 
Augsburg (KORA S3, 
KORA F4) 
The KORA studies (Cooperative Health Research in the Region of Augsburg) are a 
series of independent population based studies from the general population living in the 
region of Augsburg, Southern Germany  [Holle R, et al. (2005). Gesundheitswesen 67 
Suppl 1: S19-S25; Wichmann H-E, et al. (2005). Gesundheitswesen 67 Suppl 1: S26-
S30]. The KORA S3 study including 4,856 individuals was conducted in 1994/95. 
Spirometry was measured in 1997/98 for all participants younger than 60 years who did 
not smoke or use inhalers one hour before the test. All spirometric tests were performed 
strictly adhering to the ECRHS protocol. Tests were accounted valid if at least two 
technically satisfactory manoeuvres could be obtained throughout a maximum of nine 
trials. FEV1 was defined as the maximum value within all valid manoeuvers. Genotyping 
was performed on the Illumina Omni 2.5 and the Illumina Omni Express platform. 
Genotypes were called with Genome Studio and annotated to NCBI build 37. We 
excluded individuals with call rates <97%, mismatches of phenotypic and genetic 
gender, heterozygosity rates +/-5 SD from the mean, and population outliers. Before 
imputation we reduced to SNPs genotyped on both used platforms and excluded SNPs 
with call rates <98%, HWE p-values <5x10-6, and minor allele frequency <1% calculated 
over all samples. Pre-phasing was performed with SHAPEIT v2. Imputation was 
performed with IMPUTE v2.3.0 using the 1000G phase1 (v3) reference panel. The 
statistical analysis was performed in R v2.15.2. KORA F4 including 3,080 individuals 
was conducted from 2006-08 as a follow-up study to KORA S4 (1999-2001). Lung 
function tests were performed in a random subsample of subjects born between 1946 
and 1965 (age range 41–63 years). Spirometry was performed in line with the ATS/ERS 
recommendations using a pneumotachograph-type spirometer (Masterscreen PC, 
CardinalHealth, Würzburg, Germany) before and after inhalation of 200 µg salbutamol. 
The present study is based on maximum values of FEV1 measured before 
bronchodilation. The spirometer was calibrated daily using a 1L-calibration pump 
(CardinalHealth, Würzburg, Germany), and additionally, an internal control was used to 
ensure constant instrumental conditions. Genotyping was performed on the Affymetrix 
Axiom platform. Genotypes were called with the Affymetrix software and annotated to 
NCBI build 37. We excluded individuals with call rates <97%, mismatches of phenotypic 
and genetic gender, heterozygosity rates +/-5 SD from the mean, and population 
outliers. Before imputation we excluded SNPs with call rates <98%, HWE p-values 
<5x10-6, and minor allele frequency <1%. Pre-phasing was performed with SHAPEIT v2. 
Imputation was performed with IMPUTE v2.3.0 using the 1000G phase1 (v3) reference 
panel. The statistical analysis was performed in R v2.15.2. 
The KORA authors acknowledge all 
members of field staffs who were 
involved in the planning and conduction 
of the KORA Augsburg studies, as well 
as all KORA study participants. 
Lothian Birth Cohort 
1936 (LBC36) 
The Lothian Birth Cohort 1936 consists of 1,091 relatively healthy individuals assessed 
on cognitive and medical traits at 70 years of age. They were born in 1936, most took 
part in the Scottish Mental Survey of 1947, and almost all lived independently in the 
Lothian region of Scotland. A full description of participant recruitment and testing can be 
found elsewhere [Deary IJ, et al. (2007). BMC Geriatr 7: 28]. Lung function assessing 
FEV1 (best of three), using a Micro Medical Spirometer, was assessed sitting down 
without nose clips. The accuracy of the spirometer is ±3% (to ATS recommendations 
Standardisation of Spirometry 1994 update for flows and volumes). Ethics permission for 
the study was obtained from the Multi-Centre Research Ethics Committee for Scotland 
(MREC/01/0/56) and from Lothian Research Ethics Committee (LREC/2003/2/29). The 
research was carried out in compliance with the Helsinki Declaration. All subjects gave 
written, informed consent. 
We thank the LBC36 participants and 
research team members. We thank the 
nurses and staff at the Wellcome Trust 
Clinical Research Facility, where 
subjects were tested and the genotyping 
was performed. 
Lung Health Study 
(LHS) 
The Lung Health Study (LHS) was a clinical trial sponsored by the National Heart, Lung 
and Blood Institute (Anthonisen NR, et al. (1994). JAMA 272: 1497-1505). The LHS was 
conducted at 10 medical centers in North America and a total of 5,887 smokers aged 
35–60 with spirometric evidence of mild to moderate lung function impairment were 
recruited. Lung function measurements in the LHS were performed using standardized 
spirometry in accordance with the American Thoracic Society guidelines (Enright PL, et 
al. (1991). Am Rev Respir Dis 143: 1215-1223) and the reference equations were those 
of Crapo and coworkers (Crapo RO, et al. (1981). Am Rev Respir Dis 123: 659-664) 
based on Caucasian subjects of northern European descent in Salt Lake City. Only 
participants who self reported as non-Hispanic white were investigated in this study. 
Informed consent was obtained from all participants and this investigation received the 
approval of the relevant Research Ethics Boards. 
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Coordinating Center, University of 
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population sample of women in the provinces of Lapland and Oulu was followed since 
the 24th gestation week and gave birth to a total of 12 231 children in 1966 which 
henceforward represented the Northern Finland Birth Cohort 1966 (NFBC66). This 
cohort had spirometry done at the age of 31 years. A Vitalograph P-model spirometer 
(Vitalograph Ltd., Buckingham, UK) was used with a volumetric accuracy of ±2% or ±50 
mL whichever was greater. The spirometer was calibrated regularly using a 1-Litre 
precision syringe. The spirometric manoeuvre was performed three times but was 
repeated if the coefficient of variation between two maximal readings was >4%. 
We thank the late Professor Paula 
Rantakallio (launch of NFBC66), and Ms 
Outi Tornwall and Ms Minttu Jussila 
(DNA biobanking). The authors would 
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the late Academian of Science Leena 
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Northern Swedish 
Population Health 
Study (NSPHS) 
The Northern Swedish Population Health Study (NSPHS) is part of the European 
Network on Special Populations (EUROSPAN), focusing on remote, rural populations 
from across Europe. NSPHS is a population-based, cross-sectional study of the 
populations in the Karesuando, Soppero and Vittangi areas north of the Arctic Circle in 
Northern Sweden. The NSPHS study was approved by the local ethics committee at 
University of Uppsala (Regionala Etikprövningsnämnden, Uppsala, 2005:325) in 
compliance with the Declaration of Helsinki. All participants gave their written informed 
consent to the study including the examination of environmental and genetic causes of 
disease. In cases where the participant was not of age, a legal guardian signed 
additionally.  
We thank district nurse Svea Hennix for 
data collection, Inger Jonasson for 
logistics and coordination of the health 
survey and all the participants from the 
community for their interest and 
willingness to contribute to this study. 
Orkney Complex 
Disease Study 
(ORCADES) 
The Orkney Complex Disease Study (ORCADES) was performed in the Scottish 
archipelago of Orkney and collected data between 2005 and 2011. Data for 889 
participants aged 18 to 100 years from a subgroup of ten islands were used for this 
analysis. DNA extraction for ORCADES was carried out by the Genetics Core 
Laboratory at the Wellcome Trust Clinical Research Facility, WGH, Edinburgh, Scotland. 
SNP genotyping for ORCADES was performed by Helmholtz Zentrum München, GmbH, 
Neuherberg, Germany. This study conformed to the ethical guidelines of the 1975 
Declaration of Helsinki and was approved by appropriate ethics boards with all 
participants signing informed consent prior to participation.   
ORCADES would like to acknowledge 
the invaluable contributions of Lorraine 
Anderson, the research nurses in 
Orkney, and the administrative team in 
Edinburgh.  
Study of Health in 
Pomerania (SHIP) 
The Study of Health in Pomerania (SHIP) is a cross-sectional survey in West Pomerania, 
the north-east area of Germany [Völzke H, et al. (2011). Int J Epidemiol 40: 294-307]. A 
sample from the population aged 20 to 79 years was drawn from population registries. 
First, the three cities of the region (with 17,076 to 65,977 inhabitants) and the 12 towns 
(with 1,516 to 3,044 inhabitants) were selected, and then 17 out of 97 smaller towns 
(with less than 1,500 inhabitants), were drawn at random. Second, from each of the 
selected communities, subjects were drawn at random, proportional to the population 
size of each community and stratified by age and gender. Only individuals with German 
citizenship and main residency in the study area were included. Finally, 7,008 subjects 
were sampled, with 292 persons of each gender in each of the twelve five-year age 
strata. In order to minimize drop-outs by migration or death, subjects were selected in 
two waves. The net sample (without migrated or deceased persons) comprised 6,267 
eligible subjects. Selected persons received a maximum of three written invitations. In 
case of non-response, letters were followed by a phone call or by home visits if contact 
by phone was not possible. The SHIP population finally comprised 4,308 participants 
(corresponding to a final response of 68.8%). Lung functions were measured during the 
5-year follow-up in 1809 out of 3300 study participants. The study was approved by the 
ethics committee of the University of Greifswald (“Leben und Gesundheit in 
Vorpommern”, III UV 73/01). 
  
  
Figure S1. SAPALDIA study design for the determination of AAT associated genetic 
variants. 
a
 consisting of subjects with abnormally low AAT levels independent of PI S or Z alleles (see 
Materials and Methods). 
  
Figure S2. Q-Q plot of genome-wide -log(10) p-values for association with AAT serum 
level. 
 Figure S3. Forest plot of meta-analyzed results for the effect per minor allele of rs17580 (PI S) on FEV1 in ever-smokers, adjusted for sex, age, 
height and population stratification factors. Studies based on population isolates with a high degree of cryptic relatedness are presented separately. 
Effect estimates of meta-analyses are shown with green diamonds. I2 is a measure of the heterogeneity between studies. Random effect meta-
analyses are included if I2>0.5. Study weights (blue squares) correspond to the fixed effect meta-analyses. 
 Figure S4. Forest plot of meta-analyzed results for the effect per minor allele of rs28929474 (PI Z) on FEV1 in ever-smokers, adjusted for sex, 
age, height and population stratification factors. Studies based on population isolates with a high degree of cryptic relatedness are presented 
separately. Effect estimates of meta-analyses are shown with green diamonds. I2 is a measure of the heterogeneity between studies. Random effect 
meta-analyses are included if I2>0.5. Study weights (blue squares) correspond to the fixed effect meta-analyses. 
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Fifty Years On: GWAS Confirms the Role of a Rare Variant
in Lung Disease
Alice M. Turner1,2*
1University of Birmingham, QEHB research labs, Birmingham, United Kingdom, 2Heart of England NHS Foundation Trust, Birmingham, United Kingdom
This year, 2013, is the fiftieth anniversa-
ry of the discovery of alpha one antitrypsin
deficiency (AATD), a disease caused by
mutation in SERPINA1, which predisposes
to early onset lung disease, specifically
chronic obstructive pulmonary disease
(COPD). In this issue of PLOS Genetics, the
timely study of Thun et al. [1] investigated
alpha one antitrypsin (AAT) levels with a
genome-wide association study (GWAS)
approach in a cohort recruited primarily
for studies of asthma. They demonstrate
that, although a genome-wide association is
detected for a common variant in SER-
PINA1, the association disappears after
adjusting the results for the presence of
the known rare variants that cause AATD
(PiZ and PiS). The observation of this
‘‘synthetic association’’ illustrates the po-
tential for detection of rare genetic variants,
with minor allele frequencies (MAF) of less
than 1%, to revolutionize the understand-
ing of pathogenesis.
Importantly, the approach used by
Thun et al.—the sequencing of SERPINA1,
fine mapping, and a conditional approach
to statistical analysis in the regression
model—does not depend on knowing the
rare variants on which models need to be
conditioned, and was able to reliably
identify known variants with MAF 1%–
5%. It is therefore a nice demonstration of
the potential for sequencing to reveal rare
variants and ascertain their true contribu-
tion to traits. Thun et al. have also
compensated for known environmental
exposure that interacts with genes, such
as cigarette smoke exposure (‘‘ever
smoked’’), enhancing this analysis by use
of a proxy measure for smoke intensity
(hsCRP). The robustness of the results was
demonstrated using a second large cohort.
The clinical relevance of this work was
demonstrated by looking at lung function
as the outcome, although this revealed a
more complex scenario. The results leave
some unanswered questions, such as the
observation that variants influencing ex-
pression which lie outside SERPINA1
exons are not accounted for, and that
recent expression quantitative trait loci
(eQTL) data for SERPINA1 did not report
their associated SNPs.
Since the advent of GWAS it has
become increasingly obvious that this
research design cannot detect the majority
of the heritability of most studied traits.
Several ideas have been proposed to
explain this ‘‘missing heritability,’’ includ-
ing gene–environment interaction, re-
duced power of GWAS to detect function-
al variants due to low levels of linkage
disequilibrium with causative SNPs, and
undetected rare variants. Thun et al. [1]
provide an excellent realization of this last
hypothesis. Most GWAS have picked up
common variants that confer only a small
measured increase in risk (increased odds
ratios [ORs]), but have missed by design
rare variants that confer larger ORs of
disease. AATD and GWAS of COPD and
lung function are perfect examples of this
as they failed to detect both the PiZ and
PiS variants, despite the well-established
role of these mutations in lung disease.
Only through a huge meta-analysis of over
20,000 individuals and smoking interac-
tion modeling could the influence of PiZ
[2] on lung function be detected. Thun et
al. could use their analyses to begin to
address the longstanding debate regarding
the role of AATD in lung disease at the
population level. Specifically, does carry-
ing a single abnormal SERPINA1 allele
increase risk of lung disease at the
population level [3]? A demonstration of
an association, even at low AAT levels not
considered truly deficient, would mean
that AAT pathways are relevant to a far
larger proportion of the population than
previously thought. For this reason, the
work of Thun et al. is not only an
interesting example of synthetic associa-
tion, but has potential clinical importance
since it suggests that even small variation
in AAT level could affect lung function
[1].
Since rare variant analysis is a topic of
great interest to genetic epidemiologists at
present, it is worth reprising how under-
standing AATD has moved clinical med-
icine forward. It was first described in
1963 by Laurell and Eriksson, who
reported an absence of the a1 band on
protein electrophoresis of serum taken
from a patient at a local respiratory
hospital [4]; this missing band was due to
very low circulating levels of AAT. The
observation that people with this deficien-
cy developed early-onset emphysema and
COPD suggested a role for pathways
involving AAT in pathogenesis(summar-
ized in Figure 1). The main function of
AAT is as an anti-protease, which protects
tissues against neutrophil elastase (NE) [5];
the protease–antiprotease hypothesis of
emphysema resulted directly from this
knowledge and has driven much of the
research into COPD. Clinically significant
AATD-related lung disease occurs in
approximately 1 in 2,500 Caucasian
individuals who usually carry the PiZ or
PiS variants of SERPINA1; importantly,
both SNPs confer an increased risk of lung
disease in carriers who smoke and in
homozygous individuals who do not
smoke [6]. However, COPD is very
common, affecting up to 20% of smokers
and 11% of non-smokers worldwide, and
is projected to be the third most common
cause of death by 2030 [7]. Consequently,
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changing the direction of research in
COPD had potential to greatly affect
population health. At the time of detection
of AATD, COPD as a term was not in
common use; rather, patients were de-
scribed as having emphysema or chronic
bronchitis, both diagnosed by clinical
features and chest radiography. It is
now a common term and is diagnosed by
a reduction in FEV1/FVC ratio on
spirometry—a simple test of lung func-
tion—and may be further characterized
by more complex lung function tests and
computerized tomography (CT) scanning
of the lungs.
Genetic research into the etiology of
lung dysfunction in the general population
[2] as well as the risk of COPD [8] has
succeeded in identifying many variants
that are significantly associated with these
outcomes. Candidate gene approaches
discovered other relevant proteases [9],
and our increased understanding of the
inflammatory cascade leading to neutro-
phil activation and NE release has guided
the implementation of therapies targeting
inflammation, the most common of which
is inhaled corticosteroids (ICS). However,
anti-inflammatory therapies have not been
a magic bullet for COPD sufferers; indeed,
the main trial seeking reduction in mor-
tality showed only a trend in this direction
(p = 0.052) when ICS were combined with
long-acting beta agonists (LABA) [10].
However, lung function, flare-ups of the
disease (known as exacerbations), and
quality of life have been shown in many
studies to improve with ICS/LABA com-
binations [7]. Relevant to the current
paper on SERPINA1 variants as a predic-
tor of AAT, specific treatment for AATD
has been developed in the form of AAT
augmentation therapy. A meta-analysis of
1,509 patients in observational studies and
randomized controlled trials (RCTs) con-
cluded that it was beneficial, because
decline in lung function was slower upon
treatment [11]. More sophisticated mea-
sures of lung disease using quantitative
analysis of CT scans have shown that
augmentation is beneficial in the RCTs
alone [12]. Whether or not the recognition
that rare variants explain common variant
associations at SERPINA1 with AATD
changes clinical practice remains to be
seen, but the story should be a source of
inspiration for genetic researchers to
continue pursuing rare variants and their
potential use in disease prediction and
targeted therapy.
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Abstract
Background: Severe alpha1-antitrypsin (AAT) deficiency is a strong risk factor for COPD. But the impact of gene variants
resulting in mild or intermediate AAT deficiency on the longitudinal course of respiratory health remains controversial.
There is indication from experimental studies that pro-inflammatory agents like cigarette smoke can interact with these
variants and thus increase the risk of adverse respiratory health effects. Therefore, we tested the effect of the presence of a
protease inhibitor (Pi) S or Z allele (PiMS and PiMZ) on the change in lung function in different inflammation-exposed
subgroups of a large, population-based cohort study.
Methodology and Principal Findings: The SAPALDIA population includes over 4600 subjects from whom SERPINA1
genotypes for S and Z alleles, spirometry and respiratory symptoms at baseline and after 11 years follow-up, as well as
proxies for inflammatory conditions, such as detailed smoking history, obesity and high sensitivity C-reactive protein (hs-
CRP), were available. All analyses were performed by applying multivariate regression models. There was no overall
unfavourable effect of PiMS or PiMZ genotype on lung function change. We found indication that PiZ heterozygosity
interacted with inflammatory stimuli leading to an accelerated decline in measures in use as indices for assessing mild
airway obstruction. Obese individuals with genotype PiMM had an average annual decline in the forced mid expiratory flow
(DFEF25-75%) of 58.4 ml whereas in obese individuals with PiMZ it amounted to 92.2 ml (p = 0.03). Corresponding numbers
for persistent smokers differed even more strongly (66.8 ml (PiMM) vs. 108.2 ml (PiMZ), p = 0.005). Equivalent, but less strong
associations were observed for the change in the FEV1/FVC ratio.
Conclusions: We suggest that, in addition to the well established impact of the rare PiZZ genotype, one Z allele may be
sufficient to accelerate lung function decline in population subgroups characterized by elevated levels of low grade
inflammation.
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Introduction
Reduced lung function measures are the most common
diagnostic parameter to detect airway obstruction which is the
main characteristic of asthma and chronic obstructive pulmonary
disease (COPD). The only functionally characterized gene variants
associated with airway obstruction and increased loss of lung
PLOS ONE | www.plosone.org 1 August 2012 | Volume 7 | Issue 8 | e42728
function are infrequent polymorphisms in the SERPINA1 gene
causing deficiency of alpha1-antitrypsin (AAT) [1]. This antipro-
tease inhibits neutrophil elastase, an enzyme that degrades
pulmonary elastic fibers. Homozygosity for the protease inhibitor
deficiency variant Z (PiZZ, also referred to as severe AAT
deficiency) and compound heterozygosity for both deficiency
variants S and Z (PiSZ) are widely accepted risk factors for airway
obstruction and accelerated lung function decline, particularly
among smokers [2]. But since these allele combinations all have
frequencies below 0.1% in the general European population [3],
they only account for 2-5% of all COPD cases. The more
prevalent heterozygous genotypes PiMS and PiMZ (M stands for
the wildtype allele) reduce the AAT blood levels only slightly [4]
and are therefore referred to as mild (for PiMS) and intermediate
(for PiMZ) AAT deficiencies.
While PiMS is generally believed not to be associated with low
lung function or a higher risk of COPD [5], the evidence for PiMZ
remains unclear even in the light of a meta-analysis [6]. The few
population-based longitudinal studies have not shown adverse
health effects, but they varied with regard to the phenotype studied
and the inclusion of gene-environment interactions [7,8,9]. An
investigation restricted to smokers showed that PiMZ was
overrepresented in the group with rapid FEV1 (forced expiratory
volume in one second) decline, suggesting that susceptibility may
be refined to population subgroups with elevated inflammatory
and proteolytic stress in the lungs [10]. These processes may
locally increase cleavage, as well as oxidant-induced inactivation
[11] and polymerization [12] of AAT, leading to a further
reduction of this enzyme in PiMZ carriers. Apart from inhalant
triggers like smoking, systemic inflammation may also compromise
pulmonary health [13,14] and therefore particularly affect
individuals with reduced AAT levels.
We hypothesized therefore that the intrapulmonary anti-
proteolytic capacity in people with mild or intermediate AAT
deficiency may not be sufficient to counterbalance an excess of
inflammatory triggers targeting the respiratory system. We used
the SAPALDIA cohort (Swiss Cohort Study on Air Pollution and
Lung and Heart Diseases in Adults) to test such possibly
unfavourable effects of PiS or PiZ heterozygosity on the
longitudinal course of lung function over 11 years of follow-up
in the general population. The large and well characterized study
population allowed us to particularly study subgroups exposed to
elevated local airway or systemic inflammatory conditions, such as
active and passive smokers, and people suffering from obesity.
Results
Study Sample
A comparison of characteristics between SAPALDIA follow-up
participants included and excluded in this study is provided in
Table 1. The study population consisted of a healthier sample with
a higher percentage of never-smokers and fewer obese individuals.
A comparison between the three genotype classes showed highly
significant differences in AAT serum levels (Table 1). Compared to
PiM homozygotes, unadjusted AAT serum concentrations were
more than 16% and 38% reduced in PiS and PiZ heterozygotes,
respectively. There were no differences in circulating high-
sensitivity C-reactive protein (hs-CRP), the main marker for
systemic inflammation, between the genotype groups. Further-
more, the genotype classes differed slightly in the unadjusted
forced expiratory flow over the middle half of FVC (FEF25-75%)
at baseline and in unadjusted declines of FEF25-75%.
Adjusted Spirometric Decline Rates according to
Genotype
In adjusted models, neither PiMS nor PiMZ subjects exhibited
statistically significant steeper annual declines than PiMM
individuals in any measure of lung function (all p$0.07, Table 2
and Table 3). Hypothesizing that PiMS and PiMZ carriers can
only compensate their reduced anti-proteolytic capacity in
pulmonary tissue if no excess of pulmonary or systemic
inflammation is present, we tested if stratification by smoking or
obesity status may alter these associations. While we could not find
any significant association between the presence of a S or Z allele
and DFEV1 or DFVC (forced vital capacity) irrespective of the
smoking or obesity category (Table 2), smokers and obese
individuals with PiMZ genotype showed elevated declines in
FEF25-75% (Table 3). In ever smokers, PiMZ carriers lost on
average additional 17.4 ml per year compared to PiMM in FEF25-
75% (p= 0.05), and this difference became more pronounced in
people who smoked at baseline and follow-up (41.4 ml in persistent
smokers, p = 0.005). A similar pattern could be observed in obese
participants (DFEF25-75%=58.4 ml (PiMM) vs. 92.2 ml (PiMZ),
p = 0.03). There was no such effect in never-smokers exposed to
environmental tobacco smoke. Values for D (FEV1/FVC)
consistently confirmed this trend, but associations did not reach
statistical significance. For DFEF25-75%, the presence of a Z allele
interacted statistically significant with smoking (pinteraction=0.04
with smoking status (persistent vs. never) and pinteraction=0.002
with packyears between the two surveys), but not with obesity
status (p = 0.14). Statistically significant modification of the Z allele
effect on D (FEV1/FVC) could be observed for packyears between
the two surveys and obesity status (pinteraction=0.04 and 0.08,
respectively). As we had previously found sex differences in the
association between circulating AAT concentrations and lung
function [15], we further evaluated a possible effect modification
by sex. However, sex did not significantly modify the allele effect
on any lung function measure (all pinteraction $ 0.15).
High-sensitivity C-reactive Protein (hs-CRP) as a Proxy for Low
Systemic Inflammation
In order to strengthen the hypothesis that low grade systemic
inflammation drove the observed Z allele effect on pulmonary
function, we investigated the associations in participants with
elevated hs-CRP levels at follow-up (defined as the upper tertile of
the study population, i.e.$1.8 mg/l). Consistent with our findings
for smokers and obese people, declines in PiZ heterozygotes were
significantly enhanced for FEF25-75% (99.3 ml (PiMZ) vs. 71.2 ml
(PiMM), p = 0.006) and suggestively for FEV1/FVC (5.46%
(PiMZ) vs. 4.00% (PiMM), p= 0.07) (Table 3), but not for FEV1
or FVC. Interestingly, also PiS heterozygotes in the upper tertile of
hs-CRP values showed statistically significant larger declines in
FEF25-75% (p= 0.003) and FEV1/FVC (p= 0.04) than PiMM
subjects.
Incidence of Airway Obstruction and Respiratory
Symptoms
As a next step we tried to expand our analyses on the change of
spirometry measures with clinically relevant outcomes like the
incidence of airway obstruction or the development of respiratory
symptoms. 103 PiMZ carriers did not show airway obstruction at
baseline which was defined by FEV1/FVC , 0.7. In 17 of them a
smaller ratio than 0.7 was calculated at follow-up, which classified
them as incident cases. Comparing with PiMM individuals this
resulted in an adjusted odds ratio of 1.11 (95% CI= 0.64 to 1.93,
p = 0.70; Table 4). Corresponding investigations with individuals
exposed to elevated inflammatory conditions did not show an
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increased obstruction risk for Z heterozygotes, but were based on
very few numbers of cases. As far as the development of
respiratory symptoms like regular cough, phlegm or shortness of
breath during sleep was concerned, there seemed to be a trend
that PiMZ individuals were more susceptible than PiMM carriers,
in particular in subgroups exposed to pro-inflammatory conditions
(Table 4). But the limited statistical power did unfortunately not
allow a comprehensive evaluation of our hypothesis.
Validity
As chronic asthma is suggested to be associated with accelerated
loss of pulmonary function [16] and in the absence of post-
bronchodilation spirometry, we conducted a sensitivity analysis by
including only subjects who did not report physician-diagnosed
asthma. Furthermore, level of lung function change in adults is
also determined by lung function growth during early adulthood,
and to account for that, we performed another sensitivity analysis
by only including participants older than 30 years of age at
baseline. Neither of the two restrictions did essentially alter the
results (Table S1).
Replacing the change of FEF25-75% by the change of the ratio
FEF25-75%/FVC led to very similar conclusions (Table S2).
Finally, in order to detect potential participation bias, we weighted
each observation inverse to the probability of being included in the
study sample. None of the results of the regression analyses did
materially change (Table S3).
Discussion
In the present study, neither PiS nor PiZ heterozygosity
influenced longitudinal lung function measured by DFEV1 or
DFVC, independent of smoking or obesity status. However, PiMZ
genotype was associated with an accelerated FEF25-75% decline
in smoking and obesity subgroups from the general population.
Results for participants in the upper tertile of hs-CRP values
strengthened the notion that PiMZ carriers might be more
susceptible to systemic pro-inflammatory conditions with respect
to lung function parameters indicating narrowing of small airways.
Table 1. Characteristics of SAPALDIA follow-up participants at baseline (1991; upper part), follow-up (2002; middle part), and
between the two examinations (lower part).
Not included in Study
(N=3372)
Included in Study
(N=4675) PiMM (N=4207) PiMS (N=356) PiMZ (N=112) P-valuea
At baseline
% women 51.2 52.4 52.6 50.8 53.6 0.80
Age (y), median, IQR 42.4 (32.6, 51.1) 41.4 (31.7, 49.7) 41.5 (31.6, 49.8) 41.3 (32.9, 49.6) 38.3 (31.3, 47.3) 0.33
% never smokers 39.9 (N = 3360) 49.6 49.3 51.7 54.5 0.39
% current smokers 34.9 (N = 3360) 29.6 30.0 27.2 24.1 0.24
% ETS in never smokers 30.6 (N = 1340) 28.3 (N = 2318) 28.5 (N = 2073) 24.5 (N = 184) 34.4 (N = 61) 0.29
BMI (kg/m2), median, IQR 23.7 (21.3, 26.3; N = 3306) 23.1 (21.1, 25.6) 23.1 (21.0, 25.7) 23.3 (21.2, 25.7) 22.9 (21.3, 24.9) 0.80
% obeseb 7.6 (N = 3306) 5.3 5.4 4.5 4.5 0.72
FEV1 (mL), mean6SD 34856864 (N = 2910) 35766824 35706825 36176819 3627 6 787 0.35
FVC (mL), mean6SD 441561062 (N = 2929) 452761022 452261025 458061000 45536987 0.57
FEF25-75% (mL), mean6SD 337161228 (N = 2794) 343661223 342661221 346861212 370661320 0.05
FEV1/FVC (%), mean6SD 79.1067.93 (N = 2794) 79.2167.59 79.1867.56 79.0767.83 80.6168.01 0.14
At follow-up
% never smokers 40.7 (N = 2936) 48.1 47.8 49.7 53.6 0.40
% current smokers 32.3 (N = 2936) 22.6 22.8 21.9 16.1 0.23
% ETS in never smokers 15.1 (N = 1189) 15.4 (N = 2249) 15.5 (N = 2012) 14.7 (N = 177) 15.0 (N = 60) 0.96
BMI (kg/m2), median, IQR 25.7 (23.0, 28.8; N = 1923) 25.2 (22.7, 28.2) 25.2 (22.7, 28.2) 25.4 (22.8, 28.4) 25.2 (23.1, 27.6) 0.88
% obeseb 18.1 (N = 1923) 15.2 15.2 15.2 14.3 0.96
AAT (g/L), mean6SD 1.2560.22 (N = 1642) 1.2760.20 1.3060.19 1.0960.16 0.8060.11 ,0.001
hs-CRP (mg/L), median, IQR 1.1 (0.5, 2.3; N = 1642) 1.0 (0.5, 2.3) 1.0 (0.5, 2.3) 1.0 (0.5, 2.0) 0.9 (0.5, 2.5) 0.16
Between baseline and follow-up
DFEV1 (mL/y), mean6SD -35.2632.6 (N = 1278) -35.3629.8 -35.1629.8 -37.7630.1 -36.3628.7 0.27
DFVC (mL/y), mean6SD -26.1643.7 (N = 1266) -24.1640.2 -24.1640.2 -25.0639.7 -22.4641.5 0.82
DFEF25-75% (mL/y), mean6SD -64.2664.1 (N = 1070) -71.1665.2 -70.4664.8 -76.0664.9 -84.3677.9 0.03
D (FEV1/FVC) (%/y), mean6SD -3.4965.19 (N = 1071) -4.0564.95 -4.0164.94 -4.2665.01 -4.6264.99 0.32
AAT: Alpha1-antitrypsin; BMI: Body mass index; ETS: regularly exposed to environmental tobacco smoke; FEF25-75%: mid expiratory flow; FEV1: forced expiratory
volume in 1 second; FVC: forced vital capacity; hs-CRP: high-sensitivty C-reactive protein; IQR: Interquartile range; SD: Standard deviation.
aPearson’s x2 test for testing equal proportions, analysis of variance (ANOVA) for testing equal means of normally distributed data (AAT levels and spirometric
measurements), and Kruskal-Wallis test for testing equal distributions in not normally distributed data (age and BMI values) between the three genotype classes.
bObese subjects were defined as having a BMI$30kg/m2.
doi:10.1371/journal.pone.0042728.t001
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The Role of Smoking and Pulmonary Oxidative Stress
It is well established that smokers suffering from severe AAT
deficiency, a condition accompanied by only 15% of normal AAT
blood concentrations, are particularly vulnerable to developing
early onset COPD [2]. There is less evidence that intermediate or
even mild AAT deficiency modify the effect of smoking or other
oxidative inhalants on lung function. In a small study of 56-year-
old men, a higher mean annual decrease in FEV1 in smoking
PiMZ individuals was reported as compared with non-smoking
PiMZ or smoking PiMM individuals [17], but larger studies could
not find such an interaction [7,9]. Results of studies investigating
the impact of environmental and occupational exposure are
heterogeneous [18]. Passive smoking has been shown in school
children to be associated with cross-sectional lower lung function
only in children having low levels of AAT in the blood, and
particularly in measures of mid- to end-expiratory flow rates [19].
A recent longitudinal study found accelerated lung function
declines in New York City firefighters of PiMZ genotype
compared to PiMM in the years after World Trade Center
collapse accompanied by massive air pollution, and no such
difference could be observed prior to September 11, 2001 [20].
Support for a gene-environment interaction comes also from
genome-wide as well as from experimental studies. While genome-
wide association studies on COPD and lung function have not
found the SERPINA1 locus among the top hit signals [21,22,23], it
was the most strongly associated candidate gene in ever smokers in
a comprehensive evaluation of potential lung function associated
genes in more than 20,000 individuals from the general population
[24]. Oxidation of the Z form by cigarette smoke induced its
polymerization in lung tissue of transgenic PiZZ mice [12]. Such
polymers could also be detected on the lung surface in human PiZ
homozygotes, originating either from lung epithelial cells or
macrophages and independent of the main hepatocytic secretion
[25]. In addition to being an ineffective elastase inhibitor, these
polymers attracted a higher number of neutrophils, further shifting
the protease-antiprotease equilibrium towards proteolysis. As
subjects with PiMZ genotype also exhibit elevated levels of
intrapulmonary neutrophilic inflammation [26], they are poten-
tially more susceptible to oxidative inhalants. The observed dose-
response trend in the interaction between smoking and the
presence of a Z allele is in agreement with this biological concept.
The Role of Obesity and Systemic Low Grade
Inflammation
The observed accelerated loss of pulmonary function in obese
subjects carrying the PiMZ genotype is novel. The often observed
inverse association between obesity and lung function is in part
explained by a mechanical effect of obesity on lung volume and
airway caliber. Yet more limited evidence suggests an additional
effect of obesity on peripheral airway obstruction that may be
related to systemic low grade inflammation [27]. Adipose tissue
from subjects who are overweight or obese produces pro-
inflammatory adipokines that spill over to the blood stream.
Elevated circulating concentrations of inflammation markers such
Table 2. Adjusted mean values in DFEV1 and DFVC over 11 years of follow-up comparing different SERPINA1 genotypes.
DFEV1(ml/y) 95%CI P-value DFVC(ml/y) 95%CI P-value
Total
PiMM, N= 4207 -35.2 -36.0 to -34.4 -24.1 -25.2 to -23.0
PiMS, N = 356 -36.9 -39.7 to -34.1 0.24 -24.7 -28.3 to -21.0 0.77
PiMZ, N= 112 -36.0 -41.0 to -31.1 0.74 -23.3 -29.8 to -16.7 0.80
Passive Smokersa
PiMM, N= 691 -32.3 -34.5 to -30.2 -21.4 -24.1 to -18.6
PiMS, N = 52 -33.9 -41.5 to -26.3 0.69 -26.3 -35.9 to -16.7 0.33
PiMZ, N= 22 -41.3 -52.9 to -29.7 0.14 -34.5 -49.2 to -19.7 0.09
Ever Smokers
PiMM, N= 2194 -35.1 -36.4 to -33.8 -25.0 -26.7 to -23.2
PiMS, N = 179 -36.8 -40.8 to -32.7 0.43 -24.1 -29.5 to -18.6 0.75
PiMZ, N= 52 -35.4 -42.8 to -27.9 0.94 -21.6 -31.6 to -11.6 0.51
Persistent Smokersb
PiMM, N= 922 -35.6 -39.3 to -31.9 -26.6 -31.3 to -21.9
PiMS, N = 74 -41.7 -48.7 to -34.8 0.07 -30.6 -39.4 to -21.7 0.35
PiMZ, N= 18 -41.2 -54.5 to -27.9 0.40 -24.0 -40.8 to -7.1 0.75
Obese subjectsc
PiMM, N= 653 -36.8 -42.4 to -31.3 -33.6 -41.1 to -26.1
PiMS, N = 55 -37.1 -46.3 to -28.0 0.94 -29.7 -42.1 to -17.4 0.48
PiMZ, N= 16 -48.0 -62.9 to -33.1 0.12 -34.7 -54.8 to -14.6 0.91
CI: confidence interval. FEV1: forced expiratory volume in 1 second. FVC: forced vital capacity.
Covariates included sex, linear and squared age, recruiting area, smoking history (packyears at baseline, as well as linear and squared packyears between baseline and
follow-up), height, baseline BMI and BMI change between baseline and follow-up.
aPassive smokers were defined as never smokers who declared regular exposure to environmental tobacco smoke within one year prior to the baseline or follow-up
examination.
bPersistent smokers were classified as subjects who declared current smoking at both examinations.
cObese subjects were defined as BMI$30kg/m2 at the baseline or follow-up examination.
doi:10.1371/journal.pone.0042728.t002
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as hs-CRP or interleukin-6 (IL-6) are both, higher in obese persons
[28,29] and associated with accelerated lung function decline
[30,31]. Also in the SAPALDIA cohort, we have previously
reported that accelerated lung function decline and obesity are
both associated with increased hs-CRP, particularly in women
[32]. Mendelian randomization approaches to examine causality
between increased hs-CRP and lower respiratory function led to
conflicting results [30,33]. However, these studies did not assess
the effect of CRP gene variants on lung function separately in
groups exposed to pro-inflammatory agents such as smokers.
This Study in Context
A longitudinal study in smokers reported an overrepresentation
of PiMZ participants in rapid lung function decliners [10].
However, population-based cohort studies did not find consistent
PiMZ effects on lung function decline, neither generally, nor in
smoking strata [7,8,9]. The only marginally statistical significant
result was found in non-smoking PiMZ carriers who showed a
steeper unadjusted lung function decline than non-smoking PiMM
subjects [7]. Our study was generally in good agreement with these
results as we could not detect any statistical significant effect of
SERPINA1 genotypes on DFEV1, which was the primary focus of
the previously mentioned studies. Compared to those existing
publications we included in our analysis a wider range of
spirometry measures and found associations with the decline of
FEF25-75% as well as weaker, but relatively consistent associations
with the decline of the FEV1/FVC ratio. Both these two measures
are in use to assess early airway obstruction and may probably best
reflect the volume of the small airways [34,35]. There are hardly
any large studies which used these measures in connection with
SERPINA1 genotypes so far, apart from a recent study of two large
populations that found PiMZ genotypes associated with lower
FEV1/FVC ratio and with more severe emphysema on chest
computer tomography scan, but not with COPD status [36]. Flow
related spirometric characteristics such as FEF25-75% may be
decreased in the presence of airway abnormalities including
inflammation or alterations in elastic recoil, two important
correlates of AAT deficiency [37]. For example, interactions
between glutathione S-transferase (GST) deficiency genotypes and
passive smoking were strongest for mid expiratory flow measures
Table 3. Adjusted mean values in D (FEV1/FVC) and DFEF25-75% over 11 years of follow-up comparing different SERPINA1
genotypes.
DFEF25-75%(ml/y) 95%CI P-value D (FEV1/FVC)(%/y) 95%CI P-value
Total
PiMM, N= 4207 -70.6 -72.5 to -68.7 -4.03 -4.17 to -3.89
PiMS, N = 356 -74.4 -80.8 to -68.0 0.26 -4.14 -4.62 to -3.66 0.65
PiMZ, N= 112 -81.4 -92.8 to -70.0 0.07 -4.46 -5.31 to -3.60 0.33
Passive Smokersa
PiMM, N= 691 -67.5 -72.4 to -62.5 -3.88 -4.23 to -3.53
PiMS, N = 52 -65.5 -82.8 to -48.3 0.84 -3.01 -4.23 to -1.79 0.18
PiMZ, N= 22 -65.8 -92.3 to -39.4 0.91 -3.11 -4.98 to -1.24 0.43
Ever Smokers
PiMM, N= 2194 -70.0 -73.0 to -67.1 -3.84 -4.06 to -3.62
PiMS, N = 179 -74.9 -84.2 to -65.6 0.32 -4.16 -4.85 to -3.47 0.38
PiMZ, N= 52 -87.4 -104.5 to -70.4 0.05 -4.80 -6.07 to -3.53 0.14
Persistent Smokersb
PiMM, N= 922 -66.8 -75.2 to -58.4 -3.90 -4.53 to -3.27
PiMS, N = 74 -74.0 -89.8 to -58.3 0.34 -4.62 -5.81 to -3.44 0.21
PiMZ, N= 18 -108.2 -138.1 to -78.2 0.005 -5.25 -7.51 to -2.99 0.23
Obese Subjectsc
PiMM, N= 653 -58.4 -70.1 to -46.7 -2.81 -3.70 to -1.93
PiMS, N = 55 -59.5 -78.8 to -40.1 0.90 -3.61 -5.07 to -2.15 0.22
PiMZ, N= 16 -92.2 -123.7 to -60.6 0.03 -5.13 -7.52 to -2.75 0.05
Subjects in upper tertile
of hs-CRPd
PiMM, N= 1387 -71.2 -74.8 to -67.6 -4.00 -4.28 to -3.71
PiMS, N = 99 -89.8 -102.0 to -77.7 0.003 -5.03 -5.99 to -4.06 0.04
PiMZ, N= 36 -99.3 -119.3 to -79.4 0.006 -5.46 -7.04 to -3.88 0.07
CI: confidence interval. FEF25-75%: forced mid expiratory flow. FEV1: forced expiratory volume in 1 second. FVC: forced vital capacity.
Covariates included sex, linear and squared age, recruiting area, smoking history (packyears at baseline, as well as linear and squared packyears between baseline and
follow-up), height, baseline BMI and BMI change between baseline and follow-up.
aPassive smokers were defined as never smokers who declared regular exposure to environmental tobacco smoke within one year prior to the baseline or follow-up
examination.
bPersistent smokers were classified as subjects who declared current smoking at both examinations.
cObese subjects were defined as BMI$30kg/m2 at the baseline or follow-up examination.
dCorresponded to a level of $ 1.8 mg/l.
doi:10.1371/journal.pone.0042728.t003
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in children [38]. However, these measures have often been
criticized for being more variable and therefore less reliable than
FEV1 [39]. We observed a correlation coefficient of 0.82 between
baseline and follow-up FEF25-75% in SAPALDIA which is
smaller than the one for FEV1 (0.92) and FVC (0.91), but larger
than the one for the more commonly used FEV1/FVC ratio
(0.74). Since we consistently found main and interacting effects of
air pollution strongest for this mid flow parameter [40,41,42], it
seems unlikely that the results of the present study are driven by
measurement error. Moreover, FEF25-75% was found to have a
high heritability in families with severe COPD [37].
Strengths and Weaknesses
The strength of this study is its large sample size, its detailed
characterization of subjects, and its stringent quality control of
spirometry [43]. The credibility of our results is supported by the
fact that the reduction of AAT serum levels in PiMS and PiMZ
compared to PiMM subjects was similar to that described by
others [7]. Compared to the hitherto existing publications, we
carefully excluded carriers of additional, rare mutations influenc-
ing AAT serum levels in order to diminish misclassification of
wildtype alleles.
Our study has some limitations. First, a possible selection of
healthy individuals may limit the generalizability of the results.
However, giving more weight to underrepresented groups within
the study sample did not alter the results. Moreover, if persons
with low levels of lung function were preferentially lost among
PiMZ carriers, stated effects may be an underestimation of the true
effect. Second, PiMZ individuals showed slightly higher baseline
FEF25-75% and FEV1/FVC values which can be partially
explained by the younger age and the reduced number of smokers
in this group, but which may question the clinical relevance of the
accelerated decline in these measures. Yet, the combination of a
higher level of cross-sectional lung function and a steeper lung
function decline after exposure to inflammatory agents parallels
observations in New York City firefighters before and after the
September 11 attacks [20]. Furthermore, spirometric measure-
ments were carried out without bronchodilator [44], which
hinders a clinically acceptable definition of airway obstruction.
Unlike some comparable studies [9,10], we performed spirometry
at only two time points. This makes our change values susceptible
to imprecision, but we do not expect substantial measurement
error for several reasons. The same spirometers and stringent
quality criteria at baseline and follow-up were applied, correlation
coefficients between the measurements at the two time points were
high, and the direction of most genotype effects were consistent for
all lung function outcomes. In addition, since it would be unlikely
that any measurement error is associated with the SERPINA1
genotype, misclassification would be non-differential, which
indicates an underestimation rather than an overestimation of
Table 4. Adjusted odds ratios for developing airway obstruction (FEV1/FVC,0.7) and respiratory symptoms over 11 years of
follow-up comparing different SERPINA1 genotypes.
Incidence of Airway Obstruction Incidence of Respiratory Symptoms
N (cases/total) OR 95%CI P-value N (cases/total) OR 95%CI P-value
Total
PiMM 601/3775 ref. 380/3547 ref.
PiMS 50/315 0.97 0.70 to 1.35 0.86 33/307 1.07 0.73 to 1.57 0.73
PiMZ 17/103 1.11 0.64 to 1.93 0.70 15/101 1.52 0.86 to 2.69 0.15
Ever Smokers
PiMM 346/1920 ref. 240/1780 ref.
PiMS 30/152 1.12 0.72 to 1.74 0.62 18/144 0.99 0.58 to 1.66 0.96
PiMZ 9/47 1.20 0.56 to 2.60 0.64 10/43 1.94 0.93 to 4.06 0.08
Persistent Smokersa
PiMM 162/801 ref. 131/705 ref.
PiMS 14/63 0.90 0.46 to 1.78 0.76 8/56 0.76 0.34 to 1.68 0.50
PiMZ 1/17 0.29 0.04 to 2.33 0.25 3/13 1.19 0.31 to 4.56 0.80
Obese Subjectsb
PiMM 94/555 ref. 60/514 ref.
PiMS 6/47 0.63 0.25 to 1.62 0.34 6/43 1.26 0.49 to 3.22 0.63
PiMZ 4/15 1.98 0.57 to 6.83 0.28 4/16 3.24 0.95 to 11.07 0.06
Subjects in upper
tertile of hs-CRPc
PiMM 229/1200 ref. 140/1122 ref.
PiMS 18/88 1.01 0.57 to 1.79 0.96 13/84 1.35 0.71 to 2.56 0.35
PiMZ 7/34 1.04 0.42 to 2.55 0.93 8/32 2.51 1.07 to 5.85 0.03
CI: confidence interval. hs-CRP: high-sensitivity C-reactive protein. OR: odds ratio.
Covariates included sex, linear and squared age, recruiting area, smoking history (packyears at baseline, as well as linear and squared packyears between baseline and
follow-up), height, baseline BMI and BMI change between baseline and follow-up.
aPersistent smokers were classified as subjects who declared current smoking at both examinations.
bObese subjects were defined as BMI$30kg/m2 at the baseline or follow-up examination.
cCorresponded to a level of $ 1.8 mg/l.
doi:10.1371/journal.pone.0042728.t004
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the real effect. Another limitation is the low statistical power for
analyzing obese or persistent smoking PiMZ carriers despite the
large cohort size. Therefore, our findings must be interpreted with
caution. If a correction for multiple testing was applied, none of
the results would remain statistically significant (since all observed
p-values . 0.001). For the same reason, we could neither
distinguish emerging from persistent obesity, nor could we form
strata with enhanced hs-CRP levels of clinical relevance (i.e. 10
mg/l). Finally, the clinical meaning of the observed excess decline
in PiZ heterozygotes could not be reliably estimated, as the
numbers of incident cases with airway obstruction or respiratory
symptoms were too small to investigate differences between
SERPINA1 genotype classes with respect to inflammatory condi-
tions. Nevertheless, we found indication that those subgroups are
more likely to develop respiratory symptoms and we know from
literature that mid expiratory flow rates have been shown to be a
powerful predictor of mortality from COPD, independent of
FEV1 [45].
Conclusion
We confirm in this population-based study that neither PiMS,
nor PiMZ carriers have a substantial impact on longitudinal lung
function. There is indication however, that the presence of one Z
allele may be sufficient to accelerate loss of small airway volume
and incidence of respiratory symptoms in defined population
subgroups which are exposed to pro-inflammatory agents and
conditions. This is a potentially relevant observation as the
prevalence of PiMZ genotype is quite common in Western Europe
[3] and was 2.4% in this study sample. In order to estimate the
public health relevance of our findings, future studies must
associate subgroups of PiMZ individuals to post-bronchodilator
lung function and clinically relevant outcomes like respiratory
symptoms, emphysema by chest computer tomography and
hospitalization for COPD.
Materials and Methods
Ethics Statement
SAPALDIA was approved by the Swiss Academy of Medical
Sciences, the supraregional ethics committee for clinical research
(UREK, Project Approval Number 123/00) and the Cantonal
Ethics Committees for each of the eight examination areas (Ethics
commissions of the cantons Aargau, Basel, Geneva, Grisons,
Ticino, Valais, Vaud and Zurich). Participants were required to
give written consent before any part of the health examination was
conducted either globally (for all health examinations) or
separately for each investigation.
Study Population
In 1991, a random sample of 9651 adults, aged 18-60 years,
from eight areas in Switzerland underwent a detailed health
examination including a questionnaire about respiratory health,
occupational and lifestyle exposures [46]. Participants were
predominantly of European-Caucasian ethnicity and represented
urban and rural areas. Eleven years later, 8047 persons were
reassessed [47]. 6058 follow-up subjects provided blood samples
and consented to DNA analysis. 5274 of these subjects underwent
spirometry testing at baseline and follow-up. Not included in this
analysis were participants with missing smoking history or body
mass index (BMI) data (n = 525), subjects without valid hs-CRP
(n = 18), and subjects for whom genotyping of the S or Z allele
either failed (n = 6) or resulted in PiS homozygosity (n = 10), PiSZ
compound heterozygosity (n = 10) or PiZ homozygosity (n = 1).
Other SERPINA1 rare mutations which lower AAT blood levels
were detected according to a procedure described elsewhere [48]
in additional 29 samples which were also excluded. Our study
sample included thus 4675 subjects.
Measurements
Spirometry was assessed according to American Thoracic
Society criteria using the same spirometers in 1991 and 2002
(Sensormedics model 2200, USA) and by applying stringent
quality control criteria [43]. The forced expiratory manoeuvre
was obtained without bronchodilators. FEV1 and FVC had to
originate from the same manoeuvre in order to provide a valid
FEV1/FVC ratio. Information about the smoking history was
collected by questionnaire. Passive smoking was positive if never
smoking subjects gave an affirmative answer at baseline or follow-
up to the question if they were exposed to environmental tobacco
smoke in the 12 months prior to the examination on most days or
nights. Height and weight were measured and BMI was
calculated as weight divided by squared height. Incident cases
of airflow obstruction were defined as persons with a FEV1/FVC
ratio $ 0.7 at baseline and , 0.7 at follow-up and were
compared to individuals without obstruction at both examina-
tions. Incident cases of respiratory symptoms were defined as
people with self-reported regular cough, phlegm or shortness of
breath at follow-up, but not at baseline. They were compared
with individuals without any of these symptoms at baseline and
follow-up. Cough or phlegm had to be present during the day or
at night on most days for as much as 3 months per year and
shortness of breath had to occur during sleep in the past 12
months before the examination. Subjects who declared an asthma
diagnosis by a physician at baseline or follow-up were defined as
asthmatics.
Serum Analysis
AAT and hs-CRP concentrations were determined from blood
serum aliquots by latex-enhanced immunoturbidimetric assays
(Roche diagnostics, Germany). Lower detection thresholds for the
AAT and CRP assays were 0.21 g/l and 0.1 mg/l, respectively.
Genotyping
Genotyping of SERPINA1 PiS (rs17580) and PiZ (rs28929474)
polymorphisms was carried out using 59 nuclease fluorescent real-
time PCR (TaqMan Probes technology) on LightCycler480
(Roche) as described before [4]. Probes and primers are given in
Table S4. Genotype distributions for PiS and PiZ were both in
Hardy Weinberg equilibrium (p= 0.93, N= 6050, and p=0.99,
N= 6051, respectively).
Statistical Analysis
Statistical tests to evaluate differences in the characteristics
among the different groups of genotype carriers encompassed
Pearson’s x2 for testing equal proportions, analysis of variance
(ANOVA) for testing equal means of normally distributed
continuous data, and Kruskal-Wallis for testing equal distributions
of continuous data which were not normally distributed. Main
effects of SERPINA1 alleles on lung function decline were assessed
using multiple unconditional linear regression models adjusted for
sex, age, recruiting area, smoking history (packyears at baseline
and between baseline and follow-up), height, baseline BMI and
BMI change between baseline and follow-up. Age and packyears
between baseline and follow-up were modeled with linear and
squared terms to better fit to spirometry data. Interactions
between genotypes and other covariates were tested by integrating
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multiplicative terms in the regression models. Two-sided p-values
of ,0.05 (and of ,0.10 for interactions) were considered as
statistically significant. We performed 56 different linear regression
tests (4 respiratory outcomes * 2 genotype comparisons * 7
categories). Bonferroni correction would thus lower the signifi-
cance threshold to p= 0.05/56= 0.001. However, since all
analyses were hypothesis-driven and most tests not independent
of each other, we decided to give the results uncorrected for
multiple testing.
Logistic regression models were used to compare the odds of
developing airflow obstruction or respiratory symptoms between
baseline and follow-up among the SERPINA1 genotype classes.
The models were adjusted for the same covariates mentioned
above. All statistical analyses were performed with STATA,
release 10.1 IC (STATA corporation, USA).
Supporting Information
Table S1 Sensitivity analyses for adjusted mean values
in D(FEV1/FVC) and DFEF25-75% over 11 years of
follow-up comparing different SERPINA1 genotypes.
(PDF)
Table S2 Adjusted mean values in D (FEF25-75%/FVC)
over 11 years of follow-up comparing different SER-
PINA1 genotypes.
(PDF)
Table S3 Adjusted mean values in lung function change
over 11 years of follow-up comparing different SER-
PINA1 genotypes in unweighted and weighted models.
(PDF)
Table S4 Primers and probes for genotyping the
SERPINA1 PiS and PiZ polymorphisms (rs17580 and
rs28929474) using 59 nuclease fluorescent real-time PCR
(TaqMan Probes technology) on LightCycler480 (Roche).
(PDF)
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Table S1. Sensitivity analyses for adjusted mean values in Δ(FEV1/FVC) and ΔFEF25-75% over 11 years of follow-up  
comparing different SERPINA1 genotypes.  
All n ΔFEF25-75%(ml/y) p-value Δ;FEV/FVCͿ ;‰/yͿ p-value 
MM 4207 -70.60   -4.03   
MS 356 -74.42 0.26 -4.14 0.65 
MZ 112 -81.41 0.07 -4.46 0.33 
MM, age>30 3320 -70.93   -3.84   
MS, age>30 291 -75.20 0.25 -3.97 0.67 
MZ, age>30 90 -84.42 0.04 -4.47 0.21 
MM, non-asthmatics 3751 -71.41   -3.99   
MS, non-asthmatics 316 -73.17 0.63 -3.95 0.90 
MZ, non-asthmatics 102 -80.82 0.13 -4.39 0.38 
Ever smokers   
 
  
 
  
MM 2194 -70.02   -3.84   
MS 179 -74.91 0.32 -4.16 0.38 
MZ 52 -87.44 0.05 -4.80 0.14 
MM, age>30 1800 -69.12   -3.78   
MS, age>30 156 -73.48 0.41 -3.92 0.71 
MZ, age>30 44 -86.62 0.07 -4.65 0.22 
MM, non-asthmatics 1957 -70.52   -3.78   
MS, non-asthmatics 156 -71.52 0.85 -3.84 0.86 
MZ, non-asthmatics 46 -86.07 0.10 -4.74 0.16 
Persistent smokers   
 
  
 
  
MM 922 -66.82   -3.90   
MS 74 -74.02 0.34 -4.62 0.21 
MZ 18 -108.16 0.005 -5.25 0.23 
MM, age>30 708 -66.63   -4.03   
MS, age>30 62 -75.62 0.27 -4.61 0.37 
MZ, age>30 12 -105.47 0.03 -4.54 0.72 
MM, non-asthmatics 844 -66.81   -3.77   
MS, non-asthmatics 64 -68.99 0.79 -4.08 0.62 
MZ, non-asthmatics 18 -107.33 0.007 -5.09 0.24 
Obese Subjects   
 
  
 
  
MM 653 -58.39   -2.81   
MS 55 -59.46 0.90 -3.61 0.22 
MZ 16 -92.16 0.03 -5.13 0.05 
MM, age>30 581 -68.14   -3.19   
MS, age>30 51 -64.06 0.64 -3.56 0.59 
MZ, age>30 16 -99.22 0.04 -5.49 0.05 
MM, non-asthmatics 561 -59.56   -2.75   
MS, non-asthmatics 47 -58.67 0.92 -3.38 0.36 
MZ, non-asthmatics 14 -95.23 0.03 -5.32 0.04 
Subjects in upper 
tertile of hs-CRP   
 
  
 
  
MM 1387 -71.24   -4.00   
MS 99 -89.85 0.003 -5.03 0.04 
MZ 36 -99.32 0.006 -5.46 0.07 
MM, age>30 1174 -70.80   -3.98   
MS, age>30 86 -89.02 0.006 -5.00 0.06 
MZ, age>30 31 -94.91 0.03 -5.54 0.08 
MM, non-asthmatics 1229 -71.47   -3.86   
MS, non-asthmatics 86 -87.06 0.02 -4.55 0.20 
MZ, non-asthmatics 33 -101.16 0.006 -5.62 0.04 
Covariates included sex, linear and squared age, recruiting area, smoking history (packyears at baseline, as well as linear and squared packyears between  
baseline and follow-up), height, baseline BMI and BMI change between baseline and follow-up. 
Persistent smokers were classified as subjects who declared current smoking at both examinations. 
Obese subjects were defined as BMI ≥ 30kg/m2 at the baseline or follow-up examination.  
Subjects in the upper tertile of hs-CRP had blood levels of ≥ 1.8 mg/l. 
 
Table S2. Adjusted mean values in Δ(FEF25-75%/FVC) over 11 years of follow-up 
comparing different SERPINA1 genotypes.  
All Δ;FEF25-75%/FVCͿ ;‰/yͿ 95%CI p-value 
MM, n=4207 -13.09 -13.56 to -12.62   
MS, n=356 -13.65 -15.28 to -12.01 0.52 
MZ, n=112 -15.80 -18.70 to -12.89 0.07 
Ever smokers       
MM, n=2194 -12.77 -13.51 to -12.04   
MS, n=179 -13.75 -16.05 to -11.44 0.42 
MZ, n=52 -17.37 -21.59 to -13.15 0.03 
Persistent smokers     
MM, n=922 -12.50 -14.57 to -10.43   
MS, n=74 -13.68 -17.55 to -9.82 0.52 
MZ, n=18 -21.58 -28.94 to -14.22 0.01 
Obese subjects       
MM, n=653 -9.33 -12.45 to -6.21   
MS, n=55 -10.01 -15.16 to -4.87 0.76 
MZ, n=16 -17.67 -26.07 to -9.28 0.04 
Subjects in upper tertile of hs-CRP     
MM, n=1387 -13.05 -14.02 to -12.07   
MS, n=99 -16.77 -20.07 to -13.47 0.03 
MZ, n=36 -20.80 -26.21 to -15.38 0.006 
Covariates included sex, linear and squared age, recruiting area, smoking history (packyears at baseline, as well as linear and 
squared packyears between baseline and follow-up), height, baseline BMI and BMI change between baseline and follow-up. 
Persistent smokers were classified as subjects who declared current smoking at both examinations. 
Obese subjects were defined as BMI ≥ 30kg/m2 at the baseline or follow-up examination.  
Subjects in the upper tertile of hs-CRP had blood levels of ≥ 1.8 mg/l. 
 
Table S3. Adjusted mean values in lung function change over 11 years of follow-up comparing different SERPINA1 genotypes in unweighted and 
weighted models.  
All n ΔFEVϭ;ml/yͿ p-value ΔFVC;ml/yͿ p-value ΔFEF25-75%(ml/y) p-value Δ;FEV/FVCͿ ;‰/yͿ p-value 
MM 4207 -35.16   -24.11   -70.60   -4.03   
MS 356 -36.91 0.24 -24.68 0.77 -74.42 0.26 -4.14 0.65 
MZ 112 -36.02 0.74 -23.27 0.80 -81.41 0.07 -4.46 0.33 
MM, weighted 4207 -35.15   -24.14   -70.57   -4.02   
MS, weighted 356 -36.88 0.25 -24.55 0.84 -74.49 0.24 -4.16 0.60 
MZ, weighted 112 -36.21 0.68 -23.64 0.89 -81.61 0.10 -4.47 0.29 
The weights were calculated inverse to the probability of being included in the study sample (based on age, sex and recruiting area variables). 
 
Table S4. Primers and probes for genotyping the SERPINA1 PiS and PiZ polymorphisms 
(rs17580 and rs28929474) using 5’ nuclease fluorescent real-time PCR (TaqMan Probes 
technology) on LightCycler480 (Roche). 
 
  
PiS (rs17580) PiZ (rs28929474) 
Primer Forward 5'-GCCATCTTCTTCCTGCCTGAT-3' 5'-TCCAAGGCCGTGCATAAGG-3' 
Primer Reverse 5'-CCAGGAACTTGGTGATGATATCGT-3' 5'-GCCCCAGCAGCTTCAGT-3' 
VIC dye-labeled probe 5'-CACCTGGAAAATGAA-3' 5'-ACCATCGACGAGAAAG-3' 
FAM dye-labeled probe 5'-CACCTGGTAAATGAA-3' 5'-CATCGACAAGAAAG-3' 
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ABSTRACT
Objectives We evaluated interactions between
SERPINA1 PiMZ genotype, associated with intermediate
α1-antitrysin deficiency, with outdoor particulate matter
≤10 mm (PM10), and occupational exposure to vapours,
dusts, gases and fumes (VGDF), and their effects on
annual change in lung function.
Methods Pre-bronchodilator spirometry was performed
in 3739 adults of the Swiss Cohort Study on Air
Pollution and Lung Disease in Adults (SAPALDIA) for
whom SERPINA1 genotypes were available. At baseline
in 1991, participants were aged 18–62 years; follow-up
measurements were conducted from 2001 to 2003. In
linear mixed regression models of annual change in lung
function, multiplicative interactions were evaluated
between PiMZ genotype (PiMM as reference) and
change in PM10 (μg/m
3), and VGDF exposure (high-level,
low-level or no exposure as reference) during follow-up.
Results Annual declines in forced expiratory flow at
25–75% of forced vital capacity (FEF25–75%) (−82 mL/s,
95% CI −125 to −39) and forced expiratory volume in
1 s over forced vital capacity (FEV1/FVC) (−0.3%, 95%
CI −0.6% to 0.0%) in association with VGDF exposure
were observed only in PiMZ carriers (Pinteraction<0.0001
and Pinteraction=0.03, respectively). A three-way
interaction between PiMZ genotype, smoking and VGDF
exposure was identified such that VGDF-associated
FEF25–75% decline was observed only in ever smoking
PiMZ carriers (Pinteraction=0.01). No interactions were
identified between PiMZ genotype and outdoor PM10.
Conclusions SERPINA1 PiMZ genotype, in
combination with smoking, modified the association
between occupational VGDF exposure and longitudinal
change in lung function, suggesting that interactions
between these factors are relevant for lung function
decline. These novel findings warrant replication in larger
studies.
INTRODUCTION
Decline in lung function over time is a characteris-
tic of aging, and accelerated decline is distinctive
for obstructive lung diseases including asthma and
chronic obstructive pulmonary disease (COPD).1 2
Epidemiological evidence from occupational and
population-based studies indicates that occupational
exposures to dusts, gases, and fumes are associated
with additional decline in lung function and a
causal risk factor of COPD.3 4 There is limited evi-
dence to support that ambient air pollution is asso-
ciated with lung function decline and COPD.4–6
The best known genetic risk factor for COPD is
severe serum deficiency of α1-antitrypsin (AAT), an
anti-inflammatory protease inhibitor (PI) of neutro-
phil elastase, a protease which breaks down elastin
in the lung parenchyma.4 7 AAT is encoded by the
SERPINA1 gene and allelic variants of SERPINA1
lead to inherited low AAT serum levels. Severe AAT
deficiency is caused by rare SERPINA1 genotypes
occurring at a frequency of <0.1% in the general
population, like homozygosity for the PI deficient
Z allele (PiZZ) or compound heterozygosity for PI
deficient S and Z alleles (PiSZ).8 PiMZ and PiMS
genotypes of SERPINA1 (M being the common
non-deficient allele) lead to intermediate and mild
AAT deficiency, respectively, and are more preva-
lent in the general populations representative of
Middle European countries at 2% and 8% fre-
quency, respectively.9 Meta-analyses offer mixed
evidence to support an association between PiMZ
genotype and risk of COPD, independent of
smoking; there is no evidence of an association
between PiMS genotype and risk of COPD.10 11
Earlier studies from the follow-up of the Swiss
Cohort Study on Air Pollution and Lung Diseases
in Adults (SAPALDIA 2) identified associations
between improvements in the concentrations of
outdoor particulate matter of 10 mm or less (PM10)
and attenuation of lung function decline, with the
What this paper adds
▸ There is evidence that α1-antitrypsin (AAT)
deficiency, occupational exposure to vapours,
gas, dusts and fumes (VGDF), ambient air
pollution and smoking are all causative factors
for adverse pulmonary health. The interactions
between these factors are not well investigated.
▸ In the present study, a three-way interaction
was identified between SERPINA1 PiMZ
genotype, which is associated with
intermediate AAT deficiency, smoking and
VGDF exposure. No interactions were present
between PiMZ genotype and air pollution.
▸ Genetic predisposition for intermediate AAT
deficiency, in combination with smoking, may
increase susceptibility to occupational
exposure-related decline in lung function. These
findings should be reassessed in larger studies.
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greatest change in small airway function,5 and between high
levels of occupational exposure to vapours, dusts, gases and
fumes (VGDF) and incidence of COPD.12 A more recent study
from the same survey showed associations between PiMZ geno-
type and age-related decline in forced expiratory flow between
25% and 75% of the forced vital capacity (ΔFEF25–75%) in par-
ticipants with systemic low-grade inflammation, including per-
sistent smokers.13 For this analysis, we evaluated whether the
PiMZ genotype modified the associations between environmen-
tal and occupational exposures, including outdoor PM10, envir-
onmental tobacco smoke (ETS) exposure and occupational
exposure to VGDF, and annual change in lung function in
SAPALDIA, hypothesising that the associations between these
exposures and lung function decline would be stronger in PiMZ
carriers in comparison with PiMM carriers.
METHODS
More detailed descriptions of the SAPALDIA study population
and design are summarised in previous publications12–14 and in
the online supplement.
Study population
SAPALDIA is a multicentre, population-based prospective
cohort study consisting of a random sample of 9651 partici-
pants aged between 18 and 62 years that were recruited from
eight regions in Switzerland, and were administered medical
examinations, pre-bronchodilator spirometry testing and a
detailed health questionnaire, at baseline in 1991.15 The
follow-up survey (SAPALDIA 2) was conducted from 2001 to
2003, of which 8047 of the original study participants were
present and of whom 6058 subjects provided blood samples
and consented to DNA analysis. This analysis was restricted to
3739 participants who were either SERPINA1 PiMZ or PiMM
carriers, completed spirometry testing at both surveys, reported
information on important covariates, and for whom air pollu-
tion measurements (outdoor PM10) and occupational history
during follow-up were available. Because we identified no pres-
ence of interaction between PiMS genotype and smoking in our
previous analysis,13 and because there is no evidence of an asso-
ciation between PiMS genotype and risk of COPD, SAPALDIA
participants who were PiMS carriers were not included in this
analysis. See online supplementary figure E1 for additional
details describing the selection of participants included in this
analysis. The SAPALDIA cohort study complies with the
Declaration of Helsinki. Written informed consent was obtained
from participants in both surveys. The study was approved by
the central ethics committee of the Swiss Academy of Medical
Sciences and the respective Cantonal ethics committees of the
eight study regions.
Spirometry testing
The spirometry protocol, which complied with American
Thoracic Society (ATS) criteria,16 has been described in detail
elsewhere.17–19 No bronchodilation was applied. The outcomes
of interest for this study were annual changes in forced expira-
tory volume in 1 s (FEV1, mL), forced vital capacity (FVC, mL),
the ratio of FEV1 over FVC (FEV1/FVC, %), and forced expira-
tory flow between 25% and 75% of FVC (FEF25–75, mL/s).
Annual change in lung function was defined as the difference in
each variable between the two examinations, divided by the
follow-up time in years for the participant. See the online sup-
plement for additional details describing methods for spirom-
etry testing.
Occupational and environmental exposure assessment
ETS exposure at baseline and follow-up visits was assessed for
different environments by the question ‘How many hours per
day are you exposed to other people’s tobacco smoke: (i) at
home; (ii) at the workplace?’ ETS exposure was categorised into
three exposure groups: none, <3 h/day but not none, and ≥3 h/
day.
Current job title reported by participants at the baseline
survey (1991) and all job titles reported during the follow-up
period were standardised according to the International
Standard Classification of Occupations (ISCO-88) code’s four-
digit classification,20 and linked to the ALOHA GPJEM for
COPD.21 22 Evaluation of occupational exposure in this analysis
was restricted to exposure to high VGDF level during follow-up
(low level or no exposure as reference) and continuous cumula-
tive exposure (>0 years for exposed, 0 years for unexposed;
unit, years) during follow-up. See the online supplement for
additional descriptions of the ALOHA GPJEM and exposure
variables.
Outdoor PM10 concentrations (μg/m
3) outside of each sub-
ject’s residence were estimated for the years 1990 and 2000
using a validated dispersion model (with different emissions
inventories for both years) with a spatial resolution of
200×200 m. We estimated the change in PM10 exposure during
follow-up (ΔPM10) for each participant, which was the differ-
ence between home outdoor mean PM10 level averaged over
1 year prior to the follow-up survey (in 2001–2003) and the
corresponding mean PM10 level averaged over 1 year prior to
the baseline survey (in 1990), divided by the time between base-
line and follow-up examinations. As documented previously,
overall exposure to home outdoor PM10 declined over the
follow-up period (median, −5.3 μg/m3). Further details of the
air pollution exposure assessment and modelling have been
described previously.23 For this analysis, ΔPM10 was scaled per
10 μg increase over 10 years.
Genotyping
Genomic DNA was extracted from blood samples using the
Puregene DNA Isolation Kit (Gentra Systems, USA). DNA
samples of 6058 probands were shipped to the Center for
Diagnosis of Inherited Alpha1-antitrypsin Deficiency in Pavia
(Italy) and processed in a semi-automated medium throughput
setup, assisted by liquid handling station (Freedom EVO75,
Tecan Group, Switzerland). The PiS (rs17580) and PiZ
(rs28929474) single nucleotide polymorphisms (SNPs) of
SERPINA1 were genotyped using 50-nuclease fluorescent real-
time PCR (TaqMan Probes technology) on LightCycler480
(Roche). Genotype distributions for PiS and PiZ in this study
sample were all in Hardy–Weinberg equilibrium.
Statistical analysis
We used linear mixed regression models of annual changes in
FEV1, FVC, FEV1/FVC and FEF25–75%, with random intercept
for study area, to evaluate multiplicative interactions between
SERPINA1 PiMZ genotype (PiMM genotype as reference) and
daily ETS, ΔPM10 and high-level VGDF exposures during
follow-up. Interactions between PiMZ genotype and each
exposure type were evaluated simultaneously in all models. We
extracted the β coefficients to estimate the adjusted difference in
annual change in lung function in association with each expos-
ure in PiMZ and PiMM carriers from a single nested model
with the multiplicative interaction terms. All models were
adjusted for exposure and covariates ascertained at baseline
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including PM10 concentration, cumulative VGDF exposure, age,
age squared, sex, height (cm), body mass index (BMI, kg/m2),
early respiratory infection, parental asthma, and education; add-
itional covariates included smoking status through follow-up
(persistent smokers, former smokers, never smokers as refer-
ence), cumulative pack-years through follow-up, the interaction
PiMZ genotype and smoking status, difference in BMI over
follow-up period, and PiMZ genotype. Additionally, we tested
for three-way interaction between smoking status through
follow-up (ever smokers, never smokers), PiMZ genotype, and
either ΔPM10 or high-level VGDF exposure. All analyses were
done using SAS V.9.2. Two-sided p values <0.05 were inter-
preted as statistically significant for main and interaction effects.
Secondary analyses
A substantial number of participants with complete information
at baseline were not included in the analysis due to non-
participation, or incomplete genotyping, spirometry, or expos-
ure and other covariate information at follow-up (49.5%). The
non-participants were more likely to be older, female, heavier,
smokers, have lower lung function, report more daily exposure
to ETS, or have higher exposure to outdoor PM10 at the base-
line survey (see online supplementary table E1). No significant
difference was observed in the distribution of occupational
VGDF exposure between the participants and non-participants.
To account for the potential bias arising from differences
between participants and non-participants, we weighted the
linear mixed effect regression models by the inverse probability
for inclusion in the analysis. We also evaluated whether baseline
lung function attenuated the interactions between PiMZ geno-
type and each exposure, with additional adjustment for baseline
lung function.
RESULTS
Characteristics of the study population stratified by SERPINA1
genotype are summarised in table 1. Similar distributions
between genotypes were observed for BMI and height, but
PiMZ carriers were slightly younger, and had higher lung func-
tion at baseline on average compared with PiMM carriers. The
mean annual declines in FEV1 and FEV1/FVC over the
follow-up period were slightly larger in PiMZ carriers compared
with PiMM carriers, with a larger difference observed for
FEF25–75% (−88 mL/s vs −71 mL/s, respectively). The preva-
lence of ever smokers and mean cumulative pack-years was
lower in PiMZ carriers. Compared with PiMM carriers, fewer
PiMZ carriers reported being exposed to ETS≥3 h/day. Over
the follow-up period, PiMZ carriers had a slightly larger mean
reduction in outdoor PM10 on average compared with PiMM
carriers. The prevalence of high-level VGDF exposure at base-
line and during follow-up was also moderately lower in PiMZ
carriers.
The adjusted differences in annual changes in lung function
in association with ΔPM10 and high-level VGDF exposures
during follow-up estimated in PiMZ and PiMM carriers are pre-
sented in table 2. A statistically significant interaction
(p<0.0001) was observed between PiMZ genotype and high-
level VGDF on annual change in FEF25–75%. High-level VGDF
exposure was associated with accelerated annual decline in
FEF25–75% (−82 mL/s, 95% CI −125 to −39) in PiMZ carriers,
while a positive association was observed in PiMM carriers. A
similar interaction of statistical significance (p=0.03) was
observed between PiMZ genotype and high-level VGDF expos-
ure on annual change in FEV1/FVC. Overall, larger annual
declines in lung function in association with ΔPM10 were
observed in PiMZ carriers than in PiMM carriers, but no statis-
tically significant interactions were present. No interactions were
present between PiMZ genotype and daily ETS exposure (data
not shown).
After adjustment for baseline lung function (see online
supplementary table E2), the estimated effects of ΔPM10 and
high-level VGDF exposure on annual decline in lung function in
PiMZ carriers were smaller compared to those presented in
table 2, but the interaction between PiMZ genotype and high-
level VGDF exposure on annual change in FEF25–75% remained
statistically significant. The estimated associations presented in
table 2 were similar to those after weighting the models accord-
ing to the inverse probability of inclusion in the analysis (see
online supplementary table E3); the interaction between PiMZ
genotype and high-level VGDF exposure on annual change in
FEV1/FVC and FEF25–75% remained statistically significant.
When occupational VGDF exposure was characterised as con-
tinuous cumulative exposure (see online supplementary table
E4), the interactions between PiMZ genotype and cumulative
VGDF exposure during follow-up were similar to those pre-
sented for high-level VGDF exposure presented in table 2; stat-
istically significant excess annual declines in FEV1/FVC and
FEF25–75% per 10 years of cumulative VGDF exposure were
observed only in PiMZ carriers.
Table 3 summarises the adjusted differences in annual change in
lung function for ΔPM10 and high-level VGDF exposure by PiMZ
genotype and smoking status, as estimated from the nested model
with a three-way interaction between PiMZ genotype, smoking,
and environmental (ΔPM10) or occupational (high-level VGDF)
exposure, respectively. Overall, the largest annual declines in
FEF25–75% (−109 mL/s; 95% CI −159 to −59) and FEV1/FVC
(−0.4%; 95% CI −0.8% to −0.0%) associated with high-level
VGDF exposure during follow-up were observed for ever smoking
PiMZ carriers. A three-way interaction between ever smoking
status, PiMZ genotype and high-level VGDF exposure on annual
change in FEF25–75% was statistically significant (p=0.01).
DISCUSSION
In this prospective cohort study of Swiss working adults, we
observed the SERPINA1 PiMZ genotype, in combination with
smoking, to modify the association between occupational expos-
ure to VGDF during follow-up and annual change in lung func-
tion, particularly for FEF25–75% and FEV1/FVC such that the
excess annual decline in FEF25–75% and FEV1/FVC was
observed in ever smoking PiMZ carriers. To a lesser extent,
larger annual declines in lung function in association with
ΔPM10 were observed in PiMZ carriers than in PiMM carriers,
but no statistically significant interactions were present. We did
not detect any interaction between PiMZ genotype and daily
ETS exposure.
Earlier cross-sectional population-based studies of homozy-
gous PiZ individuals have shown that lower FEV1 was observed
in participants who reported occupational exposures compared
to unexposed participants.24 25 Similarly, a prospective study of
exposed iron-ore miners demonstrated that a larger decline in
FEV1 was observed in workers with intermediate AAT defi-
ciency compared with workers with normal AAT phenotype.26
These studies could not formally assess effect modification as
they included only AAT deficient or only exposed individuals. A
cross-sectional study of young farming apprentices and unex-
posed conscripts observed an interaction between farming occu-
pation and PiMZ phenotype on bronchial hyperresponsiveness;
no effect modification by PiMZ phenotype was observed
between farming occupation and lung function.27 A recent
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study of New York City World Trade Center (WTC) firefighters
observed that workers with moderate and mild AAT deficiency
experienced larger declines in FEV1 in comparison with partici-
pants with no AAT deficiency during the first 4 years after
September 11th.28 In the study of WTC firefighters, AAT defi-
ciency also did not enhance the rate of FEV1 decline among the
study participants pre-9/11, suggesting a novel interaction
between AAT deficiency and exposures resulting from 9/11 on
lung function decline. Our study is the first to identify inter-
action between SERPINA1 genotype for predisposition to
intermediate AAT deficiency and chronic occupational exposure
to high-levels of VGDF in a general population prospective
cohort-based setting over a long duration of follow-up.
It is of interest that PiMZ carriers were less likely to be
exposed to high-level VGDF exposures at baseline and during
the follow-up period compared with PiMM carriers. The dis-
crepancy in the VGDF exposure distribution by SERPINA1
genotype may be suggestive of a healthy selection effect asso-
ciated with occupational inhalant exposures. It may be hypothe-
sised that PiMZ carriers may select themselves away from
Table 1 Distribution of characteristics for PiMM and PiMZ carriers
SERPINA 1 genotype PiMM PiMZ
Number of participants n=3642 n=97
Lung function at baseline
FEV1, L, mean (SD) 3.64 (0.81) 3.70 (0.79)
FVC, L, mean (SD) 4.61 (1.02) 4.60 (0.97)
FEV1/FVC, %, mean (SD) 79.2 (7.5) 81.0 (8.0)
FEF25–75, L/s, mean (SD) 3.49 (1.21) 3.81 (1.31)
Annual change in lung function from baseline to follow-up
▵FEV1, mL, mean (SD) −35 (31) −37 (26)
▵FVC, mL, mean (SD) −24 (41) −23 (42)
▵FEV1/FVC, %, mean (SD) −0.4 (0.5) −0.5 (0.5)
▵FEF25–75, mL/s, mean (SD) −71 (65) −88 (75)
Covariates of interest at baseline
Age, years, mean (SD) 40.4 (11.2) 39.5 (10.9)
BMI, kg/m2, mean (SD) 23.7 (3.6) 23.5 (3.4)
Height, cm, mean (SD) 169.9 (8.8) 169.6 (9.5)
Male, n (%) 1845 (50.6) 47 (48.5)
Early respiratory infection, n (%) 321 (8.1) 6 (6.2)
Parental history of asthma, n (%) 381 (10.5) 13 (13.4)
Education level, n (%)
High 650 (17.9) 25 (25.8)
Medium 2585 (71.0) 67 (69.1)
Low 407 (11.2) 5 (5.2)
ETS and smoking status at follow-up
Daily ETS exposure in past 12 months prior to follow-up, n (%)
≥3 h/day 355 (9.8) 4 (4.1)
<3 h/day 560 (15.4) 15 (15.5)
Unexposed 2727 (74.9) 78 (80.4)
Smoking status through follow-up, n (%)
Persistent smokers 877 (24.1) 20 (20.6)
Former smokers 1178 (32.3) 28 (28.9)
Never smokers 1587 (43.6) 49 (50.5)
Cumulative pack-years through follow-up, mean (SD) 10.7 (18.3) 9.7 (15.6)
Occupational VGDF exposure
VGDF level in current occupation at baseline survey, n (%)
High 479 (13.2) 7 (7.2)
Low 1190 (32.7) 29 (29.9)
Unexposed 1973 (54.2) 61 (62.9)
Cumulative VGDF exposure at baseline survey among exposed, years, mean (SD) 13.3 (28.0) 10.5 (25.3)
Highest VGDF level in all occupations during follow-up, n (%)
High 490 (13.5) 9 (9.3)
Low 1178 (32.3) 34 (35.1)
Unexposed 1974 (54.2) 54 (55.7)
Cumulative VGDF exposure during follow-up among exposed, years, mean (SD) 7.2 (12.4) 5.4 (9.6)
Outdoor PM10 exposure
1-year average PM10 prior to baseline survey, μg/m
3, mean (SD) 27.0 (9.8) 27.0 (10.1)
Change in PM10 between follow-up and baseline surveys, μg/m
3, mean (SD) −6.2 (4.2) −6.5 (5.0)
ETS, environmental tobacco smoke; FVC, forced vital capacity; FEF, forced expiratory flow; FEV, forced expiratory volume; VGDF, vapours, dusts, gases and fumes.
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occupational respirable exposures that may be irritable. They
may not seek employment in occupations with high exposure to
VGDF due to health conditions attributable to AAT deficiency,
or they may leave occupations with high exposure to VGDF due
to health aggravation or illness prior to the baseline survey, all
of which may reduce power to observe an association between
occupational exposure and lung function decline in PiMZ car-
riers. Because we did not have SERPINA1 genotype information
at the time of the baseline survey, we cannot formally evaluate
this question, but the influence of genetic susceptibility on
healthy worker selection and survival effects merits further
research.
There is mixed evidence to support that PiMZ is associated
with accelerated lung function decline and increased risk of
COPD,11 and our previous analysis in SAPALDIA did not iden-
tify any main associations between PiMZ genotype and lung
function decline.13 However, the current findings suggest that
PiMZ genotype, only in combination with smoking, may
enhance susceptibility for occupational exposure associated lung
function decline. The biological mechanism(s) explaining this
susceptibility is not clear. Previous studies in other populations
have also observed a combined effect between occupational
exposure to VGDF and smoking on risk of COPD.29–31 Thus
the combined interactive effects between PiMZ genotype,
smoking and occupational VGDF exposure may be a reflection
of smokers with intermediate AAT deficiency exceeding their
ability to cope with additional occupational VGDF exposure, or
due to poor mucus clearance among PiMZ smokers leading to
prolonged inflammatory response after occupational VGDF
exposure. Alternatively, it may be that PiMZ individuals may be
more susceptible to lung function decline attributable to the
combination of VGDF and cigarette smoke due to a diminished
protection against tissue damage from elastase in AAT
deficiency.32
The interaction between causative factors for adverse pulmonary
health including AAT deficiency, smoking, and occupational VGDF
exposure is also of special public health relevance, particularly
because COPD and its related conditions are associated with high
morbidity and mortality, and because the prevalence of genetic pre-
disposition to intermediate AAT deficiency is estimated to be
around 30 million worldwide.33 The role of genetic screening in
the workplace is also raised as a topic of discussion34–36 in light of
the numerous studies that have documented gene–occupation inter-
actions. However, no genetic test related to an occupational disease
has been validated or accepted for use, except the use of genetic
biomarkers to measure the dose of a genotoxic exposure34; and
there are many scientific, ethical, legal and social issues to consider
for the use of genetic screening for susceptibility to workplace
exposures. In this context, it serves as an important reminder to
occupational health practitioners and researchers that occupational
exposures are the primary cause of occupational disease and will
remain the responsibility of the employer to control.35
This study has numerous strengths, including selection of SNPs
with demonstrated functionality,9 prospective study design, detailed
data on individual smoking and ETS and PM10 exposure, semi-
quantitative estimates of occupational exposures to VGDF using a
GPJEM, extensive control for confounding, and high quality of lon-
gitudinal lung function data. However, there are a number of limita-
tions to be considered. We observed that effect modification by the
PiMZ genotype on the association between VGDF exposure and
lung function decline was strongest for FEF25–75%, consistent with
previous studies of the SAPALDIA cohort that have also identified
strong main and interacting associations between air pollution and
FEF25–75%,
5 37 and between PiMZ genotype and FEF25–75% in
population subgroups indicative of low-grade systemic inflamma-
tion.13 FEF25–75% is also used as an indicator of small airways
obstruction and bronchial reactivity and correlates highly with per-
centage predicted FEV1/FVC at levels of at least moderate airflow
obstruction.38 The primary limitation of FEF25–75% is that its meas-
urement precision within subjects is lower than of FEV1.
39 In this
study sample, the correlation between baseline and follow-up mea-
surements of FEV1, FEF25–75% and FEV1/FVC were 0.92, 0.81 and
0.72, respectively. While it is unknown why an interaction was not
observed between PiMZ and exposures on annual change in FEV1,
a spirometry metric which has less error, we hypothesise, given the
previous findings in the SAPALDIA study, that the interactive effects
observed for FEF25–75% are of relevance in this study population.
The relatively high degree of non-participation in our analysis
may have also biased our observed associations. However, the
use of inverse probability weighting to account for this potential
selection bias did not result in considerable differences in the
estimated associations, which suggests that any bias from non-
participation is likely to be minimal. Finally, VGDF-associated
lung function decline was limited to ever smoking PiMZ
Table 2 Adjusted differences* in annual change in lung function in association with outdoor PM10 and occupational VGDF exposures during
follow-up in PiMZ and PiMM carriers
N
ΔFEV1 (mL) ΔFVC (mL) ΔFEV1/FVC (%) ΔFEF25–75% (mL/s)
β (95% CI)† β (95% CI)† β (95% CI)† β (95% CI)†
▵PM10 (per 10 μg/m
3 increase in 10 years)
PiMZ 97 −6 (−15 to 4) −2 (−18 to 15) −0.2 (−0.4 to 0.0) −24 (−52 to 4)
PiMM 3642 −3 (−7 to 0) −0 (−5 to 5) −0.0 (−0.1 to 0.0) −12 (−21 to −3)
High-level VGDF exposure
PiMZ 97 −8 (−27 to 11) 10 (−16 to 35) −0.3 (−0.6 to 0.0)‡ −82 (−125 to 39)‡
PiMM 3642 1 (−2 to 4) −2 (−7 to 2) 0.1 (0.0 to 0.1) 6 (−1 to 13)
*Annual change in lung function was modelled in linear mixed regression with random intercept for area consisting of the following baseline covariates: age, age squared, sex, foreign
status, height, body mass index, early respiratory infection, parental asthma, high-level education, cumulative VGDF exposure, and outdoor PM10; additional covariates included smoking
status through follow-up, cumulative pack-years through follow-up, daily environmental tobacco smoke exposure at follow-up, difference in body mass index over follow-up period,
seasonality, ▵PM10, high-level VGDF exposure during follow-up, and two-way interaction terms between environmental tobacco smoke exposure at follow-up and SERPINA1 genotype
(PiMZ, PiMM as reference), and smoking status through follow-up and SERPINA1 genotype; we estimated the effect of ▵PM10 and high-level VGDF exposure during follow-up in PiMZ
and PiMM carriers by adding interaction terms in the model.
†Negative signs indicate acceleration of decline in the lung function parameter with higher levels of exposure to the inhalants.
‡p<0.0001 and p=0.03 for interactions between SERPINA1 genotype and high-level VGDF exposure on ▵FEF25–75% and ▵FEV1/FVC, respectively.
FVC, forced vital capacity; FEF, forced expiratory flow; FEV, forced expiratory volume; VGDF, vapours, dusts, gases and fumes.
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carriers, which may be explained by insufficient power to iden-
tify an interaction between PiMZ genotype and occupational
VGDF exposure in non-smokers; seven of the nine participants
with high-level VGDF exposure and PiMZ genotype were ever
smokers. An alternative explanation is that smoking may be a
prerequisite for the interaction between PiMZ genotype and
VGDF exposure to occur as it increases inflammation and there-
fore elastase activity in the lung.
CONCLUSION
The present findings suggest that interaction between causative
factors plays an important role in the nature of lung function
decline. Genetic predisposition for intermediate AAT deficiency,
in combination with smoking, may increase susceptibility to
occupational exposure-related decline in lung function. The
interaction between PiMZ genotype and outdoor PM10 needs
to be reassessed in larger studies.
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METHODS 
Study population and design 
Online supplementary figure E1 outlines the inclusion criteria for this analysis. Of 
the 9,651 original study participants, there were 7,406 participants with complete 
information on spirometry, exposure, and covariates, at baseline. 6,268 of the 7,406 
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participants (84.6%) were also present at the follow-up survey, of which we further 
excluded 1,866 individuals without completed spirometry, or information on 
exposures and covariates at the follow-up survey. Additionally, we excluded 342 
participants with no SERPINA1 genotyping information available, and 321 
participants who were classified as having PiZZ, PiSZ, or PiMS genotype. 
Spirometry testing 
Identical spirometers (Sensormedics model 2200, Yorba Linda, California, USA) and 
protocols were used for both surveys; comparability was assessed before and after each 
survey.[E1, E2] Three to eight forced expiratory lung function manoeuvres were 
performed, and at least two acceptable measurements of forced vital capacity (FVC) and 
forced expiratory volume in one second (FEV1) were obtained. 
Respiratory questionnaire 
Presence of asthma was defined by reporting positive to the question, “Have you ever had 
asthma?” and, if yes “Was this confirmed by a doctor?” either at the baseline or follow-
up survey. Participants reporting positive to both of these questions were excluded from 
the analysis. 
Occupational exposure assessment 
Current job titles reported by participants at baseline, and all jobs titles reported 
during the follow-up period, were standardized according to the International 
Standard Classification of Occupations (ISCO-88) code’s four-digit 
classification.[E3] The ISCO-88 classification contains 390 occupational titles and 
puts more emphasis on the skills of the job than type of industry that the job belongs 
to.[E3] The current job titles were then linked by ISCO-88 classification to the 
ALOHA general population job-exposure matrix (GPJEM) for COPD,[E4, E5] and 
 4 
were assigned scores for high, low or no exposure (2, 1, or 0, respectively) for 
biological dust, mineral dust, gases/fumes, and either vapours, gases, dusts, or fumes 
(VGDF). VGDF was a composite variable based on the highest of the assigned 
scores for biological dusts, mineral dusts, and gases/fumes exposures. Participants 
classified as having no exposure to all exposure types were classified as unexposed 
to VGDF. For this analysis, we only had sufficient power to evaluate occupational 
exposure to VGDF. Participants with either low-level of VGDF exposure or no 
exposure were combined as a single reference comparison group because our 
previous analysis observed null associations between low-level occupational 
exposures and risk of COPD.[E6] Cumulative exposures at baseline and during 
follow-up were also estimated by multiplying VGDF exposure level and the number 
of years worked in the specific job (unit, years), and was weighted by exposure level 
(1 for low exposure, 4 for high exposure) on an exponential scale to allow for the 
combination of high and low exposure groups.[E4]  
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Figure E1 SAPALDIA study participants included in present analysis 
N = 7,406
SAP1 (1991)
N = 6,268
Exclusion criteria (SAP1):
Incomplete spirometry, exposure, and 
covariates (n=2,245)
n = 1,138 Loss to follow-up
SAP2 (2001-2003)
N = 3,739 Participants included in present analysis
Exclusion criteria (SAP2):
Incomplete spirometry, exposure, and 
covariates (n=1,866)                                  
No genotype (n=342)                     
PiSZ or PiZZ genotype (n=16)               
PiMS genotype (n=305)
N = 9,651
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Table E1 Characteristics of participants and non-participants at baseline survey 
Characteristics 
Participants 
(n=3,739) 
Non-participants 
(n=3,667) P-value 
   FEV1, L, mean (SD) 3.64 (0.81) 3.44 (0.86) <0.0001 
   FVC, L, mean (SD) 4.61 (1.02) 4.37 (1.04) <0.0001 
   FEV1/FVC, %, mean (SD) 79.2 (7.5) 79.0 (8.4) 0.15 
   FEF25-75, L/s, mean (SD) 3.50 (1.22) 3.33 (1.27) <0.0001 
   Age, years, mean (SD) 40.4 (11.1) 41.5 (11.9) <0.0001 
   BMI, kg/m2, mean (SD) 23.7 (3.6) 24.1 (4.2) <0.0001 
   Male, n (%) 1,892 (50.6) 1,672 (45.6) <0.0001 
   Education level, n (%)    
      High 675 (18.1) 555 (15.1) 
<0.0001       Medium 2,652 (70.9) 2,501 (68.2) 
      Low 412 (11.0) 611 (16.7) 
   Daily ETS exposure in past 12 months, n (%) 1,364 (36.5) 1,424 (38.8) 0.04 
   Smoking status, n (%)    
      Current 1,077 (28.8) 1,317 (35.9) 
<0.0001       Former 890 (23.8) 805 (22.0) 
      Never 1,772 (47.4) 1,545 (42.1) 
   Cumulative pack-years smoked, mean (SD) 9.1 (15.7) 12.1 (18.7) <0.0001 
   VGDF level, n (%)    
      High  486 (13.0) 472 (12.9) 
0.14       Low 1,219 (32.6) 1,274 (34.7) 
      Unexposed 2,034 (54.4) 1,921 (52.4) 
   Cumulative VGDF exposure , years, mean (SD) 13.2 (28.0) 13.7 (29.6) 0.51 
   1-year average PM10 prior to baseline survey, μg/m3, mean (SD) 27.0 (9.8) 29.1 (9.9) <0.0001 
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Table E2 Adjusted differences* in annual change in lung function in association with outdoor PM10 and 
occupational VGDF exposures during follow-up in PiMZ and PiMM carriers (ADJUSTING FOR 
BASELINE LUNG FUNCTION) 
 N ΔFEV1 (ml) ΔFVC (ml) ΔFEV1/FVC (%) ΔFEF25-75% (ml/s) 
 
 β (95%CI) † β (95%CI) † β (95%CI) † β (95%CI) † 
∆PM10 (per 10 μg/m3 
increase in 10 years) 
 
 
   
   PiMZ 97 -7 (-17, 2) -4 (-19, 12) -0.1 (-0.3, 0.0) -21 (-45, 3) 
   PiMM 3,642 -2 (-6, 1) -0 (-5, 5) -0.0 (-0.1, 0.0) -6 (-13, 2) 
High-level VGDF 
exposure 
     
   PiMZ 97 -4 (-22, 14) 11 (-13, 35) -0.2 (-0.5, 0.1) -51 (-87, -13) ‡ 
   PiMM 3,642 1 (-2, 4) -2 (-6, 2) 0.0 (0.0, 0.1) 5 (-2, 11) 
* Annual change in lung function was modelled in linear mixed regression with random intercept for area consisting of the following baseline 
covariates: lung function, age, age squared, sex, foreign status, height, body mass index, early respiratory infection, parental asthma, high-
level education, cumulative VGDF exposure, and outdoor PM10; additional covariates included smoking status through follow-up, cumulative 
pack-years through follow-up, daily environmental tobacco smoke exposure at follow-up, difference in body mass index over follow-up 
period, seasonality, ∆PM10, high-level VGDF exposure during follow-up, and two-way interaction terms between environmental tobacco 
smoke exposure at follow-up and SERPINA1 genotype (PiMZ, PiMM as reference), and smoking status through follow-up and SERPINA1 
genotype; we estimated the effect of ∆PM10 and high-level VGDF exposure during follow-up in PiMZ and PiMM carriers by adding 
interaction terms in the model.  
†
 Negative signs indicate acceleration of decline in the lung function parameter with higher levels of exposure to the inhalants. 
‡ p=0.004 for interaction between SERPINA1 genotype and high-level VGDF exposure on ∆FEF25-75%. 
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Table E3 Adjusted differences* in annual change in lung function in association with outdoor PM10 and 
occupational VGDF exposures during follow-up in PiMZ and PiMM carriers (WITH INVERSE 
PROBABILITY WEIGHTING) 
 N ΔFEV1 (ml) ΔFVC (ml) ΔFEV1/FVC (%) ΔFEF25-75% (ml/s) 
 
 β (95%CI) † β (95%CI) † β (95%CI) † β (95%CI) † 
∆PM10 (per 10 μg/m3 
increase in 10 years) 
 
 
   
   PiMZ 97 -4 (-14, 5) 1 (-15, 17) -0.2 (-0.4, 0.0) -28 (-56, 1) 
   PiMM 3,642 -3 (-6, 1) 1 (-3, 6) -0.0 (-0.1, 0.0) -12 (-21, -3) 
High-level VGDF 
exposure 
     
   PiMZ 97 -7 (-28, 13) 14 (-13, 42) -0.3 (-0.7, 0.0) ‡ -88 (-134, -41) ‡ 
   PiMM 3,642 1 (-2, 4) -2 (-6, 2) 0.1 (0.0, 0.1) 6 (-1, 13) 
* Annual change in lung function was modelled in linear mixed regression with random intercept for area consisting of the following baseline 
covariates: age, age squared, sex, foreign status, height, body mass index, early respiratory infection, parental asthma, high-level education, 
cumulative VGDF exposure, and outdoor PM10; additional covariates included smoking status through follow-up, cumulative pack-years 
through follow-up, daily environmental tobacco smoke exposure at follow-up, difference in body mass index over follow-up period, 
seasonality, ∆PM10, high-level VGDF exposure during follow-up, and two-way interaction terms between environmental tobacco smoke 
exposure at follow-up and SERPINA1 genotype (PiMZ, PiMM as reference), and smoking status through follow-up and SERPINA1 genotype; 
we estimated the effect of ∆PM10 and high-level VGDF exposure during follow-up in PiMZ and PiMM carriers by adding interaction terms in 
the model.  
†
 Negative signs indicate acceleration of decline in the lung function parameter with higher levels of exposure to the inhalants. 
‡ p<0.0001 and p=0.03 for interactions between SERPINA1 genotype and high-level VGDF exposure on ∆FEF25-75% and ∆FEV1/FVC, 
respectively. 
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Table E4 Adjusted differences* in annual change in lung function in association with cumulative VGDF 
exposure during follow-up (per 10 years) in PiMZ and PiMM carriers 
 N ΔFEV1 (ml) ΔFVC (ml) ΔFEV1/FVC (%) ΔFEF25-75% (ml/s) 
 
 β (95%CI) † β (95%CI) † β (95%CI) † β (95%CI) † 
   PiMZ 97 -1 (-7, 4) 5 (-2, 13) -0.1 (-0.2, -0.0) ‡ -25 (-38, -12) ‡ 
   PiMM 3,642 0 (-1, 1) -1 (-2, 1) 0.0 (-0.0, 0.0) 1 (-1, 3) 
* Annual change in lung function was modelled in linear mixed regression with random intercept for area consisting of the following baseline 
covariates: age, age squared, sex, foreign status, height, body mass index, early respiratory infection, parental asthma, high-level education, 
cumulative VGDF exposure, and outdoor PM10; additional covariates included smoking status through follow-up, cumulative pack-years 
through follow-up, daily environmental tobacco smoke exposure at follow-up, difference in body mass index over follow-up period, 
seasonality, ∆PM10, cumulative VGDF exposure during follow-up (per 10 years), and two-way interaction terms between environmental 
tobacco smoke exposure at follow-up and SERPINA1 genotype (PiMZ, PiMM as reference), and smoking status through follow-up and 
SERPINA1 genotype; we estimated the effect of ∆PM10 and cumulative VGDF exposure during follow-up in PiMZ and PiMM carriers by 
adding interaction terms in the model.  
†
 Negative signs indicate acceleration of decline in the lung function parameter with higher levels of exposure to the inhalants. 
‡
 p=0.0001 and p=0.03 for interactions between SERPINA1 genotype and high-level VGDF exposure on ∆FEF25-75% and ∆FEV1/FVC, 
respectively. 
 
 
153 
 
 
 
6 Results: Candidate SNPs that may modify the Air Pollution 
Effect on Lung Function Decline 
 
6.1 Paper 6: Follow-up on Genome-wide Main Effects: Do 
Polymorphisms Modify the Air Pollution Effect on Lung Function 
Decline in Adults? 
 
This paper is in revision by Environment International:  
Thun GA, Imboden M, Künzli N, Rochat T, Keidel D, Haun M, Schindler C, Kronenberg 
F, Probst-Hensch NM. 
 
  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
1 
 
Follow-up on genome-wide main effects: do polymorphisms modify 
the air pollution effect on lung function decline in adults? 
 
Gian Andri Thun, MSc1,2, gian.thun@unibas.ch 
Medea Imboden, PhD1,2, medea.imboden@unibas.ch 
Nino Künzli, MD PhD1,2, nino.kuenzli@unibas.ch 
Thierry Rochat, MD3, thierry.rochat@hcuge.ch 
Dirk Keidel, MSc1,2, dirk.keidel@unibas.ch 
Margot Haun, MSc4, margot.haun@i-med.ac.at 
Christian Schindler, PhD1,2, christian.schindler@unibas.ch 
Florian Kronenberg, MD4, florian.kronenberg@i-med.ac.at 
Nicole M Probst-Hensch, PhD1,2, nicole.probst@unibas.ch 
 
1 Swiss Tropical and Public Health Institute, Basel, Switzerland  
2 University of Basel, Basel, Switzerland  
3 Division of Pulmonary Medicine, University Hospital of Geneva, Geneva, Switzerland 
4 Division of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical 
Pharmacology, Innsbruck Medical University, Innsbruck, Austria 
 
Corresponding author:  
 
Prof. Dr. Nicole Probst-Hensch 
Head Unit Chronic Disease Epidemiology, 
Swiss Tropical and Public Health Institute  
Socinstrasse 57, P.O. Box, 4002 Basel 
Switzerland 
 
TEL  0041-61-284 83 78 (direct) 
  0041-61-284 83 88 (admin) 
FAX  0041-61-284 81 05 
 
EMAIL  Nicole.Probst@unibas.ch 
*Manuscript with NO changes marked
Click here to view linked References
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
2 
 
Abstract 
 
Improved air quality has been found associated with attenuated age-related decline in 
lung function. But whether genetic polymorphisms strongly associated with lung function 
play a modifying role in this attenuation process has so far not been investigated.  
 
We selected ten single nucleotide polymorphisms derived from the largest genome-wide 
association studies on lung function and examined whether they modified the association 
between the change in exposure to particulate matter ≤ 10 μm (ΔPM10) and lung function 
decline. 4310 participants from the SAPALDIA cohort provided valid spirometry 
measurements, a detailed pulmonary health questionnaire both at baseline and 11 years 
later as well as blood samples for genetic testing. Spatially and temporally resolved air 
pollution exposures were assigned on an individual level based on participants’ 
residences.  
 
Statistically significant interactions of moderate strength with ΔPM10 were detected for 
rs2284746. Individuals with the CC genotype profited from 21.0 ml slower annual 
decline of the mid expiratory flow per 10 µg/m3 PM10 reduction over an 10-year period, 
while the benefits of CG and GG carriers were smaller (14.3 and 7.0 ml per year, 
respectively; Pinteraction=0.04). The attenuated annual decline in the percentage of the 
forced expiratory volume in one second relative to the forced vital capacity (FEV1/FVC) 
was also increased with the presence of each C-allele (Pinteraction=0.009). We observed 
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further suggestive interactions of similar magnitude in never-smokers, but none of the 
results would remain statistically significant after correction for multiple testing. 
 
We could not find strong evidence that lung function benefits from improved air quality 
are modified by polymorphisms associated with lung function level in large meta-
analyzed genome-wide association studies. 
 
 
 
Key words: air pollution, lung function, genetic polymorphism, gene-environment 
interaction. 
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1. Introduction 
 
Air pollution, a term describing a complex mixture of chemicals and particles in the 
ambient air, could be linked to several adverse health outcomes and chronic diseases 
(Chen et al., 2008). Adverse short-term effects of air pollution on respiratory health are 
well documented (Brunekreef et al., 1995), and evidence is also strong for a long-term 
effect of air pollution on slowing down growth of lung function in children. This results 
in deficits by the time respiratory function starts to level off and ultimately decline 
(Gotschi et al., 2008). Evidence for adverse long-term effects of air pollution on lung 
function in adults is more limited (Kunzli et al., 2010). In the Swiss Study on Air 
Pollution and Lung Disease in Adults (SAPALDIA), a reduction of particulate matter 
smaller than 10 µm in diameter (PM10) resulted in an attenuation of age-related decline 
of two lung function measures, namely forced expiratory volume in the first second 
(FEV1), as well as forced expiratory flow between 25 and 75% of the forced vital 
capacity (FEF25-75) (Downs et al., 2007).  
 
Since susceptibility to air pollution appears to differ among subjects of the general 
population, the individual genetic background is likely to play a role in the response to 
inhaled pollutants. Gene-environment interaction studies have been hence carried out to 
find such genes which alter the association between air pollution and pulmonary disease 
or cardiovascular outcomes (Canova et al., 2012; Zanobetti et al., 2011). Studies on lung 
function have concentrated so far on candidate genes which play a role in the response to 
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free radicals (oxidative stress) (Curjuric et al., 2010; Minelli et al., 2011), in 
inflammatory processes (Yang et al., 2005), and in cell cycle regulation (Imboden et al., 
2009), assigning effect modification to variations in the genes NQO1, HMOX1, GSTM1, 
GPX1, TNF, LTA, CCND1, and TP53. These single candidate genes had been selected 
based on biological knowledge, but a more comprehensive investigation of pathways 
involving several inflammatory and oxidative stress genes led to limited results at either 
the gene or pathway level, including a suggestive interaction of the CRISP2 gene with the 
change in PM10 on lung function decline (Curjuric et al., 2012).  
 
A large meta-analysis of 23 genome-wide association studies (GWAS) on lung function 
yielded 34 single nucleotide polymorphisms (SNPs) that showed new evidence of 
association with FEV1 or with the ratio between FEV1 and the forced vital capacity 
(FVC) (Soler Artigas et al., 2011). In the replication phase, the ten most strongly 
associated SNPs were genotyped and analyzed in nine studies including SAPALDIA. We 
investigated whether these polymorphisms might represent candidate genes with the 
potential to modify the effect of air pollution exposure on lung function decline.  
 
 
2. Materials and methods  
 
2.1 Study population and sample size 
Details about the design of the SAPALDIA cohort study have been described elsewhere 
(Ackermann-Liebrich et al., 2005; Martin et al., 1997). Briefly, a random population 
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sample of adults from eight areas in Switzerland was examined in 1991 (baseline) with a 
detailed health questionnaire and spirometry measurements. 8047 out of 9651 were 
followed-up 11 years later and 6058 agreed to provide blood samples for genetic testing. 
For the current analysis, we excluded 784 subjects because of incomplete or invalid 
spirometry at either time point, 30 subjects because they had lived for less than one year 
at their last residential address at follow-up or could not be assigned PM10 values for 
other reasons, and 934 subjects due to missing covariate data. This resulted in a sample 
size of 4310 individuals. Due to unsuccessful genotyping (see below), the sample size 
was further reduced by a minimum of 22 (rs2857595) and a maximum of 41 (rs1551943) 
subjects (Table S1). Ethical approval was obtained from the Swiss Academy of Medical 
Sciences and the Regional Ethics Committees. Written informed consent was obtained 
from all participants before health examination and biological sample collection at both 
surveys.  
 
2.2 Spirometry 
Spirometry was performed without bronchodilation and according to the European 
Community Respiratory Health Survey protocol (Burney et al., 1994) and complied with 
American Thoracic Society criteria (1995). Identical spirometry protocols and devices 
(Sensormedics model 2200, Yorba Linda, USA) were used in 1991 and 2002 (Kunzli et 
al., 2005). At least two acceptable and reproducible measurements of FVC and FEV1 
were obtained. In the present study, we studied annual declines of FEV1, FVC, 
FEV1/FVC, and FEF25–75, i.e. the differences between follow-up and baseline values of 
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the respective parameters divided by the individual time of follow-up in years. Thus a 
negative value indicates an annual loss in lung function.  
 
2.3 Air pollution exposure and covariates 
Estimates of annual average exposure to PM10 for the 12 months prior to assessments 
were assigned based on the participant’s home address. They were derived from Gaussian 
dispersion models with predictions for the years 1990 and 2000, which were inter- and 
extrapolated based on continuous data from fixed air pollution monitoring stations (Liu et 
al., 2007). Individual change in PM10 exposure (ΔPM10) was calculated by subtracting 
estimates prior to the first health assessment from the respective estimates prior to the 
second assessment and scaling the difference to a 10-year time span. PM10 exposure in 
all study areas declined throughout the study period.  
Level of education, nationality, detailed information about current and past smoking 
habits, parental smoking, exposure to environmental tobacco smoke (ETS), and 
occupational exposure to vapors, gas, dust or fumes was collected through questionnaires. 
Height and weight were measured, and body mass index (BMI) was calculated as weight 
divided by squared height. Skin-prick tests were conducted at the baseline examination 
and participants were classified as having atopy if they reacted positively to one or more 
of the eight inhalant allergens tested (Martin et al., 1997). 
 
2.4 Genotyping 
Blood for DNA analysis was provided at the follow-up examination by participants 
consenting to genetic analyses (Ackermann-Liebrich et al., 2005). The ten highest-
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ranking SNPs at stage 1 of a GWAS meta-analysis on lung function were selected and 
chosen for replication in SAPALDIA and other studies (Soler Artigas et al., 2011). The 
genotyping of the 5646 SAPALDIA subjects with complete baseline spirometry and 
smoking information was done using the iPLEX Gold MassARRAY (SEQUENOM, San 
Diego, USA). Unsuccessful genotyping occurred for varying numbers of DNA samples 
(rs3743563, n=33; rs12477314, n=39; rs11001819, n=37; rs7068966, n=36; rs2865531, 
n=43; rs2857595, n=22; rs2284746, n=35; rs1551943, n=50; rs1529672, n=28; rs1036429, n=33), 
resulting in call rates exceeding 99.1% and more for each of the ten SNPs.  
 
2.5 Statistical analysis 
SNPs were tested for Hardy-Weinberg-Equilibrium (HWE) using chi-square statistics. 
We based our statistical model on the previously published analysis identifying an 
attenuation of age-related lung function decline in the SAPALDIA cohort study 
following the reduction in PM10 exposure (Downs et al., 2007). Mixed linear regression 
models were applied to calculate genotype-specific estimates of the effect of ΔPM10 on 
lung function decline with 95% confidence intervals (95% CI). Reported estimates refer 
to 10 µg/m3 declines in PM10 over 10 years of follow-up. The covariates included age, 
age squared, sex, height, parental smoking status, seasonal effects (sine and cosine 
function of day of examination), level of education at baseline and change in level, 
nationality (Swiss or other), the presence or absence of occupational exposure to vapors, 
gas, dust or fumes at both examinations, smoking status at follow-up (never vs. former 
vs. current smoking), pack-years up to and since baseline, cigarettes per day in both 
surveys, presence or absence of baseline atopy, PM10 at baseline, BMI at the first survey 
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and change in BMI as well as the interaction between the two BMI parameters. 
Furthermore, we adjusted for short-term PM10 exposure considering the three days prior 
to follow-up examination. Random effects for study area were introduced to control for 
clustering of residuals within areas. Two-sided P-values for interaction were calculated 
assuming a co-dominant genetic model.  
In the sensitivity analysis restricted to never-smokers, the same covariates were 
considered except for replacing the smoking variables by exposure to ETS at baseline and 
during follow-up. A second sensitivity analysis replaced the annual declines of lung 
function by the percent change of the annual decline. 
Analyses were conducted with STATA version 12.1. P-values < 0.05 were interpreted as 
statistically significant for main and interaction effects. Multiple testing was additionally 
considered using Bonferroni correction, i.e. by dividing the significance level by the 
number of SNPs which were investigated (n=10). The different lung function measures as 
outcomes were not considered for multiple testing as they are not independent of one 
another.  
 
 
3. Results  
 
Characteristics of the analyzed study population, as well as of the proportion of never-
smokers, are shown in Table 1. Never-smokers were younger on average, had a higher 
percentage of females, exhibited better lung function and had a lower baseline air 
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pollution level assigned to. Apart from the education level, they differed in all covariates 
of interest from the rest of the study population (i.e. from the ever-smokers). 
 
Table 1 Distribution of characteristics in the study population and in never-smokers  
 
All never-smokers P
a
 
Number of participants n=4310 n=2020  
Outcomes of interest    
ΔFEV1, ml/y, mean (SD) -35.7 (29.7) -32.9 (28.7) <0.001 
ΔFEF25-75, ml/y, mean (SD) -71.8 (64.4) -68.1 (62.6) <0.001 
ΔFVC, ml/y, mean (SD) -24.7 (40.0) -22.2 (37.8) 0.001 
ΔFEV1/FVC, (y
-1)*103, mean (SD) -4.1 (4.9) -3.9 (4.8) 0.01 
Covariates of interest at baseline    
Female, n (%) 2279 (52.9) 1226 (60.7) <0.001 
Age, years, mean (SD) 41.4 (11.2) 40.8 (11.9) 0.02 
BMI, kg/m2, mean (SD) 23.7 (3.6) 23.6 (3.5) 0.007 
Workplace exposure to VGDFb, n (%) 1304 (30.3) 527 (26.1) <0.001 
High education level, n (%) 1205 (28.0) 570 (28.2) 0.72 
PM10, μg/m3, mean (SD) 27.2 (9.7) 26.9 (9.6) 0.01 
Covariates of interest through/at follow-up    
ΔBMI, kg/m
2, mean (SD) 2.1 (2.2) 2.2 (2.1) 0.003 
Current smokers at follow-up, n (%) 944 (21.9) 0 - 
Never-smokers at follow-up, n (%) 2020 (46.9) 2020 (100.0) - 
a P-values derive from Chi-square and Mann-Whitney tests comparing distributions of categorical and continuous 
variables, respectively, between never and ever-smokers. 
b VGDF, vapors, gas, dust and fumes. 
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All SNPs were in HWE (P≥0.01) and showed minor allele frequencies (MAF) very close 
to or over 15% (Supplementary Table S1). In this study sample, a 10 μg/m3 reduction in 
the home outdoor PM10 concentration over a 10-year period reduced the annual rate of 
decline on average by 3.7 ml (95% CI 0.3 to 7.2) for FEV1, 0.5 ml (-4.1 to 5.0) for FVC, 
12.1 ml (4.3 to 19.8) for FEF25-75, and 6.2*10-4 (2.9*10-5 to 1.2*10-3) for FEV1/FVC. 
Genotype-specific estimates of the effects of a 10 µg/m3 change in PM10 on lung 
function decline are given in Table 2. The statistically significant effects of air pollution 
change on lung function decline, in particular concerning mid-term flow and to a lesser 
extent FEV1 (Downs et al., 2007), are for most SNPs visible in the genotype strata with 
the largest number of individuals. Genotype-specific differences in effect estimates were 
only moderately significant for one of the polymorphisms. While CC carriers of 
rs2284746 could profit of 21.0 ml slower annual loss of FEF25-75 per 10 µg/m3 PM10 
reduction, carriers of CG and GG genotypes had a smaller benefit (attenuation of 14.3 
and 7.0 ml per year, respectively). A similar trend could be observed in terms of the 
change in FEV1/FVC decline, whereby carriers of two G alleles did not show any profit 
at all. P-values for interaction reached statistical significance only if correction for 
multiple testing was not taken into account (P=0.04 for ΔFEF25-75 and P=0.009 for 
ΔFEV1/FVC). When replacing absolute lung function changes with relative ones (%-
change in lung function), results were similar, confirming the observed interaction and 
not pointing to any additional ones. 
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Table 2. Genotype-specific effect estimatesa for annual change in lung function decline by improved PM10 exposure. 
 
N 
ΔFEV1 
(ml) P 
ΔFVC 
(ml) P 
ΔFEF25-75 
(ml/s) P 
ΔFEV1/FVC 
(*10
4
) P 
rs3743563, GGb 2995 -4.3 0.03 -1.2 0.63 -14.3 0.001 -6.3 0.06 
rs3743563, GA 1159 -5.2 0.06 0.1 0.97 -15.6 0.01 -9.8 0.04 
rs3743563, AA 124 5.2 0.48 14.9 0.13 -4.7 0.78 -13.4 0.30 
rs12477314, CC 2650 -5.1 0.01 -0.9 0.73 -14.8 0.001 -8.7 0.01 
rs12477314, CT 1454 -3.0 0.20 -0.0 1.00 -13.7 0.01 -4.7 0.25 
rs12477314, TT 167 -1.6 0.78 0.8 0.91 -12.6 0.33 -7.4 0.45 
rs11001819, GG 1273 -6.2 0.01 -1.6 0.62 -20.7 <0.001 -8.5 0.04 
rs11001819, GA 2092 -3.1 0.15 -0.4 0.89 -10.4 0.03 -5.2 0.16 
rs11001819, AA 909 -5.1 0.07 -0.5 0.88 -15.3 0.02 -10.5 0.03 
rs7068966, TT 1275 -4.5 0.08 0.2 0.96 -16.0 0.007 -10.2 0.02 
rs7068966, TC 2046 -5.3 0.01 -2.3 0.42 -12.9 0.007 -5.8 0.11 
rs7068966, CC 956 -1.7 0.53 2.4 0.50 -16.4 0.008 -7.2 0.12 
rs2865531, AA 1450 -5.1 0.03 0.5 0.88 -15.0 0.004 -11.2 0.005 
rs2865531, AT 2050 -4.2 0.04 -1.6 0.56 -13.7 0.005 -5.0 0.17 
rs2865531, TT 773 -1.9 0.53 -0.5 0.91 -12.6 0.07 -3.5 0.51 
rs2857595, GG 3048 -3.6 0.07 0.4 0.88 -14.1 0.002 -7.9 0.02 
rs2857595, GA 1126 -6.1 0.02 -3.3 0.33 -15.0 0.01 -5.3 0.24 
rs2857595, AA 114 0.7 0.92 4.1 0.65 -0.1 1.00 -7.1 0.55 
rs2284746, CC 1152 -4.9 0.05 2.0 0.55 -21.0c <0.001 -14.1 0.001 
rs2284746, CG 2153 -4.5 0.03 -1.7 0.54 -14.3 0.003 -6.7 0.07 
rs2284746, GG 973 -3.5 0.20 -1.6 0.66 -7.0 0.26 -0.5 0.91 
rs1551943, GG 2543 -4.8 0.02 -0.5 0.86 -16.7 <0.001 -9.1 0.009 
rs1551943, GA 1512 -4.2 0.07 -1.4 0.66 -12.0 0.03 -4.4 0.28 
rs1551943, AA 214 0.1 0.98 3.0 0.68 -10.8 0.39 -8.6 0.36 
rs1529672, CC 3121 -5.0 0.009 -2.1 0.41 -14.6 0.001 -6.3 0.06 
rs1529672, CA 1060 -0.8 0.77 5.5 0.12 -11.9 0.05 -10.5 0.02 
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rs1529672, AA 99 -10.3 0.19 -9.8 0.35 -19.1 0.29 -2.1 0.88 
rs1036429, CC 2595 -4.6 0.02 -0.5 0.85 -14.2 0.002 -8.2 0.02 
rs1036429, CT 1465 -3.8 0.12 -0.6 0.86 -16.4 0.003 -5.8 0.16 
rs1036429, TT 219 -5.6 0.24 -2.6 0.68 -9.9 0.36 -7.4 0.37 
a Negative effect estimates describe an attenuated annual decline in lung function per 10 µg/m3 PM10 reduction in 10 years. 
b Genotypes refer to the + strand and are tabled according to frequency.  
c Interaction between genotype and change in PM10 is shown in bold if statistically significant without correction for multiple testing (0.005<P<0.05). None of the 
interactions between genotype and change in PM10 would reach statistical significance after correction for multiple testing (P<0.005). 
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Table 3. Genotype-specific effect estimatesa for annual change in lung function decline by improved PM10 exposure in never-smokers. 
 N 
ΔFEV1 
(ml) P 
ΔFVC 
(ml) P 
ΔFEF25-75 
(ml/s) P 
ΔFEV1/FVC 
(*10
4
) P 
rs3743563, GGb 1398 -5.2 0.05 -3.3 0.34 -16.0 0.009 -6.3 0.18 
rs3743563, GA 555 -5.1 0.20 -1.2 0.81 -16.0 0.08 -8.6 0.21 
rs3743563, AA 51 -1.0 0.93 9.3 0.52 -23.0 0.37 -22.5 0.25 
rs12477314, CC 1258 -6.7 0.02 -3.6 0.31 -17.8 0.005 -7.7 0.11 
rs12477314, CT 681 -2.8 0.42 -1.7 0.71 -12.6 0.11 -5.8 0.33 
rs12477314, TT 62 1.0 0.90 4.7 0.65 -17.2 0.35 -8.1 0.56 
rs11001819, GG 601 -10.3c 0.002 -6.3 0.14 -25.5 0.001 -8.2 0.16 
rs11001819, GA 978 -3.8 0.20 -1.9 0.62 -11.2 0.10 -6.3 0.22 
rs11001819, AA 418 0.2 0.97 2.0 0.71 -15.6 0.10 -8.5 0.24 
rs7068966, TT 595 -9.6 0.007 -2.0 0.66 -31.5 <0.001 -21.1 0.001 
rs7068966, TC 962 -4.5 0.13 -4.6 0.23 -8.9 0.19 -0.5 0.92 
rs7068966, CC 444 0.1 0.99 0.9 0.85 -10.8 0.23 -2.9 0.67 
rs2865531, AA 678 -3.8 0.25 2.0 0.63 -13.3 0.07 -12.1 0.03 
rs2865531, AT 962 -6.7 0.03 -7.1 0.07 -16.5 0.02 -2.3 0.67 
rs2865531, TT 365 -4.5 0.28 -1.4 0.79 -20.3 0.03 -9.0 0.21 
rs2857595, GG 1401 -2.7 0.34 -0.8 0.81 -11.7
d
 0.07 -6.0 0.22 
rs2857595, GA 565 -11.1 0.002 -8.1 0.07 -24.2 0.002 -8.7 0.15 
rs2857595, AA 43 -3.7 0.71 4.7 0.71 -31.7 0.16 -12.5 0.47 
rs2284746, CC 543 -6.1 0.09 0.2 0.97 -23.3 0.004 -17.3 0.005 
rs2284746, CG 1015 -6.3 0.04 -5.6 0.15 -16.1 0.02 -4.8 0.36 
rs2284746, GG 451 -2.9 0.43 -2.0 0.68 -8.4 0.32 0.8 0.91 
rs1551943, GG 1171 -3.7 0.20 1.2 0.75 -17.9 0.006 -12.2 0.01 
rs1551943, GA 731 -7.4 0.03 -8.7 0.04 -12.4 0.10 2.2 0.70 
rs1551943, AA 100 -8.6 0.28 -7.1 0.49 -23.4 0.20 -11.9 0.39 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
15 
 
rs1529672, CC 1444 -5.8 0.03 -3.3 0.35 -17.9 0.004 -7.6 0.11 
rs1529672, CA 520 -2.6 0.49 -0.1 0.98 -8.8 0.31 -5.7 0.39 
rs1529672, AA 40 -12.4 0.32 -21.0 0.19 -21.0 0.46 8.5 0.69 
rs1036429, CC 1227 -5.6 0.04 -2.2 0.53 -16.6 0.008 -9.3 0.05 
rs1036429, CT 669 -3.2 0.36 -2.9 0.52 -13.9 0.08 -1.2 0.84 
rs1036429, TT 107 -18.9 0.04 -11.5 0.32 -37.3 0.07 -25.1 0.11 
a Negative effect estimates describe an attenuated annual decline in lung function per 10 µg/m3 PM10 reduction in 10 years. 
b Genotypes refer to the + strand and are tabled according to frequency. 
c Interaction between genotype and change in PM10 is shown in bold if statistically significant without correction for multiple testing (0.005<P<0.05). None of the 
interactions between genotype and change in PM10 would reach statistical significance after correction for multiple testing (P<0.005). 
d Interaction between genotype and change in PM10 is shown in italics if borderline statistically significant without correction for multiple testing (0.05<P<0.10). 
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Results of equivalent analyses in never-smokers are presented in Table 3. While the strongest 
interaction with decline in air pollution exposure was again found for rs2284746 (P=0.01 on 
ΔFEV1/FVC), several other interactions of moderate strength could be observed. For 
rs7068966, we found suggestive interactions with air pollution change on three of the four 
spirometric parameters considered. But like for the whole sample, none remained significant 
after correction for multiple testing. Using %-changes of lung function as outcome measures 
pointed to the same moderate modifications of the effect of air pollution decline, apart from 
those by rs2857595, which were absent.  
 
 
4. Discussion 
 
The effect of reduced PM10 in the ambient air on longitudinal lung function was not 
substantially modified by SNPs selected for their strong association with lung function. In the 
whole study sample, we only found suggestive evidence for an interaction with rs2284746, an 
intronic SNP in the microfibrillar-associated protein 2 gene (MFAP2), which previously 
showed consistent gene main effects on FEV1/FVC (Soler Artigas et al., 2011).  
 
The G allele was associated with lower lung function level in the previous GWAS meta-
analysis than the C allele (Soler Artigas et al., 2011), and in our gene-environment interaction 
analysis, we identified subjects carrying the G allele to be least likely to benefit from 
improved air quality. The genotype-specific effect estimates were of similar magnitude in the 
subsample of never-smokers, which does preclude smoking-related interpretations of our 
findings. The inclusion of baseline adjustment for lung function did also not materially alter 
estimates of effect modification, which argues against a confounding of our findings by 
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differences in baseline lung function between genotypes. The rs2284746 variant has further 
been shown to be associated with height (Lango Allen et al., 2010), but its inverse association 
with lung function made it unlikely to merely be a consequence of the association with height 
(Soler Artigas et al., 2011). MFAP2, encoding for a major antigen of elastin-associated 
microfibrils (Gibson et al., 1986), seems to be important in the extracellular matrix function, 
and inactivation led to complex phenotypes in several organ systems in mice, including 
altered body size, fat deposition or wound healing (Weinbaum et al., 2008). The gene showed 
expression in several tissues of the human respiratory system, but no transcripts were found 
for example in human peripheral blood mononuclear cells (Soler Artigas et al., 2011).  
 
Nevertheless, the observed interaction was modest and did not remain significant after 
adjustment for multiple testing. In a previous candidate gene-environment interaction analysis 
in the SAPALDIA cohort study with similar inclusion criteria and sample size, 
polymorphisms in cell fate controlling genes showed very comparable effect estimates, but p-
values for interaction were slightly stronger as they were optimized for the best-fitted 
underlying genetic model (Imboden et al., 2009). 
 
The SNPs assessed in this work are common variants most consistently associated with lung 
function in a meta-analysis including 48,201 participants of European ancestry across 23 
GWAS. None of these SNPs interacted with smoking (Soler Artigas et al., 2011), and an 
attempt to find additional variants by performing a joint test for SNP main effects and 
interaction effects with smoking in the same study sample did not reveal promising genetic 
loci with statistically significant interactions with smoking (Hancock et al., 2012). However, 
interactions with environmental or lifestyle factors may explain part of the heritability of the 
different lung function measures, which are estimated at around 50% (Wilk et al., 2000). This 
number is much higher than the maximal 10% which can be explained by combining the 
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separate SNP main effect estimates having been reported up to now. In the present study, air 
pollution showed a tendency to modify effects of some of the investigated SNPs especially in 
never-smokers, a finding that supports the assumption that different mechanisms and gene 
pathways mediate air pollution and smoking effects (Curjuric et al., 2012). Of concern is, 
however, that SNPs being associated with cross-sectional lung function do not appear to be 
associated with the decline of lung function as measured in longitudinal studies (Imboden et 
al., 2012). The SNPs described here did not show association with lung function change in a 
subset of SAPALDIA for which we had genome-wide data available. GWAS on lung function 
decline, however, have so far not reported any significant results that could be confirmed in 
independent replication studies, probably in part due to insufficient statistical power or more 
complex interactions of genetic and environmental factors as main determinants of loss of 
lung function (Hansel et al., 2013; Imboden et al., 2012).  
 
Our study benefits from a large population-based sample with high-quality data on health 
parameters, lifestyle factors and genotypes, as well as validated data on exposure to air 
pollution (PM10) on an individual scale. As shown repeatedly in former SAPALDIA 
publications (Curjuric et al., 2010), follow-up participants were healthier than other recruited 
individuals at baseline. This could be of concern if the genetic profile influenced the 
participation rate. Population stratification is most likely not a relevant factor, since length of 
residency prior to the first survey and language constraints led to a predominantly Swiss 
sample, non-Swiss citizenship was adjusted for, and genotype frequencies according to 
language regions did not show any differences. Models were adjusted for a range of possible 
confounders that were derived in a careful attempt to model the impact of air pollution change 
on lung function change (Downs et al., 2007). Lung function change was determined from 
only two spirometric measurements, which is a limitation. As the same spirometers and 
stringent quality criteria were applied, measurement error is unlikely to play an important role 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
19 
 
in our measurements, and if so, it may be randomly distributed across genotypes and thereby 
reduce the statistical power. 
 
 
5. Conclusion 
 
This is the first study which tested gene-air pollution interactions for polymorphisms selected 
on the basis of their consistent contribution to lung function and not on the basis of functional 
knowledge of an underlying gene. In conclusion, we found no compelling evidence for the ten 
agnostically identified GWAS SNPs to play a role in conferring susceptibility to air pollution 
exposure. In the future, functional studies must address how these SNPs act on lung function. 
Missing interactions with smoking and modest interactions with air pollution suggest that 
these SNPs point to biological mechanisms of relevance to lung function that are not or only 
weakly related to inhaled irritants. The genes strongly interacting with air pollution need yet 
to be identified, as the present study could not substantially add to the present knowledge. 
Gene-environment interaction studies in countries with rising or very high air pollution levels 
as well as agnostic procedures like genome-wide interaction studies (GWIS) should be 
considered in the future. This may help to identify new genes and elucidate biological 
mechanisms underlying susceptibility to air pollution. 
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Supplementary Table S1. Characteristics of the genotyped single nucleotide polymorphisms 
Single Nucleotide Polymorphisms Call ratea (%) MAFa (%) P(HWE)a N 
rs3743563, G/Ab 99.4 16.4 0.62 4278 
rs12477314, C/T 99.3 21.1 0.11 4271 
rs11001819, G/A 99.3 45.4 0.12 4274 
rs7068966, T/C 99.4 46.1 0.01 4277 
rs2865531, A/T 99.2 42.0 0.25 4273 
rs2857595, G/A 99.6 16.0 0.43 4288 
rs2284746, C/G 99.4 47.9 0.56 4278 
rs1551943 G/A 99.1 22.9 0.41 4269 
rs1529672 C/A 99.5 14.8 0.10 4280 
rs1036429 C/T 99.4 22.7 0.88 4279 
a Call rate, minor allele frequency (MAF) and P-values for Hardy-Weinberg-Equilibrium (P(HWE)) refer to the 
total genotyped sample size of N=5646.  
b Given are the major and the minor allele on the +-strand.  
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7 Discussion 
 
7.1 Main Findings in a General Context 
Traditionally, human geneticists explored their research domain by concentrating on rare 
diseases with high penetrance, making use of case-reports, studies in families, pedigrees or 
isolated populations. However, the major global health burden is composed of complex 
diseases with low penetrance, including most NCDs as well as some communicable diseases 
with a chronic course. Genetic aspects of such diseases have usually been experimentally 
studied in cell cultures or animal models by researchers trained in molecular medicine. 
Epidemiologists, on the other hand, have been investigating a wide range of exogenous risk 
factors and their associations with complex diseases and disease-relevant traits using 
population-based surveys, case-control or cohort studies. Genetics has usually not played an 
important role in their research. The present PhD work has taken place in the relatively 
young and thriving discipline of genetic epidemiology where human genetics meets 
epidemiology. Its ultimate goal is the establishment of causal links between genomic 
variability, environmental influences and phenotypic variability including health. By 
clarifying mechanisms and disease susceptibilities, this research field further helps to 
improve preventive action against modifiable risk factors and to identify biomarkers for risk 
screening. 
Most projects of this PhD were related to AAT serum level, a quantitative metabolic trait 
influencing pulmonary health. Genetic causes for differing serum concentrations were 
determined and refined, the association with pulmonary health outcomes in dependence of 
the environment was investigated, and diagnostic values were specified. Side projects 
examined genetic interactions with obesity in relation to asthma and with air pollution in 
relation to lung function decline.  
 
7.1.1 The Genetics of AAT 
The GWAS on AAT serum level confirmed that genetic variation in SERPINA1 is by far the 
most influential determinant of AAT protein concentration in the blood (chapter 5.2). 
Moreover, associations with common variants in the SERPINA locus could all be attributed 
to stronger associations with the well-established non-synonymous polymorphisms PiS and 
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PiZ, which show low frequency in the general population. Replication in an independent 
study sample, targeted fine mapping of the SERPINA1 region including conditional 
analyses, additional SNP imputation in selected regions using most up-to-date 1000 
genomes reference panels, look-ups in eQTL data bases [86] and bioinformatic prediction 
tools providing functional SNP annotation all contributed to strengthen and refine the 
original GWAS findings. The strong synthetic associations which we found in this locus are 
explainable by the low genetic recombination rate in this region (i.e. by the high LD in 
terms of D). Interestingly, this is not a novel discovery. The order of the genes in the 
SERPINA cluster was clarified back in 1994 by assessing genetic recombination events 
through linkage analysis in AAT deficient families. High allelic association was already 
observed at that time, and the PiZ allele was found in a unique haplotype stretching over 60 
kb in 97% of all PiZ carriers [185]. This is in agreement with the assumption that the PiZ 
allele had only one origin and might have arisen about 2000 years ago [186].  
 
7.1.2 Causal Variants of Complex Traits, Common or Rare? 
In terms of the open debate about whether the missing heritability of human traits is hidden 
in common variants with small effects or in rare variants with larger effects [187], the 
synthetic associations observed in our GWAS are a strong supporter of the potential impact 
of rare variants. We also conclude from our results that common variants in the SERPINA 
gene cluster which were formerly associated with lung function and emphysema [112,130] 
are most likely not causal. Such dependency on rare variant effects may accordingly apply 
to many associations of common variants found in GWAS.  
Rare variants have long been acknowledged for their influence in monogenic disorders (e.g. 
[188]), but due to the different methodology, examples of a causal role in polygenic 
complex disorders have much later been reported [189,190]. From an evolutionary 
perspective and reflections about the distribution of allele frequencies in the genome, rare 
variants are more likely than common variants to be deleterious and held to low frequency 
by purifying selection [191,192]. Models that explain association results from current 
GWAS as mainly synthetic are supportive of this argument [193]. Furthermore, associated 
common variants were often observed in regions without functional annotation. This 
argument is however losing ground with the rapid progress in allocating functionality to the 
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genome. In fact, GWAS results were shown to be enriched in functional genetic regions, 
especially in 5 untranslated regions [194]. 
Supporters of the common disease-common variant hypothesis argue that balancing 
selection (and different environmental pressures in human history) may explain how a 
disease-associated variant became common. For instance, it was hypothesized that the PiZ 
allele got relatively widespread by conferring a potential advantage in the pre-antibiotic era 
(e.g. by the generation of polymers at sites of inflammation, which potentially attracted 
neutrophils leading to a stronger inflammatory response) [195]. Since smoking was less 
widespread and life expectancy much shorter than nowadays, the drawbacks of being PiZZ 
carrier might have been negligible. Many complex diseases are in fact late-onset and affect 
the fitness after the reproductive phase. We could therefore argue that selection against 
disease-associated variants becoming common is more relevant in communicable diseases, 
which affect the fitness earlier in life. Others being in favour of an important role for 
common variants mention that if effects of common variants were synthetic, the true effects 
of underlying rare variants would have to be strong enough to be detectable by genetic 
linkage analysis [196]. Moreover, for some traits like the human height, hundreds of 
independent common variants were found. If they all relied on stronger rare variants, the 
total variation explained would by far exceed the heritability [197]. Recent studies claim 
that they can explain a large amount of the heritability of many complex diseases by 
estimating the influence of thousands of common variants with very small effects [51]. The 
strong correlation between GWAS effect sizes of Europeans and East Asians for several 
diseases points also to the causality of common variants [198], but such correlation is also 
controversially discussed [199].  
Empirical examples from targeted fine-mapping studies do not clearly favour one or the 
other explanation (e.g. [200-203]). Deep sequencing studies of collections of genes or whole 
exomes in thousands of individuals were recently facilitated by the drop in sequencing 
costs. They showed that almost 90% of SNPs per individual are common, but population-
wise, there is an excess of rare variants compared to frequency spectrum estimates 
[204,205]. They arose to a large part in the past 5000 years and are geographically localized 
reflecting the recent explosive population growth combined with purifying selection [206]. 
Among those genetic variants assigned to disease-associated genes or with computationally 
predicted adverse function, the proportion of rare variants is elevated. These results infer 
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that rare variants contribute importantly to disease susceptibility. Large-scale WGS may 
eventually resolve this open debate, but many complex diseases and medically-relevant 
traits will most likely depend on both common and independently associated low-frequent 
or rare variants. They may show a heritability pattern like human height, i.e. common SNPs 
in total account for far more of the genetic variation than the statistically highly significant 
SNPs detected in GWAS, but cannot explain all of the genetic variation estimated by 
pedigree methods [207,208]. The heritability is therefore to a certain degree hidden and only 
to a probably smaller part missing in current GWAS results. This has recently been 
confirmed for COPD. In a smoking population of Non-Hispanic White and African 
Americans, heritability utilizing all SNPs within a GWAS was estimated at 38% [209], 
which is much more than what known disease-associated variants can explain (< 10%), but 
less than what pedigree-based methods suggest (see 1.2). 
 
7.1.3 AAT Deficiency Genotypes and Lung Function 
The transfer of genetic association patterns with AAT serum concentration to according 
associations with lung function proved challenging (chapter 5.2). Neither the PiS nor the 
PiZ variant were associated with lung function in ever-smokers in meta-analyses with over 
20 000 persons. This is in agreement with meta-analysed results for the general population 
[151,152] and indicates that the status of ever-smoking is not sufficient to put heterozygous 
PiS or PiZ carriers at higher risk for adverse pulmonary health than their PiMM 
counterparts. But the fact that we found dependency of lung function on the PiZ deficiency 
allele merely in patient studies strengthened again the notion that further predisposing 
factors interacting with this deficiency allele must exist. The confirmation that the PiMZ 
genotype is generally not linked to lower lung function also confers low probability to the 
assumption of a causal association between moderately reduced AAT levels and low lung 
function. Such a Mendelian randomisation approach would prove helpful since the direct 
measurement of an association between AAT blood levels and lung function was hampered 
by the fact that individuals with lung function impairment often exhibited elevated AAT 
levels due to its role as an inflammatory marker [136].  
In the search for the additional factors putting PiMZ individuals at risk, we concentrated on 
environmental factors which were known to independently impact lung function. Genetic 
factors were not assessed since the number of possible interactions with SERPINA1 would 
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be high, and neither the GWAS discovery sample nor the look-up in the eQTL database 
pointed to convincing candidate loci. Concentrating on inflammatory stimuli, the PiMZ 
genotype was associated with an accelerated FEF25-75% decline in smoking and obesity 
subgroups from the general population (chapter 5.3). The interaction was especially strong 
with pack-years, showing a dose-dependent manner. Weaker, but consistent associations 
were also observed with the FEV1/FVC decline. Results for participants exhibiting high 
CRP values (although mostly not in the clinically relevant range) strengthened the notion 
that PiMZ carriers might be more susceptible to inflammatory triggers with respect to lung 
function parameters used as indices for assessing mild airway obstruction.  
In a similar approach, PiMZ genotype modified the association between lung function 
decline and exposure to vapours, gas, dusts and fumes, an interaction which was only 
observed in smokers (chapter 5.4). Interestingly, the same lung function measures were 
concerned, namely the FEF25-75% decline and to a lesser extent the FEV1/FVC decline. The 
mid expiratory flow is not a widely assessed spirometric measure (see 1.3.1), but since we 
have repeatedly found main and interacting effects of air pollution strongest for this mid 
flow parameter [172,179,210], measurement error seems an unlikely explanation. We did 
not observe statistically significant interaction between PiMZ genotype and air pollution 
change. This could be explained by the comparably modest levels of air pollution in most 
regions of Switzerland. Heavy air pollution like New York City firefighters experienced 
after September 11 attacks resulted in a FEV1 decline dependent on AAT serum levels in a 
dose-dependent manner, while no such difference was observed before September 11 [178]. 
Taking together, these findings suggest that interaction between causative factors is an 
important process in the nature of lung function decline. This is in good agreement with the 
threshold concept related to AAT serum level and lung function. While a certain amount of 
inflammatory stress and therefore elevated elastase level seems to be tolerated, additional 
exposures and/or lack of antiprotease activity exceed this ability. In both projects, sensitivity 
analyses which either excluded self-reported asthmatics or which gave more weight to 
underrepresented groups due to a possible selection of healthy individuals (see 3.1.2) did not 
alter the results. Statistical power was an issue. Persistent smoking, obesity or high 
occupational exposure was rare in combination with PiMZ genotype. Moreover, the clinical 
meaning of the enlarged decline of PiMZ subjects remained unclear since the statistical 
power did not allow us to properly apply a definition of incident airway obstruction.  
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7.1.4 Reference Values for AAT Deficiency Alleles 
As we have just seen, subgroups of persons with PiMZ genotype may be at increased risk 
for adverse lung health if certain co-factors are present. Since the quantification of AAT 
blood level is usually the first step towards a detection of deficiency alleles, the 
specification of reference values for the most common AAT deficiency genotypes is 
important. We performed such analyses for the first time in a population-based sample and 
observed narrower ranges than present in the literature (chapter 5.1). Moreover, the overlap 
between PiMM and PiMZ individuals was substantially smaller than previously reported. 
By making use of these values, we recalculated upper (92 mg/dl) and lower (49 mg/dl) 
limits of the concentration range corresponding to an intermediate deficiency. The latter 
represents thereby the protective threshold below which a decision in favour of a 
substitution therapy may be considered. The optimal threshold in terms of sensitivity and 
specificity of having at least one PiZ allele was found at 100 mg/dl. This cut-off, above 
which further SERPINA1 genotyping or phenotyping seems not meaningful, at least in the 
absence of an inflammatory condition, may simplify existing protocols. 
Two much larger clinical populations reported in the meantime further suggestions for AAT 
reference ranges [211,212]. While their lower limits were comparable to our results, their 
upper limits were substantially higher [213]. This difference does not seem to originate from 
the quantification methods applied since one study used immunoturbidimetric assays as we 
did in our analysis [212], and the other used nephelometry [211], a method which is 
considered to produce equal results. Phenotyping was used in both studies to determine 
deficiency alleles. Some rare genotypes could therefore not be determined compared to the 
exon-sequencing method which we applied in our study, but this at most marginally affected 
the lower boundary of the reference ranges. Impact of sex or age was judged as minor as we 
also did in our analysis. The reason for the elevated upper limits was most likely the fact 
that the results were not derived from general population samples. Genotype distributions 
were in fact enriched with deficiency alleles and deviated substantially from Hardy-
Weinberg equilibrium. Since many subjects of the clinical populations may show presence 
of low inflammatory conditions, the cut-off mentioned in the previous paragraph may be too 
low in patients with clinical symptoms. 
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7.1.5 Novel Candidate SNPs for the Longitudinal Air Pollution-Lung Function 
Association 
Benefits from cleaner air are not equally distributed among people, but are influenced by the 
individual genetic profile. As shown before, SERPINA1 deficiency variants did not interact 
with air pollution decline in terms of lung function loss in SAPALDIA. Clear evidence for 
interaction with air pollution is also missing for polymorphisms in oxidative stress genes 
[119]. The strategy chosen here, namely testing GWAS-identified SNPs for interacting 
effects with environmental exposures, was successful for breast cancer [214]. However, we 
could only find modest modifications of the effect of reduced PM10 on longitudinal lung 
function by SNPs selected for their strong association with lung function (chapter 6.1). 
Interactions did not remain statistically significant after adjustment for multiple testing. 
Knowledge about the functionality of the genes in which those SNPs are localised was 
absent and could have been improved to a certain degree if compelling evidence for 
interaction had been present. The set of SNPs did not interact with smoking [131]. 
Moreover, they did not even show association with longitudinal lung function in a subset of 
SAPALDIA [133]. Their robust association with cross-sectional lung function might 
therefore be explained by influencing lung function growth during childhood and 
adolescence rather than lung function decline later in life. It remains to be determined if 
gene-environment interactions are more likely observable for SNPs not reaching genome-
wide significance. 
We should also keep the explanatory potential of epigenetics in mind. Short-term exposure 
to air pollution could already be associated with differences in DNA methylation [215]. The 
clarification of the mechanisms for the different susceptibilities to air pollution with regard 
to lung function remains of particular interest. Air pollution is unavoidable and a growing 
public health problem in densely-populated urban centres caused by production facilities, 
heating sources and traffic. Up to now, we do not know an exposure threshold for 
particulate matter below which adverse health effects can be avoided. 
 
7.1.6 Bridging the Gap between Obesity and Asthma: a Role for Altered Cell 
Division? 
Potential mechanisms how obesity could cause asthma include changes in inflammatory 
marker concentrations or in molecules secreted from adipose tissue (adipokines) [216]. This 
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may lead to remodelling processes in the airways, and genes influencing cell cycle control 
in cells of the respective tissues seemed therefore promising candidates for effect 
modification. Our results suggest that the CCND1 gene might play a role in the obesity-
asthma association (chapter 4.1).  
This first project of the PhD work has several limitations reflecting in part the 
methodological progress in genetic epidemiology since then. We tested only three candidate 
genes covered by one SNP each due to genotyping cost constraints. Although these SNPs 
were suggestively functional since previously associated with a few cancer types in case-
control studies, such a meagre selection of SNPs would hardly be envisaged today. 
Functional annotation of the SNPs (e.g. by eQTL data) or a completer SNP coverage of the 
genes would be mandatory to draw firm conclusions from the results. Cellular pathways 
shown to be important in asthma [217] would lead to a less arbitrary gene selection. 
Generally speaking, such a finding remains isolated and earns a lot of scepticism if not 
replicated in an independent study sample or, even better, in a hypothesis-free approach. A 
genome-wide search for SNPs associated with BMI in individuals with and without asthma 
did not reveal any loci which were specific for asthmatics apart from DENND1B, a gene 
functionally related to clathrin-mediated endocytosis, which was only associated in 
asthmatic children [218].  
Since asthma is a binary outcome, we could have used a case-only design to assess the gene-
environment interaction with improved statistical power. But two disadvantages would have 
applied. First, the estimation of the separate effect of the genetic and the environmental 
factor is not possible. And second, since the independence of the genetic and the 
environmental factor is a central prerequisite, the design is not suitable if the environmental 
factor is a type of behaviour like obesity (or smoking).  
 
7.1.7 Candidate Gene-Environment Interaction, a Cautionary Note 
Four of the six projects of this PhD work were based on gene-environment interactions. In 
all of them, we found some evidence of the presence of such interactions. As for the 
interactions with AAT deficiency variants, there was a lot of prior knowledge available 
which argues in favour of the presence of such interactions. The involvement of 
environmental risk factors like smoking and other inflammatory triggers seems in that case a 
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much more promising approach in order to identify associations than simply assessing 
genetic main effects. For the other interactions, findings must be treated with more caution. 
While results from candidate gene association studies do not cause much interest in the 
research community without a successful replication in independent study samples (see 
1.1.4), the scepticism towards non-replicated candidate gene-environment interaction 
studies is even higher. The general lack of compelling gene-environment interaction results 
is one reason for this and is explainable by the challenging sample size requirements as well 
as the usual non-availability of environmental factors in a uniform manner across studies 
(see 1.1.8). But owing to this latter issue, it is nonetheless important that single studies 
generate, test and publish interaction hypotheses. These results may later stimulate similar 
research in much larger and better characterized cohorts and associated biobanks, which will 
likely be available in the future (see 7.2.5). 
 
7.2 Outlook on the Epidemiological Research of Complex Diseases 
By understanding the impact and interplay of the different risk factors, large progress in 
prevention, risk prediction, diagnostics and treatment of complex diseases could be 
envisaged. We will mention here current trends from a genetic, environmental and 
combined perspective and close this chapter by listing some open questions regarding AAT, 
the main focus of this thesis. 
 
7.2.1 The Genetic Perspective 
Well-conducted candidate gene association studies may still contribute to the gain of 
knowledge in the future. In fact, a recent comparison of statistically significant cancer 
associations between meta-analyses of candidate gene association studies and GWAS found 
similar effect sizes, but nevertheless little overlap in statistically significant results [219], a 
finding which was also shown for other outcomes [220,221]. This suggests that the SNP 
selection procedure in candidate gene association studies was often suboptimal in the past. 
Common variation in regulatory regions seems more disease-relevant than common 
variation in coding regions. Candidate genes should therefore be better represented by non-
exonic SNPs with functional annotation.  
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The GWAS design will continue its success story of the past seven years by further enabling 
collaborations of many large consortia and providing knowledge about mechanisms in a 
large number of NCDs and medically-relevant traits [10]. Although the genetic and 
environmental context is in most GWAS not taken into consideration, the recent 
developments (see 1.1.6) may still be able to reveal many more robustly associated genetic 
variants. It was claimed that by increasing sample size and using most modern chip designs, 
more than five times as many GWAS hits as are currently known for chronic diseases could 
be found whereby sample size was alleged to have the far bigger influence than chip design 
[21]. The impact of meta-analyses may still grow, but the random-effect design should be 
promoted to better estimate the magnitude of the effect size [20]. Projects like the UK10K 
will increase the available reference panels substantially and will lead to high imputation 
quality down to a MAF of 0.5% or even less [222]. The increase of sample size is however 
not an infinite process. For some traits like human height or lung function, the amount of 
participants in current GWAS meta-analyses reaches already six-digit numbers. Alternative 
ideas are in need. For instance, the newest GWAS on lung function concentrated on a 
founder population which provided increased statistical power due to the homogenous 
genetics and environment [223]. This way, some of the previously known associations were 
confirmed, and by analysing several SNPs simultaneously in the same model [207], a few 
novel findings were reported. 
While a few of the follow-up methods mentioned in 1.1.7 are meanwhile regularly applied, 
others are still in its infancy and possess high potential to detect more disease-associated 
variants. WES has already proved to be valuable for the discovery of rare variants in NCDs 
[224]. It is however only a stopover to WGS, for which a first association analysis with a 
complex quantitative trait has just been published [225]. WGS still faces important 
challenges. Sequencing costs are still high, namely between US$ 5000 and 10 000 per 
genome and have currently for the first time stopped going down (Figure 4, [226]).  
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Figure 4. The development of the sequencing costs per human genome. 
Large sample sizes are needed to have sufficient power to detect disease associations with 
rare variants. The validity of such association studies is not yet established. The 
complementary use of family-based designs may help in the interpretation of results. 
Aggregating variants at the gene level improves power, but challenges the use of meta-
analyses. In this active area of research, methods using study-level specific gene-level 
summary statistics have been proposed [227]. Further unsolved issues include the correction 
for population stratification and the determination of the genome-wide significance 
threshold. 
Progress will result in detecting further disease-associated variants, probably with mostly 
small effect sizes. Some of the missing heritability might be explained, but it is well 
conceivable that due to non-additive components or generally inflated heritability estimates, 
current and future approaches will not reveal many more variants than currently known 
[39,40]. More importantly, they should help identify the causal variants underlying the 
signals already identified. 
 
7.2.2 Translation into Clinics 
The most advanced area in terms of clinical utility of GWAS findings is 
pharmacogenomics. By measuring differences in drug side effects or drug clearance in 
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affected patients, GWAS revealed several genetic variants with sometimes large effect sizes 
[202,228-232]. It can be speculated that harmful variants with large effect sizes could be 
more easily determined in this research field due to the absence of selection pressure until 
recently. A further advantage of this field is the use of RCT in order to confirm GWAS 
findings. Translation into clinics has already taken place, e.g. when starting antiretroviral 
therapy, a screening for a gene variant which provokes a strong side effect against abacavir 
may be conducted [233].  
With regard to complex diseases, the situation is more challenging. GWAS results have not 
played any clinical role yet, a fact which makes some people criticize the entire method. 
However, all GWAS findings are comparably new, and clinical applicability can certainly 
not be expected in such few years. The main problem towards a personalized medicine 
including prediction of risk, effective prevention and optimal treatment are the small effect 
sizes of the identified variants. Further issues include their incomplete penetrance, the 
moderate heritability they are able to explain and the lack of knowledge of causality. Since 
it is not clear how many risk loci should be included in a test, the non-accessibility of many 
GWAS results, especially of those below the genome-wide significance threshold, is also of 
concern.  
GWAS have already led to the discovery of novel disease mechanisms and new therapies 
may evolve from that. In terms of prevention, individual genetic prediction tests may 
become useful in the future, e.g. in order to detect the most susceptible subgroups which 
may profit most from interventions. The accuracy of such a test can be measured by its 
sensitivity, specificity and the associated area under the receiver operating characteristic 
curve (AUC). Genetic tests have a few useful properties like their time-independency and 
the easy non-invasive collection of DNA, e.g. from buccal cells. The success of a genetic 
test for a certain disease depends largely on the heritability of the disease which we can 
currently explain. There are several examples in which SNPs selected from results of 
candidate gene association studies or GWAS were of no use to predict an outcome (e.g. for 
alcohol dependence [234] or childhood asthma [235]). There is however also evidence that 
genetic tests for traits or diseases for which very large GWAS exist show better 
performance in terms of AUC [236]. For instance, tests based on current GWAS on type 2 
diabetes perform much better in terms of AUC than those based on previous GWAS 
[237,238]. Mild increases in AUC can have a large influence at the population level by 
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allocation of public health resources for prevention in risk groups. For some diseases, the 
use of formerly identified SNP associations resulted in more accurate tests than family 
history [239]. And it was suggested that the combined score over all genomic markers could 
substantially improve disease prediction [240]. A disease for which genetic prediction 
works well is type 1 diabetes. Its genetic components are comparatively well described (i.e. 
the missing heritability is small), and the AUC reaches 0.9 [236]. But since this disease is 
rare, the positive predictive value, i.e. the number of correct positive predictions compared 
to all positive predictions, may still be low. By applying type 1 diabetes prediction tests only 
to persons with a familial risk, the positive predictive value could be greatly improved. 
However, testing all persons belonging to a risk group (screening) is only useful when 
preventive strategies are available. In the case of type 1 diabetes, they are not yet available, 
but progress is being made [241].  
Polygenic risk profiles will certainly find their way into preventive medicine 
complementing environmental risk profiles, traditional clinical profiles and profiles based 
on family history. The identification of concordance and discordance among such profiles 
may confer important information for a personalized health action plan [242]. It is currently 
not clear if genetic prediction tests based on SNP genotyping may at some stage be replaced 
by WGS. The advantage of WGS would be that no genetic region has to be specified prior 
to sequencing. The power of WGS has already been shown by its use in the detection of 
monogenic disorders [243]. Moreover, there are reports in which a genetic disorder could be 
determined and, simultaneously, the same genomic information was used to decide on the 
best therapy [244]. Investments into WGS are currently huge. The Prime Minister of 
England has announced a 100k Genome Project in which up to 100 000 patients are to be 
sequenced in the next five years. This data could then be linked to medical records. It was 
suggested that consent to genetic research could be given in a similar way as for organ 
donation. The Faroe Islands with a population of about 50 000 inhabitants plan to be the 
first country in the world which sequences the genome of every citizen and link it then to 
full digital health records.  
But this boost of WGS comes at a potentially high price. There is an increasing chance to 
detect incidental findings with a large influence on health. The European Society of Human 
Genetics recommended therefore that targeted sequencing limited to genome regions linked 
to the clinical problem should still be encouraged as opposed to WES and WGS [245]. 
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Furthermore, WGS should only be an option if an unsolved clinical problem is present. 
Incidental findings should be reported if indicative of a serious health problem and if 
prevention or treatment is available. This should be weighted larger than the patients right 
not to know. Incidental findings may also have implications for the children or for family 
planning. Further challenges of WGS include the limited data storage capacity in many 
hospitals. It seems crucial that informed consent for diagnosis, research, disclosure and data 
storage is addressed separately. A new global alliance is setting out to ensure on the one 
hand the provision of suitable protection for the autonomy and privacy of the people who 
have contributed their data and on the other hand that the benefits of genomics sequencing 
for health are realised as efficiently as possible [246]. 
 
7.2.3 Direct-to-Consumer Genetic Testing 
Several companies, usually operating from the USA, offer meanwhile private genetic testing 
direct to consumers (DTC) for a modest amount of money. The concept is shown in Figure 
5. Saliva samples get genome-wide analysed and relative risks for a wide range of diseases 
are calculated. Additionally, carrier statuses for several recessive disorders are determined. 
All this information is provided online through a password-protected user account.  
 
Figure 5. The concept of direct-to-consumer genetic testing. Source: 23andMe. 
Due to the lack of counselling, DTC genetic testing is considered especially inappropriate 
for individuals with disease symptoms, for high-penetrance serious disorders, for prenatal 
screening, testing of minors and pharmacogenetic testing [247]. The legislative situation 
concerning such services is very heterogeneous among European countries [248]. In 
Switzerland as well as in several other countries, DTC genetic testing is forbidden. In the 
USA, there is a trend towards stricter regulations of DTC genetic tests as the Food and Drug 
Administration have asked the companies offering such services to seek regulatory approval 
for their tests. 
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The idea behind such services is often advertised by four Ps: predictive, preventive, 
personalized and participatory. A DTC genetic test with own DNA issued by the company 
23andMe, one of the largest providers of such services, pointed to several weaknesses 
though. The calculations for many of the traits and diseases were only based on very few 
SNPs and did insufficiently represent the current state of knowledge. Hence, the predictive 
capacity was for most diseases low if not inexistent, and claims seemed overstated and 
could potentially provoke anxiety or confusion. Results were provided independent of 
available preventive measures (e.g. results for Alzheimer-associated variants were 
conveyed). The genetic data of all participants are also included in research studies. This 
participatory idea must be acknowledged since it offers the appealing potential to build up 
huge data sets in a minimal amount of time. Participants are regularly invited to provide 
topic-specific health data, and social media are used to spread these services. 23andMe 
was for instance able to successfully replicate many GWAS findings from the literature in 
their online communities, but given the large statistical power they had, the agreement was 
lower than expected [249]. This might have to do with the shortcomings in the data-
collection process. The fact that only self-reported information by volunteers is considered 
may result in selection bias (e.g. volunteers are better educated regarding health than the 
general population) or reporting bias (e.g. individuals interested in a certain disease may 
recall relevant exposures differently than others) [250]. The sheer mass of participants 
makes such research nevertheless valuable.  
Receiving information about a considerably elevated risk of getting a severe disease in the 
absence of genetic counselling may have important implications on a persons well-being. 
Web-based networks like PatientsLikeMe try to facilitate the sharing of benefits, but they 
can neither replace the opinion by an expert nor take the personality profile of the proband 
into consideration. A recent survey including European clinical geneticists showed that 
almost all participants were opposed to any form of DTC genetic testing for medical 
conditions that were either serious or not preventable or treatable [251]. A large majority did 
not support DTC genetic tests for highly predictive conditions, but about 40% did not object 
to carrier testing. Most said they would be willing to see patients who were concerned about 
DTC genetic testing results, and almost half of them have already done so. There was some 
disagreement on the question if genetic counselling is indispensable for tests without 
potentially serious consequences.  
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While only preliminary knowledge is present about the behavioural consequences of genetic 
testing [252], it is well established that the genetic illiteracy in the average population is 
high [253]. But such literacy would be important for the decision whether or not to disclose 
genetic information to the patient. Results must be explained in an understandable way 
which includes information about the high degree of uncertainty in quantifying risk 
prediction for polygenic diseases. Carrier status of potentially dangerous and often high-
penetrance risk alleles is on the other hand information which can be determined very 
reliably and which may have stronger implications for health and family planning. The 
decision for disclosure of such information must carefully balance the patients autonomy, 
psychological welfare and health. This applies also to the disclosure of incidental findings 
outside the scope of offered services which may become important if such services switch to 
WGS. It is furthermore crucial that companies inform and get the patients separate consent 
about the storage of data, the possible use for research and the sharing of the data [250]. The 
prohibition of DTC genetic testing is probably not a reasonable permanent solution due to 
the globally easy accessibility of such tests. In fact, there are efforts in Switzerland to allow 
DTC genetic testing for providers who inform adequately about purpose and risks of such 
tests. But once legal, health insurances are expected to profit from this situation and 
complete their application forms with questions about the presence of such genetic tests. In 
that case, persons who want to carry out DTC genetic testing just out of interest must be 
aware that they may potentially regret this decision. 
Taking together, the relevance of personalized medicine is increasing in the medical as well 
as in the private sector. While genetic tests for some rare high-penetrance diseases are very 
reliable, this is not (yet) the case for most complex diseases. The limits are clearly seen by 
the fact that genetically identical twins rarely develop the same complex diseases [254,255]. 
The environment as well as related genetic and epigenetic modifications in somatic cells of 
several tissues soften the image that the genetics is an unchangeable and highly predictive 
parameter of human health [256]. It is important not to forget that chronic diseases are to a 
large part environmentally driven and often preventable by modifying the environment. 
Nevertheless, the young discipline of public health genomics features a full agenda [257]. 
Social and environmental models, public health professionals usually work with, should be 
widened by the integration of genetic knowledge. Interventions may be increasingly 
evaluated according to genetically-defined population strata. But most importantly, the 
genetic literacy of medical practitioners, who may see more patients coming with DTC 
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genetic test results to them, as well as of the public should be increased. RCTs are necessary 
to compare outcomes between patients who received counselling without genetic 
information and those who additionally received genetic information [258].  
 
7.2.4 The Environmental Perspective 
Environmental factors are much harder to describe in their completeness than genetic 
factors. Namely, for any specific place and time, not all relevant exposures are known. 
Moreover, measurement accuracy depends strongly on the type of exposure, some 
exposures fluctuate strongly over time, and biomarkers are not readily available for most 
environmental exposures. Nevertheless, the inclusion of environmental factors in prediction 
tests reaches often much higher AUC than the use of genetic factors (e.g. in risk scores for 
cardiovascular outcomes, [259]). Since many of these risk factors can be modified, they 
should stay in the centre of prevention. In order to find novel risk factors independent on 
previous knowledge, agnostic procedures analogous to GWAS (so-called environment-wide 
association studies) have been carried out (e.g. [260]). Challenges include reverse causation 
(especially if there are no longitudinal data available), confounding and dependency of 
exposures on one another (see 1.1.2). Similar to LD-considerations in GWAS, exposure 
correlations can be used to refine signals.  
An attempt to evaluate the comparative importance of various diseases and risk factors in 
the population is used in the Global Burden of Disease Study [1]. Importance of risk factors 
was estimated by comparing the effects of each exposure with a theoretical minimum 
population distribution of the exposure. Shortcomings include the assumptions that risk 
factors act independently of one another and that exposures are uncorrelated across diseases. 
Caution should therefore be applied when using the ranking of the 67 risk factors to guide 
policy in certain regions [261]. This statement is intensified by several additional issues. 
First, the ranking does not consider the feasibility or cost-effectiveness of interventions. 
Second, several risk factors are not included in the study (e.g. unsafe sex, poor hygiene, 
education or noise) due to a trade-off being made between high evidence of causality and 
data availability. Country-specific cohort studies which include the assessment of a wide 
range of risk factors would be needed to combat the widespread lack of data and thus the 
dependency on complex and error-prone estimation techniques in certain regions. Finally, it 
is worth mentioning that NCD research has been carried out mainly in high-income 
196 
 
 
 
countries. This is in contradiction with the fact that low- and middle-income countries 
(LMICs) account for 80% of NCD deaths [262], a percentage expected to even rise in future 
[263]. The transfer of knowledge from high-income countries would only partially solve the 
problem due to other distributions of exposures and confounders in LMIC. High-income 
countries may equally benefit from a boost in the allocation of resources to NCD research in 
LMIC [264], but it is ethically important that LMIC must also benefit from the 
implementation of knowledge thereafter. Stronger health information systems involving the 
registration of births and deaths are a much-needed first step towards better health data in 
poorer areas of the world [265]. 
An interesting aspect is the complete absence of genetics in the Global Burden of Disease 
Study. This is in part explainable by the fact that, although the joint influence of genetics on 
complex diseases is often well investigated and large, the single causal variants are usually 
not known with high certainty, especially not across global populations. It does however not 
seem essential to aim at expressing the risks of genetic variants in terms of DALYs. While 
genetics is crucial to determine disease mechanisms and defining susceptible subgroups in 
the population, we should not forget that the environment is the component we can 
influence most easily. The genetics is not a factor which prevention can act on.  
There is hope that sensor and mobile technology will lead to a much more accurate and 
comprehensive measurement of environmental exposures, behaviours and lifestyle factors in 
the near future. Such a development could boost the environmental research in a similar way 
like observed for the genetic research owing to the new technologies in the past decade. 
 
7.2.5 A Combined Perspective 
In terms of assessing gene-environment interactions, we may expect that, analogous to the 
genetic main effect literature, agnostic study designs like GWIS become the preferable 
approach. Such studies may elucidate mechanisms for genetic associations with an outcome, 
potentially contribute to reduce the missing heritability and identify susceptible subgroups 
in the population. Some GWIS findings have been reported up to now [94,132,266-268], but 
the methodology is less standardized than in GWAS. Results with recently suggested 
methods seem to mainly reflect the marginal effects of the genetic variants [269]. In fact, the 
scarcity of reliable examples let to the suggestion that genes involved in interactions may 
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better be detected through their marginal effects [270]. Large sample sizes are a prerequisite 
in GWIS for being sufficiently powered (see 1.1.8). This can be achieved by the use of large 
collections of environmental data or, alternatively, by the use of meta-analyses of smaller 
data collections. The latter increases the risk of heterogeneity in exposure assessment or of 
differences in the assessment of confounders. Potential higher order interactions are difficult 
to consider since they strongly increase the burden of multiple testing.  
Another approach of investigating associations between environmental factors and diseases 
in dependence of the genetics may lie in the investigation of intermediate processes (e.g. 
changes in gene expression or epigenetic modifications). The key task to clarify these 
processes is the setting-up of comprehensive biobanks. There has been considerable 
investment in biobanks recently, and internationally harmonized efforts are crucial to keep 
comparability high. Biobank research comprises scientific, infrastructural and ethical 
aspects. Focusing on the scientific aspect, a biobank should ideally include samples of many 
tissues and several time points since epigenetic and expression profiles vary tissue- and 
time-dependent. An important issue is the identification of biomarkers as proxies for 
environmental exposures. The collection of samples before and after the presence of certain 
exposures is an intriguing approach to investigate short-term exposure effects. A recent 
omics-approach showed that genomic, transcriptomic, proteomic and metabolomic 
information of the same individual over several months can reveal important pathways and 
allele-specific expressions during disease periods and can be used to predict, diagnose and 
even treat disease-related conditions [271]. This represents a future scenario how health 
monitoring and personalized medicine could work together. An additional and even less 
understood component is the epigenome. Epigenetic modifications were observed to be 
associated with many complex diseases including asthma [272]. While several exposures 
were also associated with genome-wide or gene-specific methylation, the causality in the 
epigenetic association with the disease remains an unsolved issue. 
 
7.2.6 The Potential Contribution of SAPALDIA 
SAPALDIA is the only longitudinal and population-based study in Switzerland which 
covers all language and cultural regions. Started as an air pollution and lung health study, 
researchers later widened the focus to several chronic diseases. The added biobank in the 
second survey was a key achievement for establishing many collaborations with other 
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European cohorts. Since the third survey in 2011, the biobank has contained longitudinal 
serum and DNA samples. This would potentially enable investigators to look into the 
metabolome and epigenome over the course of ten years. Another new intriguing 
opportunity is to investigate transcriptomics, metabolomics or epigenomics as a function of 
short-term exposure. The number of participants with available genome-wide data was 
recently enlarged to approximately 4000. The availability of almost one million genotyped 
SNPs and many more imputed ones making use of the newest 1000 genomes reference 
panels will generate new collaborations and foster many existing ones. Of note is that more 
than half of the study participants meanwhile attained an age of over 65 years, which shifts 
the SAPALDIA focus to a an elderly population. This is an opportunity to include more 
chronic diseases which get particularly prevalent at an older age like for instance cognitive 
diseases. 
With a sample size of roughly 5000 individuals, it is clear that the establishment of 
collaborations with all the accompanying difficulties in comparing results across different 
studies remains a crucial task. A large-scale national cohort in Switzerland would facilitate 
this situation and allow researchers to investigate NCDs in a much wider and more flexible 
framework. Other European countries like Germany or Great Britain invest in such mega-
cohorts and may serve as examples how to best make use of the profound pre-existing 
expertise with population-based cohorts present in Switzerland.  
 
7.2.7 Future Research in Relation to AAT 
After this general outlook on the future research on the aetiology of NCDs, a summary of 
open questions arising from the PhD projects regarding AAT will complete this thesis.  
We observed in SAPALDIA that subgroups of heterozygous PiZ carriers, namely persistent 
smokers, obese persons and those highly exposed to vapours, gas, dusts and fumes, are of 
increased risk for elevated lung function decline. Replication in other cohorts is a first step 
to consolidate these findings. There is evidence that smoking and high occupational 
exposure are also important for the differing susceptibility of PiZZ individuals to adverse 
pulmonary health [164,273], findings which support our results. The effects of obesity in 
combination with severe AAT deficiency have not yet been evaluated, and such a project 
could be envisaged with data from an AAT registry including ideally index (i.e. those 
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presenting symptoms of adverse lung (or liver) health) and non-index cases. Unlike in 
studies examining PiZZ individuals [149], longitudinal air pollution was not observed to 
interact with PiMZ genotype with respect to lung function decline in SAPALDIA. However, 
we must consider that exposure levels are comparably low in Switzerland. It would be 
interesting to investigate this issue in areas with high or strongly rising levels of air 
pollution like some urban regions in India or China. Projects including indoor air pollution 
may strengthen the hypothesis that individuals with intermediate AAT deficiency have less 
capacity to combat the proteolytic effects of inflammatory triggers. However, we must take 
into consideration that those regions in which indoor air pollution is a highly relevant risk 
factor for adverse pulmonary health are largely free of the PiZ allele [274].  
It is currently not clear if heterozygous PiZ carriers exposed to inflammatory triggers benefit 
equally from a reduction of the inflammatory trigger. A randomised smoking cessation 
study in smoking PiMZ individuals may clarify this issue. A better strategy would of course 
be the counselling of PiMZ subjects before the exposure exerts its effect. Studies may assess 
which type of counselling is most effective. PiMZ individuals could be randomised to 
counselling including or excluding information about AAT genetics. It could also be 
assessed in a similar way if regular counselling (e.g. on a yearly basis) is superior to one-
time counselling. The possibility of recruiting large numbers of PiMZ individuals also 
depends on complete information on PiZZ subjects in AAT registries. National AAT 
registries as well as the Alpha One International Registry, which collects data of the national 
registries of nearly 20 countries, aim to capture severely deficient individuals as completely 
as possible with the goal of encouraging research and promoting knowledge. However, by 
roughly comparing numbers of registered PiZZ individuals with those estimated based on 
population-based studies, severe AAT deficiency appears a strongly underrecognised 
genetic disorder with merely about 10% registered individuals.  
While one reason is the absence of clinical symptoms in a large group of deficiency carriers, 
the often long time-lag between the appearance of first clinical symptoms and the diagnosis 
of an AAT deficiency is another aspect. This is of high importance since the deficiency 
diagnosis may additionally motivate to give up smoking and may result in an early start of 
augmentation therapy (if available) and hence a probably better long-term prognosis. 
Moreover, family members could be tested and counselled at an earlier time point, which is 
generally the best method to detect early disease and prevent from more serious disease. 
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Reasons for the time-lag in the magnitude of seven to eight years are the inadequate 
awareness of healthcare providers and the failure to implement available guidelines [275]. 
The strongly heterogeneous opinion on AAT augmentation therapy among experts may also 
represent an important point in the decision in favour or against testing [276]. Educational 
campaigns for primary care physicians or pulmonologists, distribution of free test kits to 
measure AAT serum level to physicians and even dried blood spot kits for a home-based 
test with the offer of free genetic counselling over the telephone were measures of a testing 
programme which also aimed at detecting heterozygous PiZ carriers [277]. Services offering 
DTC genetic testing like 23andMe also routinely assess the PiS and PiZ deficiency alleles 
and could potentially provide carriers with important information about the purpose of AAT 
registries. The search for non-index cases is namely an important part of testing 
programmes since the counselling of these symptom-free individuals may be much more 
promising with regard to the prevention of severe pulmonary disease.  
To whom is it recommended to undergo genetic testing? Generally, this depends on the 
prevalence of the genetic syndrome, the prevalence of the associated diseases, the disease 
burden, the availability of interventions, the chance that an intervention is accepted, the 
accuracy of the test, the costs as well as on psychological and ethical aspects. The most 
rigorous approach would be neonatal screening. Experience with such an implementation 
comes from Sweden where all newborns between 1972 and 1974 were screened for AAT 
deficiency. More than half of the 127 PiZZ-diagnosed babies had abnormal liver tests at the 
age of three months [140], but in most cases values normalised later during childhood. This 
is in line with the fact that less than 1% of all PiZZ children need liver transplantation in 
early childhood [278]. In a follow-up study of the neonatal screening project, the families 
from the diagnosed PiZZ babies got ample information about the risks for their babies. 
Although this initiated negative emotional reactions especially in mothers, the majority of 
parents were positive towards having received the diagnosis with extensive counselling. 
While parents of PiZZ children did not smoke less than those of PiMM carriers, the PiZZ 
carriers themselves smoked substantially less as adolescents than their PiMM peers [279]. 
Adverse psychological effects in the adolescents could not be found [280]. Although these 
results from Sweden seem generally supportive of a population-wide screening before the 
age of adolescence, there is currently no country which conducts or recommends 
population-wide screening for AAT deficiency. While the genetic syndrome is indeed 
relatively frequent (e.g. more frequent than cystic fibrosis or phenylketonuria), the 
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penetrance of the associated diseases is not very high, especially if risk factors like smoking 
are avoided. The second major reason why neonatal screening is nowhere implemented is 
probably the absence of a directly beneficial intervention during childhood (apart from the 
avoidance of exposure to ETS). A screening close to the age when smoking may start would 
possibly be more beneficial and would allow the child to take part in the screening decision. 
Uncertainties include the participation rate of a voluntary AAT screening and the efficacy of 
anti-smoking advice if the information is given to school-age children [281]. 
The screening of asymptomatic individuals who are at elevated risk for adverse pulmonary 
health is a second strategy. Such groups include persons with a family history of 
unexplained liver disease, early-onset emphysema or AAT deficiency. The guidelines of the 
American Thoracic Society and the European Respiratory Society recommend testing 
especially to siblings of PiZZ carriers since they have a 25% chance of having the same 
genotype [173]. The first step in the determination process does however not yet involve 
genetic testing, but measuring levels of circulating AAT (chapter 5.1). A volunteer 
screening of smokers or people working in jobs with high exposure to vapours, gas, dusts 
and fumes could also be conceived. In order to assess the benefit of offering such a service 
to a substantial proportion of the general population, one would have to carry out a RCT in 
which the testing offer is randomly assigned to the exposed population. Since health-
relevant outcomes like lung function may show effects only years or even decades later, 
costs for such a study would be prohibitively high. It is also important to emphasize that 
prevention from inflammatory triggers is essential for all individuals. Even if genetic 
subgroups are found to be more susceptible, this does not imply that efforts for subgroups 
less susceptible are of lower importance. In that respect, the offer of a genetic test for 
subjects highly exposed at work should by no means weaken efforts to generally lower 
occupational exposure.  
A different situation applies to symptomatic individuals. Subjects with unexplained liver 
disease, with early-onset emphysema or COPD, or with airflow obstruction in the absence 
of risk factors should be screened for AAT deficiency, at least in regions where AAT 
deficiency is prevalent like in Europe and the USA [173]. Interventions for those persons 
consist of general measures for the treatment of COPD (i.e. reductions of exposure, 
provision of oxygen supply and use of bronchodilators, oral corticosteroids and antibiotics) 
as well as potentially of intravenous AAT augmentation therapy. The prescription of the 
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expensive therapy is subject to several regulations. While a few countries like the USA aim 
at generally prescribing replacement therapy to all severely deficient individuals, others like 
Switzerland allow it only for individuals who are severely obstructive and have quit 
smoking. A few other European countries like Great Britain or the Netherlands do not offer 
substitution therapy at all.  
Considering the uncertain profit from AAT replacement therapy in PiZZ individuals, there 
is at this point no indication for assessing its use in PiZ heterozygotes, not even in those 
additionally exposed to other risk factors. Experimental research is first needed to solve the 
question why the establishment of normal AAT blood levels does not convincingly result in 
a normalised rate of lung function loss. The role of locally produced PiZ polymers in the 
lung must be clarified. A difficulty in using mouse models is the deviation of the human 
SERPINA1 locus from the murine orthologue. Gene duplication led to several paralogues in 
mice, some of which seem to be essential during embryogenesis [282].  
Several new approaches are being developed in order to have alternatives to AAT 
substitution therapy. Viral vectors and liposomes have been tested as vehicles for gene 
therapy. Single administration would be the main advantage as opposed to the weekly 
administered replacement therapy, but a few challenges still need to be resolved. On the one 
hand, only slightly and short-term elevated AAT levels could be observed after vector 
injection. On the other hand, PiZ formation and polymerisation in hepatocytes remain 
unchanged by current gene-therapy approaches [283]. Aerosols instead of intravenous 
application of replacement therapy have been proposed, but delivering large proteins by 
inhalation is challenging. Production of human AAT in transgenic animals would 
substantially lower the costs as opposed to the purification of human plasma, but did so far 
not result in a molecule tolerated by humans [284]. Finally, a strategy to stimulate 
degradation pathways in order to clear hepatocytes from AAT polymers was suggested 
[285].  
Our projects concentrated on environmental factors modifying the influence of SERPINA1 
deficiency alleles on lung function decline. However, there may also exist important genetic 
modifiers. In prediction models, the inclusion of age, sex, packyears of smoking, 
bronchodilator responsiveness, chronic bronchitis and index status explained more than 50% 
of the FEV1 variance in severely AAT deficient subjects. SNPs of four candidate genes 
previously associated with pulmonary function in PiZZ individuals and their interaction 
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with smoking could not contribute to a more accurate model [286]. SNPs in CHRNA3, 
formerly associated with COPD, have been found to marginally modify airflow obstruction 
in severely deficient persons [287]. We expect more genetic co-factors to determine lung 
function in those people, and such information could be used in the decision process in 
favour or against AAT substitution therapy. A GWAS on lung function decline involving 
only PiZZ individuals would be an interesting approach to find such variation, but only a 
collaboration of different AAT national registries like the Alpha One International Registry 
would lead to sufficient samples to conceive such a project. 
The underlying genetics of AAT serum level outside the SERPINA1 coding region could not 
be clarified in this PhD work, but is unlikely to play an important role in influencing 
pulmonary health as even the PiS variant, which considerably lowers AAT serum level, 
could so far not be associated with pulmonary health. However, there is growing evidence 
that AAT is more than just a protease inhibitor of neutrophil elastase [284]. Antibacterial 
and -viral properties have been observed, and its anti-inflammatory activity affects a wide 
range of immune cells such as T lymphocytes and dendritic cells. Novel experiments in 
elastase-deficient mice as well as with a recombinant form of AAT without anti-elastase 
activity provided evidence that the anti-inflammatory and immunomodulatory properties of 
AAT are independent of elastase inhibition [288]. AAT may thus have the potential to 
achieve clinical value for a variety of diseases and is currently tested as a therapeutic agent 
for cystic fibrosis and type 1 diabetes. Its pleiotropic potential is further emphasized by its 
suggested role in CVDs. SERPINA1 variation was associated with different measures of 
atherosclerosis [28,289,290] and increased aortic stiffness [291]. AAT appears essential for 
the integrity of the connective tissue in blood vessels, and damage to the elastic fibres of the 
arterial wall is assumed in severely deficient individuals [292]. Experimental studies have 
further shown that AAT occurs in human atherosclerotic lesions [293]. Given this wide 
range of effects, it is crucial to better understand the genetics of AAT expression beyond the 
large effects of a few exonic variants leading to misfolded proteins. The meanwhile much 
larger SAPALDIA sample that is genome-wide analysed and the better reference panels for 
imputation would enhance the statistical power to detect loci which influence the serum 
level more moderately than currently known variants in a GWAS replication project. 
Pathway analysis could then be useful to test if GWAS results are enriched in inflammatory 
pathways or in cholesterol or triglyceride pathways to which SERPINA1 was recently found 
related [28]. 
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Finally, expression of inflammatory mediators may be programmed by epigenetic 
mechanisms. While SERPINA1 methylation was observed to be associated with lung 
function and COPD [117], its association with serum level has not been investigated so far. 
The data of SAPALDIA would allow an epigenome-wide association study with AAT 
serum level to potentially find further genes relevant to the SERPINA1 gene expression. 
More specifically, the SERPINA1 methylation pattern could be compared between 
subgroups with and without deficiency alleles and high exposure to inflammatory stimuli, 
potentially clarifying the observed association between SERPINA1 methylation and lung 
function.  
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